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1. PUBLIC HEALTH STATEMENT 
This public health statement tells you about 2-butoxyethanol and 2-butoxyethanol acetate and the 
effects of exposure. 
The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in 
the nation. These sites make up the National Priorities List (NPL) and are the sites targeted for 
long-term federal clean-up activities. 2-Butoxyethanol has been found in at least 20 of the 1,430 
current or former NPL sites. 2-Butoxyethanol acetate has not been found at any of the 1,430 
current or former NPL sites. However, the total number of NPL sites evaluated is not known. 
As more sites are evaluated, the sites at which 2-butoxyethanol or 2-butoxyethanol acetate are 
found may increase. This is important because exposure to these substances may harm you and 
because these sites may be sources of exposure. 
When a substance is released from a large area, such as an industrial plant, or from a container, 
such as a drum or bottle, it enters the environment. This release does not always lead to 
exposure. You are exposed to a substance only when you come in contact with it. You may be 
exposed by breathing, eating, or drinking the substance or by skin contact. 
If you are exposed to 2-butoxyethanol or 2-butoxyethanol acetate, many factors determine 
whether you’ll be harmed. These factors include the dose (how much), the duration (how long), 
and how you come in contact with it. You must also consider the other chemicals you’re exposed 
to and your age, sex, diet, family traits, lifestyle, and state of health. 
1.1 WHAT ARE 2-BUTOXYETHANOL AND 2-BUTOXYETHANOL ACETATE? 
2-Butoxyethanol (bu-tox-zi-eth-an-ol) has many names, including ethylene glycol monobutyl 
ether, ethylene glycol butyl ether, ethylene glycol n-butyl ether, Butyl Cellosolve, butyl glycol, 
butyl Oxitol, glycol butyl ether, Dowanol EB, Gafcol EB, Poly-solv EB, and Ektasolve EB. 
Common abbreviations for 2-butoxyethanol include BE and EGBE. It is a clear, colorless liquid 
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that smells somewhat like ether. Most people can begin to smell 2-butoxyethanol in air at 
0.10-0.40 parts of 2-butoxyethanol per million parts of air (ppm). These levels are about 
500 times lower than the present standard for worker exposure. 2-Butoxyethanol has been found 
in air, water, and soil as a contaminant. It is completely soluble in water and in most organic 
solvents. This means that when 2-butoxyethanol and water or 2-butoxyethanol and organic 
solvents are mixed, the mixtures form one layer, unlike mixing oil and water which separate into 
two layers. 2-Butoxyethanol is a fire hazard when exposed to heat, sparks, or open flames. 
2-Butoxyethanol in the environment comes from some industrial activities. It is usually produced 
by a reaction of ethylene oxide with butyl alcohol, but it may also be made by the reaction of 
ethylene glycol with dibutyl sulfate. 2-Butoxyethanol is widely used as a solvent in protective 
surface coatings such as spray lacquers, quick-dry lacquers, enamels, varnishes, and latex paints. 
It is also used as an ingredient in paint thinners and strippers, varnish removers, agricultural 
chemicals, herbicides, silicon caulks, cutting oils, and hydraulic fluids. It has other uses in metal 
cleaners, fabric dyes and inks, industrial and household cleaners (as a degreaser), and dry-cleaning 
compounds. It is also used in liquid soaps and in cosmetics. 
The acetate (ass-e-tate) form of this chemical is 2-butoxyethanol acetate. It is also known as 
ethylene glycol monobutyl ether acetate, butoxyethyl acetate, butyl glycol acetate, ethylene glycol 
butyl ether acetate, acetic acid 2-butoxyethyl ester, glycol monobutyl ether acetate, Butyl 
Cellosolve acetate, or Ektasolve EB acetate. Common abbreviations for 2-butoxyethanol acetate 
include BEA and EGBEA. 2-Butoxyethanol acetate has been found in air, water, and soil as a 
contaminant. It is a colorless liquid with a fruity odor. Most people can begin to smell 
2-butoxyethanol acetate in air at 0.10-0.48 ppm. It is only moderately soluble in water but is 
soluble in most organic solvents. This means that when 2-butoxyethanol acetate and water or 2­
butoxyethanol and organic solvents are mixed, the mixtures form one layer, unlike mixing oil and 
water which separate into two layers. 2-Butoxyethanol acetate is a fire hazard when exposed to 
heat, sparks, flames, or oxidizers. 
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2-Butoxyethanol acetate in the environment also comes from some industrial activities. It is 
prepared by reacting 2-butoxyethanol with acetic acid, acetic acid anhydride, or acetic acid 
chloride. 2-Butoxyethanol acetate is widely used as a slow-evaporating solvent for lacquers, 
varnishes, epoxy resins, and enamels. It is also used in polyvinyl acetate latex, and it may be used 
in some ink and spot remover formulations. 
For more information on the nature and uses of 2-butoxyethanol and 2-butoxyethanol acetate, see 
Chapters 3 and 4. 
1.2 WHAT HAPPENS TO 2-BUTOXYETHANOL OR 2-BUTOXYETHANOL
      ACETATE WHEN THEY ENTER THE ENVIRONMENT? 
2-Butoxyethanol may be released into the environment at places where it is produced or used as a 
solvent. Solvent-based household cleaners or building materials such as varnishes, lacquers, latex 
paints, and enamels may release 2-butoxyethanol into the air as they dry. Municipal landfills and 
hazardous waste sites can also release 2-butoxyethanol to water that is under the ground. 
2-Butoxyethanol can pass into air from water and soil. In the atmosphere, 2-butoxyethanol 
probably exists almost entirely as a vapor. Once in the air, 2-butoxyethanol may be removed by 
precipitation (rain, snow, ice) or may break down to other compounds within a few days. 
2-Butoxyethanol breaks down more slowly in water and soil than it does in air. It can move out 
of contaminated soil and move into groundwater. 2-Butoxyethanol does not build up in plants 
and animals. For more information on what happens to 2-butoxyethanol after it gets into the 
environment, see Chapter 5. 
2-Butoxyethanol acetate can pass into air from water and soil. It is directly released to the 
atmosphere by evaporation while it is being used as a solvent in paints, lacquers, thinners, inks, 
ink and spot removers, and resins. 2-Butoxyethanol acetate probably exists almost entirely as a 
vapor in outdoor air. It can be removed from the air by precipitation because it is moderately 
soluble in water. In air, 2-butoxyethanol acetate may also break down to other compounds within 
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air. It can move out of contaminated soil and move into groundwater. 2-Butoxyethanol acetate 
does not build up in plants and animals. For more information on what happens to 2-butoxyethanol acetate after it 
gets into the environment, see Chapter 5. 
1.3 HOW MIGHT I BE EXPOSED TO 2-BUTOXYETHANOL OR 2-BUTOXYETHANOL
 ACETATE? 
Many people are exposed to small amounts of 2-butoxyethanol and 2-butoxyethanol acetate every 
day. You can be exposed to these chemicaIs in the environment, in the workplace, and at home. 
Higher exposures usually occur in the workplace rather than in the environment or at home. The 
general population is exposed to 2-butoxyethanol and 2-butoxyethanol acetate mainly by 
breathing air or having skin contact with liquids, particularly household cleaners, that contain 
these compounds. 
You are less likely to be exposed by eating or drinking something that contains 2-butoxyethanol. 
The Food and Drug Administration has regulations to control its presence as a food contaminant. 
However, some drinking water supplies have been shown to contain 2-butoxyethanol. 
Some people have been poisoned by accidentally or intentionally drinking consumer products such 
as all-purpose liquid cleaners containing 2-butoxyethanol. Some people who work in silkscreening, 
printing, furniture production and finishing, asbestos-mastic removal, and housekeeping 
occupations that use materials containing 2-butoxyethanol have been exposed to this chemical. 
People who work in spray-painting operations, chemical production facilities, automobile repair 
shops, automobile manufacturing facilities, construction sites, and areas that have recently been 
remodeled using products that contain 2-butoxyethanol may also be exposed to this compound. 
You are most likely to be exposed to 2-butoxyethanol acetate by inhaling the vapors and by skin 
contact with liquid and vapors. Industrial exposures are most likely through inhalation of vapors, 
although excessive contact with eyes and skin may also occur. 2-Butoxyethanol acetate is used as 
a solvent in latex paints, lacquers, epoxy resins, thinners, inks, stains, and varnishes, and in ink and 
spot removers. People who use these products at work or at home can be exposed by inhaling the 
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vapors or by skin or eye contact. Exposure only occurs while these products are being used or 
while they are drying. 
1.4 HOW CAN 2-BUTOXYETHANOL AND 2-BUTOXYETHANOL ACETATE ENTER
      AND LEAVE MY BODY? 
2-Butoxyethanol and 2-butoxyethanol acetate can enter your body through your lungs when you 
breathe them. They can also enter your body through your stomach and intestines when you eat 
food or drink water that contains either one. They can enter your body through skin contact with 
liquid products such as paints, varnishes, ink and spot removers, and household cleaners. If your 
skin comes in contact with vapors of these compounds in the air, some can also enter your body 
through your skin. The amount of vapor that enters through your skin is much less than the 
amount that enters through your lungs, especially if most of your skin is covered by clothing. 
When you are exposed to high levels of 2-butoxyethanol or 2-butoxyethanol acetate in air, some 
of the compound you breathe in leaves your body when you breathe out. The remainder passes 
through the lining of your lungs and enters your bloodstream. Both can also enter your bloodstream 
from your intestines if you swallow them. They can enter your bloodstream through your 
skin if your skin comes into contact with cleaning products containing them or with the vapors in 
the air. The amount of vapor that enters through your skin is much less than the amount that 
enters through your lungs, especially if most of your skin is covered by clothing. Once in your 
bloodstream, 2-butoxyethanol and 2-butoxyethanol acetate travel through your body to many 
organs and tissues, but they don’t stay there very long. 2-Butoxyethanol and 2-butoxyethanol 
acetate are converted to products, called metabolites, in the liver. Scientists think that some of 
the effects of exposure to these chemicals are caused by metabolites. Most of the metabolites of 
2-butoxyethanol and 2-butoxyethanol acetate leave the body in the urine within 24-48 hours after 
exposure. Smaller amounts of metabolites leave the body in exhaled air and in the feces. For 
more information on how 2-butoxyethanol and 2-butoxyethanol acetate can enter and leave your 
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1.5 HOW CAN 2-BUTOXYETHANOL OR 2-BUTOXYETHANOL ACETATE AFFECT
 MY HEALTH? 
After exposure to 2-butoxyethanol or 2-butoxyethanol acetate, several factors determine whether 
harmful health effects will occur and, if they do, what the type and severity of these health effects 
might be. These factors include the amount of 2-butoxyethanol or 2-butoxyethanol acetate to 
which you are exposed and the length of time of the exposure. Other factors that must be 
considered include the other chemicals you’re exposed to and your age, sex, diet, family traits, 
lifestyle, and state of health. 
Some information about potential effects on people comes from an experiment in which men and 
women were exposed continuously to about 100 ppm or more of 2-butoxyethanol vapors in air 
for 4 or 8 hours. This level is twice as high as the occupational standard for 2-butoxyethanol. 
Some of these people reported irritation of the nose and eyes, headache, a metallic taste, or 
vomiting. None of these people had effects on blood pressure or pulse. In another experiment, 
people were exposed to 20 ppm of 2-butoxyethanol vapors in air for 2 hours. Lung tests 
(pulmonary function) and heart tests (heart rate and electrocardiogram) showed no harmful 
effects for any of these people. Exposure to these solvents in the workplace involves both 
breathing in of vapors and skin contact with the liquids and vapors. Workers are usually exposed 
to much higher levels than the levels normally encountered by the general population. 
Some information on harmful effects also comes from case reports of people who swallowed large 
amounts of cleaning agents containing 2-butoxyethanol. These harmful effects included breathing 
problems, low blood pressure, lowered levels of hemoglobin (the substance in the blood that 
carries oxygen to organs of the body), blood in the urine, and metabolic acidosis (high levels of 
acid in the body). The lowered levels of hemoglobin and blood in the urine indicate effects related 
to hemolysis, which involves destruction of red blood cells that results in the release of 
hemoglobin. Some of these people fell into a coma but recovered after successful treatment in 
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There are no data on whether 2-butoxyethanol or 2-butoxyethanol acetate cause reproductive 
effects, birth defects, or cancer in people. 
To protect the public from the harmful effects of toxic chemicals and to find ways to treat people 
who have been harmed, scientists use many tests. 
One way to see if a chemical will hurt people is to learn how the chemical is absorbed, used, and 
released by the body; for some chemicals, animal testing may be necessary. Animal testing may 
also be used to identify health effects such as cancer or birth defects. Without laboratory animals, 
scientists would lose a basic method to get information needed to make wise decisions to protect 
public health. Scientists have the responsibility to treat research animals with care and 
compassion. Laws today protect the welfare of research animals, and scientists must comply with 
strict animal care guidelines. 
Other information on the harmful effects of 2-butoxyethanol and 2-butoxyethanol acetate comes 
from animal testing. The harmful effect most often reported in animals exposed to 
2-butoxyethanol is destruction of red blood cells that results in the release of hemoglobin, which is 
known as hemolysis. Effects related to hemolysis include increased hemoglobin levels in the 
urine, blood in the urine, and the build-up of hemoglobin and destroyed red blood cells in organs 
such as the kidney, spleen, and liver. These effects have been found in monkeys, rats, mice, 
rabbits, and dogs after exposure to high levels of 2-butoxyethanol in air for short and intermediate 
periods. These effects have also been found in rats and mice that swallowed high doses of 
2-butoxyethanol for short and intermediate periods, and in rats and rabbits with skin contact for 
short periods. 2-Butoxyethanol acetate also caused these effects in rats or rabbits that breathed, 
swallowed, or had skin contact with 2-butoxyethanol acetate. Some studies showed that the red 
blood cells of animals (rats, rabbits, and baboons) are much more likely to be destroyed than the 
red blood cells of people after exposure to 2-butoxyethanol. 
Other harmful effects of 2-butoxyethanol have been seen in animals. Breathing problems occurred 
in rats and mice that breathed or swallowed large amounts of 2-butoxyethanol for short periods. 
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Bloody or reddened stomach or intestines, probably related to hemolysis, were seen in rats that 
swallowed very high doses of 2-butoxyethanol and in rabbits that had skin contact with very large 
amounts. Harmful effects on the liver and kidney were seen in some animals and may be related 
to hemolysis. 2-Butoxyethanol is also irritating to the skin and eyes of animals, as it is in people. 
2-Butoxyethanol and 2-butoxyethanol acetate do not seem to have effects on the immune system 
of animals. Like many solvents, 2-butoxyethanol causes nervous system effects in animals. Some 
rats, dogs, and rabbits developed physical weakness and unsteadiness after exposure to very high 
levels of 2-butoxyethanol in air for short periods. Some rats and mice also became sluggish, 
drowsy, or prostrate after swallowing very large doses of 2-butoxyethanol for short periods. 
Some rabbits also became inactive or prostrate, had abnormal eye movement, or had convulsions 
after skin contact with very large amounts of 2-butoxyethanol. 
2-Butoxyethanol can cause reproductive effects and birth defects in animals. Some female rats 
and rabbits that breathed in large amounts of 2-butoxyethanol while they were pregnant delivered 
fewer offspring than pregnant rats or rabbits that were not exposed. Some of the offspring had 
underdeveloped bones. Other reproductive effects and birth defects in animals have only been 
observed at doses that were toxic to the adult animals. Some female rats had changes in their 
estrous cycles after drinking water containing 2-butoxyethanol for moderate periods of time. 
Some female rats and mice had vaginal bleeding and fewer offspring after swallowing large doses 
of 2-butoxyethanol while they were pregnant. Some of the offspring of pregnant mice that 
swallowed very large doses had cleft palates. Some offspring of pregnant mice that swallowed 
large doses of 2-butoxyethanol also weighed less. 
2-Butoxyethanol does not seem to cause mutations. No studies were found that tested either 
2-butoxyethanol or 2-butoxyethanol acetate for causing cancer in animals. 
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1.6 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN
      EXPOSED TO 2-BUTOXYETHANOL OR 2-BUTOXYETHANOL ACETATE? 
Some tests can show whether you have been exposed to 2-butoxyethanol or 2-butoxyethanol 
acetate. 2-Butoxyethanol (from 2-butoxyethanol or 2-butoxyethanol acetate exposure) can be 
measured in blood and urine. In the body, both are converted to products called metabolites, such 
as 2-butoxyacetic acid. Certain metabolites of 2-butoxyethanol (2-butoxyacetic acid and others) 
can be measured in the urine. These tests will not necessarily be able to tell how much you have 
been exposed to. These tests need to be done within a day after exposure because 
2-butoxyethanol and its metabolites leave your body within 24-48 hours. Certain blood tests can 
determine if your red blood cells are damaged, but this effect is not specific for 2-butoxyethanol. 
Some of these tests may be available at your doctor’s office, or your doctor can send blood or 
urine samples to laboratories that specialize in performing these tests. If workers are exposed to 
concentrations of 5 ppm or above, the National Institute for Occupational Safety and Health 
recommends that the level of 2-butoxyacetic acid in the urine be measured. For more information 
on tests for 2-butoxyethanol exposure, see Chapters 2 and 6. 
1.7 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO
      PROTECT HUMAN HEALTH? 
The federal government develops regulations and recommendations to protect public health. 
Regulations can be enforced by law. Federal agencies that develop regulations for toxic 
substances include the Environmental Protection Agency (EPA), the Occupational Safety and 
Health Administration (OSHA), and the Food and Drug Administration (FDA). 
Recommendations provide valuable guidelines to protect public health but cannot be enforced by 
law. Federal organizations that develop recommendations for toxic substances include the 
Agency for Toxic Substances and Disease Registry (ATSDR) and the National Institute for 
Occupational Safety and Health (NIOSH). 
Regulations and recommendations can be expressed in not-to-exceed levels in air, water, soil, or 
food that are usually based on levels that affect animals; then they are adjusted to help protect 
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people. Sometimes these not-to-exceed levels differ among federal organizations because of 
different exposure times (an 8-hour workday or a 24-hour day), the use of different animal 
studies, or other factors. 
Recommendations and regulations are also periodically updated as more information becomes 
available. For the most current information, check with the federal agency or organization that 
provides it. Some regulations and recommendations for 2-butoxyethanol include the following: 
OSHA requires employers of workers who are occupationally exposed to 2-butoxyethanol to 
institute engineering controls and work practices to reduce and maintain employee exposure at or 
below the permissible exposure limit (PEL). The PEL for 2-butoxyethanol is 50 ppm. This 
regulation means that the workroom air should not contain no more than an average of 50 ppm of 
2-butoxyethanol over an 8-hour working shift of a 40-hour work week. The American 
Conference of Governmental Industrial Hygienists (ACGIH) has recommended an average 
concentration limit value of 25 ppm for occupational exposure (8-hour workday and a 40-hour 
workweek) to 2-butoxyethanol. The recommended exposure limit REL) for occupational 
exposure by NIOSH is 5 ppm for both 2-butoxyethanol and 2-butoxyethanol acetate. This 
recommendation means that the workroom air should contain no more than an average of 5 ppm 
of 2-butoxyethanol or 2-butoxyethanol acetate for up to a 10-hour working shift of a 40 hour 
workweek. OSHA recommends that workers who may be exposed to 2-butoxyethanol should 
wear personal protective equipment such as gloves, coveralls, and goggles to protect against 
exposure to the skin and eyes. 
Both 2-butoxyethanol and 2-butoxyethanol acetate are regulated under the Clean Air Act, 
including the National Emission Standards for Hazardous Air Pollutants. 
1.8 WHERE CAN I GET MORE INFORMATION? 
If you have any more questions or concerns, please contact your community or state health or 
environmental quality department or: 
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ATSDR can also tell you the location of occupational and environmental health clinics. These 
clinics specialize in recognizing, evaluating, and treating illnesses resulting from exposure to 
hazardous substances.
 * To order toxicological profiles, contact: 
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2. HEALTH EFFECTS 
2.1 INTRODUCTION 
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and other 
interested individuals and groups with an overall perspective of the toxicology of 2-butoxyethanol and 
2-butoxyethanol acetate. It contains descriptions and evaluations of toxicological studies and 
epidemiological investigations and provides conclusions, where possible, on the relevance of toxicity and 
toxicokinetic data to public health. 
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile. 
2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE 
To help public health professionals and others address the needs of persons living or working near hazardous 
waste sites, the information in this section is organized first by route of exposure─inhalation, oral, and 
dermal; and then by health effect─death, systemic, immunological, neurological, reproductive, 
developmental, genotoxic, and carcinogenic effects. These data are discussed in terms of three exposure 
periods─acute (14 days or less), intermediate (15-364 days), and chronic (365 days or more). 
Levels of significant exposure for each route and duration are presented in tables and illustrated in 
Figures. The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest-
observedadverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies. LOAELs 
have been classified into “less serious” or “serious” effects. “Serious” effects are those that evoke failure in a 
biological system and can lead to morbidity or mortality (e.g., acute respiratory distress or death). “Less 
serious” effects are those that are not expected to cause significant dysfunction or death, or those whose 
significance to the organism is not entirely clear. ATSDR acknowledges that a considerable amount of 
judgment may be required in establishing whether an end point should be classified as a NOAEL, “less 
serious” LOAEL, or “serious” LOAEL, and that in some cases, there will be insufficient data to decide 
whether the effect is indicative of significant dysfunction. However, the Agency has established guidelines 
and policies that are used to classify these end points. ATSDR believes that there is sufficient merit in this 
approach to warrant an attempt at distinguishing between “less serious” and “serious” effects. The distinction 
between “less serious” effects and “serious” effects is considered to be important because it helps the users of 
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the profiles to identify levels of exposure at which major health effects start to appear. LOAELs or NOAELs 
should also help in determining whether or not the effects vary with dose and/or duration, and place into 
perspective the possible significance of these effects to human health. 
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and figures 
may differ depending on the user’s perspective. Public health officials and others concerned with appropriate 
actions to take at hazardous waste sites may want information on levels of exposure associated with more 
subtle effects in humans or animals (LOAEL) or exposure levels below which no adverse effects (NOAELs) 
have been observed. Estimates of levels posing minimal risk to humans (Minimal Risk Levels or MRLs) may 
be of interest to health professionals and citizens alike. 
Estimates of exposure levels posing minimal risk to humans (Minimal Risk Levels or MRLs) have been made 
for 2-butoxyethanol. Insufficient data were available to estimate MRLs for 2-butoxyethanol acetate. Since 
2-butoxyethanol acetate is metabolized to the same toxic metabolite as is 2-butoxyethanol, it seems likely 
that the MRLs for 2-butoxyethanol acetate would be similar to those of 2-butoxyethanol. An MRL is defined 
as an estimate of daily human exposure to a substance that is likely to be without an appreciable risk of 
adverse effects (noncarcinogenic) over a specified duration of exposure. MRLs are derived when reliable and 
sufficient data exist to identify the target organ(s) of effect or the most sensitive health effect(s) for a specific 
duration within a given route of exposure. MRLs are based on noncancerous health effects only and do not 
consider carcinogenic effects. MRLs can be derived for acute, intermediate, and chronic duration exposures 
for inhalation and oral routes. Appropriate methodology does not exist to develop MRLs for dermal 
exposure. 
Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990a), 
uncertainties are associated with these techniques. Furthermore, ATSDR acknowledges additional 
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs. As an example, 
acute inhalation MRLs may not be protective for health effects that are delayed in development or are 
acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic bronchitis. 
As these kinds of health effects data become available and methods to assess levels of significant human 
exposure improve, these MRLs will be revised. 
A User’s Guide has been provided at the end of this profile (see Appendix B). This guide should aid in the 
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2.2.1 inhalation Exposure 
Occupational or environmental exposure to 2-butoxyethanol or 2-butoxyethanol acetate usually occurs 
through inhalation or dermal contact. Both routes of exposure are important in the industrial setting. 
Occupational exposure to 2-butoxyethanol usually involves co-exposure to other solvents and chemicals. In 
several NIOSH Health Hazard Evaluations, effects reported by workers included eye, nose, and throat 
irritation; coughing; runny nose; headache; dizziness; lightheadedness; and nausea (Apol 1981,1986; Lee 
1988). Since personal breathing zone and workplace air samples analyzed for solvents and other clremicals, 
such as toluene, xylene, methyl ethyl ketone, methyl isobutyl ketone, styrene, along with 2-butoxyethanol, 
indicated that exposure levels for each chemical were below the NIOSH, ACGIH, and OSHA criteria, NIOSH 
concluded that the effects were probably due to the additive combination of the solvents. Experimental 
studies in which humans were exposed to 2-butoxyethanol by the inhalation route, in addition to experimental 
animal studies, are discussed in this section (Section 2.2.1) and have been summarized in several publications 
(Browning and Curry 1994; EPA 1984; NIOSH 1990; Tyler 1984). Although one study was located 
regarding oral exposure of animals to the major metabolite of 2-butoxyethanol, 2-butoxyacetic acid 
(discussed in Section 2.2.2), no studies were located describing the effects of 2-butoxyacetic acid after 
inhalation exposure. 
2.2.1.1 Death 
No studies were located regarding death in humans after inhalation exposure to 2-butoxyethanol or 2-butoxy­
ethanol acetate. 
The amount of 2-butoxyethanol in air required to produce death in animals has been measured under a variety 
of conditions. Acute 4-hour LC50 (lethal concentration, 50% kill) values for Fischer 344 rats after wholebody 
exposure were determined to be 486 ppm for males and 450 ppm for females (Dodd et al. 1983). In 
another study, a 4-hour LC50 for rats was reported to be 500 ppm (Nelson et al. 1984). In addition, in a 
preliminary concentration-finding study, in which non-pregnant female Sprague-Dawley rats were exposed to 
2-butoxyethanol for 6.5 or 7 hours, death occurred in three of four rats at 450-500 ppm, in two of three rats 
at 350 ppm, and in two of three rats at 250 ppm for 7 hours (Nelson et al. 1984). Male Fischer 344 rats 
exposed to 2-butoxyethanol by nose-only inhalation at 438 ppm 2-butoxyethanol for 6 hours exhibited 50% 
(two of four) mortality (Sabourin et al. 1992a). Carpenter et al. (1956) observed death in rats at ≥375 ppm 
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deaths occurred in rats similarly exposed to ≤203 ppm for 30 days Similarly, when Fischer 344 rats were 
exposed to concentrations of 0,20,86, or 245 ppm of 2butoxyethanol for 9 days, 6 hours per day, 4-5 days 
per week, no rats died during the exposure period or the 14-day observation period (Dodd et al. 1983). 
Sprague-Dawley rats exposed to 682 ppm 2-butoxyethanol for 3 hours showed no mortality during the 
exposure or the 14-day postexposure observation period (Khmisch et al. 1988). Similarly, no Fischer 344 
rats died after 13 weeks of exposure to 77 ppm 2-butoxyethanol for 5 days per week, 6 hours per day (Dodd 
et al. 1983). An inhalation LC50 of 700 ppm was reported for mice exposed to 2-butoxyethanol for 7 hours 
(Werner et al. 1943a). C3H mice exhibited 20% (2 of 10) mortality after continuous exposure to 376 ppm 
2-butoxyethanol and 70% (7 of 10) mortality after continuous exposure to 494 ppm for 30 days (no controls 
were used), although the same strain of mice exposed to ≤400 ppm for 90 days exhibited no mortality 
(Carpenter et al. 1956). Guinea pigs seem to be less sensitive to the lethal effects of 2-butoxyethanol and 
exhibited no mortality after exposure to 691 ppm for 1 hour followed by a 14-day observation period 
(Nachreiner 1994) or to 411 ppm for up to 5 days (Dow 1986). However, Carpenter et al. (1956) reported 
death in 1 of 10 guinea pigs exposed to 376 ppm and in 2 of 10 guinea pigs exposed to 494 ppm for 7 hours 
per day, 5 days per week, for a total of 30 days. No deaths occurred at ≤203 ppm. Some studies in dogs 
have reported mortality at concentrations of 385-617 ppm, with exposures of 2-8 days or 28 days (Carpenter 
et al. 1956), whereas other reports indicate no mortality in dogs at concentrations that are similar or lower 
(Dow 1972,1986). The studies in dogs used only one or two dogs per exposure level and sometimes did not 
include a control dog. Rabbits exhibited mortality at concentrations ≥ 200 ppm after exposure for 6 or 
7 hours per day for 1-13 days (Dow 1986; Tyl et al. 1984). 
No deaths were noted in Wistar rats exposed to a saturated vapor-air mixture of approximately 400 ppm 
2-butoxyethanol acetate for 4 hours; 400 ppm for 1 month, 5 days per week, 4 hours per day; or 100 ppm for 
10 months using the same intermittent exposure regimen (Truhaut et al. 1979). No deaths were observed in 
New Zealand white rabbits exposed to 400 ppm 2-butoxyethanol acetate for 4 hours or to 100 ppm 2-butoxy-
ethanol acetate for 10 months under the same regimen as the rats. However, two of four rabbits died after 
exposure to 400 ppm 2-butoxyethanol acetate for 1 month, 5 days per week, 4 hours per day (Truhaut et al. 
1979). 
The LC50 values for rats and all LOAEL values from each reliable study for death for each species and 
duration category for 2-butoxyethanol and 2-butoxyethanol acetate are recorded in Tables 2- 1 and 2-2 and 
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2.2.1.2 Systemic Effects 
No studies were located regarding musculoskeletal, endocrine, dermal, or body weight effects in humans after 
inhalation exposure to 2-butoxyethanol. No studies were located regarding any systemic effects in humans, 
or regarding gastrointestinal, musculoskeletal, dermal, or ocular effects in animals after inhalation exposure 
to 2-butoxyethanol acetate. Available data pertaining to systemic effects of each compound are presented 
below. 
The highest NOAEL values and all reliable LOAEL values from each reliable study for systemic effects in 
each species and duration category for each compound are recorded in Tables 2-1 and 2-2 and plotted in 
Figures 2-l and 2-2. 
Respiratory Effects. Volunteers were exposed to 98, 113, or 195 ppm 2-butoxyethanol for 4-8 hours 
(Carpenter et al. 1956). The recorded responses of those exposed to 195 ppm included immediate irritation 
of the nose and throat. The subjects exposed to 113 ppm also experienced nasal irritation and a slight 
increase in nasal mucus discharge. In another study, no effects on pulmonary ventilation or respiratory 
frequency were found in seven male volunteers exposed to 2-butoxyethanol for 2 hours at the Swedish 
occupational exposure limit (20 ppm) during light physical exercise on a bicycle ergometer (Johanson et al. 
1986a). 
Respiratory effects have been observed in animals exposed to 2-butoxyethanol by inhalation for acute 
durations. In Fischer 344 rats exposed for 4 hours to 0, 202, 523, or 867 ppm 2-butoxyethanol, rapid and 
shallow breathing, followed by death, occurred at 867 ppm (Dodd et al. 1983). No respiratory effects were 
observed at ≤523 ppm. In the same study, Fischer 344 rats exposed for 9 days, 6 hours per day, 5 days per 
week to 2-butoxyethanol at 0, 20, 86, or 245 ppm exhibited audible respiration and nasal discharge in a few 
male animals only at 245 ppm (Dodd et al. 1983). Perinatal encrustation was noted in timed-pregnant female 
Fischer 344 rats exposed to 2-butoxyethanol concentrations of 100 or 200 ppm for 6 hours per day on 
gestational days 6-15 (Tyl et al. 1984). Male Swiss Webster mice exposed to a range of concentrations of 
153-1,666 ppm 2-butoxyethanol for 10-15 minutes exhibited a 20% decrease in respiratory rate at the 
lowest concentration and a 40% decrease at the highest concentration (Kane et al. 1980). The decrease in 
respiration rate occurred during the first few seconds of exposure and is an indicator of respiratory irritation. 
Male albino rabbits exposed to approximately 400 ppm 2-butoxyethanol for l-2 days at 7 hours per day 
exhibited nasal discharge and congestion of the lungs and nasal turbinates upon necropsy (Dow 1986). 
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Wetness around the nose was observed in pregnant New Zealand white rabbits exposed to 200 ppm 
2-butoxyethanol for 6 hours per day on gestational days 6-l 8 (Tyl et al. 1984). One female dog exposed 
repeatedly to 617 ppm 2-butoxyethanol for a total of 13.5 hours over 2 days exhibited moderate congestion 
of the lungs upon necropsy (Carpenter et al. 1956). Similarly, a female dog exposed to 385 ppm 2-butoxy-ethanol 
for 8 days died and was found to have severely congested and hemorrhagic lungs at necropsy. 
Clinical signs and gross necropsy observations did not reveal any adverse respiratory effects in guinea pigs 
exposed to 691 ppm (females) or 633 ppm (males) 2-butoxyethanol for 1 hour followed by a 14-day 
observation period (Nachreiner 1994). 
In intermediate-duration studies of 2-butoxyethanol, Fischer 344 rats exposed intermittently to 77 ppm for 
13 weeks showed no effects on lung weight and no histopathological lesions in the lungs (Dodd et al. 1983), 
while Sherman rats exposed to 2-butoxyethanol for 7 hours per day, 5 days per week, for a total 30 days 
exhibited congested and hemorrhagic lungs at necropsy at 432 ppm (males) and 314 ppm (females) 
(Carpenter et al. 1956). Guinea pigs also exhibited lung congestion at necropsy after intermittent exposure to 
≥ 376 ppm 2-butoxyethanol for 30 days (Carpenter et al. 1956). Severely congested and hemorrhagic lungs 
were found in one dog exposed to 385 ppm for 28 days, and slight capillary engorgement or breakdown in the 
lungs was observed upon gross necropsy (not confirmed by histological examination) of two dogs exposed to 
200 ppm for 31 days (Carpenter et al. 1956). Slightly increased nasal secretions were observed in two dogs 
exposed to 415 ppm 2-butoxyethano17 hours per day, 5 days per week, for 12 weeks (Werner et al. 1943b). 
One rhesus monkey exposed to 210 ppm 2-butoxyethanol for up to 30 days and two rhesus monkeys exposed 
to 100 ppm for 90 days exhibited no respiratory effects (Carpenter et al. 1956). 
In a study of 2-butoxyethanol acetate, Wistar rats and New Zealand white rabbits were exposed to a saturated 
vapor-air mixture of approximately 400 ppm for 4 hours, and then observed for 14 days after exposure 
(Truhaut et al. 1979). No clinical signs of respiratory distress were noted for either species. When the 
animals were sacrificed at the end of 2 weeks, no gross pathological lesions were observed in respiratory 
tissues of either rats or rabbits. No histological examinations were performed. In the intermediate-duration 
experiments in this study, in which both gross and histological examinations were performed, no respiratory 
effects were noted in either rats or rabbits after intermittent exposure (5 days per week, 4 hours per day) to 
400 ppm 2-butoxyethanol acetate for 1 month or to 100 ppm 2-butoxyethanol acetate for 10 months (Truhaut 
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Cardiovascular Effects. No adverse cardiovascular effects were observed in male volunteers exposed 
to 20 ppm 2-butoxyethanol for 2 hours during light physical exercise on a bicycle ergometer (Johanson et al. 
1986a). Specifically, no effects of exposure were noted for heart rate, and no effects were noted in the 
electrocardiograms. In an earlier study, male and female volunteers exposed to 98, 113, or 195 ppm 
2-butoxyethanol for 4-8 hours showed no adverse effects on blood pressure or pulse rate (Carpenter et al. 
1956). 
Gross necropsy did not reveal any changes in the hearts of guinea pigs exposed to 2-butoxyethanol for 1 hour 
followed by a 14-day observation period at 691 ppm for females and 633 ppm for males (Nachreiner 1994). 
No gross or histological lesions in the heart were observed in male or female Fischer 344 rats exposed to 
77 ppm 2-butoxyethanol for 6 hours per day, 7 days per week, for 13 weeks (Dodd et al. 1983) or in two 
dogs exposed to 415 ppm 7 hours per day, 5 days per week, for 12 weeks (Werner et al. 1943b) 
In a study of 2-butoxyethanol acetate, Wistar rats and New Zealand white rabbits were exposed to a saturated 
vapor-air mixture of approximately 400 ppm 2-butoxyethanol acetate for 4 hours and were then observed for 
14 days after exposure (Truhaut et al. 1979). When the animals were sacrificed at the end of 2 weeks, no 
gross pathological lesions were observed in the hearts of either rats or rabbits. No histological examinations 
were performed. In the intermediate-duration experiments in this study, in which both gross and histological 
examinations were performed, no lesions in the heart were noted in either rats or rabbits after intermittent 
exposure (5 days per week, 4 hours per day) to 400 ppm 2-butoxyethanol acetate for 1 month or to 100 ppm 
2-butoxyethanol acetate for 10 months (Truhaut et al. 1979). 
Gastrointestinal Effects. Two male volunteers exposed to 113 ppm 2-butoxyethanol for 4 hours 
experienced occasional belching (eructation), while a female volunteer exposed to 98 ppm for 8 hours 
experienced emesis after 7 hours of exposure and several times on the following day, although other male and 
female volunteers exposed to the same or higher concentrations did not react similarly (Carpenter et al. 
1956). The subject who experienced emesis, however, believed that the emesis was due to the relatively high 
chamber temperature based on her personal past experience that high temperature often caused emesis. 
One female dog, exposed repeatedly to 617 ppm 2-butoxyethanol for a total of 13.5 hours during 2 days, 
experienced emesis on both days of exposure (Carpenter et al. 1956). Similarly, a female dog exposed to 
385 ppm 2-butoxyethanol for 8 days experienced emesis several times during the first 4 days of exposure and 
died on the 8th day (Carpenter et al. 1956). Gross examination of the gastrointestinal tract did not reveal 
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adverse effects in guinea pigs exposed to 2-butoxyetbanol at 691 ppm (females) or 633 ppm (males) for 
1 hour followed by a 14-day observation period (Nachreiner 1994). Male albino rabbits exposed to 
approximately 400 ppm 2-butoxyethanol for 1-2 days at 7 hours per day exhibited hemorrhagic gastric 
ulcers upon necropsy (Dow 1986). One rhesus monkey exposed to 210 ppm 2-butoxyethanol for up to 
30 days exhibited emesis four times during the latter part of the exposure period (Carpenter et al. 1956). 
Sherman rats exposed to 2-butoxyethanol for 7 hours per day, 5 days per week, for a total 30 days exhibited 
congestion of the abdominal viscera at necropsy at 432 ppm for males and 314 ppm for females (Carpenter et 
al. 1956). Emesis and histopathological changes in the small and large intestines were not observed in two 
dogs exposed to 2-butoxyethanol at 415 ppm for 7 hours per day, 5 days per week, for 12 weeks (Werner et 
al. 1943b). 
Hematological Effects. Although hematological effects of 2-butoxyethanol exposure in animals include 
hemolysis, hemoglobinuria, and hemoglobin in the urine resulting from lysed red blood cells (Jones and Hunt 
1983), the only information regarding hematological effects in humans after inhalation exposure to 
2-butoxyethanol is negative. Male and female volunteers exposed to 98, 113, or 195 ppm 2-butoxyethanol 
for 4-8 hours showed no adverse effect on erythrocyte osmotic fragility (Carpenter et al. 1956). 
Red blood cell counts, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, 
mean corpuscular hemoglobin concentration, heptoglobin, reticulocytes, and osmotic resistance were 
measured in 31 male workers exposed to 2-butoxyethanol for l-6 years (Haufroid et al. 1997). Twenty of 
the workers were exposed to an average concentration of 0.75 ppm, and 11 workers were exposed to an 
average concentration of 0.46 ppm. The geometric mean exposure concentration for the 31 workers was 
0.6 ppm. The workers were also exposed to unspecified concentrations of methyl ethyl ketone. Studies in 
animals indicate that methyl ethyl ketone does not produce hematologic effects (ATSDR 1992). Twenty-one 
unexposed workers from the same plant matched for sex, age and smoking habits served as controls; 
however, 2-butoxyethanol concentrations in the air the controls breathed was not assayed. Urine was 
collected before the shift and at the end of the shift and assayed for free 2-butoxyacetic acid (thought to be the 
toxic metabolite), retinol binding protein, and creatinine. Rettenmeier et al. (1993) and Sakai et al. (1994) 
found that some of the 2-butoxyacetic acid (BAA) in the urine of humans is excreted as amino acid 
conjugates. Thus, free BAA in urine does not represent all internal dosing. Blood was collected and assayed 
for red blood cell counts, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, 
mean corpuscular hemoglobin concentration, haptoglobin, reticulocytes, and osmotic resistance. Serum 
alanine aminotransferase and aspartate aminotransferase were also measured. The exposed workers wore 
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gloves, thus minimizing dermal exposure. In addition, two exposure groups were combined together for the 
analysis of measured parameters. A significant correlation (r = 0.55, p = 0.0012) was observed between end 
shift free urinary 2-butoxyacetic acid concentrations and 2-butoxyethanol in air. There was no effect on red 
blood cell numeration, hemoglobin, mean corpuscular volume, mean corpuscular hemoglobin, heptoglobin, 
reticulocyte (aspartate aminotransferase, alanine aminotransferase) and renal (plasma creatinine, urinary 
retinol binding protein) parameters. Two small but statistically significant differences in hematology values 
were observed: a significant decrease (p=0.03) in hematocrit values (exposed 43.9%±2.1, range: 39.9-50.7; 
controls: 45.5%±2.7, range: 40.6-50.4) and a significant (p=0.02) increase in mean corpuscular hemoglobin 
concentration (33.6 g/dL±0.9, range: 31.8-35.6; 32.9 g/dL±l.1, range: 31.1-35.6). The differences may be 
consistent with hemolysis observed in animal studies, and may be early indicators of potential adverse effects 
in humans; however, because the changes in both hematocrit and mean corpuscular hemoglobin concentration 
were in the range of normal clinical values, the effect was considered a NOAEL. Normal clinical values of 
hematocrit are reported for males as 40-54%, with a level of 30% or less considered to indicate moderate to 
severe anemia (Fischbach 1992). Normal clinical values of mean corpuscular hemoglobin concentration are 
reported as 31-37 g hemoglobin/dL (Fischbach 1992). Increased mean corpuscular hemoglobin 
concentrations often indicate spherocytosis, while decreased mean corpuscular hemoglobin concentrations 
may indicate macrocytic anemia, chronic blood loss anemia, or pyridoxine-responsive anemia (Fischbach 
1992). The study author stated that the usefulness of hematocrit and mean corpuscular hemoglobin 
concentration as early markers of red blood cell toxicity in workers exposed to low concentrations of 2­
butoxyethanol requires further study. Based on the NOAEL of 0.6 ppm for decreased hematocrit and 
increased mean corpuscular hemoglobin concentration, a chronic-duration inhalation MRL of 0.2 ppm was 
calculated as described in the footnote to Table 2-l and in Appendix A. 
Hematological effects of 2-butoxyethanol have been observed in animals after acute and intermediate 
inhalation exposure. One male monkey and one female monkey exposed to 200 ppm 2-butoxyethanol for 
7 hours did not show any alteration of erythrocyte fragility or evidence of hemoglobinuria (Carpenter et al. 
1956). However, one rhesus monkey exposed to 210 ppm 2-butoxyethanol for up to 30 days exhibited 
elevated osmotic fragility after the fourth exposure, increased fibrinogen after the 14th day, and reduced 
erythrocyte count and hemoglobin values after 30 exposures (Carpenter et al. 1956). One male monkey and 
one female monkey exposed to 100 ppm for 90 days had transiently increased erythrocyte osmotic fragility 
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Female rats exposed to 432 ppm 2-butoxyethanol for 2-8 hours exhibited hemolysis at 2 hours, 
hemoglobinuria at 3 hours, and hemin crystalluria at 4 hours during exposure, whereas rats exposed to 
200 ppm for 7 hours per day for 9 days exhibited a decrease in red blood cell count and hemoglobin level 
(Carpenter et al. 1956). Elevation of erythrocyte fragility was seen at doses as low as 62 ppm administered to 
rats for 4 hours, or 54 ppm administered for up to 30 days (Carpenter et al. 1956). In addition, Carpenter et 
al. (1956) reported hemoglobinuria in rats after inhalation exposure to 203 ppm 2-butoxyethanol for 7 hours; 
in rats exposed to 250-800 ppm for 2-9 hours per day over l-6 days; in rats exposed to 203 ppm for 
7 hours, 5 days per week for 30 days; and in mice after inhalation exposure to 200 ppm 2-butoxyethanol for 
7 hours. Hemoglobinuria was noted in male Fischer 344 rats after 6 hours of exposure to 438 ppm (Sabourin 
et al. 1992a). 
In a study in which mice were exposed to 390-1210 ppm 2-butoxyethanol for 7 hours hemoglobinuria was 
reported (Werner et al. 1943a). The concentrations at which hemoglobinuria was observed were not stated. 
Mice exhibited increased osmotic fragility of the red blood cells after 7 hours of exposure to 100 ppm 
2-butoxyethanol, as did rabbits after exposure to 125 ppm. However, guinea pigs showed no effect of 
treatment on erythrocyte fragility after exposure to 665 ppm for 8 hours or to ≤c494 ppm for 7 hours per day 
5 days per week for 30 days, and dogs showed no effect after exposure to 665 ppm for 7 hours per day for 
2 days (Carpenter et al. 1956). C3H mice exhibited increased erythrocyte fragility after exposure to 
≥ 100 ppm for 30-90 days, as did one female dog exposed to 385 ppm for 8 days and one male dog exposed 
to 385 ppm for 28 days (Carpenter et al. 1956). Although the increase in erythrocyte fragility in the dogs was 
transient, increases in leucocyte count in the male and female dogs and fibrinogen levels in the male dog were 
also seen (Carpenter et al. 1956). In other experiments, increased osmotic fragility and leucocyte count were 
seen in one male dog and one female dog after exposure to 200 ppm for 31 days, and increased leucocyte 
counts were seen after 45 days of exposure to 100 ppm; decreased hematocrit was noted in the male dog 
throughout the exposure period of 90 days (Carpenter et al. 1956). Decreased hemoglobin and hematocrit, 
hypochromia, polychromatophilia, and microcytosis were observed in two dogs exposed to 415 ppm 
2-butoxyethanol 7 hours per day, 5 days per week, for 12 weeks (Werner et al. 1943b). 
Fischer 344 rats were exposed for 9 days, 6 hours per day, 5 days per week to 2-butoxyethanol at 0, 20, 86, 
or 245 ppm (Dodd et al. 1983). The rats were observed for signs of toxicity during exposure and for 14 days 
postexposure. There was no effect on the hematologic parameters in rats exposed to 20 ppm 2-butoxyethanol. 
At the 86-ppm exposure, both sexes exbibited a significant effect on erythroid parameters, including 
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concentration was decreased in females at 86 ppm. At the 245-ppm exposure, both male and female rats 
showed significantly depressed red blood cell count, hemoglobin, and mean corpuscular hemoglobin 
concentration and significant increases in mean corpuscular volume, nucleated red blood cell count, and 
reticulocytes. A 14-day postexposure recovery period showed substantial recovery (Dodd et al. 1983). 
Timed-pregnant Fischer 344 rats exposed to 2-butoxyethanol vapors by inhalation on gestational days 6-15 
at concentrations of 0, 25, 50, 100, or 200 ppm for 6 hours per day exhibited hemoglobinuria, reduced red 
blood cell count, reduced mean corpuscular hemoglobin concentration, increased mean corpuscular 
hemoglobin, and increased mean corpuscular volume at 100 ppm, but not at ≤ 50 ppm (Tyl et al. 1984). 
Hemoglobin concentration and hematocrit were increased at 200 ppm. In the same study, pregnant New 
Zealand white rabbits exposed on gestational days 6-l 8 to the same concentrations exhibited increased 
hemoglobin and hematocrit at 100 ppm but not at 200 ppm, suggesting to the authors a biphasic response of 
the hematological system in rabbits (Tyl et al. 1984). Based on the NOAEL of 50 ppm for hematological 
effects in rats in the study by Tyl et al. (1984), an acute inhalation MRL of 6 ppm for 2-butoxyethanol was 
calculated as described in the footnote to Table 2-l and in Appendix A. 
When rats were exposed to 5, 25, or 77 ppm 2-butoxyethanol 5 days per week, 6 hours per day, for 13 weeks, 
decreased red blood cell count was observed at 77 ppm in males and females; females also exhibited 
decreased hemoglobin and mean corpuscular hemoglobin concentration at 77 ppm (Dodd et al. 1983). Thus, 
25 ppm is the NOAEL for hematological effects in rats after intermediate-duration inhalation exposure to 
2-butoxyethanol. Based on this value, an intermediate inhalation MRL of 3.0 ppm for 2-butoxyethanol was 
calculated as described in the footnote to Table 2-l and in Appendix A. 
In a study of 2-butoxyethanol acetate, Wistar rats and New Zealand white rabbits were exposed to a saturated 
vapor-air mixture of approximately 400 ppm 2-butoxyethanol acetate for 4 hours and then observed for 
14 days after exposure (Truhaut et al. 1979). No persistent hematological effects were noted for either 
species, although rabbits exhibited slight, transient hemoglobinuria. When the animals were sacrificed at the 
end of 2 weeks, no adverse changes in hematology were observed in either rats or rabbits. In the same study, 
hemoglobinuria was noted in rats beginning 2 weeks after initiation of intermittent exposure (5 days per 
week, 4 hours per day) to 400 ppm 2-butoxyethanol acetate for 1 month, but no effect was noted in rats or 
rabbits similarly exposed to 100 ppm for 10 months (Truhaut et al. 1979). Rabbits exposed to 400 ppm 
2-butoxyethanol acetate for 1 month exhibited decreased red blood cell counts, decreased hemoglobin 
concentration, and pronounced hemoglobinuria (Truhaut et al. 1979). 
    
        
 
     
 
     
   
 
 
     
46 2-BUTOXYETHANOL AND 2-BUTOXYETHANOL ACETATE 
2. HEALTH EFFECTS 
The hemolytic effects of 2-butoxyethanol and 2-butoxyethanol acetate are reflected in changes in the spleen. 
These effects are discussed further in Section 2.2.1.3, Immunological and Lymphoreticular Effects. 
Musculoskeletal Effects. Gross lesions in bone (femur, vertebrae, joint, sternum) or skeletal muscle 
were not observed in guinea pigs exposed to 2-butoxyethanol for 1 hour followed by a 14-day observation 
period at 661 ppm for females and 633 ppm for males (Nachreiner 1994). In Fischer 344 rats exposed to 0, 
5, 25, or 77 ppm 2-butoxyethanol for 6 hours per day, 5 days per week for 13 weeks, no gross of 
histopathological lesions were found in the gastrocnemius muscle or in the sternum (Dodd et al. 1983). 
Hepatic Effects. No effects on serum alanine aminotransferase or aspartate aminotransferase were 
observed when compared to controls in 31 male workers exposed to 2-butoxyethanol for l-6 years 
(Haufroid et al. 1997). Twenty of the workers were exposed to an average concentration of 0.75 ppm, and 
11 workers were exposed to an average concentration of 0.46 ppm. The workers were also exposed to 
unspecified concentrations of methyl ethyl ketone. Twenty-one unexposed workers from the same plant 
matched for sex, age and smoking habits served as controls. 
Fischer 344 rats exposed for 9 days, 6 hours per day, 5 days per week to 2-butoxyethanol at 0, 20, 86, or 
245 ppm showed increased liver weight at ≥ 86 ppm in females and at 245 ppm in males (Dodd et al. 1983). 
Timed-pregnant Fischer 344 rats exposed to 2-butoxyethanol vapors by inhalation on gestational days 6-15 
and New Zealand white rabbits exposed on gestational days 6-18 to concentrations of 0, 25, 50, 100, or 
200 ppm for 6 hours per day exhibited no effect on liver weight (Tyl et al. 1984). Gross lesions in the liver 
were not observed in guinea pigs exposed to 2-butoxyethanol (at 661 ppm for females and 633 ppm for 
males) for 1 hour followed by a 14-day observation period (Nachreiner 1994). In male albino rabbits 
exposed to 400-411 ppm 7 hours per day for 1 or 2 days, mottled livers were observed upon necropsy (Dow 
1986). Congestion of the liver was observed at necropsy in a female dog that died following exposure to 
385 ppm 2-butoxyethanol for 8 days and in a male dog exposed to the same concentration for 28 days 
(Carpenter et al. 1956). Only one female and one male dog (both exposed to 385 ppm) were used in this 
study. 
In intermediate-duration studies, a statistically significant increase in liver weight was observed in Sherman 
rats exposed to ≥107 ppm, 7 hours per day, 5 days per week for 30 days (Carpenter et al. 1956). Cloudy 
swelling of the liver was observed in the rats exposed to 314 ppm (female) and 432 ppm (male and female). 
In C3H mice exposed for 7 hours per day, a statistically significant increase in liver weight was observed at 
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200 ppm after 60 exposure days (but not after 30 or 90 days) and at 400 ppm after 30, 60, and 90 days 
(Carpenter et al. 1956). However, no effects on liver weight and no gross or histologically observed liver 
lesions were found in guinea pigs exposed to <495 ppm for 7 hours per day, 5 days per week for 30 days. 
Gross or histopathological changes in the liver were not observed in two dogs exposed to 415 ppm 2-butoxy­
ethanol 7 hours per day, 5 days per week for 12 weeks (Werner et al. 1943b). No effects on clinical blood 
parameters and no gross or histopathological lesions were found in the livers of Fischer 344 rats exposed to 
≤77 ppm 2-butoxyethanol for 6 hours per day, 5 days per week, for 13 weeks (Dodd et al. 1983). 
In a study of 2-butoxyethanol acetate, Wistar rats and New Zealand white rabbits exposed to a saturated 
vapor-air mixture of approximately 400 ppm 2-butoxyethanol acetate for 4 hours, and then observed for 
14 days after exposure, had no gross hepatic pathological lesions when the animals were sacrificed at the end 
of 2 weeks (Truhaut et al. 1979). In the same study, no gross or histologically observed hepatic lesions were 
noted in either rats or rabbits after intermittent exposure (5 days per week, 4 hours per day) to 400 ppm for 
1 month or 100 ppm for 10 months. 
Renal Effects. No effects on serum creatinine or urinary retinol binding protein were observed in 31 male 
workers exposed to 2-butoxyethanol for l-6 years (Haufroid et al. 1997). Twenty of the workers were 
exposed to an average concentration of 0.75 ppm, and 11 workers were exposed to an average concentration 
of 0.46 ppm. The workers were also exposed to unspecified concentrations of methyl ethyl ketone. Twentyone 
unexposed workers from the same plant matched for sex, age and smoking habits served as controls. 
A common renal effect of 2-butoxyethanol exposure is hematuria, the detection of red blood cells in the urine 
(Jones and Hunt 1983). Section 2.4.2 Mechanisms of Toxicity discusses the mechanism by which this effect 
may occur. When Fischer 344 rats were exposed for 4 hours to 0, 202, 523, or 867 ppm 2-butoxyethanol, 
red discharge around the urogenital area was detected at concentrations of 523 and 857 ppm (Dodd et al. 
1983). Additionally, rats in the high- and mid-dose groups that died and were necropsied after death had red-stained 
urine in their bladders (presumably hematuria) and enlarged kidneys. This effect was not observed in 
the surviving rats in the 523-ppm group necropsied 14 days after exposure ceased. It is likelythat the red 
staining observed in the urogenital area occurred because of hematuria. In the same study, Fischer 344 rats 
were exposed for 9 days, 6 hours per day, 5 days per week to 2-butoxyethanol at 0, 20, 86, or 245 ppm 
(Dodd et al. 1983). Animals at the high concentration also exhibited red-stained urine (hematuria) after one 
or two treatments, which was not observed in the postexposure period of 14 days (Dodd et al. 1983). 
Hematuria was noted in male Wistar-derived (Alpk/Ap) rats exposed to 800 ppm for 3 hours (Doe 1984), in 
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nonpregnant female Sprague-Dawley rats exposed to 250 ppm 2-butoxyethanol for up to 7 hours, and on the 
first exposure day in pregnant Sprague-Dawley rats exposed to 150 and 200 ppm for 7 hours per day on 
gestational days 7-15 (Nelson et al. 1984). Timed-pregnant Fischer 344 rats exposed by inhalation to 
2-butoxyethanol vapor at concentrations of 0, 25, 50, 100, or 200 ppm for 6 hours per day on gestational 
days 6-15 exhibited hematuria at 100 and 200 ppm (Tyl et al. 1984). In the same study, red fluid on the tray 
paper, possibly evidence of hematuria, was observed in timed-pregnant New Zealand rabbits exposed to 
100 and 200 ppm 6 hours per day during gestation. Male albino rabbits exposed to approximately 400 ppm 
2-butoxyethanol for l-2 days at 7 hours per day exhibited darkened kidneys and hematuria (Dow 1986). 
Cloudy swelling of the convoluted tubules was observed in female rats exposed to 432 ppm 2-butoxyethanol 
for 2 hours (Carpenter et al. 1956). No effect on urine output was seen in male rats exposed to 20 or 
100 ppm 2-butoxyethanol for 12 days (Johanson 1994), or on kidney weight in pregnant rabbits exposed to 
doses up to 200 ppm during gestation (Tyl et al. 1984). In a study in which Swiss mice were exposed to 
390-1,210 ppm 2-butoxyethanol for 7 hours, interstitial nephritis was reported (Werner et al. 1943a). The 
concentrations at which nephritis was observed were not stated. Gross lesions in the kidneys were not 
observed in guinea pigs exposed to 2-butoxyethanol for 1 hour followed by a 14-day observation period at 
661 ppm for females and 633 ppm for males (Nacbreiner 1994). Gne female dog, exposed repeatedly to 
617 ppm 2-butoxyethanol for a total of 13.5 hours over 2 days exhibited congestion of the kidneys upon 
necropsy (Carpenter et al. 1956). Similar resuhs were obtained in a female dog that died after exposure to 
385 ppm 2-butoxyethanol for 8 days (Carpenter et al. 1956). The effect was not observed in the male dog 
that died after exposure to the same concentration for 28 days. This study is limited in that only one female 
dog was exposed to concentrations of 385 or 617 ppm, and only one male was used in the 385 ppm exposure 
concentration group. 
Renal effects have also been observed in animals exposed to 2-butoxyethanol in intermediate-duration 
studies. Statistically significant increases in kidney weight were observed in Sherman rats exposed to 
≥ 107 ppm and in guinea pigs exposed to ≥203 ppm for 7 hours per day, 5 days per week for 30 days 
(Carpenter et al. 1956). Cloudy swelling of the convoluted and loop tubules was observed upon necropsy of 
the guinea pigs that died at 376 and 494 ppm. No effect on kidney weight and no gross renal lesions were 
found in mice exposed to ≤400 ppm for 7 hours per day for 30-90 days. No blood or urinalysis parameters 
were affected, and no gross or histologically observed lesions in the kidneys or urinary bladder were found in 
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Gross or histopathological changes in the kidneys were not observed in two dogs exposed to 415 ppm 
2-butoxyethano17 hours per day, 5 days per week for 12 weeks (Werner et al. 1943b). 
In a study of 2-butoxyethanol acetate, Wistar rats and New Zealand white rabbits were exposed to a saturated 
vapor-air mixture of approximately 400 ppm 2-butoxyethanol acetate for 4 hours, and then observed for 
14 days after exposure (Truhaut et al. 1979). No blood was found in the urine of rats, although rabbits 
exhibited transient and slight hematuria. When the animals were sacrificed at the end of 2 weeks, no gross 
pathological lesions were observed in the renaI system of either rats or rabbits. In the same study, renal 
effects were noted in both rats and rabbits after intermittent exposure (5 days per week, 4 hours per day) to 
400 ppm 2-butoxyethanol acetate for 1 month (Truhaut et al. 1979). Hematuria and tubular nephrosis, 
ranging from cellular cloudy swelling to hemorrhagic necrosis, were noted in female rats sacrificed at the end 
of the exposure period, but not in those sacrificed 1 week after exposure ceased. Rabbits exposed for 
1 month exhibited hypertrophic kidneys filled with blood and blood-filled bladders (hematuria) at death 
during week 4. These rabbits, and those surviving to the end of the exposure period, exhibited necrotizing 
tubular nephrosis, atrophic tubular dilation, and luminar granular deposits. Effects observed in rabbits 
exposed to 100 ppm 2-butoxyethanol acetate for 10 months, 5 days per week, 4 hours per day included 
tubular nephritis with tubular enlargement, cortical atrophy, inflammatory fibrosis, and tubular Henle’s loop 
dilation. Effects in rats exposed to the same concentration for 10 months were described as similar to those 
observed in rabbits, but the lesions were more discrete and inconstant (i.e., not always present) and were 
characterized (only in males) by tubular enlargement and atrophy, nephritis, inflammatory fibrosis, dilatation 
of Henle’s loop and the distal convoluted tubules, and hyaline casts (Truhaut et al. 1979). 
Endocrine Effects. Severely hemorrhaged adrenal glands were observed at necropsy in a female dog 
that died after exposure to 385 ppm 2-butoxyethanol for 8 days (Carpenter et al. 1956). No gross or 
histologically observed lesions were found in the adrenal, parathyroid, thyroid, or pituitary in Fischer 344 rats 
exposed to ≤77 ppm, 6 hours per day, 5 days per week for 13 weeks (Dodd et al. 1983). Gross lesions in the 
pituitary, thyroid gland, pancreas, parathyroid gland, and adrenal glands were not observed in guinea pigs 
exposed to 2-butoxyethanol for 1 hour followed by a 14-day observation period at 661 ppm for females and 
633 ppm for males (Nachreiner 1994). 
In a study of 2-butoxyethanol acetate, Wistar rats and New Zealand white rabbits were exposed to 400 ppm 
2-butoxyethanol acetate for 4 hours, followed by a 14-day observation period (Truhaut et al. 1979). When 
the animals were sacrificed at the end of 2 weeks, no gross pathological lesions were observed in the adrenal 
 
 
    
50 2-BUTOXYETHANOL AND 2-BUTOXYETHANOL ACETATE 
2. HEALTH EFFECTS 
gland or pancreas of either rats or rabbits. Similarly, no gross or histologically observed lesions were noted 
in the pancreas or adrenal glands of rats and rabbits exposed for 4 hours per day, 5 days per week to 400 ppm 
of 2-butoxyethanol acetate for 1 month or to 100 ppm for 10 months (Truhaut et al. 1979). 
Dermal Effects. Nonpregnant female rats exposed to 2-butoxyethanol at concentrations of 250-500 ppm 
for up to 7 hours exhibited necrosis of the tail tip 1 week after exposure (Nelson et al. 1984). In addition, 
pregnant Fischer 344 rats exposed to 200 ppm 2-butoxyethanol for 6 hours per day during gestational 
days 6-15 exhibited necrosis of the tail tip (Tyl et al. 1984). The cause of necrosis of the tail tip was not 
clearly stated, but possibly it is associated with the effects of 2-butoxyethanol on the red blood cells, and 
subsequent vascular response. Stained fur was noted in both pregnant Fischer 344 rats dosed during 
gestational days 6-15 and pregnant New Zealand white rabbits exposed on gestational days 6-18 to 200 ppm 
2-butoxyethanol for 6 hours per day (Tyl et al. 1984). The exact cause of the stained fur was not noted. 
Ocular Effects. Male and female volunteers exposed to 98, 113, or 195 ppm 2-butoxyethanol for 
4-8 hours experienced ocular irritation during exposure to 113 and 195 ppm (Carpenter et al. 1956). 
Pregnant Fischer 344 rats exposed to 25-200 ppm during gestational days 6-15 exhibited periocular wetness 
at all concentrations, whereas New Zealand white rabbits exposed to 100 and 200 ppm, but not 25 ppm, 
2-butoxyethanol during gestation exhibited the same effect (Tyl et al. 1984). The ocular irritation in the 
human subjects and the periocular wetness in the animals were probably due to direct contact of the eyes with 
the 2-butoxyethanol vapor; these effects are also discussed in Section 2.2.3.2 for Ocular Effects. 
Ocular infections were observed in a female dog that died after 8 days and in a male dog that died after 
28 days following exposure to 385 ppm 2-butoxyethanol (Carpenter et al. 1956). It is not clear whether the 
ocular infections were due to 2-butoxyethanol exposure since no controls were included. In another 
experiment by Carpenter et al. (1956), a male and a female dog exposed to 200 ppm for 31 days showed no 
effects on the cornea after staining with fluorescein. A slight increase in ocular secretions was observed in 
2 dogs exposed to 415 ppm 2-butoxyethano17 hours per day, 5 days per week for 12 weeks (Werner et al. 
1943b). In male albino rabbits exposed to 400-411 ppm for 7 hours per day for l-2 days, a reddish ocular 
discharge accompanied by yellow discoloration of the sclera was observed upon necropsy (Dow 1986). 
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Ophthalmological examination of the eyes revealed no ocular effects in Fischer 344 rats exposed 5 days per 
week, 6 hours per day to ≤245 ppm 2-butoxyethanol for 9 days or to ≤77 ppm for 13 weeks (Dodd et al. 
1983). 
Body Weight Effects. Fischer 344 rats exposed for 4 hours to concentrations of 0, 202, 523, and 
867 ppm 2-butoxyethanol exhibited significant weight loss on the first day after exposure at concentrations 
≥ 523 ppm 2-butoxyethanol, but weight gain resumed 4 days postexposure; body weight returned to 
preexposure values between days 7-14, and continued to increase for the duration of the 14-day observation 
period (Dodd et al. 1983). Similarly, decreased weight gain was observed when male rats were exposed to 
245 ppm or female rats were exposed to 86 ppm for 9 days (Dodd et al. 1983), although no effect on body 
weight was observed in male Sprague-Dawley rats exposed to 57-58 ppm for 7 hours per day for 4 days 
(Dow 1972) or to 100 ppm 2-butoxyethanol for 12 days, 24 hours per day (Johanson 1994). However, after 
timed-pregnant Fischer 344 rats were exposed to 2-butoxyethanol vapors by inhalation on gestational 
days 6-l 5 and New Zealand white rabbits were exposed on gestational days 6-l 8 to concentrations of 0, 25, 
50, 100, or 200 ppm for 6 hours per day, reduced final body weight or reduced weight gain were observed at 
100 and 200 ppm in rats and at 200 ppm in rabbits (Tyl et al. 1984). It should be noted that the pregnant 
rats, but not the pregnant rabbits, had reduced food consumption at 100 ppm and reduced water consumption 
at 200 ppm, as discussed in Other Systemic Effects below. An unspecified weight loss was found in a female 
dog that died after exposure for 8 days and in a male dog that died after exposure for 28 days to 385 ppm; 
anorexia was observed in the female dog (Carpenter et al. 1956). However, no effects on body weight were 
found in two male dogs exposed to 400-411 ppm, 7 hours per day for l-5 days (Dow 1986). 
No effect on body weight was observed in male and female guinea pigs exposed to 633 ppm or 691 ppm 
2-butoxyethanol, respectively, for 1 hour (Nachreiner 1944). No effect on body weight was observed in male 
and female Sherman rats exposed to ≤203 ppm 2-butoxyethanol or in guinea pigs exposed to ≤495 ppm for 
7 hours per day, 5 days per week, for 30 days (Carpenter et al. 1956). However, in mice exposed for 30, 60, 
or 90 days, a significant but unspecified decrease in body weight was noted after the 60-day exposure at 
400 ppm. Two dogs exposed to 415 ppm 2-butoxyethano17 hours per day, 5 days per week, for 12 weeks 
gradually lost 6-9% of their body weight (Werner et al. 1943b). No control body weight data were provided, 
although the study authors indicated that the other dogs in the study gained weight or remained constant 
throughout the study period. In an intermediate-duration study in male and female Fischer 344 rats, female 
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unspecified decrease in body weight gain during exposure weeks 24 that was not evident at necropsy (Dodd 
et al. 1983). 
No effects on body weight were noted in Wistar rats or New Zealand white rabbits exposed intermittently 
(5 days per week, 4 hours per day) to 400 ppm 2-butoxyethanol acetate for 1 month or to 100 ppm 2-butoxyethanol 
acetate for 10 months (Truhaut et al. 1979). 
Other Systemic Effects. No effect on food or water intake was observed for male Sprague-Dawley rats 
exposed to 20 or 100 ppm 2-butoxyethanol for 24 hours per day for 12 days (Johanson 1994). 
Timed-pregnant Fischer 344 rats exposed to 2-butoxyethanol vapors by inhalation on gestational days 6-15 
at concentrations of 0, 25, 50, 100, or 200 ppm for 6 hours per day exhibited reduced food consumption at 
100 ppm and reduced water consumption at 200 ppm (Tyl et al. 1984). No effect on food or water 
consumption was observed for rabbits exposed by the same regimen on gestational days 6-l 8 (Tyl et al. 
1984). Several investigators note red staining or red fluid on cage papers or in the cages but do not further 
identify this observation (Tyl et al. 1984). Based on the observations of hematuria and hemoglobinuria by 
other investigators, it seems likely that observations of red stains or fluid represent hematuria or 
hemoglobinuria. No adverse changes were noted with respect to general appearance and appetite after 
exposure of guinea pigs and dogs to concentrations ≤58 ppm 2-butoxyethanol for 4 days, 7 hours per day 
(Dow 1972) or after exposure of guinea pigs to 400-411 ppm for l-5 days, 7 hours per day (Dow 1986). 
2.2.1.3 Immunological and Lymphoreticular Effects 
No studies were located regarding immunological and lymphoreticular effects in humans after inhalation 
exposure to 2-butoxyethanol or 2-butoxyethanol acetate. No studies were located regarding immunological 
effects in animals after inhalation exposure to 2-butoxyethanol or 2-butoxyethanol acetate. However, studies 
in animals that examined effects on lymphoreticular organs were located. 
In a study in which Swiss mice were exposed to 390-1,210 ppm 2-butoxyethanol for 7 hours,focal necrosis 
and lymphoid hyperplasia in the spleen were observed (Werner et al. 1943a). The concentrations at which 
these effects occurred were not stated. Timed-pregnant Fischer 344 rats exposed to 0, 25, 50, 100, or 
200 ppm 2-butoxyethanol by inhalation for 6 hours per day on gestational days 6-l 5 exhibited increased 
spleen weights at 200 ppm; pregnant New Zealand white rabbits exposed to the same concentrations for a 
comparable period during gestation (gestational days 6-18) showed no effect on spleen weight (Tyl et al. 
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1984). No histological examination of the spleen was performed. Gross examination did not reveal any 
effects in the spleen, thymic region, or lymph nodes in guinea pigs exposed to 2-butoxyethanol for 1 hour 
followed by a 14-day observation period at 633 ppm for males and 691 ppm for females (Nachreiner 1994). 
Histological examination of the spleen, mediastinal lymph nodes, and thymus revealed no pathological 
lesions in Fischer 344 rats exposed intermittently to <77 ppm for 13 weeks (Dodd et al. 1983). Histological 
examination did not reveal any effects in the spleen of 2 dogs exposed to 415 ppm 2-butoxyethano17 hours 
per day, 5 days per week for 12 weeks (Werner et al. 1943b). 
In a study of 2-butoxyethanol acetate, Wistar rats and New Zealand white rabbits were exposed to 400 ppm 
2-butoxyethanol acetate for 4 hours and then observed for 14 days after exposure (Truhaut et al. 1979). 
When the animals were sacrificed at the end of 2 weeks, no gross pathological lesions were observed in the 
spleen of either rats or rabbits. Similarly, no gross or histologically observed lesions were found in the 
spleens after rats and rabbits were exposed intermittently to 400 ppm of 2-butoxyethanol acetate for 1 month 
or to 100 ppm for 10 months (Truhaut et al. 1979). 
Spleen weight effects may be due to hemolysis, which is discussed under Hematological Effects. Refer to 
Section 2.4.2 Mechanisms of Toxicity for information on how this effect may occur. 
The highest NOAEL values and all LOAEL values from each reliable study for lymphoreticular effects in 
each species and duration category are recorded in Tables 2-1 and 2-2 and plotted in Figures 2-l and 2-2. 
2.2.1.4 Neurological Effects 
No studies were located regarding neurological effects in humans after inhalation exposure to 2-butoxyethanol 
acetate. Male and female volunteers exposed to 98, 113, or 195 ppm 2-butoxyethanol for 4-8 hours 
experienced headache at 98 ppm and disturbed taste sensation at 113 and 195 ppm (Carpenter et al. 1956). 
Male and female Fischer 344 rats experienced loss of coordination after exposure to 523 and 867 ppm 
2-butoxyethanol, but not to 202 ppm, for 4 hours (Dodd et al. 1983). Extreme physical weakness was 
observed in a female dog exposed to 617 ppm for 13.5 hours over 2 days, and weakness and apathy were 
observed in other dogs that died after exposure to 385 ppm for 8 days (one female) and 28 days (one male) 
(Carpenter et al. 1956). An additional study of two male beagles exposed to approximately 400 ppm 
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demeanor were observed at this or lower concentrations (Dow 1972, 1986). Male albino rabbits exhibited 
poor coordination of the extremities and loss of eqluilibrium after exposure to approximately 400 ppm 
2-butoxyethanol for 7 hours per day for 1-2 days (Dow 1986). Histological examination of the brain and 
sciatic nerve revealed no pathological lesions in Fischer 344 rats exposed to ≤77 ppm intermittently for 
13 weeks (Dodd et al. 1983). 
Wistar rats and New Zealand white rabbits exposed to 400 ppm 2-butoxyethanol acetate for 4 hours and then 
observed for 14 days after exposure showed no clinical signs of neurological effects (Truhaut et al. 1979). 
When the animals were sacrificed at the end of 2 weeks, no gross pathological lesions were observed in the 
brain of either rats or rabbits. Similarly, no clinical neurological effects and no gross or histologically 
observed lesions in brain were noted when rats and rabbits were exposed intermittently to 400 ppm of 
2-butoxyethanol acetate for 1 month or to 100 ppm for 10 months (Truhaut et al. 1979). 
The highest NOAEL values and all LOAJZL values from each reliable study for neurological effects in each 
species and duration category are recorded in Tables 2-l and 2-2 and plotted in Figures 2-l and 2-2. 
2.2.1.5 Reproductive Effects 
No studies were located regarding reproductive effects in humans after inhalation exposure to 2-butoxyethanol 
or 2-butoxyethanol acetate. 
Male Alpk/Ap (Wistar-derived) rats were exposed to 800 ppm 2-butoxyethanol for 3 hours (Doe 1984). The 
rats were then observed during exposure and throughout a subsequent 14-day observation period. On the 
15th day, animals were killed and gross macroscopic examination was conducted. No effect on testicular 
weight was observed. Effects on testicular weight were not noted in Fischer 344 rats exposed to ≤867 ppm 
for 4 hours, to ≤245 ppm intermittently for 9 days, or to ≤77 ppm intermittently for 13 weeks (Dodd et al. 
1983); histological examination of the epididymides and testes of male rats in a 13-week study revealed no 
pathological lesions. Reproductive organs of the female rats in the 13-week study by Dodd etal. (1983) were 
not examined histologically. Gross changes in male (testes, penis, seminal vesicle, epididymides, prostate) 
and female (ovaries, uterus, cervix, vagina, vulva) reproductive organs were not observed in guinea pigs 
exposed to 2-butoxyethanol for 1 hour at 633 ppm for males and 691 ppm for females, followed by a 14-day 
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Pregnant Fischer 344 rats exposed intermittently to 25-200 ppm 2-butoxyethanol during gestational 
days 6-l5 exhibited reduced maternal gravid uterine weight, a 50% decrease in viable implants and in live 
fetuses per litter, and an eight-fold increase in non-viable implants at 200 ppm, but not at the lower 
concentrations (Tyl et al. 1984). New Zealand white rabbits similarly exposed to the same concentrations on 
gestational days 6-18 also exhibited decreases in total implants and implant viability at 200 ppm (Tyl et al. 
1984). The exposure concentrations that resulted in reproductive effects following exposure of rats and 
rabbits to 2-butoxyethanol during gestation also resulted in maternal toxicity (see Section 2.2.1.2). 
Wistar rats and New Zealand white rabbits exposed to 400 ppm 2-butoxyethanol acetate for 4 hours, and 
then observed for 14 days after exposure, showed no signs of vaginal bleeding or testicular shrinkage 
(Truhaut et al. 1979). When the animals were sacrificed at the end of 2 weeks, no gross pathological lesions 
were observed in the testes or ovaries of either rats or rabbits exposed for 4 hours to 400 ppm 2-butoxyethanol 
acetate. Similarly, no gross or histologically observed lesions in the testes or ovaries were seen when 
rats and rabbits were exposed intermittently to 400 ppm of 2-butoxyethanol acetate for 1 month or to 
100 ppm for 10 months (Truhaut et al. 1979). 
The highest NOAEL values and all LOAEL values from each reliable study for reproductive effects in each 
species and duration category are recorded in Tables 2-1 and 2-2 and plotted in Figures 2-l and 2-2. 
2.2.1.6 Developmental Effects 
No studies were located regarding developmental effects in humans after inhalation exposure to 2-butoxyethanol 
or 2-butoxyethanol acetate. No studies were located regarding developmental effects in animals after 
inhalation exposure to 2-butoxyethanol acetate. 
2-Butoxyethanol was vaporized and administered at concentrations of 0, 150, or 200 ppm to pregnant rats for 
7 hours per day on gestational days 7-15 (Nelson et al. 1984). On day 20, the females were weighed and 
euthanized. The entire uterus was removed and the numbers of resorption sites and live fetuses were 
determined. Fetuses were serially removed, weighed, aud examined for visceral malformations and skeletal 
defects. No developmental effects were noted. In a similar study, timed-pregnant Fischer 344 rats were 
exposed to 2-butoxyethanol vapors by inhalation on gestational days 6-15 at concentrations of 0, 25, 50, 
100, or 200 ppm for 6 hours per day (Tyl et al. 1984). Fetuses were weighed and sexed, and evaluated for 
viability, body weight, and morphological development, including external, visceral, and skeletal 
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malformations. Fetotoxicity, observed as retarded skeletal ossification of vertebral arches or centra, 
sternebrae, or phalanges, was observed at 100 and 200 ppm, concentrations that resulted in maternal toxicity. 
For pregnant New Zealand white rabbits similarly exposed to the same concentrations on gestational 
days 6-18, fetal skeletal ossification of sternebrae and rudimentary rib was also delayed at 200 ppm but not 
at ≤ 100 ppm (Tyl et al. 1984). Gravid uterine weight was reduced and maternal toxicity was observed at 
200 ppm in rabbits (Tyl et al. 1984). 
The highest NOAEL values and all LOAEL values from each reliable study for developmental effects in each 
species in the acute-duration category are recorded in Table 2-l and plotted in Figure 2-l. 
2.2.1.7 Genotoxic Effects 
No increases in micronuclei or sister chromatid exchanges were observed in varnish production workers 
exposed to both 2-ethoxyethanol and 2-butoxyethanol (Sohnllein et al. 1993). The concentration of 
2-ethoxyethanol in the air of the workroom ranged from <0. 1-15.2 ppm, while the range for 2-butoxyethanol 
was <0.1-1.4 ppm. Postshift biological monitoring for the acetic acids in urine indicated that urinary levels 
of 2-ethoxyacetic acid (53.8 mg/L) were higher than urinary levels of 2-butoxyacetic acid (16.4 mg/L). No 
studies were located regarding genotoxic effects in animals after inhalation exposure to 2-butoxyethanol or 
2-butoxyethanol acetate. In vitro genotoxicity studies are discussed in Section 2.5. 
2.2.1.8 Cancer 
No studies were located regarding carcinogenic effects in humans or animals after inhalation exposure to 
2-butoxyethanol or 2-butoxyethanol acetate. 
2.2.2 Oral Exposure 
Oral exposure to 2-butoxyethanol or 2-butoxyethanol acetate may occur through accidental ingestion of 
contaminated food, water, or commercial products, or from intentional ingestion of commercial products 
containing these chemicals. Studies describing human oral exposure, in addition to experimental animal 
studies, are discussed in this section (Section 2.2.2) and have been summarized in several publications 
(Browning and Curry 1994; EPA 1984; NIOSH 11990; Tyler 1984). 
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2.2.2.1 Death 
No studies were located regarding death in humans after oral exposure to 2-butoxyethanol acetate, or death in 
humans or animals after oral exposure to the major metabolite, 2-butoxyacetic acid. 
An 87-year-old woman died after ingesting an unknown amount of disinfectant cleaner containing 6.5% 
2-butoxyethanol (Litovitz et al. 199 1). The other ingredients in the cleaner were not stated. Upon admission 
to the hospital the blood ethylene glycol level was 100 mg/dL. Complications included prolonged metabolic 
acidosis, hypotension, ventricular arrhythmias, hepatic and renal failure, and disseminated intravascular 
coagulation. Although the blood ethylene glycol level decreased to 10 mg/dL, she had a cardiac arrest and 
died 3 days after admission. 
Acute oral LD50 (lethal dose, 50% kill) values of 2-butoxyethanol for rats ranged from 530 to 3,000 mg/kg 
(Carpenter et al. 1956; Eastman Kodak 1988; Nelson et al. 1984; Olin 1976; Smyth et al. 1941; Union 
Carbide 1980b). In rats of an unspecified strain given 2-butoxyethanol by gavage in water, death occurred in 
three of five rats at 500 mg/kg and two of two rats at 1,000 mg/kg (Dow 1959). No deaths occurred at 
252 mg/kg. In female Fischer 344 rats, deaths occurred in two of three rats at 2,000 mg/kg, while no deaths 
occurred at ≤ 1,000 mg/kg (Dow 1981). In contrast, when male Fischer 344 rats were given 50, 100, 200, or 
400 mg/kg/day for 2 days, one of six rats died and another was moribund at 200 mg/kg/day; six of six rats 
died at 400 mg/kg/day; no rats died at ≤ 100 mg/kg/day (Smialowicz et al. 1992). When female Sprague-
Dawley female rats were treated with a single gavage dose of 1,500 mg/kg 2-butoxyethanol in water, 75% 
died (Sivarao and Mehendale 1995). When rats were treated with a non-lethal dose (500 mg/kg) followed 
7 days later by a dose of 1,500 mg/kg, only 13% died. No male Fischer 344 rats given 126 mg/kg 2-butoxyethanol 
in water by gavage died (Corley et al. 1994). Pregnant Fischer 344 rats dosed on gestational days 
9-l1 or 1l-l3 with doses of 150, 300, or 600 mg/kg/day in a preliminary dose range-finding study exhibited 
11% (1 of 9) and 17% (1 of 6) mortality within the first 24 hours at doses of 300 and 150 mg/kg/day, 
respectively (NTP 1989). Two of 6 of the pregnant rats treated on gestational days 9-l1 and 1 of 7 pregnant 
rats treated on gestational days 1l-l3 died at 600 mg/kg/day dose level. However, no mortaliiy was 
observed in the definitive study with doses ≤ 200 mg/kg/day on gestational days 9-l1 and ≤ 300 mg/kg/day 
on gestational days 11-13 (NTP 1989). Similarly, no deaths occurred in male or female Fischer 344/N rats 
dosed with ≤346 mg/kg/day or ≤265 mg/kg/day, respectively, in drinking water for 2 weeks (NTP 1993). 
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23 days, death occurred in 1 of 10 on day 13 at 443 mg/kg/day, and in 1 of 10 on day 13, and 1 of 9 on day 
23 at 885 mg/kg/day (Eastman Kodak 1983; Krasavage 1986). 
Acute oral LD50 values for mice were reported to be 1,230 mg/kg (Carpenter et al. 1956) and 1,519 mg/kg 
(Eastman Kodak 1988). When time-mated CD-l mice were treated by gavage on gestational days 6-l 3 with 
1,180 mg/kg/day 2-butoxyethanol, death occurred in 4 of 35 pregnant mice and 6 of 15 nonpregnant mice 
(Hardin et al. 1987; Schuler et al. 1984). In a similar study in mated CD-l mice given 0, 350, 650, 1,000, 
1,500, or 2,000 mg/kg 2-butoxyethanol by gavage on gestational days 8-14, three of six died at 
1,500 mg/kg/day and six of six died at 2,000 mg/kg/day (Wier et al. 1987). In Swiss CD-l mice given 
2-butoxyethanol in drinking water at doses ≤ 12,750 mg/kg/day for 2 weeks, deaths were observed in two of 
eight males and five of eight females at 12,750 mg/kg/day (Heindel et al. 1990). None of the mice died at 
doses ≤6,375 mg/kg/day. No deaths were observed in B6C3F1 mice dosed with ≤627 mg/kg/day for males or 
≤ 1,364 mg/kg/day for females in drinking water for 2 weeks (NTP 1993). 
Acute oral LD50 values for other species were reported to be 1,200 (Carpenter et al. 1956; Smyth et al. 1941) 
and 1,414 mg/kg (Shepard 1994b) for guinea pigs and 320-370 mg/kg for rabbits (Carpenter et al. 1956). 
In intermediate-duration studies of 2-butoxyethanol, no deaths occurred in male or female Sherman rats dosed 
with ≤ 1540 mg/kg/day in the diet for 90 days (Carpenter et al. 1956), in Fischer 344/N rats dosed with 
≤452 mg/kg/day for males and ≤470 mg/kg/day for females in drinking water for 13 weeks (NTP 1993), in 
male Fischer 344/N rats dosed with ≤443 mg/kg/day in drinking water for 60 days (NTP 1993), or in an 
unspecified strain of rats dosed with ≤976 mg/kg/day in the diet for 91-93 days (Weil and Carpenter 1963). 
Similarly, no deaths occurred in B6C3F1 mice dosed with ≤694 mg/kg/day (males) or ≤ 1,306 mg/kg/day 
(females) for 13 weeks (NTP 1993). However, in Swiss CD-l mice given 0, 700, 1,300, or 2,000 mg/kg/day 
in drinking water for 21 weeks, deaths occurred in 1 of 20 females at 700 mg/kg/day, 6 of 20 females at 
1,300 mg/kg/day, and 13 of 20 females at 2,000 mg/kg/day (Heindel et al. 1990). None of the male mice 
died. In addition, deaths occurred in five of five male JCL-ICR mice dosed with 2,000 mg/kg/day by gavage 
5 days per week for 5 weeks (Nagano et al. 1979, 1984). No deaths occurred in the mice given lower doses 
(≤ 1,000 mg/kg/day). 
Mortality data for 2-butoxyethanol acetate are limited to LD50 values. In Wistar rats given an oral dose of 
2-butoxyethanol acetate in olive oil by gastric intubation, the LD50 values were determined to be 3,000 mg/kg 
for males and 2,400 mg/kg for females (Truhaut et al. 1979). 
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The LD50 values and all LOAEL values from each reliable study for death in each species and duration 
category are recorded in Tables 2-3 and 2-4 and plotted in Figures 2-3 and 2-4. 
2.2.2.2 Systemic Effects 
No studies were located regarding gastrointestinal, musculoskeletal, endocrine, dermal, or body weight effects 
in humans, or metabolic effects in animals following oral exposure to 2-butoxyethanol. No reliable studies 
were located describing systemic effects in humans or animals following oral exposure to 2-butoxyethanol 
acetate. One study, Truhaut et al. (1979), gives some data for oral exposure regarding respiratory, 
cardiovascular, hematological, hepatic, renal, and endocrine effects, but does not specify the doses given. The 
data from that study have been included in this section for reference. Only one study (Foster et al. 1987) 
described systemic effects of 2-butoxyacetic acid after oral exposure in animals, consisting of hepatic, renal, 
and body weight effects. Available data pertaining to systemic effects of all three compounds are presented 
below. 
The highest NOAEL values and all LOAEL values from each reliable study for systemic effects in each 
species and duration category are recorded in Tables 2-3 and 2-5 and plotted in Figures 2-3 and 2-5. 
Respiratory Effects. A male patient who was an abuser of alcohol and had a history of trichloroethylene 
ingestion was admitted to the hospital after ingestion of 500 mL of a household cleaning fluid, Glassex 
(Bauer et al. 1992). The concentration of 2-butoxyethanol as determined by gas-chromatography was 9.1% 
(45.5 g), equivalent to a dose of 650 mg/kg. Diffuse pulmonary edema was noted. In another case report, a 
woman was admitted to the hospital after ingesting 250-500 mL window cleaner containing 12% 2-butoxyethanol 
(Rambourg-Schepens et al. 1988). The estimated dose was 467-933 mg/kg. The woman was 
ventilating poorly and required a respirator for 5 days after admittance. Similarly, a woman who ingested 
25-30 g (391-469 mg/kg) 2-butoxyethanol contained in a window cleaning agent exhibited obstructive 
respiration and was placed on a respirator upon admission to the hospital (Gijsenbergh et al. 1989). 
However, two children who accidentally ingested a window cleaning agent containing 3 or 24 mL 
2-butoxyethanol(270 or 1,862 mg/kg 2-butoxyethanol) showed no respiratory effects (Dean and Krenzelok 
1992). Gastric emptying by administration of syrup of ipecac or by gastric lavage within minutes or hours of 
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Animals also exhibit abnormal breathing after ingestion of high doses of 2-butoxyethanol. Female 
Fischer 344 rats had rapid, shallow, or difficult breathing after a single gavage dose of 2,000 mg/kg 
2-butoxyethanol (Dow 1981) or a single gavage dose of 4,510 or 9,019 mg/kg (Union Carbide 1980b). The 
2,000-mg/kg dose resulted in the death of two of three of the rats treated (Dow 198 l), while all rats (five in 
each group) treated with 4,510 mg/kg or 9,019 mg/kg died (Union Carbide 1980b). Rats (Wistar, Sherman, 
and Carworth-Wistar) also exhibited congested or hemorrhaged lungs at death after a gavage dose of 
530 mg/kg (Carpenter et al. 1956). However, no overt respiratory effects were seen in Fischer 344 rats or 
B6C3F1 mice after ingestion of 2-butoxyethanol at doses of ≤346 mg/kg/day (males) or ≤265 mg/kg/day 
(females) for rats and ≤ 627 mg/kg/day (males) or ≤ 1,364 mg/kg/day (females) for mice in drinking water for 
2 weeks (NTP 1993). Pregnant Fischer 344 rats exhibited dyspnea after oral dosing by gavage in a 
preliminary teratology study with 600 mg/kg/day 2-butoxyethanol on gestational days 9-l1 or 1l-13 (NTP 
1989). In the definitive study, no respiratory effects were noted at doses ≤200 mg/kg/day on gestational days 
9-l 1 or ≤ 300 mg/kg/day on gestational days 11-13 (NTP 1989). However, in mated CD-1 mice given 0, 
350, 650, 1,000, 1,500, or 2,000 mg/kg/day 2-butoxyethanol by gavage on gestational days 8-14, abnormal 
breathing was observed at doses of 1,500 and 2,000 mg/kg/day (Wier et al. 1987). These doses resulted in 
the deaths of three of six mice at 1,500 mg/kg/day and six of six mice at 2,000 mg/kg. 
In intermediate-duration studies, no overt signs of respiratory effects were found in male and female Sherman 
rats after ingestion of ≤ 1,540 mg/kg/day 2-butoxyethanol in the feed for 90 days (Carpenter et al. 1956). No 
overt signs of respiratory effects and no gross or histologically observed lung or nasal cavity lesions were 
observed in male COBS CD (SD)BR rats receiving 885 mg/kg/day by gavage for 6 weeks (Eastman Kodak 
1983; Krasavage 1986) or in Fischer 344 rats receiving doses ≤452 mg/kg/day (males) and ≤470 mg/kg/day 
(females) or B6C3F1 mice receiving ≤694 mg/kg/day (males) and ≤ 1,306 mg/kg/day (females) in drinking 
water for 13 weeks (NTP 1993). In addition, no histopathological lesions were found in the nasal turbinates 
of rats or mice in the NTP (1993) 13-week drinking water study. Histopathological changes in the lungs were 
not observed in DW Albino rats treated with 2-butoxyethanol at doses up to 919 mg/kg/day for males and 
976 mg/kg/day for females (Weil and Carpenter 1963). 
Rats given unspecified acute oral doses of 2-butoxyethanol acetate in olive oil as part of a lethality study 
exhibited no adverse respiratory clinical signs or gross or histopathological changes in the lungs (Truhaut et 
al. 1979). 
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Cardiovascular Effects. An 87-year-old woman died from cardiac arrest 3 days after she ingested an 
unknown amount of a cleaner containing 6.5% 2-butoxyethanol (Litovitz et al. 1991). Before death she also 
experienced hypotension and ventricular tachycardia and arrhythmias. Ingestion of 2-butoxyethanol has been 
associated with cardiovascular effects including tachycardia, and low blood pressure in a patient who ingested 
650 mg/kg (Bauer et al. 1992) and low blood pressure in a patient who ingested 391 mg/kg (Gijsenbergh et 
al. 1989). However, in another case report of a woman who ingested 467-933 mg/kg, no noticeable 
cardiovascular effects were observed (Rambourg-Schepens et al. 1988). In addition, two children who 
accidentally ingested 290 or 1,862 mg/kg 2-butoxyethanol did not exhibit adverse cardiovascular effects 
(Dean and Krenzelok 1992). Gastric emptying by administration of syrup of ipecac or by gastric lavage 
within minutes or hours of ingestion (time not specified) may have prevented any adverse effects. 
2-Butoxyethanol does not appear to cause cardiovascular effects in animals after oral exposure. In 
Fischer 344 rats receiving ≤ 346 mg/kg/day (males) and ≤ 265 mg/kg/day (females) and in B6C3F1 mice 
receiving ≤ 627 mg/kg/day (males) and ≤ 1,364 mg/kg/day (females) in the drinking water for 2 weeks, no 
changes in the heart weight and no gross pathological lesions were observed in hearts (NTP 1993). Similarly, 
in Fischer 344 rats receiving ≤ 452 mg/kg/day (males) and ≤ 470 mg/kg/day (females) and in B6C3F1 mice 
receiving ≤ 694 mg/kg/day (males) and ≤ 1,306 mg/kg/day (females) in the drinking water for 13 weeks, no 
changes in heart weight and no gross or histologically observed lesions were observed in the heart or the aorta 
(NTP 1993). No effects on heart weight and no histopathological lesions in the heart were observed in adult 
male COBS CD (SD)BR rats given undiluted 2-butoxyethanol by gavage at doses of 0, 222, 443, or 
885 mg/kg/day, 5 days per week, over a 6-week period (Eastman Kodak 1983; Krasavage 1986). 
Cardiovascular effects were not observed in DW Albino rats provided with 2-butoxyethanol in the drinking 
water for 91-93 days at doses of 919 mg/kg/day for males and 976 mg/kg/day for females (Weil and 
Carpenter 1963). 
Male and female rats given acute oral doses of 2-butoxyethanol acetate in olive oil as part of a lethality study 
exhibited no adverse cardiovascular clinical signs or gross or histopathological lesions in the heart (Truhaut 
et al. 1979). 
Gastrointestinal Effects. Very little information is available to describe gastrointestinal effects of 
2-butoxyethanol by oral exposure. Wistar rats exhibited distended stomachs filled with liquid and gas, and 
bloody intestines at necropsy after single gavage doses of 2,255-9,019 mg/kg 2-butoxyethanol (Union 
Carbide 1980b). At 2,244 mg/kg, two of five rats died, while five of five rats died at each of the two highest 
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doses (4,510 and 9,019 mg/kg). Very red small intestines were noted 1 of 10 male Wistar rats after a single 
gavage dose of 2,560 mg/kg 2-butoxyethanol, a dose that resulted in the death of 9 of 10 treated animals 
(Olin 1976). Moderate-to-mild necrosis and hemorrhage of the gastric mucosa were observed in one of five 
male guinea pigs and one of five female guinea pigs treated with a single gavage dose of 1,000 mg/kg 
2-butoxyethanol in water, a dose that resulted in the death of one of each sex; the contribution of the gavage 
procedure to these gastric effects is unclear, since there were no controls in this experiment (Shepard 1994b). 
Male COBS CD (SD)BR rats showed mild hyperkeratosis and acanthosis of the stomach after gavage doses 
of 222-885 mg/kg/day 2-butoxyethanol, 5 days per week, for 6 weeks (Eastman Kodak 1983; Krasavage 
1986). No gross pathological or histopathological lesions were found in the esophagus, cecum, colon, 
duodenum, jejunum, or ileum. No gross or histopathological changes were observed in the esophagus, 
stomach, duodenum, or colon of DW Albino rats treated with 2-butoxyethanol in the diet for 3 months at 
doses up to 919 mg/kg/day for males and 976 mg/kg/day for females (Weil and Carpenter 1963). Diarrhea 
was noted in Fischer 344 rats receiving 452 mg/kg/day (males) and 470 mg/kg/day (females) 2-butoxyethanol 
in the drinking water for 13 weeks, although this effect was not observed at lower doses 
(≤ 367 mg/kg/day) (NTP 1993). In the same study, B6C3F1 mice ingesting ≤694 mg/kg/day (males) and 
≤ 1,306 mg/kg/day (females) 2-butoxyethanol in the drinking water for 13 weeks did not develop diarrhea. In 
addition, gross and histological examination of the esophagus, cecum, colon, rectum, duodenum, jejunum, 
ileum, and stomach of the rats and the mice in the 13-week drinking water study revealed no lesions. 
Hematological Effects. A male patient who was an abuser of alcohol and had a history of 
trichloroethylene ingestion was admitted to the hospital after ingesting 650 mg/kg 2-butoxyethanol. He 
exhibited nonhemolytic anemia, low prothrombin time (longer time to clotting), and thrombopenia (Bauer et 
al. 1992). Progressive erythropenia and hemoglobinuria were noted after a woman ingested 467-933 mg/kg 
2-butoxyethanol (Rambourg-Schepens et al. 1988), and a decrease in blood hemoglobin was noted in a 
woman who ingested 391-469 mg/kg 2-butoxyethanol (Gijsenbergh et al. 1989). Hemodialysis, used in two 
of these cases (Bauer et al. 1992; Gijsenbergh et al. 1989), may have contributed to hematological effects. 
Intravascular coagulation was observed in an 87-year-old women who died of cardiac arrest 3 days after 
ingesting an unknown amount of cleaner containing 6.5% 2-butoxyethanol (Litovitz et al. 1991). Two 
children who accidentally ingested 290 or 1,862 mg/kg 2-butoxyethanol exhibited no adverse hematological 
effects (Dean and Krenzelok 1992). Gastric emptying by administration of syrup of ipecac or by gastric 
lavage within minutes or hours of ingestion (time not specified) may have prevented any adverse effects. 
Hematologic effects were also not observed in a man who ingested two doses of a concentrated glass cleaner 
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occasion he ingested 1,341 mg/kg. After both doses, this case report indicates that the man was treated with 
hemodialysis and ethanol. The treatment occurred within 8 hours of the second ingestion, but it is unclear 
from this report how much time elapsed between the first ingestion and treatment and whether there might 
have been hematological consequences had these treatments not taken place. 
Hemolysis and hemoglobinuria are common observations in animals treated orally with 2-butoxyethanol for 
acute durations (Carpenter et al. 1956; Corley et al. 1994; Dow 1959; Ghanayem and Sullivan 1993; 
Ghanayem et al. 1987a, 1987b, 1990b, 1992; Grant et al. 1985; NTP 1989). After Wistar, Sherman, and 
Cat-worth-Wistar rats were given single doses of 2-butoxyethanol by gavage, hemoglobinuria was observed in 
male rats at 3,000 mg/kg and in female rats at 1,500 mg/kg (Carpenter et al. 1956). These doses are in the 
range of the LD50 given by Carpenter et al. (1956). Male Fischer 344 rats receiving a single dose of 
500 mg/kg 2-butoxyethanol by gavage exhibited bemolysis of erythrocytes accompanied by a drastic increase 
in the concentration of free hemoglobin in the plasma (Ghanayem et al. 1987b); hemoglobinuria was 
observed in all rats. In the same experiment, rats receiving a single dose of 125 mg/kg 2-butoxyethanol 
exhibited the same effects, although to a lesser degree. Hematology profiles of male Fischer 344 rats treated 
with single doses of 125-500 mg/kg 2-butoxyethanol by gavage indicated changes at ≥ 125 mg/kg that are 
characteristic of hemolysis, including increased hematocrit, packed cell volumes, and mean cell volume, 
followed by a decrease in these parameters as hemolysis progressed (Ghanayem et al. 1990b). In male 
Fischer 344 rats given 250 mg/kg 2-butoxyethanol by gavage, hemolysis was noted, characterized by an 
increase in mean cell volume and hematocrit, followed by a decline in hemoglobin concentration and red 
blood cell count (Ghanayem and Sullivan 1993). Mean corpuscular hemoglobin and mean corpuscular 
hemoglobin concentration initially increased and then declined. In the same study, guinea pigs dosed once 
with 250 mg/kg 2-butoxyethanol had no adverse hematological effects. In a metabolism study, in which male 
Fischer 344 rats received radiolabeled 2-butoxyethanol at doses of 8.6 and 126 mg/kg by gavage in water, 
two rats in the high-dose group exhibited hemolysis and hemoglobinuria (Corley et al. 1994). These effects 
were not observed in rats that received 8.6 mg/kg. 
In another study in male Fischer 344 rats that received 125 mg/kg/day 2-butoxyethanol by gavage for 1, 2, 3, 
6, or 12 consecutive days, hemolytic anemia was noted after treatment for 1-3 days, but subsided with longer 
exposure (Ghanayem et al. 1992). In the same study, 125 mg/kg 2-butoxyethanol was administered to rats 
for 3 days; the animals were then allowed to recover for 7 days. Additional treatment with 125 or 250 mg/kg 
2-butoxyethanol caused a decrease in red blood cell count and hemoglobin. In male rats that were first bled 
and then allowed a 7-day recovery period, increased hematocrit and reticulocytes were observed in these rats 
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after treatment with 125 mg/kg 2-butoxyethanol. The purpose of the bleeding/recovery experiment was to 
assess the effect of 2-butoxyethanol on a hematopoietic system that was already responding to a depletion of 
red blood cells (Ghanayem et al. 1992). That pretreatment with 2-butoxyethanol is protective has also been 
shown by Sivarao and Mehendale (1995). In this study, blood taken from rats 7 days after treatment with a 
single gavage dose of 500 mg/kg 2-butoxyethanol in water was less sensitive to the hemolytic effects of the 
2-butoxyethanol metabolite, 2-butoxyacetic acid, than blood taken 21 days after treatment. 
Male Fischer 344 rats treated by gavage with 500 mg/kg/day 2-butoxyethanol for 4 days showed reduced red 
blood cell count and hemoglobin and increased mean corpuscular volume, reticulocyte counts, and mean 
corpuscular hemoglobin, with bone marrow hyperplasia (Grant et al. 1985). Pregnant Fischer 344 rats 
exhibited increased reticulocyte counts, mean corpuscular volume, mean corpuscular hemoglobin, and platelet 
count, and decreased red blood cell count, hemoglobin, hematocrit, and mean corpuscular hemoglobin 
concentration after oral dosing in a preliminary teratology study with 150 mg/kg/day 2-butoxyethanol on 
gestational days 9-11 or 11-13, or on gestational day 20 (NTP 1989). In the definitive study, similar effects 
were noted at 100 mg/kg/day on gestational days 9-11 or gestational days 11-13 (NTP 1989). 
In a study showing the age-dependent hemolytic effects of 2butoxyethano1, young (4-5 weeks) and adult 
(9-13 weeks, 5-6 months, and 16 months) F344 rats were dosed with 0, 32, 63, 125, 250, or 500 mg/kg 
2-butoxyethanol in water by gavage (Ghanayem et al. 1987a). Hematotoxicity of 2-butoxyethanol was 
monitored for 48 hours. In younger rats, 125 mg/kg caused no effect on hematological parameters. At 
500 mg/kg, red blood cell count, hemoglobin, and hematocrit were decreased, although not as much as in the 
older rats. In older (9-13 weeks) rats, 2-butoxyethanol at 125 mg/kg caused severe acute hemolytic anemia 
resulting in significant decreases at 8 and 24 hours after treatment in red blood cell count, hemoglobin, and 
hematocrit, and increases 8 hours after administration in the concentration of free plasma hemoglobin. At 
4 hours, peak increases in free plasma hemoglobin were seen in both younger (4-5 weeks) and older 
(9-13 weeks) rats dosed with 500 mg/kg. Older rats (9-13 weeks) were more susceptible to the hematotoxic 
effects of 2-butoxyethanol. Secondary to the hemolytic effects, 2-butoxyethanol also caused hemoglobinuria. 
The onset of the development of hemoglobinuria paralleled the observed decline in the concentration of free 
hemoglobin in the plasma. In the 32-, 63-, and 125-mg/kg dose groups, 100% of the 16-month-old rats 
developed hemoglobinuria; hemoglobinuria was not monitored in 16-month-old rats receiving 250 or 
500 mg/kg. At 6 months of age, 63 and 125 mg/kg caused hemoglobinuria; the same effect was not seen in 
younger rats (4-l 3 weeks) until doses reached 125 mg/kg. Further, both the hemolytic effects and the 
secondary effects of 2-butoxyethanol were age-dependent, with older (5-16 months) rats being more sensitive 
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than younger (4-13 weeks) rats. Young rats (4-5 weeks old) and adult rats (9-13 weeks old) were treated 
with 500 mg/kg 2-butoxyethanol and reticulocytes and leukocytes were counted up to 48 hours after 
treatment. Adult (9-13 weeks old) rats exhibited neutrophilic leukocytosis and mild lymphopenia within 
4 hours. This was not detected at 48 hours. An absolute increase in reticulocyte count occurred at 48 hours 
after dosing. In young (4-5 weeks old) rats, an absolute increase in total leukocyte, band neutrophils, 
lymphocytes, and monocytes was observed at 48 hours, but there was no significant effect on reticulocyte 
count. Based on the LOAEL of 32 mg/kg for hematological effects in the aged rats in the study by 
Ghanayem et al. (1987a), an acute oral MRL of 0.4 mg/kg,/day was calculated as described in the footnote to 
Table 2-3 and in Appendix A. 
Hematological effects reflecting hemolysis have also been found in animals after intermediate-duration oral 
exposure to 2-butoxyethanol. In adult male COBS CD (SD)BR rats given undiluted 2-butoxyethanol by 
gavage at doses of 0, 222, 443, or 885 mg/kg/day, 5 days per week, over a 6-week period, dose-related 
decrease in red blood cell counts and hemoglobin and dose-related increase in mean corpuscular hemoglobin 
and hemoglobinuria were observed at all doses (Eastman Kodak 1983; Krasavage 1986). In a similar study, 
male JCL-ICR mice exhibited a decrease in red blood cell count after oral doses of 500 and 1,000 mg/kg/day 
of 2-butoxyethanol 5 days per week for 5 weeks (Nagano et al. 1979,1984). However, while no evidence of 
blood or hemoglobin pigments were found in the urine of male and female Sherman rats after ingestion of 
≤ 1,540 mg/kg/day 2-butoxyethanol in the feed for 90 days (Carpenter et al. 1956), methods were poorly 
discussed, and data were not shown. Decreased red blood cell count and mild anemia were noted in male 
Fischer 344 rats receiving ≥ 281 mg/kg/day 2-butoxyethanol, but not ≤129 mg/kg/day, and red blood cell 
count, hematocrit, and hemoglobin were decreased in female rats receiving ≤82 mg/kg/day (lowest dose in 
females) in the drinking water for 13 weeks (NTP 1993). No hematological effects were observed in male 
rats receiving 69 mg/kg/day (lowest dose in males). Hematological evaluations were not performed in the 
B6C3F1 mice ingesting ≤ 694 mg/kg/day (males) and ≤ 1,306 mg/kg/day (females) 2-butoxyethanol in the 
drinking water for 13 weeks (NTP 1993). 
Male and female Wistar rats given unspecified acute oral doses of 2-butoxyethanol acetate in olive oil as part 
of a lethality study exhibited severe hemoglobinuria (Truhaut et al. 1979). 
The hemolytic effects of 2-butoxyethanol and 2-butoxyethanol acetate in animals have been associated with 
changes in the spleen, including increased weight, engorgement, and increased hematopoiesis. These effects 
are discussed further in Section 2.2.2.3, Immunological and Lymphoreticular Effects. 
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Musculoskeletal Effects. Male Wistar rats given single oral doses of 2,560, or 5,000 mg/kg exhibited 
muscle flaccidity at 2,560 and 5,000 mg/kg (Glin 1976), doses which resulted in the death of 9 of 10 and 
10 of 10 rats, respectively. Histological examination of thigh muscles and bones revealed no pathological 
lesions in Fischer 344 rats receiving doses of ≤452 mg/kg/day (males) and ≤470 mg/kg/day (females) and in 
B6C3F1 mice receiving doses of ≤ 694 mg/kg/day (males) and < 1,306 mg/kg/day (females) 2-butoxyethanol 
in drinking water for 13 weeks (NTP 1993). 
Hepatic Effects. No adverse hepatic effects were noted in a woman who ingested 467-933 mg/kg 
2-butoxyethanol (Rambourg-Schepens et al. 1988). However, abnormal liver function (increase in aspartate 
aminotransferase) was noted in a man who had ingested 650 mg/kg 2-butoxyethanol (Bauer et al. 1992). The 
man was known to abuse alcohol and trichloroethylene, which probably contributed strongly to the abnormal 
liver function. In a man who ingested two doses of a concentrated glass cleaner containing 2-butoxyethanol 
12 days apart, increased serum alanine aminotransferase, aspartate aminotransferase, and bilirubin were 
observed following the first ingestion (1,006-1,341 mg/kg) but not following the second ingestion 
(1,341 mg/kg) (Gualtieri et al. 1995). After both doses, this case report indicates that the man was treated 
with hemodialysis and ethanol; the treatment occurred within 8 hours of the second ingestion, but it is unclear 
how much time elapsed between the first ingestion and treatment and whether there might have been further 
hepatic effects had this treatment not taken place. Hepatic failure was reported in an 87-year-old woman 
who died of cardiac arrest 3 days after ingesting an unknown volume of glass cleaner containing 6.5% 
2-butoxyethanol (Litovitz et al. 199 1). 
Hepatic effects have been observed in animals exposed orally to 2-butoxyethanol. Mottled livers were 
observed in Wistar, Sherman, and Car-worth-Wistar rats that died after receiving ≥530 mg/kg by gavage 
(Carpenter et al. 1956). Young (4-5 weeks) and adult (9-13 weeks) Fischer 344 rats were dosed with 0, 32, 
63, 125, 250, or 500 mg/kg 2-butoxyethanol by gavage and then killed at 24 and 48 hours after dosing. The 
livers were weighed, fixed, and examined for histopathological lesions (Ghanayem et al. 1987a). 
Histopathological results were presented for the control, 125-, 250-, and 500-mg/kg dose groups. Secondary 
to the hemolytic effects, 2-butoxyethanol also caused histopathologic changes in the liver, consisting of focal 
coagulative necrosis of hepatocytes in one of six adult rats at 250 mg/kg and in five of six adult rats at 
500 mg/kg; no effects were seen in young rats even at 500 mg/kg. This effect of 2-butoxyethanol was age-, 
dose- and time-dependent, with older rats being more sensitive. The hepatic effects were more severe at 
24 hours after treatment and showed some recovery by 48 hours after treatment. Phagocytized hemoglobin 
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in hemoglobin degradation. However, although phagocytized hemoglobin was frequently present in or next 
to areas of focal necrosis, the role of phagocytized hemoglobin, if any, in the mechanism of this necrosis is 
not known. Male Fischer 344 rats receiving 500 mg/kg 2-butoxyethanol by gavage exhibited similar effects 
on hepatic tissue (Ghanayem et al. 1987b). Dark livers were observed at the necropsy of male Wistar rats 
that had been given one dose of 1,310 mg/kg (Olin 1976) or 2,255 mg/kg (Union Carbide 1980b) 2-butoxyethanol 
by gavage. In male Fischer 344 rats that received 125 mg/kg/day 2-butoxyethanol by gavage for 1, 2, 
3, 6, or 12 consecutive days, a slight decrease in relative liver weight was noted after dosing for 3 or 6 days, 
followed by a slight increase after dosing for 12 days (Ghanayem et al. 1992). An increase in liver weight 
was also noted in male Fischer 344 rats after a gavage dose of 500 mg/kg/day 2-butoxyethanol for 4 days 
(Grant et al. 1985). However, no effects on liver weight and no gross pathological hepatic effects were seen 
in Fischer 344 rats receiving ≤346 mg/kg/day (males) and ≤265 mg/kg/day (females) or in B6C3F1 mice 
receiving ≤ 627 mg/kg/day (males) and ≤ 1,364 mg/kg/day (females) of 2-butoxyethanol in drinking water for 
2 weeks (NTP 1993). 
Pregnant Fischer 344 rats exhibited decreased absolute liver weight 24 hours after oral dosing in a 
preliminary teratology study at 300 and 600 mg/kg/day 2-butoxyethanol on gestational days 9-l 1 or 11-13 
(NTP 1989). In the definitive study, decreased absolute maternal liver weight was noted at termination on 
gestational days 12 or 20 after dosing with 200 mg,Q/day on gestational days 9-l 1 and at termination on 
gestational day 14 after dosing with 300 mg/kg/day on gestational days 11-13 (NTP 1989). 
Hepatic effects have also been observed in animals after intermediate oral exposure to 2-butoxyethanol. An 
unspecified increase in relative liver weight was reported for Sherman rats that received 1,540 mg/kg/day in 
the diet for 90 days (Carpenter et al. 1956). Absolute, but not relative, liver weight was only slightly 
increased (5%) in male Sprague-Dawley rats that received 180 mg/kg/day in the drinking water for 21 days 
(Exon et al. 1991). No increase in liver weight was observed in the female rats at ≤444 mg/kg/day or in the 
males at 506 mg/kg/day. Furthermore, histological examination of livers revealed no pathological lesions. In 
DW Albino rats treated with 2-butoxyethanol in the diet for 91-93 days, relative liver weights were increased 
by 25% in males at 9 19 mg/kg/day and 27% in females at 976 mg/kg/day (Weil and Carpenter 1963). This 
effect may have been associated with decreased body weight gain and food consumption. No effects on liver 
weight were noted at lower doses (188 mg/kg/day males, 222 mg/kg/day females), nor were any 
histopathological changes observed at any dose. 






    
2-BUTOXYETHANOL AND 2-BUTOXYETHANOL ACETATE 106 
2. HEALTH EFFECTS 
Adult male COBS CD (SD)BR rats given ≤885 mg/kg/day 2-butoxyethanol for 6 weeks showed increased 
relative, but not absolute, liver weight in all dose groups (≥222 mg/kg/day) (Eastman Kodak 1983;Krasavage 
1986). Histological examination of livers revealed hemosiderin deposition in the liver at 
≥443 mg/kg/day and hepatocytomegaly at 885 mg/kg/day. Statistically significant increases were found for 
serum alkaline phosphatase at ≥443 mg/kg/day and for serum alanine aminotransferase at 885 mg/kg/day. 
In Fischer 344 rats exposed to 2-butoxyethanol in the drinking water for 13 weeks, no treatment-related 
changes in liver weight were observed (NTP 1993). Clinical chemistry evaluation revealed significantly 
increased levels of serum alkaline phosphatase in males (452 mg/kg/day) at 3 weeks and in females (363 and 
470 mg/kg/day) at 13 weeks, and significantly increased levels of serum alanine aminotransferase in males 
(452 mg/kg/day) and in females (363 and 470 mg/kg/day) at 13 weeks . The increase in alkaline phosphatase 
levels is consistent with mild cholestasis, while increased serum alanine aminotransferase levels are consistent 
with hepatocellular necrosis. Histological examination of the livers revealed hepatocellular alterations 
(hepatocytes that stained more eosinophilic and lacked the amphophilic to basophilic granularity of the 
cytoplasm) at all doses (≥69 mg/kg/day for males and ≥ 82 mg/kg/day in females); centrilobular hepatocellular 
degeneration in males at ≥281 mg/kg/day and in females at ≥ 304 mg/kg/day; and brown to green 
granular pigment staining strongly positive for iron in Kupffer cell cytoplasm in males at 452 mg/kg/day and 
in females at ≥ 151 mg/kg/day. These lesions, particularly in the females, displayed both increased doserelated 
incidence and increased dose-related severity. In contrast, no hepatic effects or gall bladder lesions 
were found in B6C3F1 mice ingesting ≤ 694 mg/kg/day (males) and ≤ 1,306 mg/kg/day (females) 2-butoxy-ethanol 
in the drinking water for 13 weeks (NTP 1993). Furthermore, no adverse effects on liver weight or 
histopathology in the liver were noted in Swiss CD-1 male and female mice dosed with 1,300 mg/kg/day 
2-butoxyethanol in the drinking water for 25 weeks (Heindel et al. 1990). However, the low- and high-dose 
mice (700 and 2,000 mg/kg/day, respectively) were not necropsied. When the offspring of these mice in the 
700-mg/kg/day dose group were continued on the same treatment beginning at weaning and evaluated after 
14 weeks, liver weight was significantly increased by 8% above the control value. Based on the LOAEL of 
69 mg/kg/day for hepatic effects in male rats in the 13-week drinking study by NTP (1993), an intermediate 
oral MRL of 0.07 mg/kg/day was calculated as described in the footnote to Table 2-3 and in Appendix A. 
Histological examination of the livers revealed no pathological lesions in male and female Wistar rats given 
unspecified acute oral doses of 2-butoxyethanol acetate in olive oil as part of a lethality study (Truhaut et al. 
1979). 
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No histopathological lesions were found in the livers of male Alpk/AP (Wistar-derived) rats that were dosed 
once by gavage with 0, 174, 434, or 868 mg/kg 2-butoxyacetic acid (Foster et al. 1987). 
Renal Effects. Intentional ingestion of 2-butoxyethanol by humans has been associated with renal 
toxicity. Renal failure was reported in an 87-year-old woman that died of cardiac arrest 3 days after ingesting 
an unknown amount of cleaner containing 6.5% 2-butoxyethanol (Litovitz et al. 1991). A male patient who 
was an abuser of alcohol and had a history of trichloroethylene ingestion was admitted to the hospital after 
ingesting 650 mg/kg 2-butoxyethanol contained in a household cleaning product; he exhibited slight 
albuminuria upon admission (Bauer et al. 1992). Similarly, a woman who ingested 467-933 mg/kg 
2-butoxyethanol (also in window cleaner) developed oxahuia and a transient rise in serum creatinine 
(Rambourg-Schepens et al. 1988). Another female patient developed hematuria after ingesting 
391-469 mg/kg 2-butoxyethanol, and also exhibited increased urinary excretion of oxalic acid, although 
within normal limits (Gijsenbergh et al. 1989). All three patients recovered after supportive therapy. In 
contrast, two children who accidentally ingested 290 or 1,862 mg/kg 2-butoxyethanol showed no adverse 
renal effects (Dean and Krenzelok 1992). Gastric emptying by administration of syrup of ipecac or by gastric 
lavage within minutes or hours of ingestion (time not specified) may have prevented any adverse effects. 
Renal effects were not observed in a man who ingested two doses (first dose, 1,006-1,341 mg/kg; second 
dose, 1,341 mg/kg) of a concentrated glass cleaner containing 2-butoxyethanol 12 days apart (Gualtieri et al. 
1995). The details about how renal function was measured were not provided in this case report. After both 
doses, the man was treated with hemodialysis and ethanol; the treatment occurred within 8 hours of the 
second ingestion, but it is unclear from this report how much time elapsed between first ingestion and 
treatment and whether there might have been renal consequences had this treatment not taken place. 
Renal effects, including hematuria, have been observed in animals after acute oral exposure to 2-butoxyethanol. 
Severely congested kidneys have been observed in rats that died after gavage doses of ≥ 530 mg/kg 
(Carpenter et al. 1956). Dark and/or enlarged kidneys were observed in male Wistar rats that received one 
dose of 1,310 mg/kg. Hematuria was observed in Wistar rats that received one dose of 2,560 or 5,000 mg/kg 
(Olin 1976) or ≥2,255 mg/kg in rats that died (Union Carbide 1980b). Hematuria was also observed in an 
unspecified strain of rats given 500 or 1,000 mg/kg, but not 250 mg/kg, by gavage (Dow 1959) and in female 
Sprague-Dawley rats given 500 mg/kg (Sivarao and Mehendale 1995). Young (4-5 weeks) and adult 
(9-13 weeks) male Fischer 344 rats were dosed with 0, 32, 63, 125, 250, or 500 mg/kg 2-butoxyethanol by 
gavage; animals were killed at 24 and 48 hours after treatment and the kidneys were weighed, fixed, and 
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125-,250-, and 500-mg/kg dose groups. Secondary to the hemolytic effects, 2-butoxyethanol also caused 
histopathologic changes in the kidney, consisting of hemoglobin casts in the proximal tubules in 100% of the 
mature rats at ≥125 mg/kg; no effects were seen in young (4-5 weeks old) rats even at 500 mg/kg. The 
effects on the kidney in the mature rats were more severe at 24 hours after treatment and showed some 
recovery at 48 hours after treatment. Thus, this effect of 2-butoxyethanol was age-, dose-, and timedependent, 
with older rats being more sensitive. Male Fischer 344 rats receiving 500 mg/kg 2-butoxyethanol 
by gavage exhibited similar effects in the kidney (Ghanayem et al. 1987b). 
Pregnant Fischer 344 rats exhibited urethral bleeding, which may represent hematuria, after oral dosing by 
gavage in a preliminary teratology study at 600 mg/kg/day (but not at ≤ 300 mg/kg/day) 2-butoxyethanol on 
gestational days 9-l 1 or 11-13 (NTP 1989). In the definitive study, no kidney effects were noted at doses up 
to 200 mg/kg/day on gestational days 9-l 1 or 300 mg/kg/day on gestational days 11-13 (NTP 1989). 
Increased kidney weight has been observed in animals after acute oral exposure to 2-butoxyethanol. Male 
rats were given 2-butoxyethanol orally for 4 consecutive days at 500 or 1,000 mg/kg/day (Grant et al. 1985). 
Animals were killed on days 1, 4, 8, and 22 after the final treatment. Increased kidney weight was observed 
at the high dose, but histological examination of the kidneys revealed no pathological lesions. No effects on 
kidney weight and no gross pathological lesions in the kidney were seen in Fischer 344 rats at 
≤346 mg/kg/day (males) or ≤265 mg/kg/day (females) or in B6C3F1 mice at ≤627 mg/kg/day (males) or 
≤ 1,364 mg/kg/day (females) in drinking water for 2 weeks (NTP 1993). 
Renal effects have also been observed in animals after intermediate-duration oral exposure to 2-butoxyethanol. An 
unspecified, but statistically significant, increase in relative kidney weight was observed in 
Sherman rats at a dose of 1,540 mg/kg/day in the diet for 90 days (Carpenter et al. 1956). In DW Albino rats 
treated with 2-butoxyethanol in the diet for 91-93 days, relative kidney weights were increased by 18% in 
males at 919 mg/kg/day and 23% in females at 976 mg/kg/day (Weil and Carpenter 1963). This effect may 
have been associated with decreases in body weight gain and food consumption. No effects on kidney weight 
were noted at lower doses (188 mg/kg/day males, 222 mg/kg/day females), nor were any histopathological 
changes observed at any dose. No dose-related effects of treatment on kidney weight and no histopathological 
lesions in the kidney were observed in Sprague-Dawley rats at ≤506 mg/kg/day (males) and 
≤444 mg/kg/day (females) 2-butoxyethanol in the drinking water for 21 days (Exon et al. 1991). After a 
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exhibited focal hemosiderin accumulation in the proximal tubules at 443 and 885 mg/kg/day (Eastman Kodak 
1983; Krasavage 1986). 
In Fischer 344 rats exposed to 2-butoxyethanol in the drinking water for 13 weeks, no treatment-related 
effects on kidney weight were observed (NTP 1993). Clinical chemistry and urinalysis revealed increases in 
blood urea nitrogen in males at ≥69 mg/kg/day at week 3 and at ≥281 mg/kg/day at week 13 and in females 
at ≥ 304 mg/kg/day at week 3 and ≥ 151 mg/kg/day at week 13; increases in blood creatinine in females at 
≥304 mg/kg/day at week 13; decreases in total blood protein in males at ≥281 mg/kg/day at week 13 and in 
females at ≥151 mg/kg/day at weeks 3 and 13; decreases in blood albumin in males at ≥281 mg/kg/day at 
week 13 and in females at ≥363 mg/kg/day at week 3 and at ≥304 mg/kg/day at week 13; decreased urine 
volume in females at ≥82 mg/kg/day at week 13; and increased specific gravity of the urine in males at 
≥69 mg/kg/day and in females at ≥151 mg/kg/day at week 13. Histological examination of the kidneys and 
urinary bladders of the rats revealed no pathological lesions. No renal effects (including no effects on kidney 
weight or clinical chemistry and urinalysis parameters, and no histopathological lesions in the kidney or 
urinary bladder) were found in B6C3F1 mice in the same study at ≤694 mg/kg/day (males) and 
≤ 1,306 mg/kg/day (females) 2-butoxyethanol in the drinking water for 13 weeks (NTP 1993). However, an 
increase in kidney weight, although with no histopathological kidney lesions, was observed at 
1,300 mg/kg/day in a reproductive toxicity study in which Swiss mice were given 2-butoxyethanol in the 
drinking water for 25 weeks; animals from the low- and high-dose groups (700 and 2,000 mg/kg/day) were 
not necropsied (Heindel et al. 1990). When the offspring of these mice in the 700-mg/kg/day dose group 
were continued on the same treatment beginning at weaning and evaluated after 14 weeks, there was also an 
increase in kidney weight. 
Male and female Wistar rats given unspecified acute oral doses of 2-butoxyethanol acetate in olive oil as part 
of a lethality study exhibited renal effects including hematuria, tubular nephrosis, cloudy swelling of cells, 
dilatation of the proximal and distal convoluted tubules, and acute inflammation of the interstitial tissue 
(Truhaut et al. 1979). 
In Alpk/AP (Wistar-derived) rats dosed once by gavage with 0, 174, 434, or 868 mg/kg 2-butoxyacetic acid, 
hematuria was noted at 868 mgLkg but not at the lower doses (Foster et al. 1987). 
Endocrine Effects. Very few data are available to describe endocrine effects of 2-butoxyethanol by oral 
exposure. Wistar rats exhibited red adrenal glands, which may be related to the hemolytic effects of 
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2-butoxyethanol, at necropsy after single gavage doses of 2,255-9,019 mg/kg (Union Carbide 1980b). It 
should be noted that two of five rats treated with 2,255 mg/kg and all rats treated with higher doses died. 
Male COBS CD (SD)BR rats showed no histopathologic changes in pancreas, adrenal glands, pituitary, 
thyroid, or parathyroid after oral exposure to doses of ≤885 mg/kg/day 2-butoxyethanol for 6 weeks, 5 days 
per week (Eastman Kodak 1983; Krasavage 1986). No adverse histological effects were noted in the adrenal 
glands, pancreas, thyroid, or parathyroid of DW Albino rats fed 2-butoxyethanol in the diet for 91-93 days at 
doses up to 919 mg/kg/day for males and 976 mg/kg/day for females (Weil and Carpenter 1963). No adverse 
histopathological effects on endocrine glands (including adrenal, pancreas, parathyroid, pituitary, and thyroid) 
were noted in Fischer 344 rats at ≤ 452 mg/kg/day (males) and 1470 mg/kg/day (females) or in B6C3F1 mice 
at ≤ 694 mg/kg/day (males) and ≤ 1,306 mg/kg/day (females) (NTP 1993). 
Male and female Wistar rats given unspecified acute oral doses of 2-butoxyethanol acetate in olive oil as part 
of a lethality study exhibited no histopathological changes in the pancreas or adrenal glands (Truhaut et al. 
1979). 
Dermal Effects. Female Fischer 344 rats exhibited rough hair coats and necrosis of the tail after a single 
dose of 1,000 mg/kg 2-butoxyethanol (Dow 1981). Necrosis of the tail tip may have been a vascular 
response to the toxic effects of 2-butoxyethanol on red blood cells. Rough coat was also observed in rats that 
died after receiving ≥530 mg/kg (Carpenter et al. 1956). Male Wistar rats exhibited piloerection after single 
doses of ≥1,310 mg/kg of 2-butoxyethanol by gavage (Olin 1976). Pregnant Fischer 344 rats exhibited pale 
coloration after oral dosing in a preliminary teratology study with 600 mg/kg/day 2-butoxyethanol on 
gestational days 9-11 or 11-13 (NTP 1989). In the definitive study, no dermal effects were noted at 
≤200 mg/kg/day on gestational days 9-11 or ≤300 mg/kg/day on gestational days 11-13 (NTP 1989). 
Histological examination of skin revealed no treatment-related dermal lesions in Fischer 344 rats at 
≤452 mg/kg/day (males) and ≤470 mg/kg/day (females) or in B6C3F1 mice at ≤694 mg/kg/day (males) and 
≤ 1,306 mg/kg/day (females) in drinking water for 13 weeks (NTP 1993). 
Ocular Effects. A woman who ingested 391-469 mg/kg 2-butoxyethanol exhibited isoco& light 
reactive mydriasis upon admission to the hospital (Cijsenbergh et al. 1989). This resolved quickly after 
supportive therapy. 
Female Fischer 344 rats exhibited palpebral closure after a single gavage dose of 2,000 mg/kg 2-butoxyethanol, a 
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chromodacryorrhea after oral dosing in a preliminary teratology study with 600 mg/kg/day 2-butoxyethanol 
on gestational days 9-l 1 or 11-13 (NTP 1989). In the definitive study, no ocular effects were noted at 
≤200 mg/kg/day on gestational days 9-l 1 or ≤300 mg/kg/day on gestational days 11-13 (NTP 1989). 
Histological examination of the eyes revealed no pathological lesions in male COBS CD (SD)BR rats dosed 
by gavage with ≤885 mg/kg/day 2-butoxyethanol for 6 weeks (Eastman Kodak 1983; Krasavage 1986), in 
Fischer 344 rats given 2-butoxyethanol in drinking water at ≤452 mg/kg/day (males) and .≤470 mg/kg/day 
(females) for 13 weeks, or in B6C3F1 mice given 2-butoxyethanol in drinking water at ≥694 mg/kg/day 
(males) and ≤1,306 mg/kg/day (females) for 13 weeks (NTP 1993). 
Body Weight Effects. Reduced body weight has been observed in animals after acute oral exposure to 
2-butoxyethanol. While female Fischer 344 rats given single gavage doses of 2-butoxyethanol ≤2,000 mg/kg 
were reported to gain weight during the post-treatment observation period, no controls were used for 
comparison (Dow 1981). Guinea pigs treated with a single gavage dose of 500, 1,000 or 2,000 mg/kg 
2-butoxyethanol were reported to gain weight during a 14-day observation period (Shepard 1994b), but no 
controls were used in this study. In male Fischer 344 rats, a gavage dose of 1,000 mg/kg/day for 4 days 
resulted in reduced body weight gain compared with controls (Grant et al. 1985). No effect on body weight 
was seen in male Fischer 344 rats that received 2-butoxyethanol in drinking water at ≤346 mg/kg/day for 
2 weeks, but the female rats displayed a decrease in body weight gain during exposure and decreased final 
body weight at 265 mg/kg/day but not at ≤ 203 mg/kg/day (NTP 1993). The decrease in body weight gain 
may have been related to decreased water consumption. Male Swiss mice lost 31% of their initial body 
weight at 12,750 mg/kg/day 2-butoxyethanol administered in the drinking water for 2 weeks (Heindel et al. 
1990). No weight loss was observed in the male mice at ≤2,550 mg/kg/day. The female mice were reported 
to respond similarly, but the degree of weight loss and the doses associated with the weight loss were not 
reported. No effect on body weight was observed in B6C3F1 mice at ≤627 mg/kg/day (males) and 
≤ 1,364 mg/kg/day (females) of 2-butoxyethanol in the drinking water for 2 weeks (NTP 1993). 
Pregnant Fischer 344 rats exhibited decreased gestational weight gain in a preliminary teratology study at 
≥150 mg/kg/day 2-butoxyethanol on gestational days 9-11 or 11-13 (NTP 1989). The decreased gestational 
weight gain may have been related to decreases in food and water intake. In the definitive study, gestational 
weight gain was reduced at 200 mg/kg/day in the pregnant rats treated on gestational days 9-11 and at 
300 mg/kg/day in the pregnant rats treated on gestational days 11-13 (NTP 1989). The decreased 
gestational weight gain may have been related to decreases in food and water intake. In a developmental 
study in which pregnant CD-l mice were given 0, 350, 650, 1,000, 1,500, or 2,000 mg/kg/day 2-butoxy­
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ethanol by gavage on gestational days 8-14 to determine prenatal responses, or 0, 650, or 1,000 mg/kg/day 
on gestational days 8-14 to determine postnatal responses, unspecified decreases in maternal body weight 
gain were reported at 2,000 mg/kg/day in the prenatal experiment and at 1,000 mg/kg/day in the postnatal 
experiment (Wier et al. 1987). Similarly, in another developmental study, pregnant CD-1 mice given a dose 
of 1,180 mg/kg/day on gestational days 6-l 3 exhibited an 80% decrease in body weight gain (Hardin et al. 
1987; Schuler et al. 1984). 
Effects on body weight have also been observed in animals exposed orally to 2-butoxyethanol for 
intermediate durations. An unspecified decrease in body weight gain was reported for Sherman rats that 
received 1,540 mg/kg/day in drinking water for 90 days (Carpenter et al. 1956). In DW Albino rats treated 
with 2-butoxyethanol in the diet for 91-93 days, body weight gain was decreased by 53% in males at 
919 mg/kg/day, and 45% in females at 976 mg/kg/day (Weil and Carpenter 1963). Body weight gain was 
decreased by as much as 91% at day 1 of the study (on day 1) in males at 188 mg/kg/day, but was only 9% 
lower than controls by the end of the study. The l88-mg/kg/day dose in males, and the 976-mg/kg/day dose 
in females, was also associated with about an 18% decrease in food intake. No effects on body weight gain 
were noted at 28 mg/kg/day in males and 222 mg/kg/day in females. Decreased body weight gain in the 
presence of reduced food consumption occurred in male COBS CD (SD)BR rats given 885 mg/kg/day by 
gavage for 6 weeks (Eastman Kodak 1983; Krasavage 1986). While no effect on body weight was observed 
in Sprague-Dawley rats given ≤506 mg/kg/day (males) and ≤444 mg/kg/day (females) in drinking water for 
21 days (Exon et al. 1991), decreased body weight gain was noted in male Fischer 344 rats treated for 
60 days at 443 mg/kg/day 2-butoxyethanol and in Fischer 344 rats treated for 13 weeks at ≥367 mg/kg/day 
(males) and ≥363 mg/kg/day (females) with 2-butoxyethanol in drinking water (NTP 1993). The decreased 
body weight gain may have been related to decreased water consumption. 
Swiss mice that were exposed to 0, 700, 1,300, or 2,100 mg/kg/day 2-butoxyethanol in the drinking water for 
25 weeks exhibited decreased terminal body (at the end of the 25 week treatment period) weight at 
1,300 mg/kg/day in females but not in males; the low- and high-dose groups were not evaluated (Heindel et 
al. 1990). The decreased body weight may have been related to decreased water consumption.When the 
offspring of these mice in the 700-mg/kg/day dose group were continued on the same treatment beginning at 
weaning and evaluated after 14 weeks, there was no effect on body weight. No effect on body weight was 
observed in B6C3F1 mice at ≤694 mg/kg/day (males) or ≤ 1,306 mg/kg/day (females) 2-butoxyethanol in 
drinking water for 13 weeks (NTP 1993). 
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Groups of male Alpk/AP (Wistar-derived) rats were dosed once by gavage with 0, 174, 434, or 868 mg/kg 
2-butoxyacetic acid (Foster et al. 1987). Body weight gain was decreased during the first 2 days after 
treatment at all doses, but returned to normal by day 14. 
Metabolic Effects. Metabolic acidosis was reported in an 87-year-old woman who died of cardiac arrest 
3 days after she ingested an unknown amount of a cleaner containing 6.5% 2-butoxyethanol (Litovitz et al. 
1991). Ethylene glycol levels were 110 mg/dL in this patient shortly after hospital admission and 10 mg/dL 
3 days later. A male patient, who had a history of alcohol and trichloroethylene abuse, was admitted to the 
hospital after ingestion of 500 mL of a household cleaning fluid containing 2-butoxyethanol, which was 
equivalent to a dose of 650 mg/kg (Bauer et al. 1992). Metabolic acidosis and hypoxemia with lactic acidosis 
were observed. In other case reports, a woman admitted to the hospital after ingesting 250-500 mL of a 
window cleaner containing 12% (467-933 mg/kg) 2-butoxyethanol developed metabolic acidosis and 
hypokalemia (Rambourg-Schepens et al. 1988) and a woman ingesting 391-469 mg/kg 2-butoxyethanol 
developed metabolic acidosis (Gijsenbergh et al. 1989). Significant acid-base disturbance, not described 
further in this case report, was observed in a man following ingestion of 1,006-l ,341 mg/kg 2-butoxyethanol 
in a concentrated glass cleaner (Gualtieri et al. 1995). A second ingestion of the glass cleaner (1,341 mg/kg 
2-butoxyethanol) 12 days later did not result in metabolic disturbances. After both doses, the man was 
treated with hemodialysis and ethanol; the treatment occurred within 8 hours of the second ingestion, but it is 
unclear from this report how much time elapsed between the first ingestion and treatment and how the 
treatment affected the observed outcome. Two children who ingested 290 or 1,862 mg/kg 2-butoxyethanol 
did not exhibit evidence of metabolic acidosis during a 24-hour observation period following gastric 
emptying (Dean and Krenzelok 1992). Metabolic acidosis is likely due to the formation of butoxyacetic acid 
from 2-butoxyethanol (see section 2.3.3 Metabolism). 
Other Systemic Effects. Decreased water consumption was seen in Fischer 344 rats ingesting 
2-butoxyethanol at ≥ 152 mg/kg/day (females) and ≥242 mg/kg/day (males) in drinking water for 2 weeks 
(NTP 1993). In B6C3Fr mice treated similarly, decreased water consumption was seen in female mice at 
≥ 150 mg/kg/day. In the same study, male mice receiving ≥370 mg/kg/day exhibited signs of dehydration. 
An unspecified decrease in fluid intake was reported for male and female Swiss mice at ≥ 1,275 mg/kg/day of 
2-butoxyethanol administered in drinking water for 2 weeks (Heindel et al. 1990). 
Pregnant Fischer 344 rats exhibited decreased food and water intake at ≥150 mg/kg/day and were cold to the 
touch at 600 mg/kg/day after gavage dosing in a preliminary teratology study with 2-butoxyethanol on 
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gestational days 9-11 or 11-13 (NTP 1989). In the definitive study, decreased food and water intake were 
noted at doses of 200 mg/kg/day on gestational days 9-l 1 or 300 mg/kg/day on gestational days 11-13 (NTP 
1989). 
Sprague-Dawley rats given ≤ 506 mg/kg/day 2-butoxyethanol in drinking water for 21 days exhibited 
decreased water consumption at the high dose (506 mg/kg/day for males and 444 mg/kg/day for females) 
(Exon et al. 1991). In male COBS CD (SD)BR rats, 885 mg/kg/day 2-butoxyethanol administered by gavage 
for 6 weeks caused decreased food consumption (Eastman Kodak 1983; Krasavage 1986). In Fischer 344 
rats given 2-butoxyethanol in drinking water for 13 weeks, decreased water consumption was observed at 
≥129 mg/kg/day (males) and ≥151 mg/kg/day (females) (NTP 1993). In B6C3F1 mice similarly exposed at 
≤694 mg/kg/day (males) and ≥ 1,306 mg/kg/day (females), average water consumption was variable, and no 
clear treatment-related patterns were evident. However, an unspecified decrease in water consumption was 
reported for male and female Swiss mice at 700 mg/kg/day 2-butoxyethanol administered in drinking water 
for up to 25 weeks (Heindel et al. 1990). Decreased food intake was observed DW albino rats treated with 2­
butoxyethanol in the diet (Weil and Carpenter 1963). Food intake was about 18% lower than controls in 
males fed 188 mg/kg/day and 23% lower than controls in females fed 976 mg/kg/day. No effects on food 
intake were observed at 28 mg/kg/day in males or at 222 mg/kg/day in females. 
Staining of the perineal region was observed in female Fischer 344 rats given single gavage doses of 
≥130 mg/kg 2-butoxyethanol (Dow 1981). In a developmental study, in which pregnant CD-l mice were 
given 350, 650, 1,000, 1,500, or 2,000 mg/kg/day on gestational days 8-14, a green-brown or red-brown 
staining of cage papers was observed at ≥650 mg/kg/day (Wier et al. 1987). At 1,500 and 2,000 mg/kg/day, 
green or red vaginal discharge was also observed. These effects were most likely the result of hematuria, 
hemoglobinuria, or vaginal bleeding (see Section 2.2.2.5), although the investigators did not draw this 
conclusion in their publications. 
2.2.2.3 Immunological and Lymphoreticular Effects 
No studies were located regarding immunological or lymphoreticular effects in humans after oral exposure to 
2-butoxyethanol or 2-butoxyethanol acetate. No studies were located regarding immunological effects in 
animals after oral exposure to 2-butoxyethanol acetate. No studies were located regarding immunological or 
lymphoreticular effects in animals or humans after oral exposure to 2-butoxyacetic acid. 
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Information on immunological effects of 2-butoxyethanol in animals exposed orally to 2-butoxyethanol is 
limited to one acute and one intermediate study. Male Fischer 344 rats were immunized with trinitrophenyl­
lipopolysaccharide (TNP-LPS) and then dosed by gavage (4 and 28 hours after immunization) to 0, 50, 100, 
200, or 400 mg/kg/day 2-butoxyethanol in distilled water for 2 consecutive days (Smialowicz et al. 1992). 
Three days later, the primary plaque-forming cell (PFC) response to TNP-LPS was determined. The PFC 
response to TNP-LPS was used to evaluate B-lymphocyte antibody production. No toxic effect of 2­
butoxyethanol in the immune system was detected. In Sprague-Dawley rats, in which males received doses of 
180 or 506 mg/kg/day 2-butoxyethanol and females received doses of 204 or 444 mg/kg/day 2-butoxyethanol 
in the drinking water for 21 days, serum samples were analyzed for antibody levels to keyhole limpet 
hemocyanin (KLH), and spleens were used as the cell source to assess natural killer cell cytotoxicity and 
interleukin 2 and interferon production. In addition, the weights of thymus and spleen were determined and 
thymuses were examined histologically. For antigen presentation, KLH was injected subcutaneously in the 
base of the tail 7 days after the beginning of treatment with 2-butoxyethanol and again on day 13 to initiate 
an IgG antibody response. On day 20, KLH was injected into the right footpad to assess the 24-hour delayed-type 
hypersensitivity reaction by subtracting the thickness of the saline-injected left footpad from the 
thickness of the KLH-injected footpad. There was no effect of 2-butoxyethanol treatment on anti-KLH IgG 
antibody production and on delayed-type hypersensitivity reaction. Splenic natural killer cytotoxic responses, 
which were assessed by the 4-hour 51Cr release from YAC-1 tumor target cells in vitro were significantly 
(p≤0.05) increased in both sexes at the low dose only. The increase in natural killer cytotoxic responses is 
not considered an adverse effect. There were no effects of 2-butoxyethanol treatment on splenocyteproduction 
of interleukin 2 and interferon, and thymus and spleen weights. No histological lesions in the 
thymus were observed. 
Several acute oral studies have examined the effects of 2-butoxyethanol on lymphoreticular organs. In a 
preliminary teratology study, pregnant Fischer 344 rats treated by gavage with ≥150 mg/kg/day 2-butoxy-ethanol 
on gestational days 9-11 or 11-13 exhibited increased absolute spleen weight at all doses compared 
with controls (NTP 1989). In the definitive study, in which the doses were 30, 100, or 200 mg/kg/day on 
gestational days 9-11 and 30, 100, and 300 mg/kg/day on gestational days 11-13, increased absolute spleen 
weight was noted at a dose level of ≥100 mg/kg/day in both experiments (NTP 1989). 
Young (4-5 weeks), adult (9-13 weeks) and older (5-16 months) male Fischer 344 rats were dosed with 0, 
32, 63, 125, 250, or 500 mg/kg 2-butoxyethanol by gavage (Ghanayem et al. 1987a). Young and adult rats 
receiving ≥125 mg/kg exhibited a dose-related increase in relative spleen weight; at 125 mg/kg the increase 
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relative to control was 110% for young rats and 150% for adult rats. Spleen weights were not recorded for 
the older rats. Ghanayem and coworkers have published other results indicating similar effects in male 
Fischer 344 rats after a single dose of 125 or 500 mg/kg 2-butoxyethanol by gavage (Ghanayem et al. 
1987b). Repeated dosing with 2-butoxyethanol seems to lessen the effect on the spleen weight increase. 
Male Fischer 344 rats received 0 or 125 mg/kg/day 2-butoxyethanol in water by gavage for 1, 2, 3, 6, or 
12 consecutive days (Ghanayem et al. 1992). Treated animals showed a time-dependent increase in spleen 
weight which reached a maximum of 62% in 6 days and declined to 45% between days 6 and 12. In the same 
study, using a different study design, male Fischer 344 rats received 125 mg/kg/day 2-butoxyethanol in water 
by gavage for 3 consecutive days. Controls received 5 mL water/kg body weight daily for 3 consecutive days. 
Rats in both groups were then allowed to recover without treatment for 7 days. These rats were then 
subgrouped with control and pretreated animals in each subgroup, and treated with water, 125 mg/kg, or 
250 mg/kg 2-butoxyethanol. Twenty-four hours after dosing, the spleen was removed and weighed. 
Pretreatment with 2-butoxyethanol resulted in a smaller increase in spleen weight than was observed in the 
rats that were not pretreated. Male Fischer 344 rats given 2-butoxyethanol orally for 4 consecutive days at 
500 or 1,000 mg/kg/day exhibited increased spleen weight and extramedullary hematopoiesis (Grant et al. 
1985). 
No effects on absolute or relative thymus weight were observed in Fischer 344 rats given 2-butoxyethanol at 
≤346 mg/kg/day (males) and ≤265 mg/kg/day (females) in the drinking water for 2 weeks (NTP 1993). 
However, male B6C3F1 mice exhibited a 38% decrease in absolute thymus weight and a 39% decrease in 
relative thymus weight after treatment with 370 mg/k/day, and a 20% decrease in absolute thymus weight 
and a 23% decrease in relative thymus weight at 627 mg/kg/day 2-butoxyethanol in the drinking water for 
2 weeks, but females dosed at ≤1,364 mg/kg/day showed no effect on thymus weight (NTP 1993). 
Effects on lymphoreticular organs have also been examined in intermediate-duration oral studies. Increased 
spleen weights were found at ≥443 mg/kg/day in male CQBS CD (SD)BR rats treated by gavage with 
2-butoxyethanol for 6 weeks (Eastman Kodak 1983; Krasavage 1986). Enlarged dark spleens were observed 
in three of nine rats exposed at 443 mg/kg/day and in four of eight rats at 885 mg/kg/day. Splenic congestion 
secondary to the hematological effects was seen at all doses (≥ 222 mg/kg/day). Histological examination of 
the thymus, mesenteric lymph nodes, and bone matrow revealed no pathological lesions, and no effect on 
white blood cells was noted. In Fischer 344 rats exposed to 2-butoxyethanol in drinking water for 13 weeks, 
bone marrow hyperplasia was found in males at ≥281 mg/kg/day and in females at ≥ 363 mg/kg/day; 
hematopoietic cell proliferation and congestion in the spleen were found in males at ≥ 367 mg/kg/day and in 
117 2-BUTOXYETHANOL AND 2-BUTOXYETHANOL ACETATE 
2. HEALTH EFFECTS 
females at ≥363 mg/kg/day; increased hemosiderin pigmentation in the spleen was found in males at 
≥129 mg/kg/day and in females at ≥ 151 mg/kg/day (NTP 1993). The absolute thymus weight was decreased 
in males at ≥367 mg/kg/day and in females at 470 mg/kg/day. No histopathological lesions were found in the 
thymus or lymph nodes. In contrast to rats, B6C3F1 mice receiving ≤ 694 mg/kg/day (males) and 
≤ 1,306 mg/kg/day (females) for 13 weeks in the drinking water showed no effect on thymus weight and no 
gross or histopathological lesion in the spleen, thymus, lymph nodes, or bone marrow (NTP 1993). No effect 
on thymus or spleen weight, and no histopathological lesions in the thymus were observed in rats given 
<506 mg/kg/day for 21 days (Exon et al. 1991). 
In a study on 2-butoxyethanol acetate, Wistar rats given unspecified acute oral doses of 2-butoxyethanol 
acetate in olive oil as part of a lethality study exhibited no bistopathological changes in the spleen (Truhaut et 
al. 1979). 
Spleen weight effects, spleen congestion, spleen and bone marrow hematopoiesis, and hemosiderin 
pigmentation in the spleen are probably related to hemolytic effects of 2-butoxyethanol, which are discussed 
in Section 2.2.2.2 under Hematological Effects 
The highest NOAEL values and all LOAEL values from each reliable study for immunological and 
lymphoreticular effects in each species and duration category are recorded in Table 2-3 and plotted in 
Figure 2-3. 
2.2.2.4 Neurological Effects 
No studies were located regarding neurological effects in humans after oral exposure to 2-butoxyethanol 
acetate or 2-butoxyacetic acid or in animals after oral exposure to 2-butoxyacetic acid. 
Intentional poisoning with 2-butoxyethanol has been associated with neurological effects. A woman who 
died of cardiac arrest 3 days after she ingested an unspecified amount of cleaner containing 6.5% 
2-butoxyethanol was comatose upon admission to the hospital (Litovitz et al. 199 1). A male patient, who 
was a known alcohol and trichloroethylene abuser, was comatose upon admission to the hospital after 
ingesting a household cleaning fluid that provided a dose of about 650 mg/kg 2-butoxyethanol (Bauer et al. 
1992). Similarly, a woman who ingested 467-933 mg/kg 2-butoxyethanol (also in window cleaner) was in a 
coma with no response to painful stimuli (Rambourg-Schepens et al. 1988), and another woman who ingested 
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391-469 mg/kg 2-butoxyethanol became comatose (Gijsenbergh et al. 1989). All three patients recovered
 
after supportive therapy. In contrast, no signs of neurological effects were seen in two children who
 
accidentally ingested 270 or 1,862 mg/kg 2-butoxyethanol and who were observed for 24 hours after gastric
 
lavage (Dean and Krenzelok 1992).
 
Clinical signs of neurotoxicity have also been observed in animals after acute oral exposure to 2-butoxyethanol.
 
Rats that died after a single gavage dose of ≥ 530 mg/kg exhibited sluggishness, prostration, and
 
narcosis (Carpenter et al. 1956). Other investigators have reported drowsiness, sluggishness, lethargy,
 
muscular flaccidity, and/or ataxia after acute exposure of rats to 252-9,000 mg/kg/day (Dow 1959, 198 1;
 
Eastman Kodak 1983; Krasavage 1986; Olin 1976; Sivarao and Mehendale 1995; Union Carbide 1980b).
 
Moderate-to-severe weakness and prostration were observed directly after dosing in guinea pigs given a
 
single gavage dose of 1,000 mg/kg 2-butoxyethanol, a dose that resulted in the death of 1 of 5 males and 1 of
 
5 females (Shepard 1994b). Slight weakness was observed directly after dosing at 500 mg/kg, a dose at
 
which all treated guinea pigs survived. Pregnant Fischer 344 rats exhibited lethargy after oral dosing in a
 
preliminary teratology study with 600 mg/kg/day 2-butoxyethanol given by gavage on gestational days 9-11
 
or 11-13 (NTP 1989). Ii-r the definitive study, no adverse neurological clinical signs were noted at
 
≤200 mg/kg/day on gestational days 9-11 or ≤300 mg/kg/day on gestational days 11-13 (NTP 1989).
 
Pregnant CD-1 mice given doses of 1,500 or 2,000 mg/kg/day 2-butoxyethanol by gavage on gestational
 
days 8-14 exhibited lethargy and failure to right when turned over, but no effect on demeanor was seen at
 
≤ 1,000 mg/kg/day (Wier et al. 1987).
 
Adult male COBS CD (SD)BR rats were given undiluted 2-butoxyethanol by gavage in doses of 0, 222, 443,
 
or 885 mg/kg/day, 5 days per week over a 6-week period, and exhibited lethargy at ≥443 mg/kg/day after the
 
first dose (Eastman Kodak 1983; Krasavage 1986). The high-dose rats were slightly weak and inactive after
 
the second and third doses. No effect on absolute brain weight was observed, but relative brain weight was
 
increased at ≥443 mg/kg/day. No histopathological changes were seen in brain tissue at any dose.
 
Fischer 344 rats that received 2-butoxyethanol at ≤452 mg/kg/day (males) and ≤470 mg/kg/day (females)
 
and B6C3F1 mice that received ≤ 694 mg/kg/day (males) and ≤ 1,306 mg/kg/day (females) in the drinking
 
water for 13 weeks showed no adverse effects on demeanor or histopathological changes in brain, spinal cord,
 
or sciatic nerve (NTP 1993).
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Wistar rats given unspecified acute oral doses of 2-butoxyethanol acetate in olive oil as part of a lethality 
study exhibited no adverse neurological clinical signs or histopathological changes in the brain (Truhaut et al. 
1979). 
The highest NOAEL values and all LOAEL values from each reliable study for neurological effects in each 
species and duration category are recorded in Table 2-3 and plotted in Figure 2-3. 
2.2.2.5 Reproductive Effects 
No studies were located regarding reproductive effects in humans after oral exposure to 2-butoxyethanol, 
2-butoxyethanol acetate, or 2-butoxyacetic acid. 
In acute studies, no effects on testicular weight and no bistopathological effects in the testes were found in 
male Fischer 344 rats given 2-butoxyethanol orally once at ≤ 500 mg/kg (Ghanayem et al. 1987a) or for 
4 consecutive days at 500 or 1,000 mg/kg/day (Grant et al. 1985). Likewise, no effects on testicular weight 
and no histopathological lesions in the testes or epididymides were found in Fischer 344 rats at 
≤ 346 mg/kg/day or in B6C3F1 mice at ≤ 627 mg/kg/day 2-butoxyethanol in drinking water for 2 weeks (NTP 
1993). 
In intermediate-duration studies, no effects on testicular weight and no histopathological lesions in the testes 
were found in Sprague-Dawley rats at ≤ 506 mg/kg/day 2-butoxyethanol for 21 days (Exon et al. 199 1). No 
effects on testicular weight and no histopathological lesions in the testes, seminal vesicles, epididymides, or 
prostate were found in COBS CD (SD)BR rats treated by gavage at ≤885 mg/kg/day for 6 weeks (Eastman 
Kodak 1983; Krasavage 1986). No effects on testicular weight and no histopathological lesions in the testes 
or epididymides (or seminal vesicles in the 13-week study) were found in Fischer 344 rats given 
≤443 mg/kg/day in the drinking water for 60 days or ≤452 mg/kg/day in the drinking water for 13 weeks 
(NTP 1993). Although spermatozoa concentrations (106/g caudal epididymal tissue) were significantly 
(p≤0.01) decreased compared to controls at ≥281 mg/kg/day, a dose-related effect was not observed (control, 
713.9±16.2; 281 mg/kg/day, 633.0±13.1; 367 mg/kg/day, 656.3±13.3; 452 mg/kg/day, 617.2 ±22.9), and 
there were no significant effects on spermatid heads (107/g tests or 107/testis), spermatid counts (mean/10-4 
mL), or percent mobile spermatozoa. A small, older study (Weil and Carpenter 1963) did find histological 
evidence of testicular atrophy after 93 days exposure to 188 mg/kg/day in DW albino rats. 
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No effects on the weights of testes/seminal vesicles and coagulating gland and no histopathological lesions in 
these tissues were found in JCL-ICR mice treated by gavage at 1,000 mg/kg/day for 5 weeks (Nagano et al. 
1979, 1984). No significant effects on the weights of testes, seminal vesicles, or prostate and no effects on 
sperm parameters were found in Swiss mice in a continuous breeding drinking water study at 
1,300 mg/kg/day or in the male offspring at 700 mg/kg/day (Heindel et al. 1990). Slight but statistically 
significant (p≤0.0l) decreases in left testis, but not right testis, weights were observed in B6C3F1 mice at 
≥210 mg/kg/day in drinking water for 13 weeks (NTP 1993). Because the effect on left testis weight was 
not dose-related (and there were no effects on right testis weight), it was not considered biologically 
significant. In addition, no histopathological changes were observed in the seminal vesicles or 
testes/epididymides, nor were there any consistent treatment-related effects on sperm parameters in mice at 
≤627 mg/kg/day in drinking water for 13 weeks (NTP 1993). 
Female Fischer 344 rats treated with 2-butoxyethanol in the drinking water for 13 weeks exhibited altered 
estrous cycles at ≥ 363 mg/kg/day, with more time spent in diestrus than in the other phases (NTP 1993). The 
total duration of the estrous cycle was not affected. No histopathological lesions were found in the mammary 
glands, ovaries, or uterus. No effect on estrous cycles and no histopathological lesions in the mammary 
glands, ovaries, or uterus were found in female B6C3F1 mice similarly treated for 13 weeks at 
≤ 1,306 mg/kg/day (NTP 1993). 
Pregnant Fischer 344 rats exhibited vaginal bleeding after oral dosing by gavage in a preliminary teratology 
study with 600 mg/kg/day 2-butoxyethanol on gestational days 9-11 or 11-13 (NTP 1989). In the definitive 
study, increased resorptions, implantation loss, and vaginal bleeding were noted at the high doses of 
200 mg/kg/day on gestational days 9-11 and 300 mg/kg/day on gestational days 11-13 (NTP 1989). These 
doses were also maternally toxic. A decrease in the incidence of viable litters was found in pregnant CD- 1 
mice treated with 1,180 mg/kg/day by gavage on gestational days 6-13, a dose that resulted in decreased 
maternal body weight gain (Hardin et al. 1987; Schuler et al. 1984). Pregnant female CD-l mice given 
350-2,000 mg/kg/day 2-butoxyethanol on gestational days 8-14 exhibited a green or red vaginal discharge 
during gestation at doses of 1,500 and 2,000 mg/kg/day; surviving animals in the 1,000- and ­
1,500-mg/kg/day dose groups had an increased incidence of resorptions (Wier et al. 1987). 
Mating pairs of Swiss mice exposed to 1,300 or 2,100 mg/kg/day 2-butoxyethanol in the drinking water for 
21 weeks exhibited a decrease in the number of litters produced per pair, and in the size of each litter, with 
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(Heindel et al. 1990). When the females that had been dosed with 1,300 mg/kg/day 2-butoxyethanol were 
mated with control males, and then maintained on treatment throughout gestation to delivery, they produced 
58% fewer litters, and the litters were 66% smaller compared to control mating pairs. When the offspring of 
the low-dose mating pairs (700 mg/kg/day) were mated, there was no adverse effect on fertility. A few 
females in the treated group (1,300mg/kg/day) had long or unclear estrous cycles, but the significance of this 
is not clear (Heindel et al. 1990). 
Wistar rats given unspecified acute oral doses of 2-butoxyethanol acetate in olive oil as part of a lethality 
study exhibited no adverse histopathological changes in the testes or ovaries (Truhaut et al. 1979). 
Groups of male Alpk/AP (Wistar-derived) rats were dosed once by gavage with 0, 174, 434, or 868 mg/kg 
2-butoxyacetic acid (Foster et al. 1987). Occasional significant decreases in the weight of the prostate and 
seminal vesicles were observed, but the decreases were not time or dose related. Histological examination of 
testes, epididymides, and prostate revealed no treatment-related lesions. 
The highest NOAEL values and all LOAEL values from each reliable study for reproductive effects in each 
species and duration category are recorded in Tables 2-3 and 2-5 and plotted in Figures 2-3 and 2-5. 
2.2.2.6 Developmental Effects 
No studies were located regarding developmental effects in humans after oral exposure to 2-butoxyethanol, 
2-butoxyethanol acetate, or 2-butoxyacetic acid. No studies were located regarding developmental effects in 
animals after oral exposure to 2-butoxyethanol acetate or 2-butoxyacetic acid. 
The offspring of pregnant Fischer 344 rats exhibited decreased fetal body weight after oral dosing of the 
dams in a preliminary teratology study with 300 and 600 mg/kg/day 2-butoxyethanol on gestational 
days 9-11 (NTP 1989). Decreased gravid uterine weight and decreased fetal body weight were found at 
600 mg/kg/day after dams were dosed on gestational days 11-13. However, no external or intera1 
malformations were observed in the fetuses after the dams were treated with ≤ 600 mg/kg/day on gestational 
days 9-11 or 11-13. The doses that resulted in fetal effects also caused maternal toxicity. In the definitive 
study, no adverse developmental effects (fetal weight or external and visceral malformations) were noted at 
≤ 200 mg/kg/day on gestational days 9-11 or ≤ 300 mg/kg/day on gestational days 11-13 (NTP 1989). CD-1 
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litter (Hardin et al. 1987; Schuler et al. 1984). As noted in Section 2.2.2.5 above, treated females had 
significantly reduced numbers of viable litters, but no adverse effects were observed in the pups that were 
born alive. However, the offspring of pregnant female CD-1 mice given 1,000 or 1,500 mg/kg/day 2-butoxy-
ethanol on gestational days 8-14 exhibited evidence of cleft palate when evaluated at term (Wier et al. 1987). 
The response was not clearly dose related; one of five litters (4/43 fetuses) and one of three litters 
(l/25 fetuses) were affected at 1,000 and 1,500 mg/kg/day, respectively. The 1,000-mg/kg/day dose was 
associated with green-brown or red-brown staining of the cage papers, while at 1,500 mg/kg/day three of six 
mice died. In a postnatal study designed to examine pup survival beyond the neonatal period, cleft palate 
effect was not evident when mice dosed with 650 or 1,000 mg/kg/day (Wier et al. 1987). In a reproductive 
toxicity study, male and female Swiss mice were given doses of 700, 1,300, or 2,100 mg/kg/day in drinking 
water for 21 weeks (Heindel et al. 1990). Decreased pup weight was observed for all treated mating pairs at 
≥700 mg/kg/day. A crossover mating trial (performed to assess which sex had been affected by treatment, or 
which sex is more affected) indicated that the reproductive effects could be attributed primarily to an effect on 
the female, although no developmental effects were observed in the offspring that were produced (Heindel et 
al. 1990). The crossover mating trial was performed after the last litter from the continuous breeding phase 
was weaned to determine the affected sex. The crossover mating trial consisted of 3 groups of 20 pairs each 
-- control males x control females, control maIes x high dose females, and control females x high dose 
males. Pairs were matched for 7 days or until a copulatory plug is detected, whichever is first. When the 
offspring of the 700-mg/kg/day animals were mated while being maintained on treatment from weaning 
throughout mating, gestation, and delivery (14 weeks), no developmental effects were observed in the pups 
(Heindel et al. 1990). 
The highest NOAEL values and all LOAEL values from each reliable study for developmental effects in each 
species and duration category are recorded in Table 2-3 and plotted in Figure 2-3. 
2.2.2.7 Genotoxic Effects 
No studies were located regarding genotoxic effects in humans or animals after oral exposure to 2-butoxyethanol,
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2.2.2.8 Cancer 
No studies were located regarding carcinogenic effects in humans or animals after oral exposure to 2-butoxy­
ethanol, 2-butoxyethanol acetate, or 2-butoxyacetic acid. 
2.2.3 Dermal Exposure 
Occupational or environmental exposure to 2butoxyethanol or 2-butoxyethanol acetate usually occurs 
through the inhalation or dermal route. Both routes of exposure are important in the industrial setting. 
Occupational exposure to 2-butoxyethanol usually involves co-exposure to other solvents and chemicals. In 
several NIQSH Health Hazard Evaluations, effects reported by workers included eye, nose, and throat 
irritation; coughing; runny nose; headache; dizziness; lightheadedness; and nausea (Apoll98 1,1986; Lee 
1988). Since personal breathing zone and workplace air samples analyzed for solvents and other chemicals 
such as, toluene, xylene, methyl ethyl ketone, methyl isobutyl ketone, styrene, along with 2-butoxyethanol, 
indicated that exposure levels for each chemical were below the NIOSH, ACGIH, and OSHA criteria, NIOSH 
concluded that the effects were probably due to the additive combination of the solvents. Experimental 
studies in humans exposed by inhalation are discussed in Section 2.2.1 and have been summarized in several 
publications (Browning and Curry 1994; EPA 1984; NIOSH 1990; Tyler 1984). Experimental studies in 
humans and animals exposed dermally to 2-butoxyethanol or 2-butoxyethanol acetate are discussed below. 
No studies were located describing the effects of dermal exposure to 2-butoxyacetic acid in humans or 
animals. 
2.2.3.1 Death 
No studies were located regarding death in humans after dermal exposure to 2-butoxyethanol or 2-butoxyethanol 
acetate. 
A dermal LD50 of 2,273 mg/kg has been reported for an unspecified strain and number of rats (Carpenter and 
Condra 1961). The compound was placed on the clipped skin of the trunk, and the skin was occluded for 
4 hours. Several investigators have reported acute dermal LD50 values for rabbits, which generally ranged 
from 406 to 1,804 mg/kg (Carpenter et al. 1956; Eastman Kodak 1988; Olin 1976; Union Carbide 1980a, 
1980b). In one determination, female New Zealand rabbits appeared to be more sensitive than male New 
Zealand rabbits to the lethality of 2-butoxyethanol, with LD50 values reported to be 568 mg/kg for females 
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and 638 mg/kg for males (Union Carbide 1980a). However, one study reported an acute dermal LD50 value 
of 220 mg/kg for an unspecified strain and sex of rabbits, in which four of four rabbits treated with 
252 mg/kg for 24 hours died within 2-7 days (Dow 1959). Another study reported an acute dermal LD50 (8­
hour) as low as 99 mg/kg for female New Zealand rabbits (Duprat and Gradiski 1979). In this study, groups 
of six female rabbits were exposed dermally (with the use of vials) to several dose levels for 8 hours and 
observed for 15 days. Mortality incidences were 0 of 6 in controls, 2 of 6 at 72 mg/kg, 2 of 6 at 90 mg/kg, 
4 of 6 at 108 mg/kg, 5 of 6 at both 135 and 180 mg/kg, and 6 of 6 at 225 mg/kg. Deaths occurred on 
days l-8 after treatment; early deaths were attributed to narcosis or failure of respiration or cardiac function, 
while delayed deaths were observed after weight loss and were probably due to renal impairment. 
In acute dermal studies by Carpenter et al. (1956), extreme congestion of the kidney, hemoglobinuria, pale 
liver, and engorged spleen were noted in the rabbits that died. Deaths occurred at dose levels of 
403-l ,804 mg/kg for undiluted 2-butoxyethanol. In New Zealand rabbits of unspecified sex to which 250, 
500, 1,000 or 2,000 mg/kg 2-butoxyethanol was applied to clipped, abraded skin and occluded for 24 hours, 
1 of 4 died at 500 mg/kg on day 12, and 10 of 10 died at 1,000 and 2,000 mg/kg on days l-2 (Olin 1976). 
At 24 hours, rabbits exposed to 1,000 mg/kg/day exhibited flaccid muscle tone and hematuria, whereas 
rabbits exposed to 2,000 mg/kg/day exhibited lacrimation, hematuria, flaccid muscle tone, and anorexia (Olin 
1976). No treatment-related deaths occurred in male or female New Zealand rabbits to which doses of 
≤ 361 mg/kg/day were applied to the clipped, occluded skin for 6 hours per day for nine applications over 
11 days (Union Carbide 1980a). 
In a developmental study, application of 2-butoxyethanol four times per day at 0.35 mL per application 
(1.4 mL/day) to the shaved interscapular skin of pregnant Sprague-Dawley rats on gestational days 7-16 was 
lethal in 10 of 11 rats on treatment days 3-7 (Hardin et al. 1984). Pregnant rats were subsequently tested at 
0.12 mL per treatment (0.48 mL/day), which caused no mortality. No deaths were observed in guinea pigs in 
which undiluted 2-butoxyethanol(2,000 mg/kg) was placed on the dorsal skin that had been clipped free of 
hair (Shepard 1994a). The treated area was covered with an occlusive wrap for 24 hours. In guinea pigs 
exposed epicutaneously to 0.5 or 2.0 mL 2-butoxyethanol and observed for 35 days, 13 of 20 guinea pigs in 
the high-dose group died within the 1 st week, but none died thereafter (Wahlberg and Boman 1979). No 
animals died in the low-dose group. 
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In an intermediate-duration study, no treatment-related deaths were found in male and female New Zealand 
rabbits exposed dermally to 2-butoxyethanol at 0, 10, 50, or 150 mg/kg/day, 6 hours per day, 5 days per 
week for 90 days (CMA 1983). 
In an acute dermal LD50 determination for 2-butoxyethanol acetate, doses of 3,191, 3,957, 4,766, 5,957, or 
10,000 mg/kg were applied to the clipped, occluded skin of New Zealand rabbits for 24 hours (Truhaut et al. 
1979). The rabbits were kept under observation for 14 days after exposure. The applied doses of 3,191, 
2,957, 4,766, 5,957, and 10,000 mg/kg were reported to correspond to absorbed doses of 610, 910, 1,130, 
1,830, and 2,200 mg/kg, respectively. The LD50 for rabbits was reported to be approximately 1,500 mg/kg 
of the absorbed dose, which would correspond to an applied dose of between 4,766 and 5,957 mg/kg. The 
rabbits generally died between 24 and 48 hours after application and no later than 4 days after exposure. 
The LD50 values for rabbits and all LOAEL values from each reliable study for death in each species duration 
category are recorded in Tables 2-6 and 2-7. 
2.2.3.2 Systemic Effects 
No studies were located regarding respiratory, cardiovascular, gastrointestinal, hematological, 
musculoskeletal, hepatic, renal, endocrine, ocular, or body weight effects in humans. No studies were located 
describing respiratory, cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, ocular, 
or body weight effects in humans or gastrointestinal, musculoskeletal, or body weight effects in animals 
following dermal exposure to 2-butoxyethanol acetate. Available data pertaining to systemic effects of both 
compounds are presented below. 
The highest NOAEL values and all LOAEL values from each reliable study for systemic effects in each 
species and duration category are recorded in Tables 2-6 and 2-7. 
Respiratory Effects. Female New Zealand outbred rabbits were epicutaneously exposed to 2-butoxyethanol 
(Duprat and Gradiski 1979). Several doses of 72-225 mg/kg of the undiluted substance (analytical 
grade, purity >99.5%) were directly applied over 8 hours onto the clipped back (using vials) of the 
unrestrained rabbits. Animals were observed daily over a 15-day period. Macroscopic and microscopic 
examinations were performed on dead animals (death was observed in all dose groups) and those surviving 
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interstitial pneumonitis. In another study, male New Zealand white rabbits given a single dose of 0.5 mL/kg 
2-butoxyethanol that remained in contact with intact skin for 24 hours showed orange-red lungs at necropsy 
(Union Carbide 1980b). Death of one of four animals occurred at this dose. Neither clinical signs of 
respiratory effects nor gross pathology changes in the trachea and lungs were observed in guinea pigs treated 
with a single dermal dose of 2,000 mg/kglday 2-butoxyethanol (Shepard 1994a). The treated area was 
occluded for 24 hours. Histological examination of the lungs revealed no adverse treatment-related lesions of 
male and female New Zealand rabbits dosed with ≤ 150 mg/kg/day 2-butoxyethano16 hours per day, 5 days 
per week, for 90 days (CMA 1983). 
New Zealand rabbits given 24-hour applications of 2-butoxyethanol acetate to the clipped, occluded skin at 
doses of 3,191-10,000 mg/kg as part of a lethality study exhibited no adverse respiratory clinical signs or 
histopathological changes in the lungs (Truhaut et al. 1979). 
Cardiovascular Effects. Gross changes in the heart at necropsy were not observed in guinea pigs 
treated with a single dermal dose of 2,000 mg/kg/day 2-butoxyethanol (Shepard 1994a). The treated area 
was occluded for 24 hours. No effects on heart weight and no histopathological lesions in the aorta or heart 
were observed in male or female New Zealand rabbits dosed with ≤ 150 mg/kg/day 2-butoxyethano16 hours 
per day, 5 days per week, for 90 days (CMA 1983). 
New Zealand rabbits given 24-hour applications of 2-butoxyethanol acetate to the clipped, occluded skin at 
doses of 3,191-10,000 mg/kg as part of a lethality study exhibited no histopathological changes in the heart 
(Truhaut et al. 1979). 
Gastrointestinal Effects. Male and female New Zealand white rabbits were dosed dermally once with 
451 or 902 mg/kg 2-butoxyethanol, and occluded exposure was maintained for 6 hours (Union Carbide 
1980a). All rabbits in the 902-mg/kg dose group died and exhibited reddened stomachs at necropsy; females 
also had reddened intestines. Rabbits in the 451-mg/kg dose group had no remarkable gastrointestinal 
findings, and all except one female survived the experiment. However, in a companion study of male New 
Zealand rabbits that were similarly exposed dermally for a 24-hour period to 451 or 902 mg/kg, gross 
necropsy of the rabbits that died at 451 mg/kg (one of four) and 902 mg/kg (four of four) revealed orange 
peritonea and intestines (Union Carbide 1980b). Very dark intestines were also observed in one rabbit dosed 
with 1,000 mg/kg 2-butoxyethanol on abraded skin (Olin 1976). All four animals treated at this dose died. 
Gross examination of the esophagus, stomach, duodenum, jejunum, ileum, cecum, colon, and rectum did not 
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reveal any adverse effects in guinea pigs treated with a single dermal dose of 2,000 mg/kg/day 2-butoxyethanol 
(Shepard 1994a). The treated area was occluded for 24 hours. Histological examination of the 
stomach (pylorus and fundus) and of the intestines (cecum, duodenum, jejunum, ileum, colon) revealed no 
pathological lesions in male and female New Zealand rabbits dosed with 10, 50, or 150 mg/kg/day 2-butoxyethanol 
6 hours per day, 5 days per week, for 90 days (CMA 1983). One male in the 50-mg/kg/day dose 
group that was found dead on day 15 of the study had a gastric ulcer. Neither the ulcer nor the death 
appeared to be related to treatment. 
Hematological Effects. Dermal exposure of animals to 2-butoxyethanol has also resulted in hemolysis 
of red blood cells and hemoglobinuria. Doses ranging from 200 to 500 mg/kg 2-butoxyethanol were applied 
to the shaved dorsal skin of female Wistar rats; hemolysis was observed in two of three animals at 
260 mg/kg, and hemoglobinuria was observed in one of three animals (Bartnik et al. 1987). A dose of 
500 mg/kg caused increased mean corpuscular volume, decreased erythrocyte count and hemoglobin level, 
and hemoglobinuria within 6 hours after exposure. In another study, 61, 181, or 299 mg/kg [14C]2-butoxy- ethanol 
was applied to the clipped backs of male Fischer 344 rats, and nonoccluded percutaneous absorption 
was measured (Sabourin et al. 1992b, 1993). In the 181-mg/kg dose group, no significant hemolysis was 
detected; hematology was not evaluated at the other doses. Water or undiluted 2-butoxyethanol(0.35 mL) 
was applied four times daily (1.4 mL/day) on gestational days 7-16 to the shaved interscapular skin of 
pregnant Sprague-Dawley rats (Hardin et al. 1984). Burgundy-colored urine, presumably from hemoglobin 
in the urine, was observed by the end of the 1st day of treatment with 2-butoxyethanol. Ten of 11 treated rats 
died during gestation days 9-l 3. 
Male albino New Zealand rabbits exhibited increased erythrocyte osmotic fragility 1 hour after a 3-minute 
skin contact period with 505 mg/kg 2-butoxyethanol (Carpenter et al. 1956). Hemoglobinuria was also 
observed in New Zealand rabbits that died after 24-hour skin contact with ≥406 mg/kg (Carpenter et al. 
1956). In male and female New Zealand rabbits to which 451 or 902 mg/kg 2-butoxyethanol was applied to 
the skin (occluded) for 6 hours, hemoglobinuria was observed in both dose groups (Union Carbide 1980a). 
Lethality was one of eight at 451 mg/kg and all 8 rabbits at 902 mg/kg. Similarly, hemoglobi&ria was noted 
prior to death in female New Zealand white rabbits treated dermally with ≥72 mg/kg 2-butoxyethanol over an 
8-hour period (Duprat and Gradiski 1979). Clipped male and female New Zealand white rabbits received 
daily dermal (occluded) applications of 1mL/day of 0%, 5%, 25%, 50%, or 100% concentrations (0, l8, 90, 
180, or 361 mg/kg/day, respectively) of 2-butoxyethanol for a total of nine applications over an 1l-day 
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Transient hemoglobinuria was observed at the high dose in males. In addition, females exhibited increases in 
mean corpuscular hemoglobin (MCH) and decreases in red blood cell count, hemoglobin, and mean 
corpuscular hemoglobin concentrations (MCHC) at 361 mg/kg/day. 
No adverse treatment-related hematological effects (on white blood cells, red blood cells, hemoglobin, 
hematocrit, and mean corpuscular volume) were noted in male or female New Zealand rabbits dosed with 
≤ 150 mg/kg/day 2-butoxyethano16 hours per day, 5 days per week, for 90 days (CMA 1983). 
New Zealand rabbits were given 24-hour applications of 2-butoxyethanol acetate to the clipped, occluded 
skin at doses of 3,191-10,000 mg/kg as part of a lethality study (Truhaut et al. 1979). In treated rabbits, a 
decrease in hemoglobin, a 20-25% decrease in red blood cell count, and marked hemoglobinuria and/or 
hematuria were observed; for each dose group, some rabbits had almost normal values while others were 
severely affected. 
The hemolytic effect of 2-butoxyethanol and 2-butoxyethanol acetate has been associated in animal studies 
with changes in the spleen, including engorgement and erythrocytic infiltration. These effects are discussed 
further in Section 2.2.3.3, Immunological and Lymphoreticular Effects. 
Musculoskeletal Effects. Flaccid muscle tone, probably neurological in origin, was observed prior to 
death in rabbits dosed with 1,000 or 2,000 mg/kg 2-butoxyethanol on abraded, occluded skin for 24 hours 
(Olin 1976). Histological examination of skeletal muscle and bone (sternum) revealed no lesions in male or 
female New Zealand rabbits dosed with up to 150 mg/kg/day 2-butoxyethano16 hours per day, 5 days per 
week, for 90 days (CMA 1983). 
Hepatic Effects. Pale livers were observed in New Zealand rabbits that died after 24-hour skin contact 
with ≥406 mg/kg (Carpenter et al. 1956). Female New Zealand outbred rabbits were epicutaneously exposed 
to ≥ 72 mg/kg 2-butoxyethanol (Duprat and Gradiski 1979). Histopathological examinations of animals that 
died prior to the end of the 15-day observation period showed congestion in the liver, with small necrotic foci 
with mesenchymatous reactions and inconstant (i.e., not always present) steatosis. A single 6-hour occluded 
dermal exposure of male and female New Zealand white rabbits to 451 and 902 mg/kg 2-butoxyethanol 
caused mottled livers with pocked surfaces in animals that died (Union Carbide 1980a). In a companion 
study, in which male rabbits were exposed to the same doses for 24 hours, discolored livers were observed at 
both doses (Union Carbide 1980b). Discolored or pale liver has also been observed in New Zealand rabbits 
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dosed with 250-l,000 mg/kg 2-butoxyethanol on abraded skin (Olin 1976). Gross examination of the liver 
did not reveal any adverse effects in guinea pigs treated with a single dermal dose of 2,000 mg/kg/day 
2-butoxyethanol (Shepard 1994a); the treated area was occluded for 24 hours. No effect on liver weight was 
seen in male or female New Zealand white rabbits exposed dermally to 0, 18, 90, 180, or 361 mg/kg/day of 
2-butoxyethanol for a total of nine applications over an 11-day period with a duration of 6 hours of exposure 
per day (Union Carbide 1980a). Histological examination of livers and gall bladders revealed no lesions in 
male or female New Zealand rabbits dosed with up to 150 mg/kg/day 2-butoxyethanol 6 hours per day, 
5 days per week, for 90 days (CMA 1983). In addition, no effects on liver weight were observed. 
New Zealand rabbits given 24-hour applications of 2-butoxyethanol acetate to the clipped, occluded skin at 
doses of 3,191-10,000 mg/kg as part of a lethality study exhibited no histopathological changes in the liver 
(Truhaut et al. 1979). 
Renal Effects. Congested kidneys were observed in New Zealand rabbits that died after 24-hour skin 
contact with ≥ 406 mg/kg (Carpenter et al. 1956). Female New Zealand outbred rabbits epicutaneously 
exposed to 2-butoxyethanol at doses of 0, 72, 90, 1108, 135, 180, and 225 mg/kg of the undiluted substance 
(directly applied over 8 hours onto the clipped back of the unrestrained rabbits) showed adverse kidney 
effects (Duprat and Gradski 1979). Enlarged kidneys with extensive hemoglobinuric nephrosis and 
interstitial reaction were observed in rabbits in each dose group (≥ 72 mg/kg) that died. Rabbits that survived 
and were sacrificed for macroscopic and microscopic examinations showed no differences from control 
animals at 72 and 90 mg/kg of exposure. Some rabbits in the groups receiving 108, 135, 180, and 
225 mg/kg showed persistent kidney lesions (not specified), but the other previously stated morphological 
changes were not observed. The study authors concluded that the morphological changes in the kidneys 
suggested damage due to in vivo hemolysis. A single 6-hour occluded dermal exposure of male and female 
New Zealand white rabbits to 451 or 902 mg/kg 2-butoxyethanol caused hematuria at both doses with 
enlarged, dark kidneys in animals in the high-dose group and kidneys with pocked surfaces in the males of the 
451 -mg/kg/day dose group (Union Carbide 1980a). One of eight rabbits died at 451 mg/kg and all eight 
rabbits died at 902 mg/kg. In a companion study in which male rabbits were exposed to the same doses for 
24 hours, dark red kidneys and bloody urine were observed at both doses (Union Carbide 1980b). Discolored 
kidneys and bloody urine (hematuria) have also been observed in New Zealand rabbits dosed with 
500-2,000 mg/kg 2-butoxyethanol on abraded, occluded skin (Olin 1976). Gross examination of the kidneys 
did not reveal any adverse effects in guinea pigs treated with a single dermal dose of 2,000 mg/kg/day 
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Increased urinary protein was seen in male and female New Zealand white rabbits exposed dermally for 
6 hours per day to 36 1 mg/kg/day of 2-butoxyethanol for a total of nine applications over an 11 -day period; 
however, rabbits exposed to 271 mg/kg/day 2-butoxyethanol nine times over 11 days had renal effects 
including dimpling of the renal surface, tubular vacuohzation, tubular degeneration, tubular cell hyperplasia, 
glomerular adhesions, and interstitial nephritis (Union Carbide 1980a). Hematuria was observed in female 
rabbits exposed to 180 or 361 mg/kg/day 2-butoxyethanol (Union Carbide 1980a). No effects on kidney 
weight and no treatment-related histopathological lesions in the kidney or urinary bladder were noted in male 
and female New Zealand rabbits dosed with ≤ 150 mg/kg/day 2-butoxyethano16 hours per day, 5 days per 
week, for 90 days (CMA 1983). 
New Zealand rabbits exposed dermally to doses of 3,191-10,000 mg/kg 2-butoxyethanol acetate for 
24 hours exhibited renal effects (Truhaut et al. 1979). Necropsy revealed bloody kidneys and the presence of 
large quantities of blood in the bladder (hematuria). The severity of the histopathological renal lesions 
(necrotizing, hemorrhagic, and atrophic acute tubular nephrosis with occasional glomemlar lesions) was 
reported to be dose-related, but the specific doses at which they occurred were not reported. Histopathologic 
examination of a section from the kidney of a rabbit treated with 10,000 mg/kg 2-butoxyethanol acetate 
showed atrophic tubular dilation, tubular fatty degeneration, vacuolar degeneration, and hemosiderin deposits 
in the glomerulus and the tubular cells, with glomerular retraction and luminar hyaline deposits, luminar 
granular deposits, foci of cellular lysis, occasional interstitial fibro-inflammatory organization, and parietal 
atrophy. Presumably, some of these lesions were also observed in rabbits that died. When the surviving 
animals were sacrificed after the 2-week observation period, no gross pathologic or histopathological lesions 
in the kidney were noted. 
Endocrine Effects. A single 6-hour occluded dermal exposure of male and female New Zealand white 
rabbits to 451 or 902 mg/kg 2-butoxyethanol caused reddened adrenal glands in both dose groups (Union 
Carbide 1980a). One of eight rabbits died at 451 mg/kg and all eight rabbits died at 902 mg/kg. Gross 
examination of the pituitary and adrenal glands did not reveal any adverse effects in guinea pigs treated with a 
single dermal dose of 2,000 mg/kg/day 2-butoxyethanol (Shepard 1994a); the treated area was occluded for 
24 hours. Histological examination of adrenals, pancreas, pituitary, thyroid, and parathyroid glands revealed 
no pathological lesions in male or female New Zealand rabbits dosed with ≤ 150 mg/kg/day 2-butoxyethanol 
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New Zealand rabbits given 24-hour dermal exposure to 2-butoxyethanol acetate at doses of 
3,191-10,000 mg/kg as part of a lethality study exhibited no histopathological changes in the pancreas or 
adrenal gland (Truhaut et al. 1979). 
Dermal Effects. Percutaneous absorption of 2-butoxyethanol was investigated in 12 exposure 
experiments with five men (Johanson et al. 1988). None had been previously exposed occupationally to 
industrial solvents. All had participated in a previous inhalation study of 2-butoxyethanol (Johanson et al. 
1986a). The subjects kept two or four fingers immersed in neat 2-butoxyethanol for 2 hours. None of the 
subjects exhibited adverse reaction from the exposure to 2-butoxyethanol. Although the skin of the exposed 
fingers was not irritated, it was wrinkled and seemed to be more rigid and less elastic after exposure. This 
effect reached a maximum at 2-4 hours after the end of the exposure. The volume and skinfold thickness of 
the exposed fingers decreased, then returned to normal. A drying pattern with small fissures appeared on the 
skin, which disappeared after l-2 days. 
Volunteers (214 men and women) were given 0.2 mL 10% 2-butoxyethanol in patches applied to the 
intrascapular area of the back, either to the right or left of the midline (CMA 1992; Greenspan et al. 1995). 
A 10% concentration was used because it is the highest concentration of 2-butoxyethanol found in cosmetic 
products, although concentrations as high as 50% can be found in cleaning products which should be diluted 
before use (OECD 1997). The entire study extended over a 6-week period and involved three phases: 
induction, rest, and challenge. The induction phase consisted of nine consecutive applications of 2-butoxyethanol 
and was assessed after 24-72 hours of patch application. The subjects were required to remove the 
patches approximately 24-72 hours after application; tbey were evaluated and identical patches reapplied. 
Following the ninth evaluation, the subjects were dismissed for a 14-day rest period. The challenge phase of 
the experiment was initiated during the 6th week of the study, with identical patches applied to sites 
previously unexposed to 2-butoxyethanol. These patches were removed by subjects after 24 hours, and the 
sites were graded 48 and 72 hours after application. Subjects who had six applications or more, with 
subsequent readings during induction, and at least one reading during challenge, were considered a completed 
case. One individual had erythema on the second challenge, 7 had barely perceptible erythemaon the first 
challenge, and 12 had barely perceptible erythema on the second challenge. The study authors concluded that 
there were no dermal effects of 10% 2-butoxyethanol under the conditions applied in this study; 201 subjects 
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Water or undiluted 2-butoxyethanol was applied four times daily (0.35 mL per application or 1.4 mL/day) on 
gestational days 7-16 to the shaved interscapular skin of pregnant Sprague-Dawley rats with an automatic 
pipetter. Progressive necrosis of the tail (which may have been associated with the toxic effects of 2-butoxyethanol 
on red blood cells and subsequent vascular response) and rough coats were noted in some treated rats 
(Hardin et al. 1984). Severe skin irritation has been noted in guinea pigs after application of 2-butoxyethanol 
(dose not specified) (Eastman Kodak 1988). In another study, female New Zealand rabbits exposed to 
≥72 mg/kg for 8 hours developed cutaneous lesions accompanied by necrosis of epidermis and dermis on the 
4th day after exposure (Duprat and Gradiski 1979). Skin lesions healed within a 2-week period. In other 
studies, application of 0.5 mL undiluted compound (Rohm and Haas 1983), unspecified amounts of undiluted 
compound (Dow 1958,1981; Eastman Kodak 1988), or doses of 200 or 252 mg/kg 2-butoxyethanol (Dow 
1959) to rabbit skin resulted in hyperemia, edema, slight exfoliation, and/or slight-to-moderate irritation. A 
single 6-hour occluded dermal application of 451 or 902 mg/kg 2-butoxyethanol to male and female New 
Zealand white rabbits caused slight necrosis in females at both doses and erythema in both sexes at both 
doses (Union Carbide 1980a). However, in a companion study in which male rabbits were exposed to the 
same doses for 24 hours, erythema and necrosis were noted at the high dose only (Union Carbide 1980b). 
Erythema was also seen in male and female New Zealand white rabbits exposed dermally to 
18-361 mg/kg/day of 2-butoxyethanol for a total of nine applications over an 11 -day period with an exposure 
duration of 6 hours per day; male and female rabbits exposed to 271 mg/kg/day for nine times over 11 days 
also showed dermal necrosis (Union Carbide 1980a). A single dose of 0.01 mL of undiluted 2-butoxyethanol 
applied to the clipped bellies of New Zealand white rabbits caused moderate capillary congestion in two of 
five rabbits (grade 2) (Union Carbide 1980b). Dermal irritation from 2-butoxyethanol exposure has been 
studied in New Zealand rabbits using both the Draize protocol (24-hour occluded exposure) and the European 
Economic Communities protocol (4-hour occluded exposure) (Zissu 1995). For both protocols, 0.5 mL of 
undiluted 2-butoxyethanol was placed on the skin. 2-Butoxyethanol was considered a severe irritant by the 
Draize protocol and an irritant by the European Economic Communities protocol. Slight-to-moderate 
erythema was noted in male and female New Zealand rabbits dosed with 10-150 mg/kg/day 2-butoxyethanol 
6 hours per day, 5 days per week, for 90 days (CMA 1983). Slight-to-moderate scaling and flaking were 
occasionally noted during weeks 2 and 3 and recurred sporadically through 91 days. 
2-Butoxyethanol acetate was used to evaluate a noninvasive human method and an in vitro cytotoxicity 
method as alternatives to the rabbit skin test for primary irritant effects (Jacobs et al. 1989). The human 
method included measurements of cutaneous blood flow values (CBFV) by laser Doppler flowmetry before 
and after patch application on the forearm; some experiments used 100% test substances (75 mg/cm2) 
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applied for 48 hours and measured 12 hours later, and other experiments used 10% solutions of test
 
substances (7.5 mg/ m3) applied for 3 hours and measured 1, 24, 48, and 72 hours later. Cutaneous blood
 
flow values (CBFV) obtained in the two series of experiments (10% for 3 hours and 100% for 48 hours)
 
resulted in a ranking of 2, which is the minimal mean erythema needed to classify substances as skin irritants.
 
The CBFV in humans correlated very well (r=0.99) with erythema scores obtained on rabbits.
 
In New Zealand white rabbits, patches soaked with 0.5 mL of undiluted 2-butoxyethanol acetate were applied
 
to one site of the prepared skin surface (Jacobs et al. 1989). The untreated skin was used as a control.
 
Erythema scores were obtained 1, 24, 48, and 72 hours after application of the undiluted substance for
 
4 hours. The erythema scores of exposure to 100% 2-butoxyethanol acetate for 4 hours in rabbits showed a
 
ranking of 2, which is the minimal mean erythema needed to classify substances as skin irritants. New
 
Zealand rabbits exposed dermally to unspecified doses of 2-butoxyethanol acetate for 24 hours exhibited
 
dermal effects (Truhaut et al. 1979). When 2-butoxyethanol acetate was tested for primary irritation of the
 
skin, four of six rabbits showed slight erythema (grade 1) at 24 hours. Dermal irritation from exposure to
 
2-butoxyethanol acetate has been studied in rabbits using both the Draize protocol (24-hour occluded
 
exposure) and the European Economic Communities protocol (4-hour occluded exposure) (Zissu 1995). For
 
both protocols, 0.5 mL of undiluted 2-butoxyethanol acetate was placed on the skin. 2-Butoxyethanol acetate
 




Ocular Effects. Male and female volunteers exposed by inhalation to 98, 113, or 195 ppm 2-butoxyethanol
 
for 4-8 hours experienced ocular irritation during exposure to 113 and 195 ppm (Carpenter et al.
 
1956). As discussed in Section 2.2.1.2, the ocular irritation was probably due to direct contact of the eyes
 
with the 2-butoxyethanol vapor.
 
Pregnant Fischer 344 rats dosed by inhalation during gestational days 6-15 with 25-200 ppm 2-butoxyethanol
 
exhibited periocular wetness at all concentrations. New Zealand white rabbits exposed to 100 and
 
200 ppm (but not to 25 ppm) during gestation exhibited the same effect (Tyl et al. 1984). As noted in
 




The eyes of rabbits instilled with unspecified amounts of undiluted 2-butoxyethanol (Dow 1958, 1959, 1981)
 
or 0.1 mL of undiluted 2-butoxyethanol (Rohm and Haas 1983; Union Carbide 1980b) exhibited severe eye
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irritation, moderate-to-extensive conjunctivitis, moderate cornea1 damage, and/or slight iritis (Dow 1958, 
1959, 1981; Rohm and Haas 1983; Union Carbide 1980b). Moderate comeal injury was observed in rabbits 
in which 0.5 mL of a 15% dilution of 2-butoxyethanol was placed in the conjunctival sac (Union Carbide 
1980b). No effects were observed with a dilution of 5%. A single 6-hour occluded dermal exposure of male 
and female New Zealand white rabbits to 451 or 902 mg/kg 2-butoxyethanol caused grey iris in males in the 
high-dose group (Union Carbide 1980a). No ocular effects were seen at the lower dose. In a companion 
study in which male rabbits were given the same dermal doses for 24 hours, iritis was observed at the high 
dose (Union Carbide 1980b). Lacrimation was also observed prior to death in New Zealand rabbits dosed 
with 2,000 mg/kg 2-butoxyethanol on abraded skin, and yellow cornea was observed in animals dosed with 
500 mg/kg 2-butoxyethanol (Olin 1976). No ocular effects were seen upon ophthalmological examination of 
male and female New Zealand white rabbits exposed dermally to 0, 18, 90, 180, or 361 mg/kg/day of 
2-butoxyethanol for a total of nine applications over an 11 -day period with an exposure duration of 6 hours 
per day (Union Carbide 1980a). 
The relationship between changes in cornea1 thickness (swelling) and Drake eye irritancy scores was 
examined to see if the former test could give equivalent results and a reduction in the variability inherent in 
the Draize procedure (Kennah et al. 1989a). The eyes of New Zealand albino rabbits were instilled with 
0.1 mL 2-butoxyethanol at concentrations of 10%, 20%, 30%, 70%, or 100% (dilutions were prepared in 
polyethylene glycol as weight/weight percentage solutions) in the conjunctival sac of one defect-free eye. The 
other eye served as a control. The cornea, iris, and conjunctiva were scored at 24, 48, and 72 hours and at 7, 
10, 14, and 21 days postdosing if irritation persisted. Cornea1 thickness was measured several hours before 
instillation of test material and thereafter at intervals coincident with the Draize scoring. A correlation with 
the Draize scoring procedure and cornea1 swelling was established. Eye irritation determination using this 
system showed that at 100% concentration, 2-butoxyethanol resulted in a Draize score of 66% with 19% 
coefficient of variation (CV), 181% cornea1 swelling with 9.9% CV, and was classified as severe. At 30% 
and 70% concentrations of 2-butoxyethanol, Draize scores were 39% and 49% with CV values of 13% and 
44%; cornea1 swelling values were 146% and 181%, with CV values of 9.7% and 18%. The Draize scores 
indicated moderate irritation. At 10% and 20% concentrations of 2-butoxyethanol, Draize scores were 1% 
and 2%, with CV values of 100% and 70%; cornea1 swelling values were 91% and 113%, with CV values of 
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Histological examination of the eyes revealed no adverse treatment-related ocular effects in male or female 
New Zealand rabbits dosed dermally with up to 150 mg/kg/day 2-butoxyethano16 hours per day, 5 days per 
week, for 90 days (CMA 1983). 
The eyes of New Zealand rabbits instilled with an unspecified amount of 2-butoxyethanol acetate for 
24 hours exhibited little effect (Truhaut et al. 1979). The eyes showed very little sign of irritancy, with only 
two of six rabbits showing slight conjunctival redness and discharge. 
Body Weight Effects. 2-Butoxyethanol caused a 13-16% decrease in body weight gain during 
treatment in pregnant Sprague-Dawley rats to which undihrted 2-butoxyethanol was applied four times daily 
(0.12 mL, per application or 0.48 mL/day) to the shaved interscapular skin on gestational days 7-16 (Hardin 
et al. 1984). In guinea pigs (sex and strain not specified) exposed epicutaneously to 0.5 or 2.0 mL 2-butoxy­
ethanol, and observed for 35 days, no effect on body weight was observed at the low dose (Wahlberg and 
Boman 1979). Mortality at the high dose was significant (65% within 1 week), and so no body weight 
measurements were made. No effects on body weight gain were observed in guinea pigs given a single 
dermal dose of 2,000 mg/kg and observed for 14 days (Shepard 1994a). The treated area was occluded for 
24 hours. A slight but unspecified initial weight loss occurred in rabbits to which 200 mg/kg 2-butoxyethanol 
was applied to the skin for 24 hours (Dow 1959). No effect on body weight was seen in male New 
Zealand white rabbits exposed dermally to 0, 18, 90, 180, or 361 mg/kg/day of 2-butoxyethanol for a total of 
nine applications over an 11-day period with an exposure duration of 6 hours per day, but female rabbits 
exhibited a decrease in weight gain of 121% on day 3 at 361 mg/kg/day compared to control animals, and 
continued to lose weight until sacrificed on day 35 (Union Carbide 1980a). No adverse treatment-related 
effects on body weight were noted in male and female New Zealand rabbits that received dermal doses 
≤ 150 mg/kg/day 2-butoxyethano16 hours per day, 5 days per week, for 90 days (CMA 1983). 
Other Effects. Pregnant Sprague-Dawley rats treated dermally four times daily with 2-butoxyethanol 
(0.35 mL per application or 1.4 ml/day) during gestation exhibited dark stains around the muzzle and 
anogenital area (Hat-din et al. 1984). This may have resulted from grooming activities in the presence of 
hemoglobinuria. Female New Zealand white rabbits that died after dermal application of 2-butoxyethanol at 
≥72 mg/kg exhibited hypothermia (Duprat and Gradiski 1979). Yellowed peritoneal fat was observed in 
male and female New Zealand white rabbits that died after a single 6-hour occluded dermal exposure to 
902 mg/kg 2-butoxyethanol (Union Carbide 1980a). This effect was not noted in animals exposed to 
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2.2.3.3 lmmunological and Lymphoreticular Effects 
No studies were located regarding immunological or lymphoreticular effects in humans after dermal exposure 
to 2-butoxyethanol acetate or regarding lymphoreticular effects in humans after dermal exposure to 2-butoxy­
ethanol. No studies were located regarding immunological effects in animals after dermal exposure to 
2-butoxyethanol or 2-butoxyethanol acetate. 
Volunteers (214 men and women) were given 0.2 mL 10% 2-butoxyethanol in patches applied to the 
intrascapular area of the back, either to the right or left of the midline (CMA 1992; Greenspan et al. 1995). 
A 10% concentration was used because it is the highest concentration of 2-butoxyethanol found in cosmetic 
products. The entire study extended over a 6-week period and involved three phases: induction, rest, and 
challenge. The induction phase consisted of nine consecutive applications of 2-butoxyethanol, and the 
subjects were assessed after 24-72 hours of patch application The subjects were required to remove the 
patches approximately 24-72 hours after application; they were evaluated and identical patches reapplied. 
Following the ninth evaluation, the subjects were dismissed for a 14-day rest period. The challenge phase of 
the experiment was initiated during the 6th week of the study, with identical patches applied to sites 
previously unexposed to 2-butoxyethanol. These patches were removed by subjects after 24 hours, and the 
sites were graded 48 and 72 hours after application Subjects who had six applications or more, with 
subsequent readings during induction, and at least one reading during challenge, were considered completed 
cases. One individual had erythema on the second challenge, 7 had barely perceptible erythema on the first 
challenge, and 12 had barely perceptible erythema on the second challenge. The study authors concluded that 
there was no evidence of sensitization to 10% 2-butoxyethanol in human subjects under the conditions 
applied in this study; 201 subjects completed the study. However, only a 10% dilution of 2-butoxyethanol 
was used; concentrations as high as 50% can be found in cleaning products which should be diluted before 
use (OECD 1997). 
2-Butoxyethanol has also been tested for dermal sensitization in guinea pigs using the maximized Magnusson 
and Kliman test (Zissu 1995). The sensitization test was completed over a 4-week period. The sensitization 
exposure involved an injection of 2-butoxyethanol with Freund’s adjuvant. The animals were injected behind 
the shoulders at the beginning of the 1st week of this study. On the 8th day of the study, the animals received 
a 48-hour topical application of 2-butoxyethanol. The doses for the sensitization exposures were not stated. 
The guinea pigs were allowed to rest during the 3rd week. On the 24th day of the study, 0.5 mL of a 1% 
2-butoxyethanol solution was applied for 48 hours to the left sheared flank using an occlusive patch. The 
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intensity of the erythema and edema was scored, and histopathological examinations were completed 
24 hours after the removal of the patch. By this assay, 2-butoxyethanol did not result in dermal sensitization 
of guinea pigs. 
Effects on lymphoreticular organs have been observed in animals after dermal exposure to 2-butoxyethanol. 
Congestion in the spleen, erythrocytic infiltration, and white atrophic pulp were noted in female New Zealand 
white rabbits that died after ≥72 mg/kg 2-butoxyethanol was applied to their clipped backs for 8 hours 
(Duprat and Gradiski 1979). Similarly, engorged spleen was noted in rabbits that died after acute dermal 
doses of ≥406 mg/kg (Carpenter et al. 1956). In addition, enlarged spleens were found in female New 
Zealand rabbits that died after a 6-hour occluded exposure to 902 mg/kg 2-butoxyethanol (Union Carbide 
1980a), and dark red spleens were found in male rabbits that died after a 24-hour exposure to 451 mg/kg 
(Union Carbide 1980b). Gross examination of the thymus, spleen, lymph nodes, and bone marrow did not 
reveal any adverse effects in guinea pigs treated with a single dermal dose of 2,000 mg/kg and observed for 
14 days (Shepard 1994a). The treated area was occluded for 24 hours. No effects on spleen or thymus 
weight and no histopathological lesions in the spleen, lymph nodes, or thymus were observed in male or 
female New Zealand rabbits that received dermal doses of ≤ 150 mg/kg/day 2-butoxyethano16 hours per day, 
5 days per week, for 90 days (CMA 1983). Increased spleen weight, dark spleens, and spleen engorgement 
effects are probably due to hemolysis, which is discussed under Hematological Effects. 
For 2-butoxyethanol acetate, histological examination of spleens revealed no lesions in New Zealand rabbits 
exposed dermally to doses of ≤ 10,000 mg/kg for 24 hours (Truhaut et al. 1979). 
The highest NOAEL values and all LOAEL values from each reliable study for immunological or lympho-reticular 
effects in each species and duration category are recorded in Tables 2-6 and 2-7. 
2.2.3.4 Neurological Effects 
No studies were located regarding neurological effects in humans after dermal exposure to 2-butoxyethanol or 
2-butoxyethanol acetate. 
Prostration and narcosis prior to death were noted in female New Zealand white rabbits after 2-butoxyethanol 
was applied to their clipped backs for 8 hours at ≥ 72 mg/kg (Duprat and Gradiski 1979). Anorexia and lack 
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2,000 mg/kg 2-butoxyethanol for 24 hours on abraded skin (Olin 1976). Muscular flaccidity was also seen in 
the rabbits at 1,000 and 2,000 mg/kg. Ataxia progressing to moderate-to-marked inactivity and death 
occurred in pregnant Sprague-Dawley rats treated dermally four times daily with 2-butoxyethanol(0.35 mL 
per application or 1.4 mL/day) on gestational days 7-16 (Hardin et al. 1984). Female, but not male, New 
Zealand rabbits receiving a 6-hour occluded dermal applicatiou of 902 mg/kg 2-butoxyethanol exhibited 
nystagmus and convulsions prior to death (Union Carbide 1980a). In an intermediate-duration study, 
histological examination of the brain and sciatic nerve revealed no pathological lesions in male or female New 
Zealand rabbits dosed dermally at ≤ 150 mg/kg/day 2-butoxyethanol6 hours per day, 5 days per week, for 
90 days (CMA 1983). 
For 2-butoxyethanol acetate, histological examination of the brain revealed no lesions in New Zealand rabbits 
exposed dermally to ≤ 10,000 mg/kg for 24 hours (Truhaut et al. 1979). 
The highest NOAEL values and all LOAEL values from each reliable study for neurological effects in each 
species and duration category are recorded in Tables 2-6 and 2-7. 
2.2.3.5 Reproductive Effects 
No studies were located regarding reproductive effects in bumans after dermal exposure to 2-butoxyethanol 
or 2-butoxyethanol acetate. 
Information regarding reproductive effects in animals after dermal exposure to 2-butoxyethanol or 2-butoxy­
ethanol acetate is limited to data on reproductive organ weights and histological examination of reproductive 
organs No studies assessing reproductive function were Located. Gross changes at necropsy were not 
observed in the reproductive organs (epididymides, testes, ovaries, fallopian tubes, uterus, vagina, cervix, 
uteri) of guinea pigs given a single dermal(24 hours occluded) dose of 2,000 mg/kg and observed for 14 days 
(Shepard 1994a). No effect on testicular weight was found in male New Zealand white rabbits given dermal 
applications of 18-361 mg/kg/day 2-butoxyethanol for 6 hours per day for nine applications over 11 days 
(Union Carbide 1980a). The reproductive organ weights of female rabbits were not determined. Histological 
examination of testes, epididymides, seminal vesicles, prostate, mammary glands, ovaries, uterus, and vagina 
revealed no pathological lesions in male or female New Zealand rabbits dosed with 10, 50, or 150 mg/kg/day 
2-butoxyethanol for 6 hours per day, 5 days per, week for 90 days (CMA 1983). A slight (5.2%), but 
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statistically significant, increase in relative testicular weight was noted for males in the 150-mg/kg/day dose 
group, but no effects on the weight of the ovaries were found in the females at any dose. 
For 2-butoxyethanol acetate, histological examination of the testes and ovaries revealed no pathological 
lesions in male or female New Zealand rabbits exposed dermally to ≤ 10,000 mg/kg for 24 hours (Truhaut et 
al. 1979). 
The highest NOAEL values and all LOAEL values from each reliable study for reproductive effects in each 
species and duration category are recorded in Tables 2-6 and 2-7. 
2.2.3.6 Developmental Effects 
No studies were located regarding developmental effects in humans after dermal exposure to 2-butoxyethanol 
or 2-butoxyethanol acetate or regarding developmental effects in animals after dermal exposure to 2-butoxyethanol 
acetate. 
Water or undiluted 2-butoxyethanol was applied four times daily (0.12 mL per application or 0.48 mL/day) 
on gestational days 7-16 to the shaved interscapular skin of pregnant Sprague-Dawley rats (Hardin et al. 
1984). No embryotoxic, fetotoxic, or teratogenic effects were detected in the offspring. At necropsy, no 
gross malformations were observed in the fetuses 
The NOAEL value for developmental effects in rats after acute dermal exposure to 2-butoxyethanol is 
recorded in Table 2-6. 
2.2.3.7 Genotoxic Effects 
No studies were located regarding genotoxic effects in humans or animals after dermal exposure to 2-butoxy­
ethanol or 2-butoxyethanol acetate. In vitro genotoxicity studies are discussed in Section 2.5.­
2.2.3.8 Cancer 
No studies were located regarding carcinogenic effects in humans or animals after dermal exposure to 
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2.3 TOXICOKINETICS 
2-Butoxyethanol is well-absorbed following inhalation, oral, and direct dermal exposure. Dilution with water 
has resulted in more rapid absorption of 2-butoxyethanol following in vitro exposure of rat skin. Small 
amounts of the vapor can also be absorbed through the skin. There is little information concerning the 
absorption of 2-butoxyethanol acetate. 2-Butoxyacetic acid has been detected in persons occupationally 
exposed to 2-butoxyethanol acetate, and the compound was absorbed following direct dermal exposure of 
rabbits. 
Metabolism of 2-butoxyethanol and 2-butoxyethanol acetate to 2-butoxyacetic acid and further metabolism 
to carbon dioxide is the major pathway of metabolism in both humans and animals. The production of 
ethylene glycol is a minor pathway of metabolism in both animals and humans. 2-Butoxyethanol and 2­
butoxyacetic acid are widely distributed throughout the body, with no site of accumulation identified. 
Following all routes of exposure, urinary excretion of 2-butoxyacetic acid and its conjugates is the major 
route of elimination. 
2.3.1 Absorption 
2.3.1.1 Inhalation Exposure 
Information describing human absorption of 2-butoxyethanol after inhalation exposure comes from both 
controlled experiments and occupational exposure. Seven male volunteers were exposed to 2-butoxyethanol 
at the Swedish occupational exposure limit (20 ppm or 0.85 mmol/ m3) for 2 hours during light physical 
exercise on a bicycle ergometer (Johanson et al. 1986a). Expired air was collected at regular time intervals 
for estimation of the respiratory uptake of the solvent. Capillary blood was sampled during and after the 
exposure period and analyzed for 2-butoxyethanol. The respiratory uptake of 2-butoxyethanol averaged 
10.1 µmol/minute (1.2 mg/minute) or 57% of the inspired amount. The concentration in blood reached a 
plateau level of 7.4 µmol/L (0.9 mg/L) within 1-2 hours. In another experimental study in humans, venous 
blood samples were collected from five healthy male volunteers prior to and after inhalation exposure to 
20 ppm 2-butoxyethanol (the Swedish permissible exposure limit) for 2 hours during light physical exercise 
(Johanson and Johnsson 1991). Samples were collected at 0, 2, 4, and 6 hours from the start of exposure, 
and analysis indicated that 2-butoxyacetic acid, the major metabohte of 2-butoxyethanol, was found in all 
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samples except those collected prior to exposure. The minimum and maximum observed concentrations of 
2-butoxyacetic acid in blood ranged from 20 to 57 µM (2.6-7.5 mg/L) with average concentrations of 22, 44, 
39, and 28 µM at 1, 3, 4.9, and 7.1 hours, respectively. The 2-butoxyacetic acid blood level peaked after 
2-4 hours. 
Healthy male volunteers were exposed to 50 ppm 2-butoxyethanol vapor for 2 hours by mouth through a 
respiratory valve (Johanson and Boman 199 1) Capillary blood samples were collected at regular intervals 
and analyzed for 2-butoxyethanol. Duplicate experiments were carried out on each volunteer, with normal or 
increased temperature and humidity. The concentration of 2-butoxyethanol increased during the 1 st hour and 
appeared to approach steady state at about 3 µM during the 2nd hour. The respiratory uptake rate during 
mouth exposure was 1.3 mmole over a period of 2 hours, or 11 µmol/minute. 
Seventeen people (2 women and 15 men), who were exposed to glycol ethers in a varnish production plant, 
were examined to determine their environmental and internal solvent exposure (Angerer et al. 1990). The 
workers in the production plant (n=12) were exposed to an average 2-butoxyethanol concentration of 
1.1 ppm, among other solvents. Internal exposure was estimated by measuring free 2-butoxyethanol in blood 
as well as free 2-butoxyacetic acid in urine samples. Urine samples were taken pre- and postshift. The 
exposure of varnish workers to 2-butoxyethanol ranged from <0.1 to 8.1 ppm, compared to <0.1 ppm for 
workers in the store or the laboratory. The average permissible exposure limit was 20 ppm (Germany). 
Biological monitoring indicated 2-butoxyethanol levels in postshift blood of 121.3 µg/L for varnish 
production (range: <5.0-570.0 µg /L), compared to 49.4 µg /L for store workers (range: <5.0-143.1 µg/L) 
and <5.0 µg /L for laboratory workers. Pre- and postshift levels of 2-butoxyacetic acid in urine (mg/L) were 
3.3 and 10.5 for varnish workers, 2.1 and 4.5 for store workers, and 0.2 and 4.2 for laboratory workers, 
respectively. Values were not normalized to creatinine. There was little correlation between external and 
internal levels of exposure, presumably because there was significant direct dermal exposure that was not 
measured. The study authors indicate that “At these working places glycol ethers were absorbed through the 
skin on a major scale. Because the workers were cleaning instruments, floor and skin with the solvents, skin 
contact was far from negligible.” 
Individual exposure to 2-butoxyethanol acetate was measured by personal air sampling and biological 
monitoring of urine from 19 employees during an 8-hour workday in four silk-screen printing installations 
(Johanson et al. 1989). The samples were analyzed by gas chromatography. Urine was quantitatively 
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personal air samples of 5 individuals at an average concentration of 0.44 ppm. Free 2-butoxyacetic acid was 
detected in the urine of 12 individuals at an average concentration of 8 µmol/L. 
The data on absorption of 2-butoxyethanol after inhalation exposure in animals is scanty. In an early study, 
rats, guinea pigs, dogs, and rabbits exposed to 100-400 ppm 2-butoxyethanol for 4 hours excreted 
2-butoxyacetic acid in the urine, with most of the metabolite excreted within 24 hours, indicating pulmonary 
absorption (Carpenter et al. 1956). Dogs and monkeys exposed to 100-398 ppm 2-butoxyethanol for 
28-90 days also excreted 2-butoxyacetic acid in the urine. 
In a more definitive study, the uptake, metabolism, and excretion of 2-butoxyethanol following 6-hour 
nose-only inhalation exposure of male Fischer 344 rats was determined at different inhaled concentrations 
(Sabourin et al. 1992a). Three to five rats per group were exposed to 4.3, 49, or 438 ppm 2-butoxyethanol 
for 6 hours for the determination of respiratory uptake and excretion. Additional groups of rats were used to 
determine fractional uptake of inhaled 2-butoxyethanol and body burden at the end of the exposure. Rats 
selected for body burden determination were euthanized, and the entire carcass was digested at the end of the 
6-hour exposure period. Rats selected for metabolism determination were put into metabolism cages 
following the 6-hour exposure to determine excretion of the compound. The uptake was 4.49 µmol/ppm at 
4.3 ppm, 4.58 µmol/ppm at 40 ppm, and 3.58 µmol/ppm at 438 ppm. A less-than-proportional amount of 
2-butoxyethanol was inhaled at the high dose because of decreased minute volume. 
In a more recent study, eight male Sprague-Dawley rats were exposed to 20 or 100 ppm 2-butoxyethanol 
24 hours per day for 1, 2, 3, 4, 6, 8, 10, or 12 days (Johanson 1994). Urine was collected at 24-hour 
intervals. At the end of the exposure period, animals were killed and blood, muscle, liver, and testis were 
collected. Blood and tissue samples were analyzed for 2-butoxyethanol and 2-butoxyacetic acid by electron 
capture gas chromatography. No control group was used. The concentration of 2-butoxyethanol in the 
four tissues examined increased rapidly during the first l-3 days of exposure. The average peak concentration 
of 2-butoxyethanol in the blood was 15.1 µmol/L in the 20-ppm group and 72.3 µmol/L in the 100-ppm 
group, indicating linear uptake by blood. Respiratory uptake averaged 0.31 mmol/day at 20 ppm and 
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2.3.1.2 Oral Exposure 
Case reports of intentional poisonings with 2-butoxyethanol provide some kinetic information for human oral 
exposure. A report on a woman admitted to the hospital after ingestion of 250-500 mL of a window cleaner 
containing 12% 2-butoxyethanol(467-933 mg/kg 2-butoxyethanol) in a suicide attempt indicated metabolic 
acidosis, hypokalemia, a rise in serum creatinine level, and markedly increased urinary excretion of oxalate 
crystals, indicating substantial absorption from the gastrointestinal tract (Rambourg-Schepens et al. 1988). 
Similar effects have been observed in other case reports of humans who ingested 2-butoxyethanol at 
391-650 mg/kg (Bauer et al. 1992; Gijsenbergh et al. 1989). In the case reported by Rambourg-Schepens et 
al. (1988), kinetic evaluation of urinary excretion of 2-butoxyethanol indicated that 2-butoxyethanol was at 
the highest level of excretion at 1 day after ingestion. 
Studies in animals indicate that absorption of 2-butoxyethanol after oral exposure is rapid and extensive 
(Ghanayem et al. 1987c). Male Fischer 344 rats were given a single oral dose of [14C]2-butoxyethanol at 
125 or 500 mg/kg. Rats were placed in metabolism cages and monitored for 48 hours after treatment. At 
48 hours, animals were killed and the 14C -radioactivity in each tissue, as well as in the blood, was determined. 
Detectable exhalation of radioactivity began l-2 hours after treatment, indicating rapid absorption and 
distribution. Approximately 18% and 10% of the administered doses of 125 and 500-mg/kg, respectively, 
was exhaled as 14CO2 in 48 hours. Cumulative urinary excretion of radioactivity amounted to approximately 
32% and 18% of the 125-and 500-mg/kg doses at 8 hours, to approximately 64% and 30% of the respective 
doses at 24 hours, and to approximately 70% and 40% of the respective doses at 48 hours. Fecal excretion of 
radioactivity amounted to 2-3% of the doses in 48 hours, and may represent biliary excretion (biliary 
metabolites were identified, see below) as well as unabsorbed 2-butoxyethanol. Thus, by adding the 48-hour 
excretion of radioactivity in the expired air and urine, at least 88% of the 125-mg/kg dose and at least 50% of 
the 500-mg/kg dose were absorbed. The fact that the percentage of radioactivity excreted was less at the 
higher dose than at the lower dose may indicate saturation of a metabolic pathway rather than lower 
absorption of the high dose, based on the finding that the urinary levels of the glucuronide conjugate of 
2-butoxyethanol of the high-dose rats remained constant for 24 hours, while the glucuronide l&els declined 
after 8 hours in the low-dose rats (see Section 2.3.3 on Metabolism, below). 
In male Fischer 344 rats given single gavage doses of 8.6 or 126 mg/kg [14C]2-butoxyethanol, 59% of the 
low dose of radioactivity and 38-70% of the high dose of radioactivity were excreted in the urine during the 
first 24 hours (Corley et al. 1994). Excretion of 14CO2 in the expired air amounted to 7.2% of the low-dose 
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and 8% of the high dose in 24 hours. Thus, at least 66.2% of the low dose and 46-78% of the high dose were 
absorbed. 
Male Fischer 344/N rats were allowed access for 24 hours to uniformly labeled [14C]2-butoxyethanol in 
drinking water at three doses (Medinsky et al. II 990). Elimination of radioactivity was monitored for 
72 hours. 2-Butoxyethanol was administered at doses of 290, 860, or 2,590 ppm in drinking water, resulting 
in consumption of 237, 401, or 1,190 µmol//kg (28, 47, or 141 mgIkg/day). The majority of the 14C was 
excreted in urine (50-60% of the dose as 2-butoxyacetic acid and 10% as ethylene glycol) or exhaled as CO2 
(8-10% of the dose). Less than 5% of the dose was exhaled as unmetabolized 2-butoxyethanol. 
2.3.1.3 Dermal Exposure 
Worker exposures to 2-butoxyethanol were evaluated by euvironmental and biological monitoring for 
29 employees in five shops where window-cleaning agents had been used (Vincent et al. 1993). Each of the 
29 employees was exposed to 2-butoxyethanol. Eleven men and two women were involved in cleaning cars 
in four garages. The remaining 16 were office cleaners. Only two of the workers who cleaned new cars wore 
protective gloves. The study authors suggested that the primary route of exposure was dermal, although 
some inhalation exposure necessarily occurred. Each of the window-cleaning agents sampled contained 
2-butoxyethanol in concentrations ranging from 0.9% to 21.2% in volume. The duration of window-cleaner 
use ranged from 120 to 320 minutes per day, and quantities of cleaning agents ranged from 220 to 
1,200 mL/day for individuals involved in cleaning new cars. The corresponding figures for cleaners of used 
cars were 20-50 minutes and 50-100 mL. For office cleaners, the corresponding figures were 15 minutes a 
day and <50 mL of cleaning agent used per day. For cleaners of new cars, the mean 2-butoxyethanol 
exposure was 2.33 ppm (range, <0.10-7.33 ppm), and the mean urinary 2-butoxyacetic acid concentration in 
endshift samples was 111.3 mg/g creatinine (range 12.7-371 mg/g creatinine). Mean preshift (average of 
Monday and Friday) urinary 2-butoxyacetic acid concentration was 17.9 mg/g creatinine (range, 
<2-98.6 mg/g creatinine). For cleaners of used cars, the mean 2-butoxyethanol exposure was 0.36 ppm 
(range, <0.10-l .52 ppm), and the mean urinary 2-butoxyacetic acid concentration in endshift samples was 
6.3 mg/g creatinine (range, 2-24.4 mg/g creatinine). Mean preshift urinary concentration of 2-butoxyacetic 
acid was 4.8 mg/kg creatinine (range, 2-33 mg/g creatinine). For the office cleaners, the mean 
2-butoxyethanol exposure concentration was 0.32 ppm (range, <0.30-0.73 ppm), and the mean urinary 
2-butoxyacetic acid concentration in endshift samples was 2.1 mg/g creatinine (range, 2-3.3 mg/g creatinine). 
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creatinine). Correlations of 2-butoxyethanol exposure in air and endshift concentrations of urinary 
2-butoxyacetic acid from cleaners of new and used cars (for which the data were most complete) indicated a 
log-linear relationship. From these results, the study authors estimated that exposure to window cleaners 
containing 5.7-21.2% 2-butoxyethanol by volume for a period of 160 minutes would result in an endshift 
urinary 2-butoxyacetic acid concentration of 60 mg/g creatinine. A similar relationship was observed for 
urinary 2-butoxyacetic acid concentrations and utilization time for office cleaners. The positive correlations 
between exposure levels of 2-butoxyethanol and 2-butoxyacetic acid in the urine indicate dermal (and 
probably some pulmonary) absorption of 2-butoxyethanol by these workers. 
Experimental evidence exists that dermal absorption of 2-butoxyethanol vapors may contribute to the overall 
absorption of 2-butoxyethanol during vapor exposure (Johanson and Boman 1991). Healthy male volunteers 
were exposed to 50 ppm 2-butoxyethanol vapor for 2-hour periods, first by mouth only through a respiratory 
valve, then by skin only while wearing respiratory protection. Capillary blood samples (finger prick) were 
collected at regular intervals and analyzed for 2-butoxyethanol. Duplicate experiments were carried out on 
each volunteer, with normal or increased temperature and humidity. In the mouth-only study, the 
concentration of 2-butoxyethanol increased during the 1st hour and appeared to approach steady state at 
about 3 µM during the 2nd hour. The respiratory uptake was 1.3 mmole over 2 hours or 11 µmol/rninute and 
the apparent blood clearance was 3.8 L/minute. In the percutaneous exposure, the concentration of 2-butoxy­
ethanol increased to about 9 µM during the 2nd hour. The half-life of 2-butoxyethanol in the blood after skin 
exposure was about 34 minutes. The average concentration in blood and the calculated rate of uptake of 
2-butoxyethanol were about 3-4 times higher during dermal exposure than during inhalation exposure, 
suggesting that about 75% (45-85%) of the total uptake during normal vapor exposure could be accounted 
for by dermal absorption. However, the experimental subjects wore only shorts, which is dissimilar from the 
usual occupational or consumer exposure scenario. In addition, it has been suggested that the finger prick 
method of blood sampling provides a sample of venous blood draining the skin, rather than a sample of 
systemic blood (Corley et al. 1997). Therefore, the estimate of dermal absorption by Johanson and Boman 
( 1991) is most likely an overestimate. 
A study of 6 men exposed one arm-only to 50 ppm 2-butoxyethanol (13C2 labeled on the ethylene glycol 
backbone) for 2 hours, in which blood samples were taken from the unexposed arm, and from a finger prick 
of the exposed arm, shows much lower dermal absorption of 2-butoxyethanol vapor (Corley et al. 1997) than 
noted by Johanson and Boman (1991). Concentrations of 2-butoxyethanol in the finger prick sample from 
the exposed arm were about 1,500 times greater than the blood concentration in the sample from the 
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unexposed arm. Concentrations of 2-butoxyacetic acid were about 37 times greater in the finger prick sample 
from the exposed arm compared to the sample from the unexposed arm, confirming that the finger prick 
method of blood sampling provides a sample of venous blood draining the skin. Based on data from the 
Corley et al. (1997) study and from the Johanson and Boman (1991) study, skin permeability coefficients (kp) 
of 2 and 4 cm/hour were estimated for normal (23ºC, 29% relative humidity) and elevated (33°C, 71% 
relative humidity) temperature and relative humidity, respectively. The Corley (1994) model was further 
refined by modifying it to better reflect human metabolism as measured by urinary metabolite levels in Corley 
et al (1997), and to include a new permeability coefficient. Dermal uptake was estimated under worst-case 
resting conditions (respiration rates at their lowest, no clothing worn) and under more realistic conditions 
(35% of the body surface area exposed). Under the worst case conditions, 15-27% of the total uptake of 
2-butoxyethanol vapor would be through the skin, while dermal uptake would be 4.4-8.4% of the total if only 
25% of the body surface was exposed. Under simulated exercise (50 W, increased respiratory rates and 
cardiac output), uptake was estimated as 4.6-8.7% and 1.2-2.3% of the total assuming 100% or 25% of the 
body surface area was exposed, respectively. 
The percutaneous absorption of liquid 2-butoxyethanol was investigated in 12 exposure experiments with 
five men (Johanson et al. 1988). All were nonsmokers and stated low or no consumption of alcohol. None 
had been exposed to industrial solvents. All had participated in a previous study of 2-butoxyethanol 
(Johanson et al. 1986a). The subjects kept two or four fingers immersed in neat 2-butoxyethanol for 2 hours. 
Capillary blood samples were collected from the other hand before, during, and up to 4 hours after the 
exposure and analyzed for 2-butoxyethanol. The presence of 2-butoxyethanol in blood and 2-butoxyacetic 
acid in urine confirmed that 2-butoxyethanol enters the systemic circulation in human males during in vivo 
dermal exposure. The shape of the uptake profile varied considerably among individuals and also among 
experiments. Percutaneous uptake rates were calculated from measured blood levels of 2-butoxyethanol with 
the use of kinetic parameters (clearance and volume of distribution) obtained in earlier experiments with the 
same subjects. The uptake rates ranged from 7 to 96 nmol/minute/cm2 (0.83-/ 1.35 mg/minute/cm2), with a 
geometric mean of 20 nmol/minute/cm2 (2.36 mg/minute/cm2). The results indicate that persons exposing 
large portions of their skin to 2-butoxyethanol are likely to absorb significant doses. 
An in vitro study indicated that 2-butoxyethanol is absorbed through human abdominal epidermis (Dugard et 
al. 1984). Undiluted 2-butoxyethanol was applied to human abdominal epidermal membranes for a period of 
8 hours. The absorption rate was 0.2 mg/cm2/hour. In another in vitro study, a 10% solution of 
2-butoxyethanol was applied to a 3- cm2 area on frozen human arm skin, which was obtained at autopsy, 
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under semiocclusive or nonocclusive conditions (Bartnik et al. 1987). The percentage of absorption was 
6.9% for the nonocclusive condition and 17.3% for the semiocclusive condition. 
2-Butoxyethanol is also absorbed by animal skin. 2-Butoxyethanol was applied to the shaven skin of male 
and female rats on a 12- cm2 area at a dose of 200 mg/kg (Bartnik et al. 1987). The application site was 
protected with a glass capsule to prevent oral uptake. Urine was collected at intervals of 0-8, 8-24, and 
24-48 hours following application and stored at -80°C. Total radioactivity was determined for urine, cage 
rinse water, skin, and glass capsule. Percutaneous absorption was assessed by using the measurements of 
urinary excretion of 14C from 0 to 48 hours following cutaneous application of 2-butoxyethanol. Radioactivity 
measured during the 48 hours following cutaneous application of radiolabeled 2-butoxyethanol 
showed that 20-23% of the applied dose was found in the urine, including cage rinse water, with no notable 
differences by sex. Over 95% of the radioactivity excreted in the urine was eliminated during the first 
24 hours (metabolite not identified). Small amounts of radioactivity were found on the treated skin of male 
(4.7%) and female (8.3%) rats. Percutaneous absorption was determined to be 25-29% of the applied dose. 
Percutaneous absorption was measured after three different doses of the [14C]2-butoxyethanol (61, 181, or 
299 mg/kg) were applied to same-sized areas on the clipped backs of Fischer 344/N rats; the sites of 
application were nonoccluded but were protected with a perforated covering (Sabourin et al. 1992b, 1993). 
The rates of excretion of the 14C-labeled parent compound and metabolites by different routes were measured, 
as well as the amount of 14C remaining in the carcass. Within the dose range studied, the absorption and 
metabolism of 2-butoxyethanol by Fischer 344/N rats was linearly related to the dermally applied dose. The 
absorption was approximately 21-26%, regardless of the dose administered. A small fraction of the applied 
dose (0.3-2%) was still present at the application site 72 hours following dosing, representing unabsorbed 
parent compound, dermally excreted parent compound, or metabolites in the skin. The remainder of the 
applied dose was recovered as volatilized radioactivity. The total recovery was 78-90%. The majority of the 
absorbed dose was excreted in the urine. Peak levels of radioactivity were reached at about 1 hour, with a 
half-life of about 4 hours. 
The percutaneous absorption rate and elimination kinetics of 2-butoxyethanol were estimated in the guinea 
pig (Johanson and Femstrom 1986). An intravenous bolus dose of 5 or 11 mg/kg was administered into the 
jugular vein of 10 pentobarbital-anesthetized animals in order to calculate total clearance and mean residence 
time of the compound in guinea pigs. Following the intravenous dose, the apparent total clearance and mean 
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respectively. At 2.5 hours after the intravenous dose, which was sufficient time for clearance of the 
intravenous dose, 1 mL neat 2-butoxyethanol was applied in two sealed glass rings on the clipped back of the 
animal for 2 hours. The concentration of 2-butoxyethanol in blood rose rapidly following the dermal 
application, and then approached a plateau level of 21 , µmol/L (2.482 mg/L) during the latter half of the 
exposure period. The absorption rate through the skin was estimated to be 0.25 (range, 0.05-0.46) 
µmol/minute/cm2 (29.6 µg/minute/cm2). The percutaneous uptake rate of 2-butoxyethanol in the present 
study was comparable to that obtained in vitro with human skin (i.e., 0.03 µmol/minute/cm 
[3.55 µg/minute/ cm2]) once species differences were taken into account. The time lag of 21-60 minutes 
observed in the present study is in accordance with that reported for the penetration of 2-butoxyethanol 
through human skin in vitro (Dugard et al. 1984). 
In in vitro experiments, frozen human skin from the flexus side of arms (obtained at autopsy), fresh dorsal 
skin of hairless rats, and frozen dorsal skin of pigs were used in a comparison absorption study of 2-butoxyethanol 
(Bartnik et al. 1987). Connective tissues and fat were removed. The solutions of [14C]2-butoxyethanol 
were applied to a skin area of 3 cm2 for human skin and 5 cm2 for animal skin for 1 hour. The 
solutions (30 µL) of 2-butoxyethanol administered were as follows: 100% 2-butoxyethanol; 3.5% 2-butoxyethanol 
in water; 10% 2-butoxyethanol in water; 3.5% or 10% 2-butoxyethanol with 5% linear sodium 
dodecylbenzene sulfonate (LAS) in water; and 3.5% or 10% 2-butoxyethanol with 5% isopropanol in water. 
Both semioccluded and nonocclusive conditions were used. Absorption was determined after exposure 
durations of 1, 6, and 16 hours (semiocclusive) in rat skin 6 hours (semiocclusive) in pig skin, and 1 hour 
nonocclusive in rat skin. 2-Butoxyethanol at 3.5% (0.21 mg/ cm2) in water was also tested after 10, 30, and 
60 minutes under nonocclusive conditions in both rat and pig skin. Absorbed and nonabsorbed radioactivity 
levels were determined. In rat skin under semiocclusion, the applied dose of 2-butoxyethanol was rapidly 
absorbed (19% of 100% 2-butoxyethanol, 62.7% of 10% 2-butoxyethanol, and 45.6% of 3.5% 2-butoxyethanol 
in water at 1 hour) and after 16 hours was almost completely absorbed through the skin (94.3% of 
100% solution, 82.6% of 10% solution, and 88.4% of 3.5% solution). The amount of penetration depended 
on time as well as concentration. The penetration of pure 2-butoxyethanol was initially slower than from 
aqueous solutions, but was more complete after 16 hours. In nonoccluded rat skin, 5.6% of the 100% 
2-butoxyethanol, 10.4% of the 10% solution, and 11 .1% of the 3.5% solution were absorbed within 1 hour. 
In pig skin under semiocclusion, the applied dose of 2-butoxyethanol was less rapidly absorbed (2-3 times 
slower) than through rat skin. The penetration of pure 2-butoxyethanol was slower than from aqueous 
solutions and reached 11.2% after 6 hours, compared with 36.9% of the 10% solution and 47.5% of the 3.5% 
solution of 2-butoxyethanol. Isopropanol and LAS had little effect on absorption. In nonoccluded skin 
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treated with 3.5% 2-butoxyethanol, rat skin absorbed 10.4% in 10 minutes, 11.5% in 30 minutes, and 11.0%
 
in 60 minutes, while pig skin absorbed 2.8% at 10 minutes, 6.6% at 30 minutes, and 5.4% at 60 minutes. In
 
the comparison of in vitro skin penetration for humans, rats, and pigs, the data for 100 µg/cm2 exposure for
 
1 hour were presented. For nonocclusive exposure, the percentages of absorption were 11% for rat skin,
 
8.6% for pig skin, and 6.9% for human skin. For semiocclusive exposure, the percentages of absorption were
 
43.3% for rat skin, 17.7% for pig skin, and 17.3% for human skin. Thus, the absorption pattern was:
 
hairless rat>>>pig≥ human skin.
 
In a study on 2-butoxyethanol acetate in groups of six New Zealand rabbits to which the compound was
 
applied dermally under occlusion for 24 hours, the doses of 3,319, 3,957, 4,766, 5,957, and 10,000 mg/kg
 
were reported to correspond to absorbed doses (mg/kg±SE) of 610±310, 910±140, 1,130±390, 1,830±290,
 
and 2,200±530 mg/kg, respectively (Truhaut et al. 1979). The absorbed doses were determined by
 
comparing the amount of 2-butoxyethanol acetate applied under occlusion with the amount of 2-butoxyethanol
 
acetate remaining after 24 hours of contact with the skin. The absorbed doses showed wide
 
variability, which may be because this method is not very accurate.
 
2.3.2 Distribution 
2.3.2.1 Inhalation Exposure 
Some information describing distribution of 2-butoxyethanol and its major metabolite, 2-butoxyacetic acid 
after human inhalation exposure can be found in reports of controlled experiments. Venous blood samples 
were collected from five healthy male volunteers prior to and after inhalation exposure to 20 ppm 2-butoxyethanol 
during light physical exercise for 2 hours (Johanson and Johnsson 1991). 2-Butoxyacetic acid was 
found in all blood samples except those collected prior to exposure. Binding of 2-butoxyacetic acid to blood 
components is indicated by the low apparent volume of distribution of approximately 15 L, which is 
approximately equal to the volume of extracellular water, and the fact that the renal clearance rate is about 
one-third of the glomerular filtration rate. In another human study, seven male volunteers were exposed to 
2-butoxyethanol for 2 hours at 20 ppm during light physical exercise on a bicycle ergometer (Johanson et al. 
1986a). For 2-butoxyethanol, the apparent value of steady-state volume of distribution was 54 L and the 
mean residence time was 42 minutes. 2-Butoxyethanol was no longer detectable in the blood 2-4 hours after 
the end of exposure (Johanson et al. 1986a). 
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In animal studies, the body burden of [14C]2-butoxyethanol following 6-hour nose-only inhalation exposure 
of male Fischer 344 rats was determined at several inhaled concentrations (Sabourin et al. 1992a). The 
uptake (4.49 µmol/ppm at 4.3 ppm; 4.58 µmol/ppm at 49 ppm; 3.58 µmol/ppm at 438 ppm) and metabolism 
(0.79 µmol/ppm at 4.3 ppm; 0.95 µmol/ppm at 49 ppm; 0.88 µmol/ppm at 438 ppm) of 2-butoxyethanol, 
expressed as [14C]2-butoxyethanol equivalents, were essentially linear up to 438 ppm. Most (greater than 
80%) of the [14C]2-butoxyethanol-derived material in blood was in the plasma. 2-Butoxyacetic acid was the 
major metabolite of 2-butoxyethanol in plasma. Ratios of ethylene glycol to 2-butoxyacetic acid in plasma 
were higher than those in urine. The 2-butoxyethanol-derived 14C in plasma rapidly became associated with 
the acid-precipitable (protein) fraction, probably because of binding of metabolites to proteins or 
incorporation of the 2-butoxyethanol metabolites into the carbon pool. 
In a more recent study, eight male Sprague-Dawley rats were exposed to 20 or 100 ppm 2-butoxyethanol 
24 hours per day for 1, 2, 3, 4, 6, 8, 10, or 12 days (Johanson 1994). Urine was collected at 24-hour 
intervals. At the end of the exposure period, animals were killed and blood, muscle, liver, and testis were 
collected. Blood and tissue samples were analyzed for 2-butoxyethanol and 2-butoxyacetic acid by electron 
capture gas chromatography. The concentrations of 2-butoxyethanol in blood, in the 20-ppm group were as 
follows: 7.5-29.0 µmol/L, with an average of 15.1 µmol/L; muscle, 0.9-13.0 µmol/kg, average of 
9.1 µmol/kg; testis, 1.3-11.6 µmol/kg, with an average of 3.9 µmol/kg; and liver 5.1-16.4 µmol/kg, with an 
average of 10.8 µmol/kg. In the 100-ppm group, the concentrations were as follows: blood, 
23.0-103 µmol/L, with an average of 72.3 µmol/L, muscle, 13.6-49.8 µmol/kg, with an average of 
30.4 µmol/kg; testis, 4.7-36.1 µmol/kg, average, with an average of 12.6 µmol/kg; and liver, 
42.4-129 µmol/kg, with an average of 83.8 µmol/kg. Although data points were reported on exposure days 
1-12, the averages were calculated for 2-12 exposure days. The concentration of 2-butoxyethanol increased 
rapidly in the tissues during days l-3 and continued to increase, but more slowly, during the remaining days. 
Tissue concentrations in the 100-ppm group conformed to expected linear kinetics. Concentration ratios 
(100 ppm/20 ppm) were 5.1 for blood, 3.5 for muscle, 3.6 for testis, and 7.5 for liver. The kinetic pattern of 
2-butoxyacetic acid was similar to 2-butoxyethanol. The concentrations in the 20-ppm group were as 
follows: blood, 31.8-48.8 µmol/L, with an average of 41.0 µmol/L; muscle, 5.8-14.9 µmol/kg, with an 
average of 9.3 µmol/kg; testis, 9.7-23.3 µmol/kg, with an average of 14.1 µmol/kg; and liver, 
9.5-26.4 µmol/kg, with an average of 16.4 µmol/kg. In the 20-ppm group, the concentrations were as 
follows: blood, 125-226 µmol/L, with an average of 179 µmol/L; muscle, 17.9-63.6 µmol/g, with an 
average of 36.2 µmol/kg; testis, 11.6-48.5 µmol/kg, with an average of 26.7 µmol/kg; and liver, 
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days l-l 2, but the averages were calculated for 2-12 exposure days. As with 2-butoxyethanol, the 
2-butoxyacetic acid concentration increased rapidly in the tissues during the first l-3 days and then more 
slowly during the remaining days. Tissue concentrations in the 100-ppm group conformed to expected linear 
kinetics. Concentration ratios (100 ppm/20 ppm) were 4.4 for blood, 4.7 for muscle, 2.3 for testis, and 
5.3 for liver. Thus, the disposition of 2-butoxyethanol and 2-butoxyacetic acid was linear at the exposure 
concentrations used, and although the number of tissues examined was limited, the data indicated extensive 
distribution. 
2.3.2.2 Oral Exposure 
Studies in animals indicate that distribution of 2-butoxyethanol after oral exposure is rapid (Ghanayem et al. 
1987c). Male Fischer 344 rats were given a single oral dose of [14C]2-butoxyethanol of 125 or 500 mg/kg. 
Rats were placed in metabolism cages and monitored for 48 hours after treatment. At 48 hours, animals were 
killed and the 14C -radioactivity in each tissue, as well as in the blood, was determined. Tissue distribution of 
2-butoxyethanol revealed that 2-butoxyethanol is distributed to all tissues, with the highest levels (determined 
48 hours after dosing) detected in the forestomach (654 nmol/g at 125 mg/kg and 7,606 nmol/g at 
500 mg/kg). The increase in the tissue concentration in rats treated with 500 mg/kg (as compared to that in 
rats treated with 125 mg/kg) was not proportional to the increase in dose. While the ratio of the administered 
doses was 1:4, the ratio of the tissue concentration in most tissues was greater than 1: 10. This may be related 
to saturation of 2-butoxyethanol metabolism at the high dose. There seems to be a positive correlation 
between tissue levels and the tissues exhibiting toxicity. Other levels were as follows: liver, 107 nmol/g at 
125 mg/kg and 1,666 nmol/g at 500 mg/kg; skin, 75 nmol/g at 125 mg/kg and 806 nmol/g at 500 mg/kg; 
kidney, 69 nmol/g at 125 mg/kg and 1,304 nmol/g at 500 mg/kg; lung, 68 nmol/g at 125 mg/kg and 
1,352 nmol/g at 500 mg/kg; the glandular stomach, 61 nmol/g at 125 mg/kg and 1,743 nmol/g at 500 mg/kg; 
spleen, 54 nmol/g at 125 mg/kg and 1,149 nmol/g at 500 mg/kg; fat, 40 nmol/g at 125 mg/kg and 
162 nmol/g at 500 mg/kg; heart, 36 nmol/g at 125 mg/kg and 927 nmol/g at 500 mg/kg; blood, 34 nmol/g at 
125 mg/kg and 1,288 nmol/g at 500 mg/kg; testes, 22 nmol/g at 125 mg/kg and 659 nmol/g at 500 mg/kg; 
and muscle, 17 nmol/g at 125 mg/kg and 571 nmol/g at 500 mg/kg. 
In a companion study in male Fischer 344 rats, 2-butoxyethanol was given orally by gavage at 500 mg/kg 
alone or after pretreatment with pyrazole, which was found to inhibit the metabolism of 2-butoxyethanol to 
2-butoxyacetic acid (Ghanayem et al. 1987b) (see Section 2.3.3). The levels of 2-butoxyethanol in tissues 
measured 48 hours after dosing with 2-butoxyethanol alone were those reported above by Ghanayem et al. 
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(1987c) for the 500-mg/kg dose. In rats pretreated with pyrazole followed by 500 mg/kg 
[14C]2-butoxyethanol, the levels of 2-butoxyethanol-derived radioactivity in these tissues were appreciably 
lower: 2,384 nmol/g in forestomach, 417 nmol/g in liver, 144 nmol/g in skin, 282 nmol/g in kidney, 
231 nmol/g in lung, 380 nmol/g in glandular stomach, 303 nmol/g in spleen, 120 nmol/g in fat, 102 nmol/g in 
heart, 135 nmol/g in blood, 104 nmol/g in testes, and 65 nmol/g in muscle (Ghanayem et al. 1987b). 
Analysis of radioactivity in the liver revealed that 2-butoxyacetic acid was the only radioactive species. 
These observations, along with the effects of pyrazole on the metabolic pathway (see Section 2.3.3) and 
excretion (see Section 2.3.4.2) of 2-butoxyethanol, indicated that pyrazole enhanced the elimination of 
2-butoxyethanol and protected the rats from its hematoxic effects. 
2.3.2.3 Dermal Exposure 
Three different amounts of the [14C]2-butoxyethanol (61, 181, or 299 mg/kg) were applied to same-sized 
areas on the clipped backs of Fischer 344/N rats, and nonoccluded percutaneous absorption was measured 
(Sabourin et al. 1992b, 1993). A small amount of the applied dose (0.3-2%) was still present at the 
application site 72 hours following dosing, representing unabsorbed parent compound, absorbed parent 
compound, or metabohtes in the skin. The majority of the absorbed dose was excreted in the urine. At 
72 hours, 7-l 6% of the absorbed radioactivity remained in the carcass. Over 80% of the blood radioactivity 
was associated with the plasma, and less than 20% was associated with the red blood cells. 
2.3.2.4 Other Routes of Exposure 
After injection of male Wistar rats in the scapular region with a single subcutaneous dose of 118 mg/kg 
[14C]2-butoxyethanol, not exceeding 99 µCi/kg, the tissue distribution of radioactivity was determined 
(Bartnik et al. 1987). With the exception of plasma, all organs showed a higher relative specific radioactivity 
than blood 72 hours after dosing. If the specific radioactivity found in blood is given a value of 1, values for 
specific radioactivity (relative to blood) were as follows: 3.02 in liver, 1.99 in kidney, 6.62 in spleen, 1.55 in 
testis, 7.39 in thymus, 0.93 in plasma, 1.14 in carcass, 2.74 in fat, and 1.25 in sternum. However, the 
percentages of the applied dose of radioactivity in these tissues were reported to be 0.49% in liver, 0.07% in 
kidney, 0.06% in spleen, 0.08% in testis, 0.06% in thymus, 0.16% in plasma, 4.05% in carcass, and 1.60% in 
fat. The percentage of applied radioactivity in blood was 0.32%. The percentage of applied radioactivity in 
the sternum was not calculated. 
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2.3.3 Metabolism 
There is no available evidence to suggest that the route of administration has any substantial effect on the 
subsequent metabolism of 2-butoxyethanol in humans. However, data from animals indicate that route of 
exposure may make some difference in the relative amounts of metabolites produced (Medinsky et al. 1990; 
Sabourin et al. 1992a, 1992b, 1993). Data regarding metabolism of 2-butoxyethanol have been obtained 
from a large volume of work done on other glycol ethers with specific experiments carried out on 2-butoxyethanol 
(summarized in EPA 1984; Miller 1987; NIOSH 1990). The metabolic scheme for 2-butoxyethanol 
is shown in Figure 2-6. 2-Butoxyethanol is oxidized in the liver by alcohol dehydrogenase to butoxy-acetaldehyde, 
which is further oxidized to 2-butoxyacetic acid by acetaldehyde dehydrogenase. In animals 
and humans, 2-butoxyacetic acid can be conjugated with glycine to form N-butoxyacetylglycine, or it can be 
broken down to CO2 (Ghanayem et al. 1987b; Marxhall 1982; Medinsky et al. 1990; Rettenmeier et al. 
1993). 2-Butoxyethanol can also be dealkylated by CYP2El to form ethylene glycol and butyraldehyde; 
ethylene glycol is then broken down to oxalic acid and ultimately to CO2. Rettenmeier et al. (1993) identified 
an additional amino acid conjugate, N-butoxyacetylglutamine, in human urine samples, which accounted for 
an average of 50% of the total 2-butoxyacetic acid detected; the remainder was free. The formation of the 
N-butylacetylglutamine conjugate in humans has been confirmed in humans exposed (one arm only) to 
2-butoxyethanol; 213 of total urinary 2-butoxyacetic acid was conjugated with glutamine (Corley et al. 1997). 
In rats, 2-butoxyethanol can also be detoxified by conjugation with sulfate to form butoxyethanol sulfate, or 
with glucuronic acid to form the glucuronide (Ghanayem et al. 1987b; Ghanayem et al. 1987c). Clinical 
reports and animal experiments that have contributed to the elucidation of this metabolic scheme are 
described below. Corley et al (1997) found no free or conjugated ethylene glycol or its metabolite, glycolic 
acid, in the urine. 
A report on a woman admitted to the hospital after ingestion, in a suicide attempt, of 250-500 rnL, of a 
window cleaner containing 12% (467-933 mg/kg) 2-butoxyethanol indicated that metabolic acidosis, 
hypokalemia, a rise in serum creatinine level, and a markedly increased urinary excretion of oxalate crystals 
were observed, suggesting a metabolic pattern after absorption from the stomach (Rambourg-Schepens et al. 
1988). The high output of the oxalate in the urine was explained by the metabolism of 2-butoxyethanol to 
ethylene glycol, which was further metabolized to oxalic acid. This assumption was supported by the 
existence of metabolic acidosis coincidental with the urinary peak oxalate level; however, 2-butoxyacetic acid 
can also cause metabolic acidosis. Similar metabolic effects have been reported by others (Bauer et al. 1992; 
Gijsenbergh et al. 1989). 
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Venous blood samples were collected from five healthy male volunteers prior to and after inhalation exposure 
to 20 ppm 2-butoxyethanol (the Swedish permissible exposure limit) for 2 hours under light physical exercise 
(Johanson and Johnsson 1991). Blood samples were collected at 0, 2, 4, and 6 hours from the start of 
exposure and analyzed by gas chromatography. The minimum and maximum observed concentrations of free 
2-butoxyacetic acid in blood ranged from 20 to 57 µM (2.6-7.5 mg/L) with average concentrations of 22, 44, 
39, and 28 µM at 1, 3, 4.9, and 7.1 hours, respectively. Free 2-butoxyacetic acid was found in all samples 
except those collected prior to exposure. These concentrations were about two orders of magnitude lower 
than those causing swelling and hemolysis of human erythrocytes in vitro (Ghanayem 1989). The 
2-butoxyacetic acid blood level peaked after 2-4 hours. The decrease between 4-6 hours indicates an 
average half-time of 2-butoxyacetic acid in blood of about 4 hours, which is in accordance with half-times in 
urine observed by Johanson et al. (1986a) in humans similarly exposed (see Section 2.3.4.1). An interfering 
peak with a retention time similar, but not identical, to 2-butoxyacetic acid was found in all samples with the 
area of the peak corresponding to 1.8 µM 2-butoxyacetic acid. 2-Butoxyacetic acid was also detected in the 
urine of seven male subjects exposed to 20 ppm of 2-butoxyethanol for 2 hours (Johanson et al. 1986a). 
These subjects excreted 15.2-55% of the respiratory uptake in the urine. 
The effect of genetic polymorphism of CYP 2El was studied in 32 male workers exposed to 2-butoxyethanol 
(Haufroid et al. 1997). Only one worker expressed the c2 allele (heterozygote c1/c2), while the other 
30 workers were homozygous for c1. The heterozygous worker was the only worker for whom urinary 
2-butoxyethanol acid was similar before and after his work shift, although he was exposed to 0.53 ppm 
2-butoxyethanol. The study author indicated that the reduced 2-butoxyacetic acid excretion in their 
heterozygous subject was likely a result of increased activity of the c2 compared to the c1 allele; however, no 
firm conclusions can be drawn since only free 2-butoxyacetic acid was measured and it is therefore unknown 
how much conjugated 2-butoxyacetic acid was in the urine. 
In an early study, rats, guinea pigs, dogs, and rabbits exposed to 100-400 ppm 2-butoxyethanol for 4 hours 
excreted free 2-butoxyacetic acid in the urine (Carpenter et al. 1956). Dogs and monkeys exposed to 
100-398 ppm 2-butoxyethanol for 28-90 days also excreted free 2-butoxyacetic acid in the urine. These 
data indicate that the metabolism of 2-butoxyethanol to 2-butoxyacetic acid is a common pathway in 
mammalian species. 
Other studies in animals also indicate that 2-butoxyethanol is metabolized to 2-butoxyacetic acid (Ghanayem 
et al. 1987c). Male Fischer 344 rats were given a single oral dose of [14C]2-butoxyethanol at 125 or 
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500 mg/kg. Rats were placed in metabolism cages and monitored for 48 hours after treatment. Urine, feces, 
and bile were collected for metabolite analysis. Urinary metabolites detected at any one time point included 
free 2-butoxyacetic acid as the primary constituent (74-100%), the 2-butoxyethanol-glucuronide (0-24%), 
and a minor amount of the 2-butoxyethanol-sulfate conjugate (0-3%) detected only at the lower dose. In the 
animals treated with 500 mg/kg 2-butoxyethanol, a larger proportion of the administered dose was detected 
as the glucuronide, suggesting that the enzymes were saturated in the high-dose animals. In the bile, flow 
increased significantly at 0.5 hour after treatment and remained above pretreatment levels for the following 
4 hours. Biliary metabolites included free 2-butoxyacetic acid, the 2-butoxyethanol-glucuronide, and the 
parent compound. The parent compound was detected only in the first 2 hours after treatment. In contrast to 
the urine, the 2-butoxyethanol-glucuronide was the major metabolite in the bile, while 2-butoxyacetic acid 
increased with time at the expense of the glucuronide. 
In studies designed to investigate the metabolic basis of 2-butoxyethanol-induced hematotoxicity in male 
Fischer 344 rats, treatment with pyrazole, an alcohol dehydrogenase inhibitor, protected the rats against 
2-butoxyethanol hematotoxicity and prevented the metabolism of 2-butoxyethanol to 2-butoxyacetic acid 
(Ghanayem et al. 1987b). Inhibition of 2-butoxyetbanol metabolism to 2-butoxyacetic acid was accompanied 
by an increase in the production of the glucuronide and sulfate conjugates of 2-butoxyethanol. Rats treated 
with pyrazole and 2-butoxyethanol exhibited a 10-fold decrease in the proportion of free urinary 2-butoxyacetic 
acid to 2-butoxyethanol-glucuronide and 2-butoxyethanol-sulfate (total production), compared to rats 
treated with 2-butoxyethanol alone. Pretreatment of rats with cyanamide, an aldehyde dehydrogenase 
inhibitor, also protected the animals against the hematotoxicity and modified 2-butoxyethanol metabolism in 
a manner similar to that with pyrazole. Further experiments indicated that hematotoxicity could result from 
treatment with 2-butoxyethanol, the metabolic intermediate butoxyacetaldehyde, or the ultimate toxic 
metabohte 2-butoxyacetic acid. Cyanamide also served to protect from the butoxyacetaldehyde-induced 
toxicity. Pyrazole significantly increased bile flow, even more than 2-butoxyethanol alone, and excretion of 
radioactivity from 2-( l-[14C]butoxy)ethanol in bile was higher in rats pretreated with pyrazole (16%) than in 
rats given 2-butoxyethanol alone (8%). The composition of biliary metabolites also differed in animals 
treated with 2-butoxyethanol alone compared with animals treated with 2-butoxyethanol in conjunction with 
pyrazole. Free 2-butoxyacetic acid constituted 10%, 21%, and 46% of the total radioactivity excreted in the 
bile at 0-l, 2-4, and 6-8 hours, respectively, after dosing with 2-butoxyethanol alone. In contrast, no 
2-butoxyacetic acid was detected in any bile fractions from animals treated with pyrazole. In these rats, 
approximately 12% of the radioactivity was excreted in the 1st hour as unchanged 2-butoxyethanol, with the 
remaining portion being the glucuronide. No other metabolites were detected in the bile. Further evidence of 
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the requirement for metabolic activation prior to the onset of hematotoxicity was observed with the 
administration of deuterium-labeled 2-butoxyethanol. The onset of hematotoxicity was significantly delayed, 
indicating the slower oxidation of 2-butoxyethanol due to the deuterium substitution in place of the somewhat 
smaller hydrogen atoms. This study provided conclusive evidence of the following: there is a good 
correlation between the 2-butoxyethanol-induced hematotoxicity and the amount of free 2-butoxyacetic acid 
in the urine; alcohol and aldehyde dehydrogenase are essential to the metabolic activation of 2-butoxyethanol 
to 2-butoxyacetic acid; and hematotoxicity induced by 2-butoxyethanol can be attributed to its metabolite, 
2-butoxyacetic acid. 
Experiments designed to determine the effect of age on the toxicity and metabolism of 2-butoxyethanol 
indicate that in rats, young animals (4-5 weeks old) are more resistant to the toxic effects than are older rats 
(9-13 weeks old) receiving an equivalent dose (Ghanayem et al. 1987a). Young rats excreted less free 
2-butoxyacetic acid than adult rats, and more 2-butoxyethanol-glucuronide. No sulfate conjugate of 
2-butoxyethanol was detected in the urine of young rats. High-performance liquid chromatographic analysis 
of the urinary metabolites of 2-butoxyethanol in adult and young rats showed that the ratio of free 
2-butoxyacetic acid to the total amount of the glucuronide and sulfate conjugates of 2-butoxyethanol 
(previously thought to reflect an activation/detoxification index of 2-butoxyethanol) was significantly higher 
in older rats. An unknown metabohte was found in the urine of both young and adult rats in amounts of 
6-8% and 1%, respectively. Additional studies on the effect of dose, age, and inhibition of metabolism on 
the toxicity of 2-butoxyethanol indicated that total metabolism was dose dependent, but there was no effect of 
dose on half-life or volume of distribution (Ghanayem et al. 1990a). There was no effect of age on half-life, 
volume of distribution, or clearance of 2-butoxyethanol. Inhibition of metabolism of 2-butoxyethanol with 
pyrazole (inhibition of alcohol dehydrogenase) or cyanamide (inhibition of aldehyde dehydrogenase) 
significantly increased the half-life and decreased the clearance. Although pyrazole had no effect on volume 
of distribution, cyanamide pretreatment caused a decrease in the volume of distribution for 2-butoxyethanol; 
the reason for this was not clear. Analysis of toxicokinetic parameters of free 2-butoxyacetic acid indicated 
that the half-life and maximum plasma concentration were directly related to the age of the animals and the 
dose of 2-butoxyethanol. Pyrazole decreased the maximum plasma concentration and half-life of free 
2-butoxyacetic acid, presumably because of inhibition of metabolism of 2-butoxyethanol. Cyanamide 
increased the half-life and decreased the plasma concentration of free 2-butoxyacetic acid. The study authors 
noted that the effects of cyanamide are probably related to the inhibition of the conversion of butoxyacetaldehyde 
to 2-butoxyacetic acid, but the reason that cyanamide increased the half-life of 2-butoxyacetic acid is 
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volume of distribution, or clearance of free 2-butoxyethanol, but it did increase the half-life of free 
2-butoxyacetic acid. 
In an effort to identify underlying mechanisms associated with the development of tolerance to the hemolytic 
effects of 2-butoxyethanol, male Fischer 344 rats were treated with 125 mg/kg/day of unlabeled 2-butoxyethanol 
for 3 or 7 days by gavage followed by a single dose of 125 mg/kg of [14C]2-butoxyethanol 
(40-50 µCi/kg) administered on day 4 or day 8, respectively (Ghanayem et al. 1992). Three untreated rats 
received the same dose of [14C]2-butoxyethanol(40-50 µCi /kg). Tissue disposition and urine analyses of 
2-butoxyethanol metabolites were performed. No quantitative or qualitative alterations of 2-butoxyethanol 
metabolism or its disposition were caused by repeated exposure to 2-butoxyethanol as compared to treatment 
with a single dose. The ratios of free 2-butoxyacetic acid, the 2-butoxyethanol-glucuronide and 2 butoxyethanol­
sulfate conjugates, and parent 2-butoxyethanol excreted in the urine of rats treated for 4 or 8 days 
were relatively similar to those from rats treated with a single dose. 
Male Fischer 344/N rats were allowed access for 24 hours to uniformly labeled [14C]2-butoxyethanol in 
drinking water at three doses (Medinsky et al. 1990). Elimination of radioactivity was monitored for 
72 hours. The labeled 2-butoxyethanol was administered at doses of 290, 860, or 2,590 ppm in drinking 
water, resulting in consumption of 237, 401, or 1,190 µmol/kg/body weight (28, 47, or 141 mg/kg/day). The 
majority of the 14C was excreted in urine, with 50-60% of the dose as free 2-butoxyacetic acid, or exhaled as 
CO2 (8-10% of the dose); less than 5% of the dose was exhaled as unmetabolized 2-butoxyethanol. Ethylene 
glycol was excreted in urine, representing approximately 10% of the dose of 2-butoxyethanol. 
Unmetabolized 2-butoxyethanol and its glucuronide conjugate were also identified in the urine of animals 
dosed with 2-butoxyethanol. 
A metabolism study was conducted to assist in validation of a PBPK model for 2-butoxyethanol kinetics 
(Corley et al. 1994). Two groups of male Fischer 344 rats with indwelling jugular cannulae received 
radiolabeled 2-butoxyethanol at doses of 8.6 and 126 mg/kg by gavage in water. Animals were immediately 
placed in metabolism cages for collection of urine, feces, and CO2. Samples of blood were taken from each 
rat at 1, 3, 6, 12, and 24 hours postdosing for determination of 2-butoxyethanol and free 2-butoxyacetic acid. 
Urine was collected at intervals of 0-12 and 12-24 hours postdosing. Urine samples were analyzed for total 
radioactivity and metabolite profile. The overall disposition of 2-butoxyethanol in this study was similar to 
that reported by Ghanayem et al. (1987c). At the low dose, approximately 59% of the dose was excreted in 
the urine during the first 24 hours, and 7.2% was excreted as CO2. At 126 mg/kg, 38-70% of the dose was 
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eliminated in the urine, and 8% was eliminated as CO2. Metabolite profiles in the urine were similar to those 
reported by Ghanayem et al. (1987c) and Medinsky et al. (1990), and indicated that nearly 40% of the 
radioactivity in the urine was present as free 2-butoxyacetic acid during the first 12 hours following 
administration of 8.6 mg/kg, and nearly 65% after 126 mg/kg. An additional 15% of the radioactivity in the 
urine was present as the glucuronide conjugate of 2-butoxyethanol at the lower dose, and 10% was present at 
the higher dose. There was no evidence of further conjugation of 2-butoxyacetic acid under the enzyme/ 
hydrolysis conditions used in this study. Ethylene glycol was present in smaller quantities (2-l 1% of the 
total radioactivity). An explanation of the analytic preparation is provided in Chapter 6. 
The metabolism of 2-butoxyethanol following 6-hour nose-only inhalation exposure of male Fischer 344 rats 
was determined at different inhaled concentrations (Sabourin et al. 1992a). The uptake and metabolism of 
2-butoxyethanol were essentially linear up to 438 ppm. From 17% to 24% of the inhaled compound was 
metabolized. Most (64-76%) of the inhaled [14C]2-butoxyethanol was eliminated in the urine, with free 
2-butoxyacetic acid being the major urinary metabolite (37-43%), accompanied by lesser amounts of 
ethylene glycol(8-16%) and 2-butoxyethanol glucuronide (3-10%). A small proportion (5-8%) of the 
retained 2-butoxyethanol was exhaled as 14CO2. Most (>80%) of the [14C]2-butoxyethanol-derived material 
in blood was in the plasma. Free 2-butoxyacetic acid was the major metabolite of 2-butoxyethanol in plasma. 
Ratios of ethylene glycol to 2-butoxyacetic acid in plasma were higher than those in urine. Urinary 
metabolites were monitored at various times up to 66 hours postexposure. More than 88% of the total 
radioactivity excreted was excreted during the first 41 hours. Free 2-butoxyacetic acid was the major 
metabolite in the urine at all exposure concentrations; ethylene glycol and 2-butoxyethanol glucuronide were 
also found in lesser amounts. As the exposure concentration increased, the proportion of two unidentified 
minor metabolites increased, and the time required for urinary excretion of [14C]2-butoxyethanol equivalents 
also increased. At 49 ppm, metabolism to the glucuronide was favored during exposure, whereas metabolism 
to free 2-butoxyacetic acid and ethylene glycol was favored at later times postexposure. The pattern was 
even more apparent at the higher dose. CO2 production most closely followed ethylene glycol production. 
The study authors suggested that these results indicate that, in rats, overall metabolism of 2-butoxyethanol to 
2-butoxyacetic acid, the hemolytic metabolite, was linearly related to the exposure concentration up to a 
concentration that caused severe toxicity (438 ppm). Assuming that the toxicity of inhaled 2-butoxyethanol 
is directly proportional to the formation of 2-butoxyacetic acid, the authors suggested that the toxicity of 
inhaled 2-butoxyethanol can be expected to be linearly related to the exposure concentration up to exposure 
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Three different amounts of [14C]2-butoxyethanol (61, 181, and 288 mg/kg) were applied to same-sized areas 
on the clipped backs of Fischer 344/N rats, and nonoccluded percutaneous absorption was measured 
(Sabourin et al. 1992b, 1993). The rates of excretion by different routes of the 14C -labeled parent compound 
and metabolites were measured, as well as the amount of 14C remaining in the carcass. Within the dose range 
studied, the absorption and metabolism of 2-butoxyethanol by Fischer 344/N rats were linearly related to the 
dermally applied dose. Free 2-butoxyacetic acid was the major metabolite. The 2-butoxyethanol-glucuronide 
was also detected in the urine. The formation of small amounts of ethylene glycol indicated cleavage of the 
ether bond. Plasma metabolites were evaluated at the mid-dose, in which no significant hemolysis was 
detected. Over 80% of the blood radioactivity was associated with the plasma and less than 20% was 
associated with the red blood cells. The concentration of total plasma metabolites was nine times higher than 
that of the parent compound, 2-butoxyethanol, in the plasma. Peak levels of radioactivity were reached at 
about 1 hour, with a half-life of about 4 hours. Free 2-butoxyacetic acid was the major metabolite and 
represented 53-75% of the plasma radioactivity. 
Comparison of the profiles of urinary metabolites from inhalation, oral, and dermal exposure of rats to 
2-butoxyethanol at low, middle, and high doses suggests that the route of administration influences the 
relative amount of metabolites (Medinsky et al. 1990; Sabourin et al. 1992a, 1992b, 1993; Shyr et al. 1993). 
In all exposure routes, free 2-butoxyacetic acid is the major metabolite of 2-butoxyethanol, but the relative 
proportions of minor metabolites can be influenced by route of exposure. Exposure by oral (drinking water) 
or inhalation routes generally favors production of ethylene glycol as compared to the glucuronide, with the 
exception of low-level drinking water exposure and the high-dose inhalation exposure, after which the 
amounts of the two metabolites were not statistically different. Dermal exposure favors production of the 2­
butoxyethanol-glucuronide, possibly because of the more rapid administration of 2-butoxyethanol by this 
route, which in turn saturates the metabolic pathway and shift metabolism to 2-butoxyethanol-glucuronide 
conjugation. 
The metabolism of 2-butoxyethanol (14C -labeled at both ethanol carbons) by human and rat hepatocytes has 
been studied in vitro (Green et al. 1996). Following a 4-hour incubation period, rat hepatocytes produced 
more ethylene glycol and more free 2-butoxyacetic acid at all concentrations tested (0.02, 0.2, 2, and 10 mM). 
As indicated in Table 2-8, there was evidence of saturation of the ethylene glycol pathway in both species at 
0.2 mM, and of the 2-butoxyacetic acid pathway in rats at 10 mM, and in humans at 2 mM. The glucuronide 
conjugate of 2-butoxyethanol was tentatively identified in the incubation media of both species. Kinetic 
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74 1±265 nmol/hour/106 hepatocytes for humans and rats, respectively, and metabolism rate constants (Km) of 
0.9±0.3 and 0.9±0.5 mM for humans and rats, respectively. 
The metabolism of 2-butoxyethanol acetate has not been extensively studied, presumably because 2-butoxy-ethanol 
acetate is assumed to be metabolized to 2-butoxyethanol in the body, and then to follow the same 
pathway as 2-butoxyethanol, since 2-butoxyacetic acid has been detected in human urine after 2-butoxyethanol 
acetate exposure (Johanson et al. 1989). 
2.3.4 Elimination and Excretion 
2.3.4.1 Inhalation Exposure 
Elimination and excretion of 2-butoxyethanol after inhalation exposure appears to be similar in both humans 
and animals. Human studies suggest that excretion of 2-butoxyacetic acid is variable. Volunteers were 
exposed to 98 or 195 ppm 2-butoxyethanol for 8 hours (Carpenter et al. 1956). Urinalyses for free 
2-butoxyacetic acid were conducted on urine samples collected during the 24 hours following the end of the 
exposure period. Results showed that at the 195-ppm exposure level, one male excreted 175 mg and one 
female excreted 300 mg of 2-butoxyacetic acid in the 24-hour period. Another male exposed to 195 ppm 
excreted only trace amounts of 2-butoxyacetic acid. Subjects exposed to 98 ppm (n=4) showed the following 
values for excreted 2-butoxyacetic acid: 100 mg (one female), 183 mg (one female), 75 mg (one male), 
250 mg (one male). Since a substantial fraction of butoxyacetic acid can be excreted in the urine as the amino 
acid conjugate, some of the observed variability could come from the proportion conjugated. 
Seven male volunteers were exposed to 2-butoxyethanol for 2 hours at the Swedish occupational exposure 
limit (20 ppm or 0.85 mmol/ m3) during light physical exercise on a bicycle ergometer (Johanson et al. 
1986a). Expired air was collected at regular time intervals for estimation of the respiratory uptake of the 
solvent. Capillary blood and urine were sampled, during and after the exposure period, and analyzed for 
2-butoxyethanol and its metabolite, free 2-butoxyacetic acid. 2-Butoxyethanol was no longerdetectable in 
the blood 2-4 hours after the end of exposure. The apparent values of elimination half-time, mean residence 
time, total blood clearance, and steady-state volume of distribution were 40 minutes, 42 minutes, 
1.2 L/minute, and 54 L, respectively, for 2-butoxyethanol. The half-life for 2-butoxyethanol in urine was 
1.36 hours. The amount of 2-butoxyethanol excreted in urine was less than 0.03% of the total uptake, while 
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as well as the concentration varied more than 10-fold among subjects. There were increases in the concentra-tion 
and excretion rate during the first few hours, with maximums reached after 5-12 and 2-10 hours, 
respectively. The half-life of 2-butoxyacetic acid in urine was 5.77 hours. The total urinary excretion 
averaged 496 µmol. Relative to the uptake of 2-butoxyethanol, the excretion averaged 41% on an equimolar 
basis. 
Venous blood samples were collected from five healthy male volunteers prior to and after inhalation exposure 
to 20 ppm 2-butoxyethanol (the Swedish permissible exposure limit) during light physical exercise for 
2 hours (Johanson and Johnsson 199 1). The low renal clearance of free 2-butoxyacetic acid 
(22-39 mL/minute) compared with the average glomerular filtration rate of about 125 mL/minute indicates 
extensive binding to blood proteins and poor tubular secretion of the substance. Binding of 2-butoxyacetic 
acid to blood components is also indicated by the low apparent volume of distribution of approximately 15 L, 
which is about the volume of the extracellular water compartment. The study authors applied a one-compart-ment 
model for the kinetics of 2-butoxyacetic acid in blood with an average half-life of 4.3 hours, 
extrapolated to 1 workday (8 hours) of continuous exposure, and predicted a blood level of 114 µmol 
(15.1 mg/L) and a steady-state of 157 µmol/(20.7 mg/L). The authors suggested that if dermal contact is 
avoided, inhalation exposure to 20 ppm 2-butoxyethanol, even for extended periods of time, is unlikely to 
cause adverse effects in humans. 
Individual exposure to 2-butoxyethanol acetate was measured by personal air sampling (air samples collected 
from the breathing zone of workers and samples analyzed by gas chromatography) and biological monitoring 
of urine from 19 employees in an 8-hour work day in four silk-screen printing installations (Johanson et al. 
1989). The samples were analyzed by gas chromatography. Urine was quantitatively collected from each 
subject two or three times during the day. Free 2-butoxyacetic acid could be detected in the low FM range in 
the personal air samples and in the urine. 2-Butoxyethanol acetate was detected in the personal air samples 
of five individuals, with an average concentration of 0.44 ppm. The detection limit was 0.015 ppm in air. 
Free 2-butoxyacetic acid was detected in the urine of 12 individuals, at an average concentration of 8 µM 
(0.132 mg/L). 
Studies have addressed the issue of excretion of conjugated forms of 2-butoxyacetic acid in the urine of 
exposed individuals (Rettenmeier et al. 1993; Sakai et al. 1994). In the study by Rettenmeier et al. (1993), 
urine samples (end of shift on Friday and prior to shift on the following Monday) were taken from six lacquer 
workers who used a 2-butoxyethanol-containing detergent to clean car body parts. Samples from the end of 
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shift on Friday contained relatively large amounts of both 2-butoxyacetic acid and its glutamine conjugate, 
whereas only trace amounts of these metabolites were detectable in the Monday samples. The end of shift 
Friday urinary concentrations of 2-butoxyacetic acid averaged 1.49 mmolL (range: 0.13-5.9 1 mmol/L), and 
the urinary concentrations of the glutamine conjugate averaged 0.82 mmol/L (range: 0.12-2.45 mmol/L). 
The fraction of 2-butoxyacetic acid that was excreted in the urine as the amino acid conjugate, 
N-butoxyacetylglutamine, averaged 48% (16-64%) of the total 2-butoxyacetic acid excreted. Thus, the 
urinary excretion of 2-butoxyacetic acid (up to 45-fold) and the glutamine conjugate (up to 20-fold) varied 
widely in the six subjects, even though their exposure conditions were similar. In a similar study, Sakai et al. 
(1994) compared 2-butoxyacetic acid levels in the urine of workers exposed to 2-butoxyethanol, both with 
and without acid hydrolysis to convert conjugated metabolites to free 2-butoxyacetic acid. Conjugated 
metabolites accounted for 71% (44-92%) of the total 2-butoxyacetic acid found in the urine over a Monday 
through Friday work week. Sakai et al. (1994) attributed the differences in their data compared with the 
findings of Rettenmeier et al. (1993) to differences in the derivatization methods and the possible differences 
in the 2-butoxyethanol exposure concentrations. Furthermore, Sakai et al. (1994) found that the fraction 
excreted as the conjugate during the first 2 days of the work week was greater than the amount excreted 
during the remainder of the work week, indicating a gradual depression of metabolic capacity of 
2-butoxyacetic acid conjugation over subsequent work days. Variability in the rate of conjugate formation 
probably accounts for the large variation in excretion of free 2-butoxyacetic acid observed in earlier studies of 
persons exposed to 2-butoxyethanol. In order to determine the amount of total 2-butoxyacetic acid, it is 
necessary to measure both free butoxyacetic acid as well as the conjugate form. An explanation of analytic 
preparation is provided in Chapter 6. 
Animal studies indicate that 2-butoxyacetic acid, the urinary metabolite found in humans, is also found in 
laboratory animals after inhalation exposure (Carpenter et al. 1956; Ghanayem et al. 1987a; Jijnsson and 
Steen 1978; Sabourin et al. 1992a). Twenty-seven female rats were exposed to 400 ppm (-561 mg/d), 
17 female rats to 200 ppm (~281 mg/d), and 12 female rats to 100 ppm (~ 140 mg/d) 2-butoxyethanol 
(Carpenter et al. 1956). The estimated amount of metabolite (free 2-butoxyacetic acid) excreted was 
calculated from the urine samples collected during the 24-hour exposure period. The estimated amounts of 
free 2-butoxyacetic acid excreted were as follows (mean value per animal): 14 mg from rats exposed to 
400 ppm, 7 mg from rats exposed to 200 ppm, and 1 mg from rats exposed to 100 ppm. Concurrent studies 
showed that most of the metabolite was excreted within 24 hours. In the same experiment, guinea pigs 
exposed to 100 ppm (~ 194 mg/d) or 200 ppm (~387 mg/d) 2-butoxyethanol excreted 4-5 mg in 24 hours, 
dogs exposed to 200 (~4,162 mg/d) and 400 ppm (~8,325 mg/d) excreted 42-100 mg, and rabbits exposed 
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to 200 ppm (~1,936 mg/d) and 400 ppm(~ 3,872 mg/d) excreted 12-23 mg and 89-302 mg, respectively, A 
correlation between vapor concentration and excretion of 2-butoxyacetic acid was observed for all animals 
tested except dogs. Additional studies of monkeys and dogs exposed to doses of 100-385 ppm 2-butoxyethanol for 
28-90 days were also conducted, but the information was scanty and did not serve to clarify 
relative excretion rate by different species (Carpenter et al. 1956). The excretion of 2-butoxyethanol 
following 6-hour nose-only inhalation exposure of male Fischer 344 rats was determined at different inhaled 
concentrations (Sabourin et al. 1992a). The majority of the inhaled [14C]2-butoxyethanol was eliminated in 
the urine, with free 2-butoxyacetic acid being the major urinary metabolite, accompanied by lesser amounts of 
ethylene glycol and 2-butoxyethanol glucuronide. A small proportion (5-8%) of the retained 2-butoxy-
ethanol was exhaled as 14CO2. Ratios of ethylene glycol to 2-butoxyacetic acid in plasma were higher than 
those in urine. Feces accounted for l-2% of the absorbed dose, whereas the carcass contained 13-20%. 
After exposure, 2-5% of the absorbed 2-butoxyethanol was exhaled unchanged. Urinary metabolites were 
monitored at various times up to 66 hours postexposure. More than 88% of the total radioactivity excreted 
was excreted during the first 41 hours. Free 2-butoxyacetic acid was the major metabolite in the urine at all 
exposure concentrations. Ethylene glycol and 2-butoxyethanol glucuronide were also found in lesser 
amounts. As the exposure concentration increased, the proportion of two unidentified minor metabolites 
increased. As the exposure concentration increased, the time required for urinary excretion of [14C]2-butoxy-
ethanol equivalents also increased. At 4.3 ppm, about 60% of the urinary radioactivity was excreted during 
the 6-hour exposure, whereas at 438 ppm, only 10% was excreted during the exposure period. At 49 ppm, 
metabolism to the glucuronide was favored during exposure, whereas metabolism to free 2-butoxyacetic acid 
and ethylene glycol was favored at later times postexposure. The pattern was even more apparent at the 
higher dose. CO2 production most closely followed ethylene glycol production and may represent the 
breakdown of this metabolite. 
Experiments designed to determine the effect of age on the toxicity and metabolism of 2-butoxyethanol 
indicate that in rats, young animals (4-5 weeks old) are more resistant to the toxic effects than are older rats 
(9-13 weeks old) receiving an equivalent dose (Ghanayem et al. 1987a). A significantly higher percentage of 
the administered dose was exhaled as CO2 in young rats compared to adult rats (22% versus 10%). Young 
rats excreted a higher percentage of the dose in the urine compared to adult rats (60% versus 40%). Young 
rats excrete less free 2-butoxyacetic acid than adult rats, and more 2-butoxyethanol-glucuronide; and no 
sulfate conjugate of 2-butoxyethanol was detected. High-performance liquid chromatography analysis of the 
urinary metabolites of 2-butoxyethanol in adult and young rats showed that the ratio of free 2-butoxyacetic 
acid to the total amount of the glucuronide and sulfate conjugates of 2-butoxyethanol (previously thought to 
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reflect an activation/detoxification index of 2-butoxyethanol) was significantly higher in older rats. An 
unknown metabolite was found in the urine of both young and adult rats at 6-8% and 1%, respectively. 
In a more recent study, eight male Sprague-Dawley rats were exposed to 20 or 100 ppm 2-butoxyethanol 
24 hours per day for 1, 2, 3, 4, 6, 8, 10, or 12 days (Johanson 1994). Urine was collected at 24-hour 
intervals. At the end of the exposure period, animals were killed and blood, muscle, liver, and testes samples 
were collected. Blood and tissue samples were analyzed for free 2-butoxyethanol and free 2-butoxyacetic 
acid by electron capture gas chromatography. No control group was used. Total blood clearance values were 
2.3 L/hour/kg for the 20-ppm group and 2.2 L/hour/kg for the 100-ppm group, and rates were not 
significantly different The urinary excretion rate for 2-butoxyacetic acid in the 20-ppm group averaged 
0.20 mmol/day, whereas the 100-ppm group excreted 1 .03 mmol/day. The observed urinary excretion rate 
corresponded to 64% of the calculated respiratory uptake and renal clearance of 0.53 L/hour for both groups. 
2.3.4.2 Oral Exposure 
A case report of a woman admitted to the hospital after ingestion in a suicide attempt of 250-500 mL of a 
window-cleaner containing 12% (467-933 mg/kg) 2-butoxyethanol, indicated that metabolic acidosis, 
hypokalemia, a rise in serum creatinine level, and a markedly increased urinary excretion of oxalate crystals 
were observed, suggesting a metabolic pattern after absorption from the stomach (Rambourg-Schepens et al. 
1988). Kinetic evaluation of urinary excretion of 2-butoxyethanol, free 2-butoxyacetic acid, and oxalate 
indicated that 2-butoxyethanol was at the highest level of excretion at 1 day after ingestion (2-3 g/g 
creatinine). 2-Butoxyacetic acid peaked between the 2nd and 3rd days of ingestion at 40 g/g creatinine and 
was not detectable on day 8. Oxalate excretion was biphasic, reaching similar peak levels of approximately 
40 g/g creatinine on day 1 and day 7 after ingestion. The high output of the oxalate in the urine was 
explained by the metabolism of 2-butoxyethanol to ethylene glycol which is further metabolized to oxalic 
acid. The biphasic aspect of the oxalate excretion was not specifically addressed by the study authors, but 
since the two pathways of metabolism (to 2-butoxyacetic acid and ethylene glycol-oxalic acid) occur 
simultaneously, the biphasic response may be the result of competition for the pathways. This assumption 
was supported by the existence of metabolic acidosis contemporary with the urinary peak oxalate level. 
Similar metabolic effects have been reported by others (Bauer et al. 1992; Gijsenbergh et al. 1989). 
A 23-year-old woman weighing 64 kg was admitted to the hospital approximately 1 hour after ingesting 
500 mL window-cleaner containing 2-butoxyethanol(391-469 mg/kg) and ethanol (Gijsenbergh et al. 1989). 
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The half-lives of ethanol (from the cleaning fluid) and 2butoxyethanol in the blood were 20 and 210 minutes, 
respectively. The half-life of 2-butoxyethanol was longer than expected, perhaps because of saturation of 
metabolism and competitive inhibition by ethanol. 2-Butoxyacetic acid was highest in the dialysis fluid (738 
mg/L) at the initiation of dialysis and decreased thereafter. A concomitant increase in 2-butoxyacetic acid in 
the urine was seen with the initiation of dialysis, and concentrations reached a peak of approximately 8 g/g 
creatinine 1.3 hours after the start of dialysis. The half-life of free 2-butoxyacetic acid in the urine after the 
start of dialysis was 5.3 hours. 
Studies in animals indicate that 2-butoxyethanol is excreted through the urine, lungs, feces, and bile after 
exposure (Ghanayem et al. 1987b, 1987c). Male Fischer 344 rats were given single oral doses of 
[14C]2-butoxyethanol of 125 or 500 mg/kg. Rats were placed in metabolism cages and monitored for 
48 hours after treatment. Expired air, urine, and feces were collected and monitored for “C-associated 
radioactivity. Bile was collected from the common bile duct. The major route of elimination was the urine 
(40-70%), followed by exhalation (11-18%). A small portion was excreted in the bile (8% at the 500-mg/kg 
dose) 8 hours after dosing, and a small amount was detected in the feces (2-3%). 
Ghanayem et al. (1992) studied the differences m elimination of single or multiple oral doses of 2-butoxyethanol 
administered to rats, and found no quantitative or qualitative alterations of metabolism or disposition 
caused by repeated exposure to 2-butoxyethanol as compared to treatment with a single dose. Elimination of 
14CO2 and 2-butoxyethanol-derived radioactivity in the urine of rats receiving multiple doses of 2-butoxy­
ethanol was essentially the same as for rats receiving a single dose. The ratios of free 2-butoxyacetic acid, the 
2-butoxyethanol-glucuronide and 2-butoxyethanol-sulfate conjugates, and parent 2-butoxyethanol excreted in 
the urine of rats treated for 4 or 8 days were relatively similar to those from rats treated with a single dose. 
Male Fischer 344/N rats were allowed access for 24 hours to uniformly labeled [14C]2-butoxyethanol in 
drinking water at three doses (Medinsky et al. 1990). Elimination of radioactivity was monitored for 
72 hours. 2-Butoxyethanol was administered at doses of 290, 860, or 2,590 ppm in drinking water, resulting 
in consumption of 237, 401, or 1,190 µmol/kg/day (28, 47, or 141 mg/kg/day). The majority of the 14C was 
excreted in urine as free 2-butoxyacetic acid (50-60% of the dose), or exhaled as CO2 (8-10% of the dose). 
Less than 5% of the dose was exhaled as unmetabolized 2-butoxyethanol. Ethylene glycol was excreted in 
urine, representing approximately 10% of the dose of 2-butoxyethanol. Elimination in the feces was a minor 
pathway for 2-butoxyethanol(1.6-2.8% of the dose) . Unmetabolized 2-butoxyethanol and its glucuronide 
conjugate were also identified in the urine of animals dosed with 2-butoxyethanol. The time course for 
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excretion of 2-butoxyethanol metabolites during and after exposure to the lowest dose indicated that the 
maximum excretion occurs during the first 12-24 hours after the start of exposure. This time course 
corresponds to the active period (nocturnal) for these animals, and the period during which they are likely to 
drink the most water. No evidence of the glycine conjugate of 2-butoxyacetic acid was found. The amount of 
14C -derived radioactivity found in the carcasses of animals ranged from 3 to 23.7 µmoles (2.8-9.8% of the 
dose) for the low- to high-dose groups. 
2.3.4.3 Dermal Exposure 
Worker exposures to 2-butoxyethanol were evaluated by environmental and biological monitoring for 
29 employees in five shops where window-cleaning agents bad been used (Vincent et al. 1993). Each of the 
29 employees was exposed to 2-butoxyethanol. Eleven men and two women were involved in cleaning cars 
in four garages. The remaining 16 were office cleaners. Only two of the workers who cleaned new cars wore 
protective gloves. The study authors suggested that the primary route of exposure was dermal, although 
some inhalation exposure necessarily occurred. Each of the window-cleaning agents sampled contained 
2-butoxyethanol in concentrations ranging from 0.9% to 21.2% in volume. Window-cleaner use times ranged 
from 120 to 320 minutes per day, and quantities of cleaning agents ranged from 220 to 1,200 mL/day for 
individuals involved in cleaning new cars. The corresponding figures for cleaners of used cars were 
20-50 minutes and 50-100 mL. For office cleaners, the corresponding figures were 15 minutes per day and 
<50 mL, of cleaning agent used per day. For cleaners of new cars, the mean 2-butoxyethanol exposure was 
2.33 ppm (range: <0.10-7.33 ppm), and the mean urinary free 2-butoxyacetic acid concentration in endshift 
samples was 111.3 mg/g creatinine (range: 12.7-371 mg/g creatinine). The mean preshift (average of 
Monday and Friday) urinary free 2-butoxyacetic acid concentration was 17.9 mg/g creatinine (range: 
2-98.6 mg/g creatinine). For cleaners of used cars, the mean 2-butoxyethanol exposure was 0.36 ppm 
(range: <0.10-1.52 ppm), and the mean urinary free 2-butoxyacetic acid concentration in endshift samples 
was 6.3 mg/g creatinine (range: 2-24.4 mg/g creatinine). The mean preshift urinary concentration of free 
2-butoxyacetic acid was 4.8 mg/kg creatinine (range: 2-33 mg/g creatimne). For the office cleaners, the 
mean 2-butoxyethanol concentration was 0.32 ppm (range: <0.30-0.73 ppm), and the mean u&mry free 
2-butoxyacetic acid concentration in endshift samples was 2.1 mg/g creatinine (range: 2-3.3 mg/g 
creatinine). The mean preshift urinary concentration of free 2-butoxyacetic acid was 2.1 mg/g creatinine 
(range: 2-4.6 mg/g creatinine). Correlations of 2-butoxyethanol exposure in air and endshift concentrations 
of urinary free 2-butoxyacetic acid from cleaners of new and used cars (for which the data were most 
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window cleaners containing 5.7-21.2% 2-butoxyethanol by volume for a period of 160 minutes would result 
in an endshift urinary concentration of free 2-butoxyacetic acid of 60 mg/g creatinine. A similar relationship 
was observed for urinary free 2-butoxyacetic acid concentrations and utilization time for office cleaners. 
The percutaneous absorption of 2-butoxyethanol was investigated in 12 exposure experiments with five male 
volunteers. All were nonsmokers and stated low or no consumption of alcohol (Johanson et al. 1988). None 
had been exposed to industrial solvents. All had participated in a previous study of 2-butoxyethanol 
(Johanson et al. 1986a). The subjects kept two or four fingers immersed in neat 2-butoxyetbanol for 2 hours. 
Urine was collected for 24 hours and analyzed for the metabolite free 2-butoxyacetic acid. The presence of 
2-butoxyethanol in blood and of free 2-butoxyacetic acid in urine, detected by gas chromatography, 
confirmed that 2-butoxyethanol enters the systemic circulation in human males during even minimal dermal 
exposure. The half-life of 2-butoxyethanol during the decay phase ranged from 0.6 to 4.8 hours (geometric 
mean: 1.3 hours). The excretion rate of 2-butoxyacetic acid increased during the first hours after exposure, 
reached a maximum at about 5 hours (3 hours postexposure), and then declined, with an average half-life of 
3.1 hours. Seventeen percent of the absorbed dose was excreted as 2-butoxyacetic acid in 24 hours. The 
cumulative excretion of free 2-butoxyacetic acid ranged from 8.7 to 3 13 µM (1.15-41.37 mg). 
In six men exposed one-arm only to 50 ppm [13C2] 2-butoxyethanol for 2 hours, about two-thirds of the 
2-butoxyacetic acid excreted in the urine was in the form of the N-butoxyacetyl glutamine conjugate (Corley 
et al. 1997). No free 2-butoxyethanol, free or conjugated ethylene glycol ether, or glycolic acid (a metabolite 
of ethylene glycol) were detected in the urine. 2-Butoxyacetic acid was eliminated in the urine primarily 
during the first 12-hour collection period. 
In a study in male and female Wistar rats, [14C]2-butoxyethanol was applied to the shaven skin on a 12- cm2 
area under a protective glass capsule at a dose of 200 mg/kg (Bartnik et al. 1987). Urine was collected at 
intervals of 0-8, 8-24, and 24-48 hours following application and stored at -80° C. Radioactivity of urine, 
cage rinse water, skin, and glass capsule was determined. Percutaneous absorption was assessed by using the 
measurements of urinary excretion of 14C from 0 to 48 hours following cutaneous application of 2-butoxyethanol. 
Radioactivity in 48 hours following cutaneous application of radiolabeled 2-butoxyethanol showed 
that 20-23% of the applied dose was found in the urine, including cage rinse water, with no notable 
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Three different amounts of the [14C]2-butoxyethanol (61, 181, or 299 mg/kg) were applied to same-sized 
areas on the clipped backs of Fischer 344/N rats, and nonoccluded percutaneous absorption was measured 
(Sabourin et al. 1992b, 1993). The rates of excretion of the 14C -labeled parent compound and metabolites 
were measured, as well as the amount of 14C remaining in the carcass. The majority of the absorbed and 
metabolized glycol ether was excreted in the urine (82-83%); 3-5% was found as CO2, 3-6% was found in 
the feces, and 3-13% was found in the carcass. The percentage of glycol ether found tended to increase with 
increasing dose, although this was not consistently the case. Urinary metabolites were analyzed up to the 
time at which <10% of the excreted radioactivity. Urine was collected up to 23 hours postexposure. Free 
2-butoxyacetic acid was the main metabolite (66-70%), followed by the 2-butoxyethanol-glucuronide 
(13-15%), and ethylene glycol(4-6%). CO2 expired in the air was 3-4% in this experiment. The formation 
of small amounts of ethylene glycol indicated cleavage of the ether bond. Minor amounts of unidentified 
metabolites made up the remainder of the detected radioactivity. 
2.3.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models 
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and 
disposition of chemical substances to quantitatively describe the relationships among critical biological 
processes (Krishnan et al. 1994). PBPK models are also called biologically based tissue dosimetry models. 
PBPK models are increasingly used in risk assessments, primarily to predict the concentration of potentially 
toxic moieties of a chemical that will be delivered to any given target tissue following various combinations 
of route, dose level, and test species (Clewell and Andersen 1985). Physiologically based pharmacodynamic 
(PBPD) models use mathematical descriptions of the dose-response function to quantitatively describe the 
relationship between target tissue dose and toxic end points. 
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to delineate 
and characterize the relationships between: (1) the external/exposure concentration and target tissue dose of 
the toxic moiety, and (2) the target tissue dose and observed responses (Andersen et al. 1987; Andersen and 
Krishnan 1994). These models are biologically and mechanistically based and can be used to extrapolate the 
pharmacokinetic behavior of chemical substances from high to low dose, from route to route, between 
species, and between subpopulations within a species. The biological basis of PBPK models results in more 
meaningful extrapolations than those generated with the more conventional use of uncertainty factors. 
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The PBPK model for a chemical substance is developed in four interconnected steps: (1) model 
representation, (2) model parametrization, (3) model simulation, and (4) model validation (Krishnan and 
Andersen 1994). In the early 1990s, validated PBPK models were developed for a number of toxicologically 
important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 1994; Leung 1993). 
PBPK models for a particular chemical substance require estimates of the chemical substance-specific 
physicochemical parameters, and species-specific physiological and biological parameters. The numerical 
estimates of these model parameters are incorporated within a set of differential and algebraic equations that 
describe the pharmacokinetic processes. Solving these differential and algebraic equations provides the 
predictions of tissue dose. Computers then provide process simulations based on these solutions. 
The structure and mathematical expressions used in PBPK models significantly simplify the true complexities 
of biological systems. This simplification, however, is desirable if the uptake and disposition of the chemical 
substance(s) is adequately described because data are often unavailable for many biological processes and 
using a simplified scheme reduces the magnitude of cumulative uncertainty. The adequacy of the model is, 
therefore, of great importance and thus the importance of model validation. 
PBPK models improve the pharmacokinetic extrapolation aspects of the risk assessment process, which seeks 
to identify the maximal (i.e., safe) levels for human exposure to chemical substances (Andersen and Krishnan 
1994). PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in 
humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste 
sites) based upon the results of studies where doses were higher or were administered in different species. 
Figure 2-7 shows a conceptualized representation of a PBPK model. 
PBPK models for 2-butoxyethanol are discussed below. No specific models were found for 2-butoxyethanol 
acetate. However, it is expected that 2-butoxyethanol acetate follows a similar model after absorption and 
conversion to 2-butoxyethanol. However, the absorption of 2-butoxyacetic acid may be different from 
2-butoxyethanol because of its different chemical form. 
2.3.5.1 Summary of PBPK Models 
PBPK models of 2-butoxyethanol absorption, metabolism, disposition, and excretion have been published by 
Johanson and coworkers (Johanson 1986,199la; Johanson and Naslund 1988), Shyr et al. (1993), and 
Corley et al. (1994). They are presented in the order that they were published in the literature, since each 
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successive author used the data and results from the previous authors. Each successive model is more 
complete and more closely approaches modeling 2-butoxyethanol kinetics accurately. The Johanson model 
(Johanson 1986, 199 1 a; Johanson and Naslund 1988) addressed human inhalation exposure to 2-butoxyethanol 
during rest and exercise, whereas the Shyr model (Shyr et al. 1993) addressed high-low dose and 
route of administration extrapolation based on animal data. The Corley model (Corley 1996; Corley et al. 
1994) combined aspects of each of the other two models and also addressed 2-butoxyacetic acid disposition 
and competing metabolic pathways. Because no chronic data are available for either humans or animals, 
these models have not been validated for chronic exposure to 2-butoxyethanol. 
2.3.5.2  2-Butoxyethanol PBPK Model Comparison 
Three PBPK models that describe the disposition of 2-butoxyethanol have been identified from the open 
literature (late 1980s and forward). The first model (Figure 2-8) is based on human inhalation and perfused 
rat liver data, with later refinements (Johanson 1986, 1991a; Johanson and Naslund 1988). The second 
model (Figure 2-9) is based on rat data collected after inhalation, drinking water, and dermal exposure (Shyr 
et al. 1993). Shyr et al. (1993) also presented a model of the metabolic pathway of 2-butoxyethanol, as 
shown in Figure 2-10. The third model (Figure 2-l 1) was developed by Corley et al. (1994) and is an 
expansion of the Johanson model (Johanson 1986,199la; Johanson and Naslund 1988). It includes 
additional routes of exposure, physiological descriptions for rats, competing pathways for metabolism of 
2-butoxyethanol, and measured partition coefficients for 2-butoxyethanol and 2-butoxyacetic acid. This 
model was further modified on the basis of data on human metabolites and dermal absorption of 
2-butoxyethanol vapor (Corley et al. 1997). 
2.3.5.3 Discussion of Models 
The Johanson Model 
The Johanson model, with its refinements (Johanson 1986,199l a; Johanson and Naslund 198%), is one of the 
original PBPK models developed to describe and ultimately predict the effects of occupational inhalation 
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Risk assessment. This model successfully described the arterial blood concentrations of 2-butoxyethanol 
in a 70-kg man after inhalation exposure. Specifically, the model simulations indicated that for 
inhalation concentration of 20 ppm (the Swedish permissible exposure limit; U.S. limit = 25 ppm) for 2 hours 
accompanied by light physical exercise on an exercise bicycle, predicted arterial blood concentrations of 
2-butoxyethanol agreed well with human experimental data (Johanson et al. 1986a). Simulations of 
inhalation exposure indicated that in humans, the concentration in blood increased in a linear manner 
throughout the 2-hour exposure, then declined rapidly to nearly non-detectable levels at 6 hours. By 
simulating different levels of physical activity at the same exposure level, but for 8 hours, mimicking a 
standard work day, Johanson’s model was used to predict 2-butoxyethanol levels in blood after increased 
work load. As might be expected, the model predicts that with increased activity, and thus increased 
pulmonary blood flow and uptake of 2-butoxyethanol, arterial levels of 2-butoxyethanol increase 
proportionally during exposure, then decline rapidly after exposure ceases. 
Simulations of co-exposure to ethanol (0.1% in the blood) during an S-hour exposure to 20 ppm 2-butoxyethanol 
with no exercise predict that the arterial levels of 2-butoxyethanol will be elevated because of a 
decrease in elimination rate (Johanson 1986). Because the increase is due to decreased elimination and not 
increased uptake, the rise and fall of blood concentration of 2-butoxyethanol are slower in the ethanol 
co-administration model than in the increased workload model. 
Description of the model. The Johanson 2-butoxyethanol PBPK model was designed to describe 
organic solvent kinetics in general. Certain limiting assumptions were made in the model. For instance, the 
organs are lumped into compartments according to blood flow and fat content (Johanson 1986). Muscles and 
skin form a separate compartment because of their wide variation in blood flow at different workloads. In the 
model, solvent uptake is assumed to occur only in the Jung; elimination is assumed to occur in the liver. 
Instantaneous homogeneous distribution of the solvent in each compartment is assumed, and as a 
consequence, the solvent retained in the respiratory airways immediately reaches the arterial blood. A 
schematic representation of the Johanson model is shown in Figure 2-8, with only the inhalation route 
represented. 
The tissue compartments included in the Johanson model are as follows: the lungs, presumed to be the only 
site of uptake, and arterial blood; the liver, presumed to be the only organ where transformation of 2-butoxyethanol 
takes place; the gastrointestinal tract in equilibrium with the liver; a group of richly perfused tissues; 
a group of poorly perfused tissues; a fat compartment; and muscles and skin. Support for the assumption 
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that the liver is the primary site of transformation of 2-butoxyethanol (as opposed to the kidney, for instance) 
comes from the investigator’s observation that very little 2-butoxyethanol was recovered from the urine of 
men exposed to 2-butoxyethanol experimentally (Johanson et al. 1986a). All partition ratios between blood 
and other compartments were set to unity, based on preliminary studies on 2-butoxyethanol indicating a weak 
preference for water as compared to fat or protein. Diffusion equilibrium between end-capillary blood and 
tissue was assumed for all compartments. 
Physiologic parameters used, biochemical constants, and partition coefficients in the model are shown in 
Table 2-9. Physiologic constants (organ volume, blood flows, etc.) and tissue and blood coefficients were 
taken from literature sources (Astrand 1983; Fiserova-Bergerova 1983a). Elimination constants for the liver 
were taken from experiments in the perfused rat liver (Johanson et al. 1986b). Venous equilibrium was 
assumed, and competitive inhibition between ethanol and 2-butoxyethanol was assumed. 
Validation of the model. Since the model was developed using the data of Johanson et al. (1986a, 
1986b), the model accurately reflects these data. Factors not taken into account in the model, but that may 
influence cardiac output and distribution and hepatic blood flow and thus, may have to be considered, include 
posture, thermal stress, food intake, pathological conditions, and the presence of other substances including 
drugs. 
Target tissues. The model correctly described arterial blood concentrations of 2-butoxyethanol in 
human males during and after a 2-hour inhalation exposure to 20 ppm, accompanied by light physical 
exercise. Predictions of 2-butoxyethanol concentrations in muscle and skin may reflect blood sampled from 
peripheral veins, as would be accomplished in a biomonitoring program. The model shows that the rise and 
fall of 2-butoxyethanol in the arterial blood and lungs are faster than in the muscle and skin compartment. 
This suggests that venous blood sampling may be more useful than arterial sampling. A later refinement of 
the model included factors for “resting” and “working” skin and muscle, and data on tissueair partition 
coefficients were included, thus improving the predictive qualities of the model in an occupational setting 
(Johanson and Naslund 1988). Further refinement included modeling of the retention and excretion of 
solvent vapors in the various parts of the lung, including the trachea, main bronchi, lobar bronchi, segmental 
bronchi, subsegmental bronchi, small bronchi, bronchioles, terminal bronchioles, respiratory bronchioles, 
alveolar ducts, and alveoli, prior to equilibrating with other systemic compartments (Johanson 1991a). Data 
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The data clearly indicate that, for accurate biomonitoring, sampling should take place during exposure because 
of the rapid disappearance of 2-butoxyethanol from tissue compartments. Even in the compartment that 
shows the longest residence time (poorly perfused organs), practically no 2-butoxyethanol is present the 
morning following exposure. The model suggests that bioaccumulation does not generally occur, although 
accumulation by a particular organ (or in a disease state) could not be ruled out. The study authors state that 
human data, combined with the physicochemical properties of the chemical, do not suggest that specific organ 
binding would substantially alter the total body burden. The model does not address the kinetics of the major 
metabolite, 2-butoxyacetic acid. 
Species extrapolation. The Johanson model uses human data to predict occupational exposure 
parameters. The author notes that the validity of the assumptions used to extrapolate to humans from in vitrs 
hepatic elimination data on rats is not known. 
High-low dose extrapolation. The model predicts nonlinearity due to saturated elimination at 
concentrations well above 100 ppm, even in combination with physical exercise and ethanol. The comparison 
between the simulated arterial blood levels and experimental arterial blood levels obtained after exposure to 
20 ppm 2-butoxyethanol for 2 hours indicates linear kinetics at this concentration, which is lower than the PEL 
in the United States (PEL = 50 ppm, OSHA 1974). Thus, linear kinetics would be expected in ordinary 
occupational inhalation exposure, although low-dose extrapolation was not specifically addressed in this 
model. 
Interroute extrapolation. The Johanson model was not used to predict the kinetic behavior of 2-butoxyethanol 
after dermal or oral exposure. The study author comments that saturation kinetics may occur after 
accidental or intentional ingestion of large amounts or after accidental dermal exposure to large volumes of 
2-butoxyethanol, but not after exposure in a controlled occupational setting. 
The Shyr Model 
The Shyr model (Shyr et al. 1993) is based on experimental data from inhalation, drinking water, and dermal 
exposure experiments in rats (Figure 2-9). The major metabolite, 2-butoxyacetic acid, was included in the 
model in addition to the 2-butoxyethanol-glucuronide and ethylene glycol. A model formulation of the 
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Risk assessment. This model successfully described the differences in disposition of 2-butoxyethanol, 
based on urinary profiles of metabolites, in various exposure routes by taking into account the differences in 
absorption rate and by incorporating a minor pathway for metabolism (glucuronidation) by skin (Shyr et al. 
1993). The model was reasonably successful in predicting the experimental rat data produced by Johanson et 
al. (1986a). The value of the model lies in the ability to extrapolate to the human situation from the routes of 
exposure likely to be used in experimental assays. 
Description of the model. The Shyr 2-butoxyethanol PBPK model (Shyr et al. 1993) was based on an 
earlier PBPK model developed by Ramsey and Andersen (1984) to describe the disposition of styrene 
exposure in mice and rats, and on the Johanson (1986) model. A schematic representation of the Shyr model 
is shown in Figure 2-9, with inhalation, drinking water, and dermal routes represented. Parameters used in the 
model are summarized in Table 2-10. 
The tissue compartments included in the Shyr model are as follows: respiratory tract; liver; gastrointestinal 
tract; fat; and a group of richly perfused tissues including kidney, bone marrow, and heart. Muscle and skin 
were separated into individual compartments to allow for the simulation of dermal exposure. The distribution 
of 2-butoxyethanol among compartments was assumed to be limited only by blood flow rate because the lipid 
solubility of 2-butoxyethanol allowed it to penetrate cell membranes rapidly. Liver was a major site of 
metabolism in the Shyr model with a minor amount of 2-butoxyethanol-glucuronide formed in the skin at the 
site of application for dermal exposure. 
Drinking water exposure was simulated by estimating nocturnal drinking patterns of rats as a continuous 
activity. For dermal exposure, the rate of 2-butoxyethanol absorption through the skin was also estimated and 
adjusted according to the in vitro absorption data of Bartnik et al. (1987). A factor was included for dermal 
metabolism to the 2-butoxyethanol-glucuronide. Inhalation exposure was estimated using the model of 
Ramsey and Andersen (1984) with a factor for nasal absorption (Dahl et al. 199 1). Nasal absorption includes 
dissolution of the compound in the nasal mucous membrane upon inhalation, and vaporization and elimination 
from the membranes into expired air. Based on the work of Dahl et al. (199 1) in dogs, a high nasal uptake 
was assumed for compounds with high blood/air partitions. Increasing nasal absorption for soluble 
compounds is also suggested by Dahl et al. (1991). More recent work on kinetic models for respiratory uptake 
of inhaled volatiles has been done by Medinsky et al. (1993). Physiologic, biochemical constants and partition 
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and tissue and blood coefficients were taken from Ramsey and Andersen (1984) or were taken from other 
literature sources. 
Validation of the model. Since the model (Shyr et al. 1993) was developed concurrently with 
toxicokinetic experiments being conducted in the same laboratory, the model was used to predict the outcome 
of experiments that were yet to be run (Medinsky et al. 1990; Sabourin et al. 1992a, 1992b, 1993). Variables 
that were not predictive were modified according to the experimental data. Thus, the model was developed 
and refined in conjunction with the data it used for validation. The model was successful in predicting urinary 
metabolites from the three routes of exposure. 
Target tissues. The model attempted to predict the urinary profiles of 2-butoxyethanol metabolites in rats 
after inhalation, oral (drinking water), and dermal exposure (Shyr et al. 1993). For 2-butoxyacetic acid, the 
major urinary metabolite, the values predicted by the model were in reasonable agreement with the 
experimental data. The exception was inhalation exposure at the high dose. The study authors indicated that 
the lack of agreement at the high dose for inhalation exposure may have been due to several factors, including 
a wide variability in the experimental data and an overestimation of the formation rate of 2-butoxyacetic acid 
in the liver at the high dose. For the other metabolites in the urine, ethylene glycol and 2-butoxyethanol 
glucuronide, the model predicted well for inhalation, oral, and dermal exposure. However, the predicted 
values for ethylene glycol after dermal exposure at the low dose were relatively high. Shyr et al. (1993) 
presented a model formulation of the metabolic pathway of 2-butoxyethanol, leading to urinary excretion 
(Figure 2-10). Based on the data of Medinsky et al. (1990) and Sabourin et al. (1992a, 1992b, 1993), 
2-butoxyethanol was primarily metabolized to 2-butoxyacetic acid, ethylene glycol, and the glucuronide of 
2-butoxyethanol. Both ethylene glycol and 2-butoxyacetic acid could be metabolized further to CO2. The 
unexcreted glucuronide was also available for hydrolysis back to 2-butoxyethanol. The rates at which 
2-butoxyacetic acid and ethylene glycol were metabolized to CO2 were proposed to be less than the rates at 
which these metabolites were excreted in the urine, since the amount of urinary metabolites was greater than 
the amount of CO2 exhaled. Based on work done with ethylene glycol (Marshall 1982), small amounts of 
ethylene glycol and 2-butoxyacetic acid may be bound to macromolecules, such as protein, resulting in a 
longer retention time in the body. In the Shyr model (Shyr et al. 1993), the major compartment for 2-butoxyethanol 
metabolism was the liver, based on the study of Johanson et al. (1986b). Minor amounts of 
glucuronide are also assumed to be formed in the skin after dermal application, but there is little data to 
support this assumption. 
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Species extrapolation. Shyr et al. (1993) used the human inhalation data of Johanson et al. (1986b, 
1988). Pulmonary ventilation and body weight data from Johanson et al. (1986a) were used, while other 
kinetic parameters were the same as the rat model. The metabolic parameters were adjusted for humans (Km 
and Vmax) according to Ramsey and Andersen (1984). The model adequately predicted urinary excretion of 
2-butoxyacetic acid, which was similar to that of rats. Wben the model was applied to human dermal exposure 
data (Johanson et al. 1988), it overestimated 2-butoxyacetic acid excretion in the urine by 33%, as compared 
to experimental data. 
High-low dose extrapolation. Three doses were used for each route of administration. The model 
accurately predicted the outcome with exception of predicting urinary 2-butoxyacetic acid excretion after the 
high-dose inhalation exposure (382 µmol absorbed dose). The study authors (Shyr et al. 1993) indicated that 
the discrepancy may have resulted from variability in the experimental levels of urinary 2-butoxyacetic acid 
and because the estimates did not include a factor for the unidentified metabohtes experimentally observed in 
rat urine after inhalation exposure. No low-dose extrapolation, mimicking doses to which most consumers 
would be exposed, was conducted. 
Interroute extrapolation. The model (Shyr et al. 1993) accurately predicted the urinary metabolite 
profile of 2-butoxyethanol after inhalation, oral (drinking water), and dermal absorption in rats (Medinsky et 
al. 1990; Sabourin et al. 1992a, 1992b, 1993). The same set of parameters was used to predict data from all 
three routes of exposure. Metabolic pathways were proposed based on experimental data, and the relative 
significance of each pathway was quantified by fitting the model to the experimental data. The model 
predicted the change in profiles of urinary metabolites for different exposure routes. 
The Corley Model 
The Corley model (Corley et al. 1994) is an expansion of the model of human inhalation exposure by 
Johanson (1986). In the Corley model, disposition of 2-butoxyacetic acid was included, and the model was 
expanded to include data on rats, the most commonly used species in experimental toxicity tests of 2-butoxy­
ethanol. This model was further modified on the basis of data on human metabolites and dermal absorption of 
2-butoxyethanol vapor (Corley et al. 1997). other routes of exposure, including oral, dermal, and intravenous 
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Risk assessment. In proposing the parameters necessary for a useful model to be used in the risk 
assessment of 2-butoxyethanol exposure, Corley et al. (1994) indicated that since human exposure is most 
likely by inhalation and dermal routes, these routes should be included in a model. In addition, formation of 
the toxic metabolite, 2-butoxyacetic acid, should be a focus of the model. Since species differences in 
hemolytic sensitivity to 2-butoxyethanol are known (Ghanayem and Sullivan 1993), these differences should 
be factored in also. The model was reasonably successful in simulating the concentration of 2-butoxyethanol 
in human blood after inhalation exposure (assuming no dermal absorption), in agreement with the data of 
Johanson (1986). In addition, total respiratory uptake of 2-butoxyethanol, the area under the 2-butoxyethanol 
blood concentration-time curve, and the amount of 2-butoxyacetic acid excreted in the urine were predicted 
with reasonable agreement. Corley et al. (1994) suggested that risk assessments can be strengthened through 
the use of an internal dose factor, such as the maximum concentration of 2-butoxyacetic acid in the blood, or 
the area under the curve for 2-butoxyacetic acid in blood in place of the administered dose, especially in 
interspecies comparisons. Maximum concentration is sensitive to dose rate (e.g., gavage bolus versus drinking 
water), whereas the area under the curve is sensitive to saturation of metabolism and elimination. 
Description of the model. To develop the model Corley et al. (1994) used several types of data, 
including physiological constants for rats and humans, partition coefficients for 2-butoxyethanol and 
2-butoxyacetic acid in various tissues, and biochemical constants describing the metabolism of 2-butoxy-ethanol 
and excretion of 2-butoxyacetic acid. The values used are presented in Tables 2-l 1 and 2-12. 
Partition coefficients were available from the literature for 2-butoxyethanol in bloodair and salineair 
(Johanson and Dynesius 1988). Partition coefficients were determined experimentally for 2-butoxyethanol 
and 2-butoxyacetic acid in human blood and in the blood, liver, kidney, muscle, fat, skin, lung, stomach, small 
intestine, and cecum of male Fischer 344 rats(Corley et al. 1994). The metabolism of 2-butoxyethanol to 
2-butoxyacetic acid was assumed to take place only in the liver through the alcohol/aldehyde dehydrogenase 
pathway, as described previously by Johanson (1986). A saturable metabolic pathway was added to account 
for all other possible pathways causing the disappearance of 2-butoxyethanol from the liver. Parameters for 
this pathway were estimated from the model of Medinsky et al. (1990) and scaled for humans. The 
assumption was made in the Corley model (1994) that 2-butoxyacetic acid was bound to proteins in the blood 
and was eliminated by a saturable process in the kidneys (i.e., renal acid transport) as suggested by the work of 
Ghanayem et al. (1990a). Incorporation of protein binding was necessary to reduce the amount of “free” 
2-butoxyacetic acid available for elimination in order to closely simulate data in rats and humans. Elimination 
constants were estimated from the data of Ghanayem et al. (1990a). The maximum concentration (Cmax) and 
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“internal dose” or “delivered dose” for extrapolations between species, routes, and high and low doses. 
Concentration-response relationships for 2-butoxyacetic acid-induced hemolysis in rat and human blood have 
been shown (Bartnik et al. 1987; Ghanayem 1989; Ghanayem et al. 1987, 1992; Udden 1994). 
Validation of the model. The reliability of the model was tested using data sets reported by several 
laboratories, in addition to data produced by Corley et al. (1994). Data from previous reports were used to 
derive estimates of biochemical parameters describing dermal uptake of 2-butoxyethanol by humans 
(Ghanayem et al. 1990a; Johanson and Boman 199 1; Medinsky et al. 1990). Validation of these parameters 
was performed by comparing model predictions with other studies having relevant data. A simulation was 
conducted of 2-butoxyethanol and 2-butoxyacetic acid concentrations in the blood of young and old rats dosed 
intravenously with 2-butoxyetbanol. Reasonable agreement was obtained for simulations for the younger rats. 
The model tended to overpredict the concentration of 2-butoxyacetic acid at low doses soon after 
administration but was adequate thereafter. In older rats, adjustments to the parameters, including increasing 
the volume of the fat compartment, and reducing the rate of elimination of the kidneys to simulate the renal 
disease common in aged rats, improved the simulations. 
The parameters associated with the disposition of 2-butoxyacetic acid were validated against experimental 
data produced by Corley et al. (1994). Reasonable agreement was reached for 2-butoxyacetic acid in the 
blood. Model simulations of the amounts of 2-butoxyacetic acid excreted by young male rats (16-18 weeks) 
and older rats (12 or 13 months) were compared with tbe data of Ghanayem et al. (1987a, 1987b). The best 
predictions were for young rats at doses where hemolysis did not occur. The model did not adjust for the toxic 
effects of the compound on the kidney or liver that may have been secondary to the hemolytic effect. The 
Corley model was responsive to the normal changes in age and weight in animals. 
The Corley model achieved reasonable agreement between simulations and experimental data on 
2-butoxyacetic acid excreted in the urine of rats after exposure to 2-butoxyethanol in the drinking water 
(Medinsky et al. 1990). Excellent agreement was also reached with the data of Sabourin et al. (1992a) after 
inhalation exposure of rats, for respiratory uptake of 2-butoxyethanol, total amounts of 2-butoiyethanol 
metabolized, and total amounts of 2-butoxyacetic acid excreted. The exception was for the total amount of 
2-butoxyacetic acid excreted at the high dose, which caused hemolysis in the experimental animals (Sabourin 
et al. 1992a). The model over-predicted the amount excreted, another indication that the PBPK model did not 
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Simulations of the human inhalation data of Johanson et al. (1986a) for the concentration of 2-butoxyethanol 
in the blood were comparable to the original data, assuming no dermal uptake. Instead of using a standardized 
weight, the actual body weights of the volunteers in the study were used, and the parameters were scaled by 
body weight for each. The predicted pulmonary ventilation rate for the volunteers who engaged in light 
exercise agreed with those observed (Johanson et al. 1986a). Reasonable agreement was also obtained for 
respiratory uptake, area under the curve for 2-butoxyethanol blood concentration-time, and the amount of 
2-butoxyacetic acid excreted in the urine. Simulations of the data of Johanson and Boman (1991), including 
dermal uptake through exposure to the vapor, suggested that dermal uptake was not as important as was 
indicated by Johanson and Boman (1991). When the assumption was made that the finger prick blood 
samples taken in the Johanson and Boman (1991) study were venous blood samples draining the skin, rather 
than mixed arterial blood, the model adequately predicted the data (Corley 1996). Data from an additional 
dermal exposure study, in which volunteers were exposed one arm only to 50 ppm 2-butoxyethanol for 2 hours 
and in which blood samples were taken from the unexposed arm (Corley et al. 1997) confirmed this theory. 
The Corley model was further refined by changing it to better reflect human metabolism as measured by 
urinary metabolite levels in Corley et al. 1997, and using a new permeability coefficient for dermal absorption 
of vapors The model was changed to make a majority of total urinary butoxyacetic acid in the form of the 
glutamine conjugate and to eliminate urinary excretion of free and conjugated butoxyethanol and free or 
conjugated ethylene glycol or its metabolite, glycolic acid. 
Target tissues. Reasonable agreement was achieved between the model and experimental data for 
2-butoxyacetic acid levels in the blood of rats after gavage exposure and in the urine of rats after drinking 
water exposure, respiratory uptake of 2-butoxyethanol, total amount metabolized, and total 2-butoxyacetic 
acid excreted after inhalation exposure of rats, as long as the doses were below those that caused hemolysis. 
In humans, reasonable agreement was achieved between the model and experimental data for respiratory 
uptake, the area under the curve for 2-butoxyethanol blood concentration-time, and the amount of 
2-butoxyacetic acid excreted in the urine after inhalation exposure (Corley et al. 1994). 
Species extrapolation. To compare species, Corley et al. (1994) ran simulations of the maximum 
concentration and area under the curve for 2-butoxyethanol and 2-butoxyacetic acid in rat and human blood 
after a 6-hour dermal exposure to aqueous 2-butoxyethanol. A 10% body surface exposure was assumed, with 
no evaporation of the chemical. Maximum absorption was predicted at 40% solutions, with less absorbed at 
higher and lower doses. Although the reasons for these results are not clear, they suggest that under normal 
circumstances, humans are unlikely to absorb enough 2-butoxyethanol through dermal exposure alone to cause 
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hemolysis. Following inhalation exposure, the model predicts that humans would not be expected to produce 
enough 2-butoxyacetic acid to result in hemolysis even if they were exposed to concentrations up to 
1,160 ppm 2-butoxyethanol, the saturated vapor concentration (Corley 1996). This conclusion was reached 
even with the inclusion of dermal absorption of vapor, the estimate of which was subsequently reduced on the 
basis of Corley et al. (1997) human dermal absorption data. 
High-low dose extrapolation. The model seems to predict well for animals at low and middle doses that 
do not cause hemolysis for oral (drinking water) and inhalation exposure (Medinsky et al. 1990; Sabourin et 
al. 1992a). The model was not designed to adjust for toxicity in the kidney and liver that may have been 
secondary to the hemolytic effects of 2-butoxyethanol. Low dose extrapolation, modeling doses similar to 
those at which most consumer exposure occurs, was not conducted. 
Interroute extrapolation. The model seemed to predict well for different routes of exposure in animals, 
as long as the doses were below those causing hemolysis. The model predictions did not agree with human 
dermal absorption estimations of Johanson and Boman (1991) when it was assumed that finger prick blood 
samples represented arterial blood. The model predictions did agree with human data when it was assumed 
that finger prick blood samples represented venous blood draining the skin, and they predicted the one 
arm-only exposure scenario (Corley 1996). Human inhalation exposure was predicted well (Johanson et al. 
1986a). 
2.4 MECHANISMS OF ACTION 
2-Butoxyethanol toxicity has been studied in some detail, and current understanding of 2butoxyethanol 
includes its metabolic fate, mechanism of toxicity, pharmacokinetic models for disposition, and impact of 
exposure on human health. These aspects of 2-butoxyethanol toxicity will be addressed in the following 
sections. The toxicity of 2-butoxyethanol acetate has been studied far less than 2-butoxyethanol toxicity, 
presumably because 2-butoxyethanol acetate is assumed to be metabolized to 2-butoxyethanol in the body. 
2.4.1 Pharmacokinetic Mechanisms 
Pharmacokinetic models of 2-butoxyethanol disposition have been developed (Bartnik et al. 1987; Corley et 
al. 1997; Corley et al. 1996; Corley et al. 1994; Ghanayem et al. 1990a; Medinsky et al. 1990; Sabourin et al. 
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2-butoxyethanol by the alcohol/aldehyde dehydrogenases is a prerequisite for the development of the 
characteristic hematotoxicity (Dow 1982; Ghanayem et al. 1987b, 1987c; ICI 1989). Metabolism is presumed 
to take place in the liver; excretion takes place primarily via the urine. 
2-Butoxyethanol metabolism to its reactive intermediate, 2-butoxyacetic acid, presumably through the 
intermediate 2-butoxyacetaldehyde, takes place through oxidation by the alcohoValdehyde dehydrogenases. 
Nontoxic pathways include conjugation of 2-butoxyethanol with glucuronic acid, which is excreted in the 
urine; thus, the conjugate formation leads to elimination and the prevention of formation of toxic metabolites. 
Some evidence exists that ethylene glycol is also a metabolite of 2-butoxyethanol under certain circumstances 
through dealkylation; ethylene glycol formation may depend on the route of administration (Corley et al. 1994; 
Medinsky et al. 1990; Rambourg-Schepens et al. 1988; Sabourin et al. 1992a, 1992b, 1993; Shyr et al. 1993). 
At higher doses, saturation of the 2-butoxyacetic acid and ethylene glycol pathways favors the formation of 
glucuronide conjugates of 2-butoxyethanol (Sabourin et al. 1992a). Ethylene glycol itself has been shown to 
cause hepatic, renal, and developmental toxicity, as summarized in the ATSDR Toxicological Profile for 
Ethylene Glycol and Propylene Glycol (ATSDR 1993). However, ethylene glycol is a minor metabolite of 2­
butoxyethanol, and the toxicity of 2-butoxyethanol in humans and animals can be understood on the basis of 
on its metabolism to 2-butoxyacetic acid. 
2.4.2 Mechanisms of Toxicity 
The most characteristic toxic effect of 2-butoxyethanol in animal models is on the hematologic system and 
includes elevated osmotic fragility of erythrocytes, hemolysis, decreased hematocrit, hemoglobinuria, 
hemoglobinemia, and hemolytic anemia (Bartnik et al. 1987; Carpenter et al. 1956; Corley et al. 1994; Dodd 
et al. 1983; Dow 1959; Duprat and Gradiski 1979; Eastman Kodak 1983; Ghanayem and Sullivan 1993; 
Ghanayem et al. 1987a, 1987b, 1990b, 1992; Grant et al. 1985; Hardin et al. 1984; Krasavage 1986; Nagano 
et al. 1979,1984; NTP 1993,1989; Sabourin et al. 1992a, 1992b, 1993; Union Carbide 1980a). Evidence of 
the early stages of hemolysis, characterized by erythrocytic swelling and detected as increased mean cell 
volume, increased hematocrit, and decreased mean cell hemoglobin concentration, has also been observed after 
exposure to 2-butoxyethanol (Bartnik et al. 1987; Dodd et al. 1983; Ghanayem and Sullivan 1993; Tyl et al. 
1984). These effects have also been observed after 2-butoxyethanol acetate exposure (Truhaut et al. 1979). 
Compensatory erythropoiesis, occurring in response to hemolysis, results in an increase in reticulocytes, 
increased mean cell volume, increased or normal mean cell hemoglobin, and decreased mean cell hemoglobin 
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in some animal studies of 2-butoxyethanol (Dodd et al. 1983; Ghanayem et al. 1987a, 1992; Grant et al. 1985; 
NTP 1989; Tyl et al. 1984). 
Hemolysis can occur within the circulatory system, or outside the circulatory system in the spleen, bone 
marrow, or liver (McGrath 1993). Hemoglobinemia (the presence of free hemoglobin in the blood) and 
hemoglobinuria (the presence of free hemoglobin in the urine) are indicators of destruction of red blood cells 
within the circulatory system (Jones and Hunt 1983; McGrath 1993). Hemoglobin is normally contained in 
erythrocytes. When hemoglobin is released from damaged erythrocytes, it is detectable in the blood, is 
normally decomposed in the spleen and other organs of the reticula-endothelial system, and is eliminated as 
bilirubin. When the amount of free hemoglobin in the blood is such that the spleen and other organs of the 
reticula-endothelial system cannot completely remove it from the circulation, it appears in the urine 
(hemoglobinuria). When hemoglobinuria is detectable, it is reasonable to assume that hemolytic anemia is 
occurring. Hemoglobinuria is normally identified by the brownish or reddish-brown color of the urine (Jones 
and Hunt 1983). Increased hemosiderin, resulting from free hemoglobin in the circulatory system, may also be 
present in the kidney tubules (McGrath 1993). Hemolysis occurring outside the circulatory system is 
characterized by increased spleen size and weight, and hemosiderin deposits in the spleen and liver. 
Most of the toxic effects of 2-butoxyethanol or 2-butoxyethanol acetate observed in animal studies may be 
secondary to the hemolytic effects of these chemicals. Free hemoglobin resulting from intravascular hemolysis 
can cause renal damage (pigment nephropathy) which may result in renal failure (Rosenstock and Cullen 
1994). Hemolysis can cause accumulation of hemoglobin in renal tubular cells, and may also result in anemia, 
insufficient blood supply, and renal ischemic injury culminating in acute tubular necrosis. Adverse renal 
effects secondary to hemolysis, including tubular necrosis and other histopathological changes, have been 
noted in animals after inhalation (Carpenter et al. 1956), oral (Eastman Kodak 1983; Ghanayem et al. 1987a, 
1987b; Krasavage 1986), or dermal exposure to 2-butoxyethanol (Duprat and Gradiski 1979; Union Carbide 
1980a) and after inhalation, oral, or dermal exposure to 2-butoxyethanol acetate (Truhaut et al. 1979). 
Extravascular hemolysis results in accumulation of heme pigments in the liver and spleen; thus, necrosis, 
pigment deposition, and increased organ weight in these organs are most likely secondary to the hemolytic 
effects of 2-butoxyethanol (Dodd et al. 1983; Duprat and Gradiski 1979; Eastman Kodak 1983; Ghanayem et 
al. 1987a, 1987b; Grant et al. 1985; Krasavage 1986; NTP 1989, 1993). As a result of hemolysis, anemia 
and insufficient blood supply may occur, resulting in effects such as cold extremities (NTP 1989; Tyl et al. 
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Hematuria, the presence of whole red blood cells in the urine, can be identified by the reddish color of the urine 
(Jones and Hunt 1983). Hematuria results from hemorrhaging into the urinary system. Although 
hemoglobinuria and hematuria may both be present, whether or not the mechanisms of toxicity producing the 
two effects are related is unclear. It is possible that hematuria occurs after 2-butoxyethanol exposure via 
leakage of erythrocytes through renal structures that have been damaged by the presence of free hemoglobin 
resulting from hemolysis . 
As indicated above in Section 2.3.3, metabolic activation of 2-butoxyethanol to 2-butoxyacetic acid via the 
alcohol/aldehyde dehydrogenase pathway is necessary for hematotoxicity. Ghanayem and coworkers 
(Ghanayem 1989; Ghanayem and Sullivan 1993) undertook studies to determine the mechanisms of hemolytic 
effects in rat and human erythrocytes in vitro, and to determine the relative sensitivity of human erythrocytes 
to 2-butoxyacetic acid. Incubation of 5 or 10 mM 2-butoxyethanol with rat blood resulted in no significant 
hemolysis; no evidence of 2-butoxyethanol metabolites was found (Ghanayem 1989). Incubation of rat 
erythrocytes with 20 mM 2-butoxyethanol resulted in hemolysis that was determined to be nonspecific in 
nature, because as with the 5- and 10-mM doses, no metabolites of 2-butoxyethanol were detected at this 
higher dose. Addition of either alcohol or aldehyde dehydrogenase to whole blood with 2-butoxyethanol did 
not cause either hemolysis or production of 2-butoxyetbanol metabolites. Thus, the work of Ghanayem (1989) 
suggests that whole blood is not capable of metabolizing 2-butoxyethanol in vitro to 2-butoxyacetic acid, the 
hemolytic metabolite. Incubation of rat erythrocytes with butoxyacetaldehyde or 2-butoxyacetic acid caused 
time- and concentration-dependent swelling of red blood cells followed by hemolysis, which has also been 
observed in vivo (Ghanayem et al. 1990b). Butoxyacetaldehyde was less effective in causing hemolysis than 
was 2-butoxyacetic acid, suggesting that, although whole rat blood may contain enough aldehyde 
dehydrogenase to cause some conversion of the aldehyde to 2-butoxyacetic acid, the 2-butoxyacetic acid is the 
hemolytic agent. Addition of aldehyde dehydrogenase and its cofactors, followed by butoxyacetaldehyde, 
resulted in a significant increase in hemolysis, which could be decreased with the addition of cyanamide, an 
aldehyde dehydrogenase inhibitor, thus supporting the evidence that production of 2-butoxyacetic acid is the 
important step in 2-butoxyethanol-specific hemolysis (Ghanayem et al. 1989). Further experiments indicated 
that in rat erythrocytes, 2-butoxyacetic acid and butoxyacetaldehyde caused a decrease in blood adenosine 
triphosphate (ATP) concentration. The observation that 2-butoxyethanol-induced hemolysis is preceded by 
cellular swelling and that this was associated with the depletion of ATP, suggests that the red blood cell 
membrane is the target of toxicity, although the primary effect on the erythrocyte is not clear. Studies on the 
direct effect of 2-butoxyacetic acid on the red blood cell also suggest that the red blood cell membrane is the 
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of 2-butoxyacetic acid in vitro, suggesting differences between the human cell membrane and that of the rat 
(Ghanayem 1989; Ghanayem and Sullivan 1993; ICI 1989). Studies of erythrocytes from guinea pigs, dogs, 
pigs, and cats indicated these species were resistant to the effects of 2-butoxyacetic acid, whereas rats, mice, 
and rabbit erythrocytes were susceptible (Ghanayem and Sullivan 1993; ICI 1989). Blood from mice, rats, 
hamsters, rabbits, and baboons exposed in vitro is susceptible to the hemolytic effects of 2-butoxyacetic acid, 
which produces time- and concentration-dependent increases in mean corpuscular volume and hematocrit at 
concentrations at or above 1 mM (Ghanayem and Sullivan 1993). Ghanayem et al. (1992) conducted a series 
of experiments on the in vitro effect of 2-butoxyacetic acid on blood from 2-butoxyethanol-treated rats. Red 
blood cells from rats exposed to 125 mg/kg 2-butoxyethanol for 3 days and allowed to recover for 7 days prior 
to bleeding were less sensitive to the hemolytic effects of 2-butoxyacetic acid than red blood cells from 
untreated rats. This work confirms the observation that young erythrocytes, formed in response to recovery 
from the hemolytic effects of the first exposure to 2-butoxyacetic acid, are more resistant to the hemolytic 
effects of 2-butoxyacetic acid than mature erythrocytes. This work suggests that chronic exposure to 
2-butoxyethanol might result in tolerance since the aging erythrocytes would be lysed, and since the remaining 
circulating erythrocytes would be younger and more resistant to hemolysis. The resilience of newly formed red 
blood cells to 2-butoxyethanol exposure has been confirmed by Sivarao and Mehendale (1995). These 
investigators also showed that bleeding rats, which increases new red blood cell formation, provided protection 
against the hemolytic effects of 2-butoxyethanol. 
In an effort to further elucidate the mechanism of toxicity of 2-butoxyethanol, Foster et al. (1987) dosed rats 
directly with 2-butoxyacetic acid once by gavage with 0, 174, 434, or 868 mg/kg/day 2-butoxyacetic acid in 
water. Hematuria resulted from direct exposure to a single dose of 2-butoxyacetic acid at 868 mg/kg/day, but 
not at 434 mg/kg/day or less. The results of this study confirmed that the metabolite of 2-butoxyethanol (i.e., 
2-butoxyacetic acid) could produce hematological effects similar to those observed after 2-butoxyethanol 
exposure. It is unknown why such a high dose of 2-butoxyacetic acid was needed to produce hemolysis since 
this metabohte is thought to cause the hemolytic effects resulting from exposure to 2-butoxyethanol. It is 
possible that the differences in the rate of uptake and excretion of the metabolite may account for the need of a 
higher dose level. 
Evidence of anemia has also been observed in cases of intentional human poisoning with 2-butoxyethanol 
(Bauer et al. 1992; Gijsenbergh et al. 1989; Rambourg-Schepens et al. 1988). It has been suggested that 
support with fluids (Bauer et al. 1992; Gijsenbergh et al. 1989; Rambourg-Schepens et al. 1988) and 
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following ingestion of large doses of 2-butoxyethanol (Udden 1996). Before hemolysis is considered as the 
mechanism for anemia in humans, Udden (1996) suggests that additional information regarding 2-butoxy-ethanol 
ingestion is needed, including review of morphology of red blood cells, reticulocyte count, mean cell 
volume, and tests for intravascular hemolysis (lactate dehydrogenase, haptoglobin, hemoglobinuria). 
Hemoglobinuria should be distinguished from myoglobinuria, a condition in which myoglobin is excreted in 
the urine. Myoglobin resembles blood hemoglobin but contains only one heme as part of the molecule. 
Metabolic acidosis has been observed following exposure to 2butoxyethanol. Metabolic acidosis may be due 
to production of lactate and 2-butoxyacetic acid (Gijsenbergh et al. 1989). Metabolic acidosis, if left 
uncorrected, leads to hyperventilation and renal failure, which have been identified as possible toxic sequellae 
to 2-butoxyethanol exposure (Gijsenbergh et al. 1989; Litovitz et al. 1991; Rambourg-Schepens et al. 1988). 
No specific mechanism of toxicity has been described for other toxic effects of 2-butoxyethanol, including 
respiratory, cardiovascular, gastrointestinal, neurological, reproductive, and developmental effects. 
Respiratory effects observed in humans include irritation of the nose and throat and a slight increase in nasal 
mucus discharge after inhalation or dermal exposure (Carpenter et al. 1956), and pulmonary edema or 
respiratory insufficiency after oral ingestion (Bauer et al. 1992; Gijsenbergh et al. 1989). In animals, 
inhalation exposure has been shown to cause rapid and shallow breathing, audible respiration, nasal discharge, 
perinasal encrustation, decrease in respiratory rate, and congested or hemorrhagic lungs (Carpenter et al. 1956; 
Dodd et al. 1983; Dow 1986; Duprat and Gradiski 1979; Kane et al. 1980; Tyl et al. 1984). After oral 
exposure, dyspnea has been observed (NTP 1989; Wier et al. 1987). Some of these effects, including changes 
in respiratory rate and hemorrhaging of the respiratory tissues, may be related to metabolic acidosis and 
hemolysis, respectively. After oral exposure, humans exhibit cardiovascular effects including tachycardia and 
low blood pressure (Bauer et al. 1992), but similar effects have not been observed in animals. Gastrointestinal 
effects, including emesis, have been observed in humans, monkeys, and dogs after inhalation exposure 
(Carpenter et al. 1956), but the cause is unknown. other gastrointestinal effects, including hyperkeratosis and 
acanthosis, and diarrhea observed in animals after oral dosing may be related to contact irritation of the 
gastrointestinal tissues (Eastman Kodak 1983; Krasavage 1986; NTP 1993). Hemorrhagic orred stomach or 
intestines observed after oral or dermal dosing in animals may be related to the hemolytic activity of 
2-butoxyethanol (Union Carbide 1980a, 1980b). No mechanism has been described for neurological effects, 
including headache, CNS depression, and disturbed taste sensation in humans after inhalation exposure 
(Carpenter et al. 1956), and loss of coordination, excess salivation, and weakness in animals after inhalation, 
oral, or dermal exposure (Carpenter et al. 1956; Dodd et al. 1983; Dow 1959, 1972, 1981, 1986; Duprat and 
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Gradiski 1979; Eastman Kodak 1983; Hardin et al. 1984; Krasavage 1986; NTP 1989; Olin 1976; Union 
Carbide 1980a, 1980b; Wier et al. 1987). Coma has been observed after human poisoning (Bauer et al. 1992; 
Gijsenbergh et al. 1989; Rambourg-Schepens et al. 1988). With the exception of decreased pup weight 
observed in mice at 700 mg/kg/day (Heindel et al. 1990), developmental effects (including a decrease in viable 
implants and an increase in malformations in animals) reported occurred at 2-butoxyethanol doses that 
resulted in moderate to severe maternal toxicity (Hardin et al. 1987; NTP 1989; Tyl et al. 1984; Wier et al. 
1987). Reproductive effects have been observed at doses that resulted in other adverse effects in adult animals 
(Hardin et al. 1987; Heindel et al. 1990; NTP 1989, 1993; Schuler et al. 1984; Tyl et al. 1984; Wier et al. 
1987). Mechanisms for the reproductive and developmental effects of 2-butoxyethanol have not been 
identified. 
Several in vitro studies have investigated the action of 2-butoxyethanol on cells in culture, the results of which 
may suggest additional or related areas of research that may lead to an explanation of 2-butoxyethanol’s effect 
on erythrocytes. 2-Butoxyethanol has been shown to effectively block metabolic cooperation between Chinese 
hamster V79 cells in culture at nontoxic doses (Loch-Caruso et al. 1984). At higher doses, the cells died. 
Metabolic cooperation is a manifestation of the transfer of metabolites between cells coupled at a specific 
junction (gap junction), a process that has been implicated in cell division, morphological development, and 
differentiation. Disruption of this process could contribute to cellular death or dysfunction, teratogenesis, or 
tumor promotion. In another study, 2-butoxyethanol and 2-butoxyacetic acid were shown to be cytotoxic to 
Chinese hamster ovary cells in culture, as indicated by a reduction in cloning efficiency (Jack et al. 1985). In 
support of this observation, the study authors cited the work of others, Loch-Caruso et al. (1984) and Johnson 
et al. (1984), who observed that 2-butoxyethanol exposure resulted in developmental toxicity of the hydra. 
Jackh et al. (1985) also noted that the hemotoxicity of 2-butoxyethanol observed in small rodents in vivo and 
in vitro (Ghanayem et al. 1987a, 1987b, 1989, 1992) also suggests cytotoxicity. In another study, 2-butoxy-ethanol 
was shown to decrease maximum calcium uptake by rabbit sarcoplasmic reticulum vesicles and to 
markedly increase the subsequent calcium efflux rate (Mayahara et al. 1982). In addition, 2-butoxyethanol 
caused tetany in an isolated phrenic nerve-diaphragm preparation of the rat. The significance of these results 
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2.4.3 Animal-to-Human Extrapolations 
Recent physiologically based pharmacokinetic models have tried to address 2-butoxyethanol metabolism and 
disposition in an effort to derive animal-to-human extrapolations (Medinsky et al. 1993; Shyr et al. 1993). 
Other models have also been developed based on human data (Johanson 1986,199la; Johanson and Naslund 
1988). Each model was multicompartmental and attempted to relate the generation of metabolites to end 
points of 2-butoxyethanol toxicity. Primary focus has been on absorption from the respiratory system and the 
skin (Johanson 199 1 a; Shyr et al. 1993). Absorption from the gastrointestinal tract has also been addressed 
(Shyr et al. 1993). Additional data have recently been published to more adequately model the metabolism 
and disposition of 2-butoxyethanol in rats (Johanson 1994), as well as additional animal and human data and 
revised modeling parameters that more adequately address issues of routes of exposure and competing 
metabolic pathways (Corley et al. 1997; Corley et al. 1994). With this additional work, the database and 
resulting model are more complete, and come close to adequately modelling data for both animals and humans 
Additional study, including regarding dermal uptake, protein binding parameters, renal elimination, 
mechanism of hemolysis of rat erythrocytes and its relevance in humans, and further evaluation of the 
metabolism and kinetics of 2-butoxyethanol and its metabohtes in animals with erythrocytic sensitivity similar 
to humans (less sensitive than rats), has been recommended to improve the ability of the model to predict 
outcome in different species (Corley et al. 1994). 
In vitro studies have shown that, compared to rat blood cells, human red blood cells are insensitive to the 
hemolytic effects of 2-butoxyacetic acid. Concentrations of 2-butoxyacetic acid that caused hemolysis of rat 
red blood cells did not cause hemolysis of human red blood cells (Bartnik et al. 1987). For example, following 
a 60-minute exposure of rat red blood cells to 7.5 mM 2-butoxyacetic acid, 100% hemolysis was observed. 
Following a 60-minute exposure of human red blood cells to 15 mM 2-butoxyacetic acid, no hemolysis was 
observed (Bartnik et al. 1987). An in vitro study measuring more sensitive end points of red blood cell 
effects, i.e., mean cell volume and hematocrit, has also shown rat red blood cells to be more sensitive to 2­
butoxyacetic acid compared to human red blood cells (Ghanayem and Sullivan 1993). For example, following 
a 1 -hour exposure to 2 mM 2-butoxyacetic acid, mean corpuscular volume was about 150% of controls in rat 
red blood cells and 105% of controls in human red blood cells; hematocrit was about 155% of controls in rat 
red blood cells and 105% of controls in human red blood cells. Red blood cells of rabbits, hamsters, mice, and 
baboons were also sensitive to 2-butoxyacetic acid, while red blood cells of cats, pigs, dogs, and guinea pigs 
were not sensitive to 2-butoxyacetic acid (Ghanayem and Sullivan 1993). The molecular mechanism for the 
resistance of red blood cells from some species but not others is not known. Until the mechanism is known, it 
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has been suggested that 2-butoxyethanol should be treated as a chemical with the potential for causing human 
toxicity (Ghanayem 1996). 
2.5 RELEVANCE TO PUBLIC HEALTH 
Overview 
2-Butoxyethanol and, to a lesser extent, 2-butoxyethanol acetate are found in a wide variety of industrial and 
consumer products. For 2-butoxyethanol, the exposure scenario of most concern to the general public is 
inhalation or dermal absorption while using household cleaners, metal cleaners, spray lacquers, quick-dry 
lacquers, enamels, varnishes, varnish removers, and latex paints. 2-Butoxyethanol acetate is used in 
nitrocellulose lacquer, epoxy and acrylic enamels, latex coatings, and some ink and spot remover formulations. 
Individuals employed in industries that make or use 2-butoxyethanol or 2-butoxyethanol acetate (e.g., 
hospitals and medical facilities, silk screen shops, furniture finishers, print shops, paint manufacture) are 
probably exposed to the highest concentrations of atmospheric 2-butoxyethanol or 2-butoxyethanol acetate. In 
the general population, people residing around certain chemical manufacturing sites or living near waste sites 
containing 2-butoxyethanol or 2-butoxyethanol acetate may theoretically be exposed to concentrations higher 
than background air concentrations; however, neither of these chemicals has been measured in air near NPL 
sites. 
Several in vivo and in vitro studies have conclusively demonstrated that 2-butoxyethanol and 2-butoxyethanol 
acetate can be absorbed through human skin. Dermal absorption can occur from exposure to the liquid form 
and small amounts of the vapor can be absorbed dermally. Since over half of the products containing 
2-butoxyethanol marketed in the United States are intended for household use, the potential for dermal 
exposure is great. All-purpose cleaners comprise the largest proportion of consumer products containing 
2-butoxyethanol. Consumers generally do not wear respiratory protection or protective gloves when 
performing general cleaning chores such as washing windows, mopping floors, cleaning cars, etc. Thus, the 
potential for exposure through both the derrnal and inhalation routes is substantial. 
Occupational exposure to 2-butoxyethanol usually involves co-exposure to other solvents and chemicals. In 
several NIOSH Health Hazard Evaluations, effects reported by workers included eye, nose, and throat 
irritation; coughing; runny nose; headache; dizziness; lightheadedness; and nausea. Since personal breathing 
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ethyl ketone, methyl isobutyl ketone, styrene) along with 2-butoxyethanol indicated that exposure levels for 
each chemical were below the NIOSH, ACGIH, and OSHA criteria, NIOSH concluded that the effects were 
probably due to the additive combination of the solvents. 
Acute oral exposures of humans to large amounts of 2-butoxyethanol have been shown to cause coma and 
respiratory depression, in addition to hematotoxic effects Although this route of exposure is the least likely 
for the general population, the existence of many household products containing 2-butoxyethanol or 2-butoxy­
ethanol acetate makes accidental poisoning a potential problem, particularly for children. 
Acute- and intermediate-duration inhalation, oral, and dermal exposures to 2-butoxyethanol have been shown 
to cause death in animals. There is a report of human death following the ingestion of an unknown amount of 
cleaner containing 6.5% 2-butoxyethanol. Only scanty data are available for 2-butoxyethanol acetate. These 
data suggest that in animals 2-butoxyethanol acetate may be less lethal than 2-butoxyethanol. No studies were 
located regarding death in humans or animals after exposure to 2-butoxyacetic acid by any route. 
The most noted systemic effect in animals resulting from acute and intermediate exposure to 2-butoxyethanol 
or 2-butoxyethanol acetate is hematotoxicity. Hemolysis occurs in several stages, including swelling, popping, 
reduction in volume, and hemoglobin leakage. Some or ah of these stages have been observed in at least three 
cases of human poisoning and in animal studies. Hemodialysis may have contributed to the hemolytic effects 
in humans. The hematotoxicity is characterized in humans by decreased hemoglobin content, progressive 
erythropenia, and hemoglobinuria, and in animals by swelling of the erythrocytes, followed by hemolytic 
anemia, and decreases in circulating red blood cells, hemoglobin concentration, and hematocrit. A causal 
relationship has been established for animals, with the proposed target being the red blood cell membrane. 
Hemoglobinuria observed in animals is a consequence of the hemolytic effects of the 2-butoxyethanol 
metabolite, 2-butoxyacetic acid. An in vitro study has shown that the red blood cells of rats, mice, hamsters, 
rabbits, and baboons are more susceptible to the hemolytic effects of 2-butoxyacetic acid than the red blood 
cells of guinea pigs, dogs, pigs, and cats. In contrast to animals, human red blood cells appear to be more 
resistant to the hemolytic effects of 2-butoxyacetic acid, although presumably the same over&mechanism is 
operational in humans. 
Other notable systemic effects observed in humans exposed to high doses inelude respiratory depression, 
metabolic acidosis, alteration of cardiac rhythm, and hematuria. In animals, hepatic and renal toxicity have 
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spleen weight and splenic congestion have been observed after 2-butoxyethanol exposure in animals. Many of 
the effects observed may be due to the hemolytic effects of 2-butoxyethanol. 
Data on effects of 2-butoxyethanol and 2-butoxyethanol acetate on male reproductive tissues in animals 
generally indicate that male reproductive organs are not affected, but one study indicated decreased sperm 
concentration in rats after intermediate-duration oral exposure to 2-butoxyethanol. However, no significant 
effects on spermatid heads (107/g testis), spermatid counts (mean/10-4 mL), or percent mobile spermatozoa 
were observed. Reproductive effects in female animals consist of vaginal bleeding and altered estrous cycles. 
Data on reproductive and developmental competence in animals indicate that at sufficiently high doses, 
especially those that result in adult animal toxicity, 2-butoxyethanol can adversely affect these processes. 
Reduced fetal viability and retarded skeletal ossification were the most frequently observed effects. 
Limited in vitro data indicate that 2-butoxyethanol is not genotoxic. No studies were located regarding cancer 
in humans or animals after exposure to 2-butoxyethanol. 
In studies of 2-butoxyethanol exposure in humans, the information provided on exposure levels and their 
correlation with observed effects were sufficient for derivation of a chronic inhalation MRL. Data from 
animal studies were used to derive other MRL’s. 
Minimal Risk Levels for 2-Butoxyethanol 
Inhalation MRLS 
•	 An MRL of 6 ppm has been derived for acute-duration inhalation exposure (14 days or less) to 
2-butoxyethanol. 
The MRL was calculated from a NOAEL of 50 ppm for hematotoxicity in pregnant rats in a study by 
Tyl et al. (1984). See Appendix A for details. In the study by Tyl et al. (1984), timed-pregnant 
Fischer 344 rats (n=36) were exposed to 2-butoxyethanol vapors by inhalation on gestational days 
6-15 at concentrations of 0, 25, 50, 100, or 200 ppm for 6 hours per day. The animals were 
observed for clinical signs throughout the study, and food and water consumptions (withheld during 
exposures) was measured. Maternal body weights were taken on gestational days 0, 6, 9, 12, 15, and 
21. The animals were sacrificed on gestational day 21 after blood samples were collected. 
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Hematologic determinations on dams (at 100 and 200 ppm but not 50 ppm) showed statistically 
significant reductions in erythrocyte (red blood cell) count and mean corpuscular hemoglobin 
concentration, and an increase in hemoglobin per cell (mean corpuscular hemoglobin) and size of the 
red blood cell (mean corpuscular volume). There were significant increases in hemoglobin and 
hematocrit at 200 ppm. Clinical signs that occurred with an incidence different from the controls 
were observed in 75% of dams in the 200-ppm group during the exposure period. They included the 
clear evidence of hematuria or hemoglobinuria, periocular wetness, perinasal encrustation, pale and 
cold extremities, and necrosis of the tail tip. Periocular wetness, clear evidence of hematuria, and 
perinasal discharge were also noted in 25-50% of the dams in the 100-ppm group. In the 25- and 
50-ppm groups, 25% of the dams showed signs of periocular wetness. Maternal body weight gain 
was decreased 29% in the 100-ppm group at gestational days 6-15, compared to the control group. 
Exposure resulted in negative weight gain (weight loss during specific periods of time, at 200 ppm), 
decreased maternal body weight (gestational days 6-21, 1 l-12% at 200 ppm), decreased food 
consumption (gestational days 6-15, 13% at 100 ppm), and evidence of anemia (200 ppm) that was 
not observed at lower concentrations. Decreased water consumption (14%) was noted at 200 ppm. 
There was a reduction in maternal gravid uterine weight at 200 ppm. Relative kidney weight was 
elevated compared to controls at 200 ppm in the presence of decreased body weight. No 
treatment-related effects were observed on the weights of the liver. 
Although periocular wetness was observed at high incidences in the rats at ≥25 ppm, indicating that 
25 ppm is a minimal LOAEL for eye irritation (from direct contact of the eyes with the vapor during 
inhalation exposure), hemolysis is the most consistently observed critical effect of concern for 
exposure to 2-butoxyethanol. 
Other studies have shown hematotoxicity after acute inhalation exposure at similar concentrations. 
Fischer 344 rats (eight males, eight females) were exposed for 9 days, 6 hours per day, 5 days per 
week to 2-butoxyethanol target concentrations of 0, 25, 100, or 250 ppm (mean average 
concentrations determined by gas chromatography to be 0, 20, 86, or 245 ppm, respectively) (Dodd 
et al. 1983). Rats were observed for signs of toxicity during exposure and for 14 days postexposure. 
Necropsies were performed on animals that died and on survivors killed at the end of the observation 
period. Biological assessments included daily animal observations, determination of body and organ 
weight (kidney, liver, lungs, and testes), and ophthalmologic, hematologic, and gross pathologic 
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nasal discharge. There was no effect on the hematologic parameters in rats exposed to 20 ppm 
2-butoxyethanol. At 86 ppm, both sexes showed evidence of a significant, but less profound, effect 
on the erythroid parameters. At 245 ppm, both male and female rats showed significantly depressed 
red blood cell counts (20% below control values), hemoglobin, and mean corpuscular hemoglobin 
concentration, and significant increases in mean corpuscular volume, nucleated red blood cells, and 
reticulocytes. Red stained urine (hematuria) was also observed in rats of both sexes exposed to 245 
ppm. Female rats exposed to 86 ppm showed significantly increased liver weights. Male and female 
rats of the 245 ppm group also showed increased liver weights. Decreased mean body weight gains 
(percentage not provided) were also found. A 14-day postexposure recovery showed substantial 
reversal of the affected blood parameters. 
•	        An MRL of 3 ppm has been derived for intermediate-duration inhalation exposure (15-364 days) to 
2-butoxyethanol. 
The MRL was derived from a NOAEL of 25 ppm for hematotoxicity in female rats in a study by 
Dodd et al. (1983). See Appendix A for further details. The female rat was used since females 
appeared to have more severe hematological effects than the male rats. In the study by Dodd et al. 
(1983), Fischer 344 rats (16 males, 16 females) were exposed for 90 days, 6 hours per day, 5 days 
per week to 2-butoxyethanol target concentrations of 0, 5, 25, or 75 ppm (mean average 
concentrations determined by gas chromatography were 0, 5, 25, or 77 ppm, respectively). Rats 
were observed for signs of toxicity during exposure and for 14 days postexposure. Necropsies were 
performed on animals that died and on survivors killed at the end of the observation period. 
Biological assessments included daily animal observations, body weight and organ (kidney, liver, 
lungs, and testes) weight determinations, and ophthalmologic, hematologic, and gross pathologic 
examinations. In addition, red blood cell osmotic fragility tests, serum chemistries, urinalyses, and 
histologic examinations of selected tissues of the high 2-butoxyethanol concentrations were 
performed. No deaths occurred throughout the study. No clinical signs of toxicity were observed. 
There was a transient decrease in body weight gain (exposure weeks 2-4; data not shown) of females 
exposed to 77 ppm 2-butoxyethanol. After 6 weeks (3 1 exposures), female rats exposed to 77 ppm 
had slight but significant decreases (13% below control values) in red blood cell counts and 
hemoglobin concentrations, accompanied by au 11% increase above control values in mean 
corpuscular hemoglobin. At the end of the 90-day study, the hematologic effects seen in the exposed 
female rats either lessened or returned to control value ranges. The only significant hematologic 
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blood cell osmotic fragility tests of both 2-butoxyethanol-treated rats and controls were similar. No 
treatment-related differences were found in body weight, organ weights, urine or serum chemistries, 
gross lesions, or microscopic lesions in males or females. In light of the results of the Dodd et al. 
(1983) study of acute-duration inhalation exposure of rats to doses up to 245 ppm, and the more 
severe hematological effects observed, which were accompanied by changes in liver weight, 
respiratory effects, and decreased body weight gain, it seems reasonable to accept the hematological 
effects seen in the intermediate inhalation exposure experiment as being the most sensitive indicator 
of toxicity. No other suitable supporting studies were found. 
•	 An MRL of 0.2 ppm has been derived for chronic-duration inhalation (≥365 days) to 2-butoxy-
ethanol. 
The MRL was derived from NOAEL of 0.6 ppm for decreased hematocrit and increased mean 
corpuscular hemoglobin concentration observed in 31 male workers exposed to an average 
concentration of 0.6 ppm for 1 to 6 years (Baufroid et al. 1992). See Appendix A for further details. 
An uncertainty factor of 3 for human variability was used because the results of in vitro data suggest 
that 2-butoxyethanol does not cause significant hemolysis of normal and potentially susceptible 
erythrocytes (Udden 1996). In this study, 31 male workers exposed to 2-butoxyethanol were studied. 
Twenty workers were exposed to an average concentration of 0.75 ppm, and 11 workers were exposed 
to an average concentration of 0.46 ppm. The weighted average of the means for the two groups of 
workers is 0.6 ppm. The workers were also exposed to methyl ethyl ketone. Studies in animals 
indicate that methyl ethyl ketone does not produce hematologic effects (ATSDR 1992). Exposure 
concentrations of methyl ethyl ketone were not provided. Twenty-one unexposed men that worked for 
the same company served as controls. Urine was collected before the shift and at the end of the shift 
and assayed for free 2-butoxyacetic acid, retinol binding protein, and creatinine. Blood was collected 
and assayed for red blood cell counts, hemoglobin, hematocrit, mean corpuscular volume, mean 
corpuscular hemoglobin, mean corpuscular hemoglobin concentration, haptoglobin, reticulocytes, and 
osmotic resistance. Serum alanine aminotransferase and aspartate aminotransferase were also 
measured. 
Urinary concentrations of 2-butoxyacetic acid ranged from not detected to 1.1 mg/g creatinine before 
shift (average 0.3), and 0.3 to 51.4 mg/g creatinine after shift (average 12.2) in persons exposed to an 
average of 0.75 ppm. Urinary concentrations of 2-butoxyacetic acid ranged from not detected to 
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in persons exposed to an average of 0.46 ppm. A significant correlation (r = 0.55, p = 0.0012) was 
observed between end shift urinary 2-butoxyacetic acid concentrations and 2-butoxyethanol in air. 
Two small but statistically significant differences in hematology values were observed: a significant 
decrease (p=0.03) in hematocrit values (43.9% exposed, 45.5% controls) and a significant (p=0.02) 
increase in mean corpuscular hemoglobin concentration(33.6 g/dL exposed, 32.9 g/dL controls). 
These differences are consistent with hemolysis observed in animal studies, and might be early 
indicators of potential adverse effects in humans. However, because the changes in both hematocrit 
and mean corpuscular hemoglobin concentration were in the range of normal clinical values, the effect 
was not considered significant. Normal clinical values of hematocrit are reported as 40-54%, with a 
level of 30% or less considered to indicate moderate to severe anemia (Fischbach 1992). Normal 
clinical values of mean corpuscular hemoglobin concentration are reported as 31-37 g hemoglobin/dL 
(Fischbach 1992). Increased mean corpuscular hemoglobin concentrations often indicates 
spherocytosis, while decreased mean corpuscular hemoglobin concentrations may indicate macrocytic 
anemia, chronic blood loss anemia, or pyridoxine-responsive anemia (Fischbach 1992). None of the 
red blood cell end points were correlated with internal exposure as assessed by free urinary 
2-butoxyacetic acid and the amount of conjugated 2-butoxyacetic acid is unknown. Serum creatinine 
and urinary retinol binding protein were not affected. No difference was observed for serum alanine 
transaminase or serum aspartate transaminase. No supporting chronic-duration inhalation studies in 
either animals or humans were identified. 
No MRLs were derived specifically for 2-butoxyethanol acetate since human and animal data are limited. 
Only one acute-duration inhalation study was found in the literature (Truhaut et al. 1979). The study used 
only one concentration (400 ppm) administered to rats and rabbits for 4 hours. Hemoglobinuria and hematuria 
were observed in the rabbits but not in the rats. Similarly, only one study was found in the literature for 
intermediate-duration inhalation exposure (Truhaut et al. 1979). The study used only concentrations of 
400 ppm for 1 month and 100 ppm for 10 months in rats and rabbits, and serious effects (hemoglobinuria, 
hematuria, or renal nephrosis) were observed at both concentrations. No chronic-duration inhalation exposure 
studies of 2-butoxyethanol acetate were found in the literature. Since 2-butoxyethanol acetateis metabolized 
to the same toxic metabolite as is 2-butoxyethanol, it seems likely that the MRLs for 2-butoxyethanol acetate 








2-BUTOXYETHANOL AND 2-BUTOXYETHANOL ACETATE 219 
2. HEALTH EFFECTS 
Oral MRLs 




The MRL was derived from a LOAEL of 32 mg/kg for hematotoxicity in rats in a study by 
Ghanayem et al. (1987a). See Appendix A for details. In the study by Ghanayem et al. (1987a), 
young (4-5 weeks) and adult (9-13 weeks, 5-6 months, and 16 months) rats were dosed with 0,32, 
63, 125, 250, or 500 mg/kg 2-butoxyethanol by gavage. Hematotoxicity, metabolism, and excretion 
of 2-butoxyethanol were monitored for 48 hours. Animals were killed at 48 hours after treatment, 
and spleen, liver, kidney, testes, and urinary bladder were weighed, fixed, and examined. 2-Butoxyethanol 
at 125 mg/kg caused severe acute hemolytic anemia in older rats, resulting in significant 
decreases in red blood cells, hemoglobin, and hematocrit, and increases in the concentration of free 
plasma hemoglobin. Secondary to the hemolytic effects, 2-butoxyethanol also caused hemoglobinuria 
in 16-month-old rats at ≥ 32 mg/kg, in 6-month-old rats at ≥ 63 mg/kg, and in younger rats 
(4-13 weeks) at ≥ 125 mg/kg. Other effects secondary to hemolysis consisted of histopathologic 
changes in the liver and kidney in adult rats, including focal disseminated coagulative necrosis of 
hepatocytes at 250 mg/kg and hemoglobin casts in the proximal tubules of the kidney at 125 mg/kg. 
Relative spleen weight was drastically increased (180-230% of control values). These effects of 
2-butoxyethanol were dose- and time-dependent. Both the hemolytic effects and the secondary 
effects of 2-butoxyethanol were age-dependent, with older rats being more sensitive than younger 
rats. Since the severity of hemoglobinuria in the 16-month-old rats increased as the dose levels 
increased and since hemoglobinuria occurred in younger rats only at higher doses, the 32-mg/kg dose 
was considered to be a less serious LOAEL. The use of 32 mg/kg as a less serious LOAEL for the 
derivation of the acute oral MRL is supported by a study in pregnant rats in which no hematological 
effects were found at a similar dose of 30 mg/kg/day given for 3 days during gestation (NTP 1989). 
Hemolytic anemia is the characteristic toxic reaction to 2-butoxyethanol. Sperm-positive 
Fischer 344 rats (27-33 per dose group) were administered 0, 30, 100, and 200 mg/kg/day 
2-butoxyethanol in distilled water by gavage on gestational days 9-l 1 (NTP 1989). The biological 
effects of 2-butoxyethanol on dams were assessed during treatment as well as 24 hours after 
treatment and on gestational day 20, and effects on fetuses were observed at sacrifice (gestational 
day 20); 22-24 females per group were confirmed pregnant. At sacrifice on gestational days 12 or 
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liver, right and left kidneys, spleen, and uterus. For females sacrificed on gestational day 20, the 
uterine contents were also evaluated (i.e., number of implantation sites, resorptions, and dead and 
live fetuses). The fetuses were sexed and examined for external and visceral malformations 
Maternal and fetal blood (pooled by litter) was analyzed for red blood cell and white blood cell 
counts, hemoglobin, hematocrit, mean corpuscular hemoglobin, mean corpuscular volume, mean 
corpuscular hemoglobin concentration, and platelet count. Red blood cell counts and corresponding 
measures of hematocrit and hemoglobin were significantly reduced in the 100- and 200-mg/kg/day 
dose groups at approximately 24 hours after the final dose. Mean corpuscular hemoglobin 
concentration was significantly decreased in the high-dose group. The blood dyscrasia produced at 
approximately 24 hours after the last treatment also included increases in reticulocytes, white blood 
cell count, platelet count, mean corpuscular volume, and mean corpuscular hemoglobin in the 100 and 
200-mg/kg/day dose groups. On gestationall day 20, maternal hematological end points 
recovered toward control values, although a majority of values remained different from controls in 
the 100- and 200-mg/kg/day dose groups. Red blood cell counts measured on gestational day 20 in 
the 100- and 200-mg/kg/day dose groups of each treatment period were still lower than control 
values, but counts had increased since cessation of treatment (i.e., in the 200-mg/kg/day dose group, 
the red blood cell count increased to 91% of control levels by gestational day 20). Similarly, 
reticulocytes declined from values measured earlier in the 100- and 200-mg/kg/day dose groups but 
were still significantly above the control level. Corrected white blood cell counts measured on 
gestational day 20 after dam treatment were similar across dose groups. Platelet counts determined 
at the end of the study showed a significant decreasing trend with respect to dose which appeared to 
be determined by a nonsignificant decrease in the high dose compared to the control group. The 
mean corpuscular volume and mean corpuscular hemoglobin on gestational day 20 exhibited 
significant dose-related trends, with the values of the two highest dose groups greater than the 
control values. Calculated values of mean corpuscular hemoglobin concentration showed significant 
decreasing dose-related trends with the high-dose group values lower than controls. The changes in 
mean corpuscular hemoglobin concentration were significant in the high-dose group, but were 
relatively slight in magnitude. The maternal hematological profiles at 24 hours afterfinal treatment 
and at gestational day 20 indicate that 2-butoxyethanol-induced hemolysis triggered a compensatory 
hematopoietic response leading to reticulocytosis. Furthermore, recovery was more complete by 
gestational day 20 for dams treated on gestational days 9-l 1 than for those exposed on gestational 
days 1 l-13. 
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In a similar experiment conducted by NTP (1989), sperm-positive Fischer 344 rats (29-31 per dose 
group) were administered 0, 30, 100, and 300 mg/kg/day 2-butoxyethanol in distilled water by 
gavage on gestational days 11-13. The biological effects of 2-butoxyethanol on dams were assessed 
during treatment as well as 24 hours after treatment and on gestational day 20, and effects on fetuses 
were assessed at sacrifice (gestational day 20). Maternal and fetal blood (pooled by litter) was 
analyzed for red and white blood cell counts, hemoglobin, hematocrit, mean corpuscular hemoglobin, 
mean corpuscular volume, mean corpuscular hemoglobin concentration, and platelet count. Red 
blood cell count and corresponding measures of hematocrit and hemoglobin were significantly 
reduced in the 100- and 300-mg/kg/day dose groups at approximately 24 hours after the final dose. 
Mean corpuscular hemoglobin concentration was significantly decreased in the high-dose group. The 
blood dyscrasia produced at approximately 24 hours after the last treatment also included increases 
in reticulocytes, white blood cell count, platelet count, mean corpuscular volume, and mean 
corpuscular hemoglobin in the 100- and 300-mg/kg/day dose groups. On gestational day 20, 
maternal hematological end points recovered toward control values, although a majority of values 
remained different from controls in the 100- and 300-mg/kg/day dose groups. Red blood cell counts 
measured on gestational day 20 in the 100- and 300-mg/kg/day dose groups for each treatment 
period were still significantly lower than control values, but counts had increased after cessation of 
treatment (i.e., in the 300-mg/kg/day dose group, the red blood cell count increased from about 45% 
of control levels at 24 hours after the final treatment to 80% of control levels by gestational day 20). 
Similarly, reticulocytes declined from values measured earlier in the 100- and 300-mg/kg/day dose 
groups, but were still significantly above the control level. Corrected white blood cell count 
measured on gestational day 20 after dam treatment still exhibited a significant increasing trend with 
respect to dose, which appeared to be determined by a nonsignificant increase in the high-dose group. 
Platelet counts determined at the end of the study showed a significant increase at the high dose. The 
mean corpuscular volume and mean corpuscular Remoglobin on gestational day 20 exhibited 
significant dose-related trends with the values of the two highest dose groups significantly greater 
than the control values. Calculated values of mean corpuscular hemoglobin concentration showed 
significant decreasing dose-related trends, with the high-dose group values lower than controls. The 
changes in mean corpuscular hemoglobin concentration with treatment, although significant at the 
high-dose group, were relatively slight. The maternal hematological profiles at 24 hours after final 
treatment and at gestational day 20 indicate that 2-butoxyethanol-induced hemolysis triggered a 
compensatory hematopoietic response leading to reticulocytosis. Furthermore, recovery was more 
complete by gestational day 20 for dams treated on gestational days 9-l 1 than those exposed on 
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gestational days 11-13. Thus, 30 mg/kg/day was the NOAEL for hematological effects in both 
experiments in the NTP (1989) study, lending support for the use of the LOAEL of 32 mg/kg for 
hematological effects in the aged rats in the Ghanayem et al. (1987a) study for the derivation of the 
acute oral MRL. 
Other studies show similar effects. In a study by Corley et al. (1994), which was conducted 
primarily to assist in the validation of a PBPK model (see Section 2.3.5), groups of two or three male 
Fischer 344 rats were given radiolabeled 2-butoxyethanol at doses of 8.6 or 126 mg/kg by gavage in 
water. Hemolysis and hemoglobinuria were observed in the two rats given the 126-mg/kg dose, but 
not in the three rats given 8.6 mg/kg. 
In another study (Ghanayem et al. 1992), six male Fischer 344 rats received 125 mg/kg/day 
2-butoxyethanol by gavage for 1, 2, 3, 6, or 12 consecutive days. Controls received 5 mL water/kg 
body weight daily for 12 consecutive days. Twenty-four hours after the last dose, blood samples 
were collected for hematological measurements and determination of blood ATP concentration in red 
blood cells in order to confirm previous observations (Ghanayem 1989; Ghanayem et al. 1990b) that 
hemolysis is preceded by cellular swelling, resulting in increased hematocrits and mean cell volume, 
and ATP depletion. Spleen and liver were removed and weighed. Organ weight/100 g body weight 
ratios were calculated. Treatment of rats with 2-butoxyethanol daily (125 mg/kg/day) for 
l-3 consecutive days resulted in a time-dependent increase in the hemolysis of erythrocytes. 
However, when daily treatment with 2-butoxyethanol continued beyond 3 days, the number of 
erythrocytes began to rebound and approached pretreatment levels within 12 days despite continued 
daily exposure, suggesting development of tolerance to the hemolytic effect of 2-butoxyethanol. 
Mean cell volumes, ATP concentration, and the number of reticulocytes increased to the 6th day and 
then decreased on the 12th day. Liver weight/body weight ratios were minimally affected by 
repeated dosing; they declined on days 3 and 6 but increased on day 12 compared to controls. Spleen 
weight increased in a time-dependent manner. In other studies, hematotoxic effects were observed at 
higher doses. For instance, hemolysis was observed in rats receiving one dose of 250 mg/kg/day; 
reduced red blood cell counts and hemoglobin, and increased mean corpuscular volume, 
reticulocytes, and mean corpuscular hemoglobin in the presence of increased liver and spleen weight 
were observed in rats at 500 mg/kg/day after 1 or 4 days (Ghanayem et al. 1987b; Grant et al. 1985). 
Hepatic and renal histopathology similar to that observed in Ghanayem et al. (1987a) at 
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•	 An MRL of 0.07 mg/kg/day has been derived for intermediate-duration oral (15-364 days) 
exposure to 2-butoxyethanol. 
The MRL was derived from a LOAEL of 69 mg/kg/day for hepatic effects in male rats in a study by 
NTP (1993). See Appendix A for details. In the NTP (1993) study, F344/N rats (10 males, 
10 females) were given targeted concentrations of 0, 750, 1,500, 3,000, 4,500, or 6,000 ppm 
2-butoxyethanol in drinking water daily for 13 weeks. Actual doses, determined by the study authors 
from drinking water consumption and body weight data, were as follows: 0, 69, 129, 281, 367, and 
452 mg/kg/day for males and 0, 82, 151, 304,363, and 470 mg/kg/day for females. Animals were 
observed twice daily and weighed at the start of the studies, weekly thereafter, and at necropsy. 
Clinical observations were recorded weekly. Water consumption by cage was measured twice a 
week. Complete necropsies were performed on all animals in the base studies. The heart, liver, right 
kidney, lung, thymus, and right testis were weighed, examined for gross lesions, fixed or embedded 
in paraffin, and stained for microscopic examination. The protocol for the 13-week studies required 
that tissues be examined microscopically in all control animals, animals in the highest dose group 
with at least 60% survivors, and all animals in the higher-dose group (inclusive of early deaths and 
survivors). In the clinical pathology study, 20 males and 20 females per dose group were used. On 
days 5 and 21, blood samples were collected for the clinical pathology and hematology studies. 
Week-13 analyses were conducted on samples obtained from rats in the base studies. Urinalysis was 
done on week-13 samples collected overnigbt from the base study animals. In the sperm morphology 
and vaginal cytology evaluations, males were evaluated for necropsy body and reproductive tissue 
weights and spermatozoa1 data and females were evaluated for necropsy body weight, estrous cycle 
length, and percentage of cycle spent in the various stages. Hematological effects were noted at 
≥82 mg/kg/day in females and at 281 mg/kg/day in males, but no hematological effects were found 
in males at 69 or 129 mg/kg/day. Hepatic effects were also noted at ≥82 mg/kg/day in females and 
at ≥69 mg/kg/day in males. The hepatic effects included significantly increased levels of serum 
alkaline phosphatase in high-dose males (452 mg/kg/day) and in females at 363 and 470 mg/kg/day, 
and of serum alanine aminotransferase in males at 452 mg/kg/day and in females at 363 and 
470 mg/kg/day. Histological examination of livers revealed hepatocellular alterations (hepatocytes 
that stained more eosinophilic and lacked the amphophilic-to-basophilic granularity of the 
cytoplasm) at all doses (≥69 mg/kg/day for males and ≥ 82 mg/kg/day for females). The changes in 
staining may be indications of early degenerative changes in hepatocytes. Centrilobular hepatocellular 
degeneration was observed in males at ≥281 mg/kg/day and in females at ≥304 mg/kg/day; 
and brown-to-green granular pigment staining strongly positive for iron in Kupffer cell cytoplasm in 
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males at 452 mg/kg/day and in females at ≥151 mg/kg/day. Renal effects were also seen in males 
and females Renal effects included moderate increases in blood urea nitrogen in males at 
≥69 mg/kg/day at week 3 and at ≥281 mg/kg/day at week 13 and in females at ≥304 mg/kg/day at 
week 13; increases in blood creatinine in females at ≥304 mg/kg/day at week 13; decreases in total 
blood protein in males at ≥281 mg/kg/day at week 13 and in females at ≥151 mg/kg/day at weeks 3 
and 13; decreases in blood albumin in males at ≥281 mg/kg/day at week 13 and in females at 
≥363 mg/kg/day at week 3 and at ≥304 mg/kg/day at week 13; decreased urine volume in females at 
≥82 mg/kg/day at week 13; and increased specific gravity of the urine in males at ≥69 mg/kg/day 
and in females at ≥151 mg/kg/day at week 13. However, histological examination of the kidneys and 
urinary bladder revealed no pathological lesions. No hepatic or renal effects were found in B6C3F1 
mice in the same study at ≤694 mg/kg/day (males) and ≤1,306 mg/kg/day (females). The renal 
effects observed in rats may have reflected dehydration since drinking water consumption was 
decreased. Thus, the 69-mg/kg/day dose in male rats is a less-serious LOAEL for both hepatic and 
renal effects and therefore is an appropriate dose for the derivation of the intermediate oral MRL. 
The only other comprehensive intermediate oral study was conducted in adult male albino rats 
(COBS CD (SD)BR) that were given undiluted 2-butoxyethanol by gavage in doses of 0 ,222, 443, 
or 885 mg/kg/day, 5 days per week over a 6-week period (Eastman Kodak 1983; Krasavage 1986). 
Body weights and feed consumption were recorded. Clinical signs of toxicity and deviations from 
normal appearance and behavior were observed. Animals were checked daily for mortality, and dead 
animals were necropsied; tissues (lung, heart, thymus, kidneys, liver, spleen, brain, salivary glands, 
stomach, cecum, colon, duodenum, jejunum, ileum, pancreas, esophagus, adrenal glands, pituitary, 
thyroid, parathyroid, trachea, mesenteric lymph nodes, testes, epididymides, prostate, seminal 
vesicles, coagulating gland, bone marrow, tongue, and nasal cavities) were collected for histologic 
examination. Eyes were fixed in Zenker’s sohttion. Organ weights of liver, kidneys, heart, testes, 
brain, and spleen were determined. The LOAEL (serious) for hematological effects was 
222 mg/kg/day, and there was no NOAEL for that effect. Hepatic and renal effects associated with 
the hemolytic effects occurred at 443 mg/kg/day (less serious LOAEL), but not at 222 mg/kg/day, 
and included hemosiderin disposition and an increase in alkaline phosphatase activity. 
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No oral MRLs were derived for 2-butoxyethanol acetate, specifically, because human and animal data are very 
scarce. Only one study of acute-duration oral exposure was found in the literature (Truhaut et al. 1979). The 
doses used were not specified. Thus, the data were not complete enough to derive an MRL. No studies were 
found for intermediate- or chronic-duration oral exposure. Since 2-butoxyethanol acetate is metabolized to the 
same toxic metabolite as is 2-butoxyethanol, it seems likely that the MRLs for 2-butoxyethanol acetate would 
be similar to those for 2-butoxyethanol. 
Death. No data are available on death in humans following inhalation or dermal exposure to 2-butoxyethanol 
or inhalation, oral, or dermal exposure to 2-butoxyethanol acetate. An 87-year-old woman died of a 
cardiac arrest 3 days after ingesting an unknown amount of disinfectant cleaner containing 6.5% 2-butoxyethanol 
(Litovitz et al. 1991). Additional case reports of bumans who ingested 2-butoxyethanol at doses of 
391-1,862 mg/kg suggest that death could easily occur without supportive therapy (Bauer et al. 1992; Dean 
and Krenzelok 1992; Gijsenbergh et al. 1989; Rambourg-Scbepens et al. 1988). Coma, respiratory 
depression, cardiovascular effects, hematuria, hemoglobirmria, metabolic acidosis, and oxaluria have been 
observed in humans after ingestion of 391-933 mg/kg 2-butoxyethanol (Bauer et al. 1992; Gijsenbergh et al. 
1989; Rambourg-Schepens et al. 1988). 
Acute- or intermediate-duration inhalation exposure to high concentrations (≥200 ppm) of 2-butoxyethanol 
(Carpenter et al. 1956; Dodd et al. 1983; Dow 1986; Nelson et al. 1984; Sabourin et al. 1992a; Tyl et al. 
1984; Werner et al. 1934a) and 2-butoxyethanol acetate (Truhaut et al. 1979) has caused death in animals. 
Four-hour LC50 values for 2-butoxyethanol were 486 ppm for male rats and 450 ppm for female rats (Dodd et 
al. 1983). A 7-hour LC50 value of 700 ppm has been reported for mice (Werner et al. 1943a). Death in 
animals has been reported at concentrations of 2-butoxyethanol as low as 250 ppm for 7 hours in nonpregnant 
female rats (Nelson et al. 1984), 200 ppm for 6 hours per day during gestation for pregnant female rabbits 
(Tyl et al. 1984), and 400 ppm for 7 hours per day for 1 or 2 days in male rabbits (Dow 1986). Death was 
also reported in rats exposed to ≥314 ppm, and mice and guinea pigs exposed to ≥376 ppm for 30 days 
(Carpenter et al. 1956). For 2-butoxyethanol acetate, rabbits, but not rats, died after exposure to 400 ppm 
intermittently for 1 month (Truhaut et al. 1979). 
Death after oral exposure to 2-butoxyethanol and 2-butoxyethanol acetate has been reported in animals. Acute 
oral LD50 values for 2-butoxyethanol range from 530 to 3,000 mg/kg for rats (Carpenter et al. 1956; Eastman 
Kodak 1988; Nelson et al. 1984; Olin 1976; Smyth et al. 1941; Union Carbide 1980b), from 1,230 to 
1,5 19 mg/kg for mice (Carpenter et al. 1956; Eastman Kodak 1988), from 1,200 to 1,414 mg/kg for guinea 
 
2-BUTOXYETHANOL AND 2-BUTOXYETHANOL ACETATE 226 
2. HEALTH EFFECTS 
pigs (Carpenter et al. 1956; Shepard 1994b; Smytb et all. 194P), and from 320 to 370 mg/kg for rabbits 
(Carpenter et al. 1956). Death in acute oral studies of 2-butoxyethanol has occurred at doses as low as 
200 mg/kg/day for 2 days in male rats (Smialowicz et al. l992), 150 mg/kg/day in pregnant rats (NTP 1989), 
1,180 mg/kg/day in pregnant or nonpregnant mice (Hardin et al. 1987; Schuler et al. 1984), and 1,500 mg/kg 
in pregnant mice (Wier et al. 1987). The acute oral LD50 for 2-butoxyethanol acetate in rats is reported to be 
2,400 mg/kg for females and 3,000 mg/kg for males (Truhaut et al. 1979). In intermediate oral studies of 
2-butoxyethanol, deaths occurred in male rats at 885 mg/kg/day (Eastman Kodak 1983; Krasavage 1986) and 
in female mice at ≥1,300 mg/kg/day (Heindel et al. 1990; Nagano et al. 1979, 1984). 
Death has also been reported in animals exposed dermally to 2-butoxyethanol and 2-butoxyethanol acetate. 
Acute dermal LD50 values in rabbits were reported as low as 99 mg/kg 2-butoxyethanol (Duprat and Gradiski 
1979) or 220 mg/kg (Dow 1959), and as high as 406-1,804 mg/kg (Carpenter et al. 1956; Eastman Kodak 
1988; Olin 1976; Union Carbide 1980a, 1980b). Death has been observed in rabbits (two of six) at a dose as 
low as 72 mg/kg 2-butoxyethanol (Duprat and Gradiski 1979). A 4-hour dermal LD50 of 2,273 mg/kg 2-
butoxyethanol has been reported in females rats (Carpenter and Condra 1961). Rats exhibited 91% mortality 
after receiving undiluted 2-butoxyethanol on the skin four times daily (1.4 ml/day) during gestation (Hardin et 
al. 1984). Sixty-five percent of guinea pigs exposed to 2.0 mL 2-butoxyethanol in a single dose died within 
the 1 st week after exposure (Wahlberg and Boman 1979). The acute dermal LD50 for rabbits for 2-butoxy-ethanol 
acetate has been reported to fall between 4,766 and 5,957 mg/kg (Truhaut et al. 1979). 
Exposure of humans to 2-butoxyethanol or 2-butoxyethanol acetate at levels found in the ambient environment 
or at hazardous waste sites does not seem likely to result in death. However, the existence of many household 
products containing 2-butoxyethanol or 2-butoxyethanol acetate makes accidental poisoning a potential 
problem, particularly for children. 
Systemic Effects 
Respiratory Effects. Respiratory effects have been observed in humans exposed experimentally to 2-butoxy-ethanol 
and in humans who intentionally ingested 2-butoxyethanol. No studies were located regarding 
respiratory effects in humans after dermal exposure to 2-butoxyethanol or after exposure by any route to 
2-butoxyethanol acetate. While no adverse respiratory effects were reported after a 2-hour inhalation exposure 
of humans to 20 ppm 2-butoxyethanol (Johanson et al. 1986a), humans exposed for 4 or 8 hours experienced 
nasal irritation and increased nasal mucus discharge at 113 ppm, and nose and throat irritation at 195 ppm 
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(Carpenter et al. 1956). In humans who intentionally ingested 2-butoxyethanol, respiratory effects consisted 
of diffuse pulmonary edema at a dose of 650 mg/kg in a male patient who was an abuser of alcohol and had a 
history of trichloroethylene ingestion (Bauer et al. 1992), poor ventilation at 467-933 mg/kg in a woman 
(Rambourg-Schepens et al. 1988), and obstructive respiration at 391-469 mg/kg in another woman 
(Gijsenbergh et al. 1989). 
Respiratory effects have also been observed in animals after acute- and intermediate-duration inhalation 
exposure; acute, but not intermediate, oral exposure; and acute, but not intermediate, dermal exposure to 
2-butoxyethanol. No adverse respiratory effects have been reported in animals after inhalation, oral, or dermal 
exposure to 2-butoxyethanol acetate (Truhaut et al. 1979); bowever, the data are limited. In acute-duration 
inhalation studies on 2-butoxyethanol, respiratory effects consisted of rapid and shallow breathing prior to 
death in rats exposed to 867 ppm for 4 hours, audible respiration and nasal discharge in rats exposed 
intermittently to 245 ppm for 9 days (Dodd et al. 19839, perinasal encrustation in pregnant rats exposed to 
≥100 ppm intermittently on gestational days 6-15 (Tyl et al. 1984), decreased respiratory rate in mice exposed 
to ≥153 ppm for 10-15 minutes (Kane et al. 198(a), congestion of lungs and nasal turbinates and nasal 
discharge in rabbits exposed to 400 ppm intermittently for l-2 days (Dow 1986), perinasal wetness in 
pregnant rabbits exposed to 200 ppm intermittently on gestational days 6-l 8 (Tyl et al. 1984), and congestion 
of lungs in dogs exposed to 617 ppm intermittently for 2 days and congestion and hemorrhage of the lungs in 
dogs exposed to 385 ppm for 8 days (Carpenter et al. 1956). In intermediate-duration inhalation studies of 
2-butoxyethanol, respiratory effects consisted of congestion and hemorrhage of the lungs in rats at 432 ppm 
(males) and 314 ppm (females), in guinea pigs at 376 ppm, and in dogs at 200 or 385 ppm for 30 days 
(Carpenter et al. 1956). Slightly increased nasal secretions were observed in two dogs exposed to 415 ppm 
2-butoxyethanol 7 hours per day, 5 days per week, for 12 weeks (Werner et al. 1943b). 
In acute oral studies of 2-butoxyethanol, respiratory effects consisted of rapid, shallow, or difficult breathing 
in rats after a single gavage dose of 2,000 mg/kg/day, a dose that resulted in the death of two of three of the 
treated rats (Dow 1981), or a single gavage dose of 4,510-9,019 mg/kg (Union Carbide 1980b); congested or 
hemorrhaged lungs at death in rats after a gavage dose of 530 mg/kg (Carpenter et al. 1956); dyspnea in 
pregnant rats at 600 mg/kg/day on gestational days 9-11 or 11-1 3 (NTP 1989); and abnormal breathing in 
pregnant mice at gavage doses of ≥1,500 mg/kg/day on gestational days 8-14 (Wier et al. 1987). In acute 
dermal studies on 2-butoxyethanol, respiratory effects consisted of congestion and thickening of the alveolar 
walls in rabbits at ≥72 mg/kg (Duprat and Gradiski 1979), and orange-red lungs in rabbits given a single dose 
of 0.5 mL/kg 2-butoxyethanol that remained in contact with intact skin for 24 hours (Union Carbide 1980b). 
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Based on results observed in humans, it seems likely that exposures to high concentrations of 2-butoxyethanol 
in air of high doses of 2-butoxyethanol would cause respiratory irritation in humans. It also seems likely that 
oral exposures to high concentrations of 2-butoxyethanol would cause pulmonary edema, poor ventilation, and 
obstructive respiration. Based on results in dermal studies in animals, skin contact of humans with high doses 
of 2-butoxyethanol could also cause respiratory effects. Although studies on 2-butoxyethanol acetate were 
limited, 2-butoxyethanol acetate is readily metabolized to 2-butoxyethanol, indicating that respiratory 
irritation and other effects might occur in humans exposed to high doses by any route. 
Cardiovascular Effects. No studies regarding cardiovascular effects were located in humans after dermal 
exposure to 2-butoxyethanol or after exposure to 2-butoxyethanol acetate by any route. While no 
cardiovascular effects, as evidenced by blood pressure and pulse rate measurements and/or 
electrocardiography, were observed in humans exposed by experimental inhalation exposure to 2-butoxy-ethanol at 
98-195 ppm for 4-8 hours (Carpenter et al. 1956) or 20 ppm for 2 hours (Johanson et al. 1986a), 
case reports of intentional ingestion of household products containing 2-butoxyethanol have indicated 
tachycardia and low blood pressure in a patient with a history of alcohol and trichloroethylene abuse who 
ingested 650 mg/kg (Bauer et al. 1992) and low blood pressure in a patient who ingested 391 mg/kg 
(Gijsenbergh et al. 1989). An 87-year-old woman died from cardiac arrest 3 days after she ingested an 
unknown amount of a cleaner containing 6.5% 2-butoxyethanol (Litovitz et al. 1991). Before death she also 
experienced ventricular tachycardia and arrhythmias, and hypotension. Studies in animals that determined 
heart weights and/or that performed histological examination of the heart and/or the aorta after inhalation 
(Dodd et al. 1983), oral (Eastman Kodak 1983; Krasavage 1986; NTP 1993) or dermal (CMA 1983) 
exposure to 2-butoxyethanol or 2-butoxyethanol acetate (Truhaut et al. 1979) did not reveal any adverse 
effects. 
Although information on cardiovascular effects in humans and animals exposed by inhalation to 2-butoxy-ethanol 
are limited, it is unlikely that exposure of humans to occupational and ambient environmental air levels 
and air levels at hazardous waste sites of 2-butoxyethanol or 2-butoxyethanol acetate would result in 
cardiovascular effects. Oral and dermal studies of animals exposed to 2-butoxyethanol and 2-butoxyethanol 
acetate also indicate little concern for human exposure in environmental and hazardous waste site scenarios. 
However, the case reports of human ingestion of household products containing 2-butoxyethanol indicate that 
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Gastrointestinal Effects. The only information regarding gastrointestinal effects in humans after exposure to 
2-butoxyethanol or 2-butoxyethanol acetate is the subjective report of occasional belching (eructation) of a 
male volunteer exposed to 113 ppm for 4 hours and emesis in a female volunteer exposed to 98 ppm 
2-butoxyethanol for 8 hours (Carpenter et al. 1956). The subject who experienced emesis, however, believed 
that the emesis was due to the relatively high chamber temperature based on her personal historical experience 
that high temperature often caused emesis. However, emesis was observed in a dog exposed intermittently to 
617 ppm 2-butoxyethanol for 2 days, a dog exposed to 385 ppm 2-butoxyethanol for 8 days, and a monkey 
exposed to 210 ppm for 30 days (Carpenter et al 1956). Hemorrhagic gastric ulcers were observed in rabbits 
exposed intermittently to 400 ppm 2-butoxyethanoI for l-2 days (Dow 1986), and congestion of the 
abdominal viscera was observed in rats exposed intermittently to 432 ppm (males) or 314 ppm (females) for 
30 days (Carpenter et al. 1956). 
In oral studies on 2-butoxyethanol in animals, gastrointestinal effects consisted of distended stomachs filled 
with liquid and gas, and bloody intestines in rats after single gavage doses of 2,255-9,019 mg/kg (Union 
Carbide 1980b); very red small intestines in rats at a single gavage dose of 2,560 mg/kg (Olin 1976); mild 
hyperkeratosis and acanthosis of the stomach in rats at gavage doses of 222-885 mg/kg/day for 6 weeks 
(Eastman Kodak 1983; Krasavage 1986); and diarrhea in rats at 452 mg/kg/day (males) and 470 mg/kg/day 
(females) in the drinking water for 13 weeks (NTP 1993). Moderate-to-mild necrosis and hemorrhage of the 
gastric mucosa was observed in guinea pigs treated with a single gavage dose of 1,000 mg/kg 2-butoxyethanol 
in water, a dose that also resulted in the death of one of each sex (Shepard 1994b). However, histological 
examination of the gastrointestinal tract revealed no pathological lesions in rats at ≤470 mg/kg/day or mice at 
≤ 1,306 mg/kg/day in the 13-week drinking water study (NTP 1993). 
In dermal studies on 2-butoxyethanol in animals, gastrointestinal effects consisted of reddened stomachs and 
intestines in rabbits that died at a dose of 902 mg/kg for 6 hours (Union Carbide 1980a), orange peritonea and 
intestines in rats that died at a dose of ≥451 mg/kg for 24 hours (Union Carbide 1980b), and very dark 
intestines in a rabbit dosed with 1,000 mg/kg 2-butoxyethanol on abraded skin (Olin 1976). Although one 
rabbit that died at 50 mg/kg/day on day 15 in a 90-day dermal study had a gastric ulcer, histological 
examination of gastrointestinal tracts of the rabbits at ≤150 mg/kg/day revealed no lesions (CMA 1983). 
Neither the gastric ulcer nor the death was related to 2-butoxyethanol exposure. 
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The available data in humans and animals indicate that emesis, diarrhea, and ulcers might occur in humans 
exposed to very high levels of 2-butoxyethanol. 
Hematological Effects. Hematological effects of 2-butoxyethanol exposure include hemolysis of red blood 
cells, and hemoglobinuria-the detection of hemoglobin in the urine resulting from lysed red blood cells (Jones 
and Hunt 1983). No adverse effect on erythrocyte osmotic fragility, which has been observed in animals, was 
found in humans experimentally exposed by inhalation to ≤195 ppm 2-butoxyethanol for 4-8 hours 
(Carpenter et al. 1956). Statistically significant changes in hematocrit (decrease) and mean corpuscular 
hemoglobin concentration (increase) were reported in men occupationally exposed to 0.46-0.75 ppm of 
2-butoxyethanol (Haufroid et al. 1997). The changes were small and within normal biological variability, and 
so are considered a NOAEL. The effects are consistent with hemolysis observed in animal studies, and they 
may be indicators of potential adverse effects in humans Hematological effects in humans who ingested 
household cleaning agents that contain 2-butoxyethanol consisted of nonhemolytic anemia, low prothrombin 
time, and thrombopenia at 650 mg/kg (Bauer et al. 1992); progressive erythropenia and hemoglobinuria at 
467-933 mg/kg (Rambourg-Schepens et al. 1988); and decreased blood hemoglobin at 391-469 mg/kg 
(Gijsenbergh et al. 1989). Hemodialysis, used in two cases (Bauer et al. 1992; Gijsenbergh et al. 1989), may 
have contributed to the hematological effects. No particularly sensitive population of humans has been 
identified; for a discussion of in vitro results with hypothetically sensitive human red blood cells see section 
2.8 Populations That Are Unusually Susceptible. 
Hematological effects of 2-butoxyethanol have been observed in animals after inhalation, oral, and dermal 
exposure. In inhalation studies, the hematological effects observed in animals include increased erythrocyte 
osmotic fragility in monkeys at 210 ppm for 30 days and at 100 ppm for 90 days, in rats at 62 ppm for 4 hours 
or ≥ 54 ppm for 30 days, in mice at 100 ppm for 7 hours and ≥100 ppm for 30-90 days, in rabbits at 125 ppm 
for 7 hours, and in dogs at 200-385 ppm for 8-30 days (Carpenter et al. 1956). Other hematological effects 
related to hemolysis included hemoglobinuria and hemin crystalluria in rats at 432 ppm for 2-8 hours, 
decreased red blood cell counts and hemoglobin levels in rats at 200 ppm for 7 hours per day for 9 days, 
hemoglobinuria in rats at 203 ppm for a single 7-hour exposure or for 7 hours per day for 30 days, at 
250-800 ppm for 2-9 hours per day for l-6 days (Carpenter et al. 1956), and at 438 ppm for 6 hours 
(Sabourin et al. 1992a); hemoglobinuria, reduced red blood cells and mean corpuscular hemoglobin 
concentration, and increased mean corpuscular hemoglobin and mean corpuscular volume in pregnant rats at 
≥100 ppm during gestation, and increased hemoglobin and hematocrit in pregnant rabbits at 100 ppm during 
gestation (Tyl et al. 1984); decreased hematocrit in dogs at 100 ppm for 90 days (Carpenter et al. 1956); 
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decreased hemoglobin, increased mean corpuscular volume, and decreased mean corpuscular hemoglobin 
concentration in rats at 2 86 ppm and depressed red blood cell counts and increased nucleated red blood cells 
and reticulocytes at 245 ppm for 6 hours per day for 9 days (Dodd et al. 1983), and decreased red blood cell 
counts, hemoglobin levels, and mean corpuscular hemoglobin concentration at 77 ppm for 13 weeks (Dodd et 
al. 1983). Decreased hemoglobin and hematocrit, and hypochromia, polychromatophilia, and microcytosis 
were observed in two dogs exposed to 415 ppm 2-butoxyetbanol 7 hours per day, 5 days per week, for 
12 weeks (Werner et al. 1943b). 
In oral studies on 2-butoxyethanol in animals, similar hematological effects have been observed, consisting of 
hemoglobinuria in rats at ≥ 1,500 mg/kg (Carpenter et al. 1956); hemoglobinuria, hemolysis, and increased 
concentration of free hemoglobin in plasma in rats at 500 mg/kg (Ghanayem et al. 1987b); and hemolysis, 
including decreased red blood cell counts, increased hematocrit, packed cell volumes, and mean cell volume in 
rats at ≥125 mg/kg (Corley et al. 1994; Ghanayem et al. 1987b, 1990,1992; Ghanayem and Sullivan 1993; 
Sivarao and Mehendale 1995). Similar effects related to erythrocyte hemolysis have been found in rats at 
500 mg/kg/day for 4 days (Grant et al. 1985) and in pregnant rats at ≥ 100 mg/kg/day during gestation (NTP 
1989). Hematological effects reflecting hemolysis have also been found in animals after intermediate-duration 
oral exposure to 2-butoxyethanol: decreased red blood cell counts and hemoglobin, increased mean 
corpuscular hemoglobin, and hemoglobinuria at ≥222 mg/kg/day for 6 weeks (Eastman Kodak 1983; 
Krasavage 1986); decreased red blood cell counts in mice at ≥ 500 mg/kg/day for 5 weeks (Nagano et al. 1979, 
1984); and decreased red blood cell count, hematocrit, and hemoglobin in rats at ≥ 82 mg/kg/day in drinking 
water for 13 weeks (NTP 1993). 
In dermal studies of 2-butoxyethanol in animals, hemolytic effects have also been found as follows: hemolysis 
and hemoglobinuria in rats at ≥ 260 mg/kg and increased mean corpuscular volume, decreased red blood cell 
count, and decreased hemoglobin in rats at 500 mg/kg applied to the skin for 6 hours (Bartnik et al. 1987); 
hemoglobinuria in pregnant rats at 1.4 mL/day applied during gestation (Hardin et al. 1984); increased 
erythrocyte osmotic fragility in rabbits after a 3minute skin contact at 505 mg/kg (Carpenter et al. 1956); and 
hemoglobinuria in rabbits at ≥ 72 mg/kg on the skin for 6-24 hours (Carpenter et al. 1956; Duprat and 
Gradiski 1979; Union Carbide 1980a) or hemoglobinuria with hemolytic effects on erythrocytes in rabbits at 
361 mg/kg/day for 11 days (Union Carbide 1980a). 
Similar hemolytic effects have been observed in animals after inhalation, oral, and dermal exposure to 
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inhalation to 400 ppm for 4 hours per day for 1 month- Rabbits also had decreased red blood cell counts and 
hemoglobin concentration. In an oral study, severe hemoglobinuria was observed in rats given an unspecified 
single dose. A decrease in hemoglobin and red blood cell count and hemoglobinuria occurred in rabbits after 
dermal application of ≥ 3,191 mg/kg 2-butoxyethanol acetate. 
The hemolytic properties of 2-butoxyethanol have been found to be age-related in F344 rats, with greater 
sensitivity of rats 16 months old than of rats 5-6 months old, followed by rats 9-13 weeks old. Rats 
4-6 weeks old were the least sensitive (Ghanayem et al. 1987a). Furthermore, in vitro experiments with 
human and animal erythrocytes indicate species-dependent sensitivity to the hemolytic effects of 2-butoxyethanol, 
with rodents, rabbits, and baboons more sensitive than pigs, dogs, cats, guinea pigs, and humans 
(Bartnik et al. 1987; Ghanayem and Sullivan 1993). In addition, an in vitro study showed that human 
erythrocytes were resistant to the hemolytic effects of 2-butoxyacetic acid, the hemolytic metabolite of 
2-butoxyethanol (Udden 1994). 
In addition to the hemolytic effects of 2-butoxyethanol, other hematological effects, which also appear to be 
age-related, were observed in young rats (4-5 weeks old) and adult rats (9-l 3 weeks old) at an oral dose of 
500 mg/kg (Ghanayem et al. 1987a). Adult rats exhibited neutrophilic leukocytosis and mild lymphopenia 
within 4 hours, but not 48 hours. In young rats, an absolute increase in total leukocytes, band neutrophils, 
lymphocytes, and monocytes was observed at 48 hours. 
In vitro data show that human red blood cells are much less sensitive to the hemolytic effects of the 
2-butoxyethanol metabolite, 2-butoxyacetic acid. Concentrations of 2-butoxyacetic acid that caused hemolysis 
of rat red blood cells did not cause hemolysis of human red blood cells (Bartnik et al. 1987). For example, 
following a 60minute exposure of rat red blood cells to 7.5 mM 2-butoxyacetic acid 100% hemolysis was 
observed. Following a 60minute exposure of human red blood cells to 15 mM 2-butoxyacetic acid, no 
hemolysis was observed (Bartnik et al. 1987). An in vitro study measuring more sensitive end points of red 
blood cell effects (mean cell volume and hematocrit) has also shown rat red blood cells to be more sensitive to 
2-butoxyacetic acid compared to human red blood cells (Ghanayem and Sullivan 1993). For example, 
following a l-hour exposure to 2 mM 2-butoxyacetic acid, mean corpuscular volume was about 150% of 
controls in rat red blood cells and 105% of controls in human red blood cells, and hematocrit was about 155% 
of controls in rat red blood cells and 105% of controls in human red blood cells. Red blood cells of rabbits, 
hamsters, mice, and baboons were also sensitive to the red blood cell effects of 2-butoxyacetic acid, while red 
blood cells of cats, pigs, dogs, and guinea pigs were not sensitive to the effects of 2-butoxyacetic acid 
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(Ghanayem and Sullivan 1993). The molecular mechanism for the resistance of red blood cells in some 
species but not others is not known. Until the mechanism is known, it has been suggested that 2-butoxyethanol 
be treated as a chemical with the potential for causing human toxicity (Ghanayem 1996). 
The hematological and, in particular, the hemolytic effects of 2-butoxyethanol are the most consistent and 
most sensitive effects observed in animals. Although humans may be less sensitive than rats and rabbits, 
which are the most consistently tested animals, concern exists that humans exposed to high levels of 2-butoxy­
ethanol may develop hemolytic effects. 
Musculoskeletal Effects. No studies were located regarding musculoskeletal effects in humans after exposure 
to 2-butoxyethanol or 2-butoxyethanol acetate by any route, or in animals after exposure to 2-butoxyethanol 
acetate by any route. Muscular flaccidity, which may represent neurotoxicity rather than a direct effect on the 
muscle, was observed in rats that died at single gavage doses of ≥ 2,560 mg/kg and in rabbits that died after 
dermal doses of  ≥1,000 mg/kg of 2-butoxyethanol (Olin 1976). In 13-week studies, histological examination 
of skeletal muscle and bone revealed no pathological lesions in rats exposed intermittently by inhalation to 
≤77 ppm (Dodd et al. 1983), in rats receiving oral doses of ≤470 mg/kg/day and mice receiving oral doses of 
≤ 1,306 mg/kg/day in drinking water (NTP 1993), or in rabbits exposed dermally to ≤ 150 mg/kg/day (CMA 
1983). 
Musculoskeletal effects are unlikely to occur in humans exposed to 2-butoxyethanol in environmental or 
hazardous waste site scenarios. 
Hepatic Effects. No effects on serum alanine aminotransferase or aspartate aminotransferase were observed 
in 31 male workers exposed to 0.46-0.75 ppm 2-butoxyethanol for l-6 years (Haufroid et al. 1997). Case 
reports provide evidence that 2-butoxyethanol can result in hepatic effects following high oral doses. In a man 
who ingested 2 doses of a concentrated glass cleaner containing 2-butoxyethanol 12 days apart, increased 
serum alanine aminotransferase, aspartate aminotransferase, and bilirubin were observed following the first 
ingestion, but not following the second ingestion (Gualtieri et al. 1995). Hepatic failure was reported in an 87­
year-old woman who died of cardiac arrest 3 days after ingesting an unknown volume of glass cleaner 
containing 6.5% 2-butoxyethanol (Litovitz et al. 1991). Abnormal liver function was noted in a man who had 
ingested 650 mg/kg 2-butoxyethanol (Bauer et al. 1992). The man was a known alcohol and trichloroethylene 
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Hepatic effects have been observed in animals after inhalation, oral, and dermal exposure to 2-butoxyethanol. 
In inhalation studies in animals exposed to 2-butoxyethanol, hepatic effects consisted of increased liver weight 
in rats exposed intermittently for 9 days to ≥ 86 ppm (females) and 245 ppm (males) (Dodd et al. 1983) or 
intermittently to ≥ 107 ppm for 30 days (Carpenter et al. 1956); mottled livers in rabbits exposed to 
400-411 ppm intermittently for 1 or 2 days (Dow 1986); congestion of the liver in dogs exposed for 8 or 
28 days to 385 ppm (Carpenter et al. 1956); and cloudy swelling of the liver in rats exposed intermittently to 
≥ 314 ppm for 30 days (Carpenter et al. 1956). 
In oral studies in animals exposed to 2-butoxyethanol, hepatic effects consisted of mottled livers in rats that 
died at gavage doses ≥530 mg/kg (Carpenter et al. 1956); focal coagulative necrosis of hepatocytes 
accompanied by phagocytized hemoglobin in adult rats, but not young rats, at ≥250 mg/kg (Ghanayem et al. 
1987a, 1987b); dark livers in rats at 1,310 mg/kg (Olin 1976) or 2,255 mg/kg (Union Carbide 1980b); 
increased liver weight in rats at 125 mg/kg/day for up to 12 days (Ghanayem et al. 1992), at 500 mg/kg/day 
2-butoxyethanol for 4 days (Grant et al. 1985), at 180 mg/kg/day in the drinking water for 21 days (Exon et al. 
199 l), at 1,540 mg/kg/day in the diet for 90 days (Carpenter et al. 1956), and at ≥ 222 mg/kg/day by gavage 
for 6 weeks (Eastman Kodak 1983; Krasavage 1986); decreased absolute liver weight in pregnant rats at 
≥200 mg/kg/day during gestation (NTP 1989); and hemosiderin deposition in the liver and increased serum 
alkaline phosphatase levels at ≥ 443 mg/kg/day and hepatocytomegaly and increased serum alanine 
aminotransferase levels at 885 mg/kg/day in rats dosed for 6 weeks (Eastman Kodak 1983; Krasavage 1986). 
In rats treated with 2-butoxyethanol in the diet for 91-93 days, relative liver weights were increased by 25% in 
males at 919 mg/kg/day and by 27% in females at 976 mg/kg/day (Weil 1963). No effects on liver weight 
were noted at lower doses (188 mg/kg/day males, 222 mg/kg/day females), nor were any histopathological 
changes observed at any dose. Serum alkaline phosphatase and alanine aminotransferase levels were also 
increased in rats at ≥363 mg/kg in drinking water for 13 weeks (NTP 1993). In addition, hepatocellular 
alterations (hepatocytes that stained more eosinophilic and lacked the amphophilic to basophilic granularity of 
the cytoplasm) occurred at ≥ 69 mg/kg/day, centrilobular hepatocellular degeneration occurred at 
≥ 281 mg/kg/day, and brown to green granular pigment staining strongly positive for iron in Kupffer’s cell 
cytoplasm occurred at ≥ 151 mg/kg/day in the rats in the 13-week drinking water study. These lesions, 
particularly in the females, displayed both increased dose-related incidence and increased dose-related severity. 
None of these effects occurred in mice similarly exposed (NTP 1993). 
In dermal studies on 2-butoxyethanol in animals, hepatic effects consisted of pale livers in rabbits that died 
after 24-hour skin contact with ≥406 mg/kg (Carpenter et al 1956), congestion in the liver with necrotic foci 
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and inconstant (i.e., not always present) steatosis in rabbits that died at ≥ 72 mg/kg 2-butoxyethanol (Duprat 
and Gradiski 1979), mottled livers with pocked surfaces in rabbits at ≥ 451 mg/kg for 6 hours (Union Carbide 
1980a) or 24 hours (Union Carbide 1980b), and discolored or pale liver in rabbits dosed with 
250-1,000 mg/kg on abraded skin (Olin 1976). However, histological examination of liver and gall bladder 
revealed no lesions in rabbits at ≤150 mg/kg/day 2-butoxyethanol for 90 days (CMA 1983). In addition, no 
effects on liver weight were observed. 
Limited data are available on hepatic effects in animals exposed to 2-butoxyethanol acetate or 2-butoxyacetic 
acid. Histological examination of the livers revealed no pathological lesions in rats given unspecified acute 
oral doses of 2-butoxyethanol acetate or in rabbits given dermal applications of ≤ 10,000 mg/kg of 2-butoxy-
ethanol acetate (Truhaut et al. 1979). Likewise, no histopathological lesions were found in the livers of rats 
dosed by gavage with ≤ 868 mg/kg 2-butoxyacetic acid (Foster et al. 1987). 
The data in animals indicate that hepatic effects might occur in humans exposed to very high levels of 
2-butoxyethanol. 
Renal Effects- No effects on serum creatinine or urinary retinol binding protein were observed in 3 1 male 
workers exposed to 0.46-0.75 ppm 2-butoxyethanol for l-6 years (Haufroid et al. 1997). Renal effects 
observed in persons who intentionally ingested bousehold cleaning agents containing 2-butoxyethanol include 
albuminuria in a known alcohol and trichloroethylene abuser who ingested 650 mg/kg 2-butoxyethanol (Bauer 
et al. 1992); oxaluria and increased serum creatinine in a patient who ingested 467-933 mg/kg (Rambourg-
Schepens et al. 1988); and hematuria in a patient who ingested 391-469 mg/kg (Gijsenbergh et al. 1989), and 
renal failure in an 87-year-old woman who died after ingesting an unknown amount of 2-butoxyethanol 
(Litovitz et al. 1991). 
Similar renal effects have been observed in animals after inhalation, oral, and dermal exposure to 2-butoxy-ethanol, 
with hematuria, the detection of red blood cells in the urine (Jones and Hunt 1983) being a prevalent 
finding. In inhalation studies of 2-butoxyethanol in animals, renal effects consisted of evidence of hematuria 
(red-stained urine) and enlarged kidneys in rats exposed to ≥523 ppm for 4 hours or to 245 ppm, 6 hours per 
day for 9 days (Dodd et al. 1983); hematuria in rats exposed to 800 ppm for 3 hours (Doe 1984), to 250 ppm 
for 7 hours (Nelson et al. 1984), or to 100 ppm for 6 or 7 hours per day during gestation (Nelson et al. 1984; 
Tyl et al. 1984); evidence of hematuria in rabbits at ≥100 ppm for 6 hours per day during gestation (Tyl et al. 
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tubules in rats at 432 ppm for 2 hours and in guinea pigs at ≥376 ppm for 7 hours per day for 30 days 
(Carpenter et al. 1956); congestion of the kidneys in dogs at 617 ppm for 2 days and 385 ppm for 8 days 
(Carpenter et al. 1956); and increased kidney weight in rats at ≥ 107 ppm and in guinea pigs at ≥203 ppm, 
7 hours per day for 30 days (Carpenter et al. 1956). 
In oral studies of 2-butoxyethanol in animals, renal effects consisted of severely congested kidneys in rats at 
gavage doses ≥500 mg/kg (Carpenter et al. 1956; Sivarao and Mehendale 1995); dark and/or enlarged kidneys 
in rats at 1,310 mg/kg (Olin 1976); hematuria in rats at ≥ 500 mg/kg (Dow 1959; Olin 1976; Union Carbide 
1980b) and in pregnant rats at 600 mg/kg/day during gestation (NTP 1989); and increased kidney weights in 
rats at ≥ 500 mg/kg/day for 4 days (Grant et al. 1985) and at 1,540 mg/kg/day in the diet for 90 days 
(Carpenter et al. 1956), and in mice at ≥ 700 mg/kg/day in the drinking water in a continuous breeding study 
(Heindel et al. 1990). In a 13-week drinking water study, renal effects were found in rats, but not in mice 
(NTP 1993). The effects in rats consisted of increased blood urea nitrogen at ≥ 69 mg/kg/day, increased blood 
creatinine at ≥304 mg/kg/day, decreased total blood protein at ≥ 151 mg/kg/day, decreased blood albumin at 
≥ 281 mg/kg/day, decreased urine volume at ≥ 82 mg/kg/day, and increased specific gravity of the urine at 
≥ 69 mg/kg/day. However, histological examination of the kidneys and urinary bladders of the rats revealed no 
pathological lesions. In rats treated with 2-butoxyethanol in the diet for 91-93 days, relative kidney weights 
were increased in by 18% in males at 919 mg/kg/day, and 23% in females at 976 mg/kg/day (Weil and 
Carpenter 1963). No effects on kidney weight were noted at lower doses (188 mg/kg/day males, 
222 mg/kg/day females), nor were any histopathological changes observed at any dose. 
Renal effects that are secondary to the hemolytic effects of 2-butoxyethanol were found in rats after oral 
exposure, as evidenced by hemosiderin accumulation in the proximal tubules at ≥443 mg/kg/day by gavage for 
6 weeks (Eastman Kodak 1983; Krasavage 1986) and hemoglobin casts in the proximal tubules at 
≥ 125 mg/kg by gavage (Ghanayem et al. 1987a). The finding of hemoglobin casts in the proximal tubules 
was found to be age-related, with adult rats (≥ 9 weeks old) being more sensitive than immature rats 
(Ghanayem et al. 1987a). This is consistent with the age-related hemolytic effects of 2-butoxyethanol, as 
discussed above under Hematological Effects. 
In dermal studies of 2-butoxyethanol in animals, renal effects consisted of congested kidneys in rabbits after 
24-hour skin contact with ≥ 406 mg/kg (Carpenter et al. 1956); enlarged kidneys with hemoglobinuric 
nephrosis and interstitial reactions (secondary to hemolysis) in rabbits at ≥72 mg/kg for 8-hour dermal contact 
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rabbits at ≥451 mg/kg for 6 hours (Union Carbide 1980a) or 24 hours (Olin 1976; Union Carbide 1980b); 
and hematuria at ≥180 mg/kg/day for 9 dermal6-hour applications (Union Carbide 1980a). In the rabbits 
given 9 dermal applications of 2-butoxyethanol, other renal effects consisted of increased urinary protein at 
361 mg/kg/day and dimpling of the renal surface, tubular vacuolization, tubular degeneration, tubular cell 
hyperplasia, glomerular adhesions, and interstitial nephritis at ≥ 271 mg/kg/day (Union Carbide 1980a). 
Renal effects have also been observed in animals after inhalation, oral, and dermal exposure to 2-butoxyethanol 
acetate and after oral exposure to 2-butoxyacetic acid. In an inhalation study of 2-butoxyethanol 
acetate, renal effects consisted of slight hematuria in rabbits, but not rats, exposed to 400 ppm for 4 hours; 
hematuria and tubular nephrosis in rats and rabbits at 400 ppm, 4 hours per day for 1 month; and tubular 
nephritis with tubular enlargement and Henle’s loop dilation, cortical atrophy, and inflammatory fibrosis in 
rats and rabbits at 100 ppm, 4 hours per day for 10 months (Truhaut et al. 1979). Similar effects were seen in 
rats given unspecified single oral doses of 2-butoxyethanol acetate by gavage and in rabbits exposed dermally 
to ≥ 3,191 mg/kg of 2-butoxyethanol acetate. Hematuria was also found in rats given a single gavage dose of 
2-butoxyacetic acid at 868 mg/kg (Foster et al. 1987). 
The finding of hematuria in a patient who ingested 2-butoxyethanol and the consistent finding of hematuria in 
animals after inhalation, oral, and dermal exposure to 2-butoxyethanol and 2-butoxyethanol acetate and after 
oral exposure to 2-butoxyacetic acid strongly suggests that hematuria is a concern for humans exposed to high 
levels of 2-butoxyethanol. 
Endocrine Effects. No studies were located regarding endocrine effects in humans after inhalation, oral, or 
dermal exposure to 2-butoxyethanol or 2-butoxyethanol acetate. Severely hemorrhaged adrenal glands were 
found in a dog that died after exposure to 385 ppm for 8 days (Carpenter et al. 1956). Histological 
examination of the adrenal, parathyroid, thyroid, or pituitary glands showed no lesions in rats at ≤ 77 ppm, 
6 hours per day, 5 days per week for 13 weeks (Dodd et al. 1983). In oral studies on 2-butoxyethanol in 
animals, red adrenal glands, which may be related to the hemolytic effects, were seen in rats at 
2,255-9,019 mg/kg (Union Carbide 1980b). Histological examination of the pancreas, adrenal glands, 
pituitary, thyroid, or parathyroid revealed no lesions in rats at ≤885 mg/kg/day for 6 weeks, 5 days per week 
(Eastman Kodak 1983; Krasavage 1986) or in rats at ≥470 mg/kglday and mice at ≤ 1,306 mg/kg/day in 
drinking water for 13 weeks (NTP 1993). Likewise, in dermal studies, reddened adrenal glands, probably 
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examination of adrenals, pancreas, pituitary, thyroid, or parathyroid glands revealed no lesions in rabbits at 
≤ 150 mg/kg/day 2-butoxyethano16 hours per day, 5 days per week for 90 days (CMA 1983). 
Similarly, in studies on 2-butoxyethanol acetate, no gross or histologically observed lesions were noted in the 
pancreas or adrenal glands of rats and rabbits exposed by inhalation for 4 hours per day, 5 days per week to 
400 ppm for 1 month, or to 100 ppm for 10 months in rats at an unspecified single gavage dose, or in rabbits 
at dermal doses ≤ 10,000 mg/kg for 24 hours (Truhaut et al. 1979). 
Since the only endocrine effects were hemorrhaged or reddened adrenal glands in animals exposed to high 
inhalation concentrations and high oral or dermal doses of 2-butoxyethanol, it is unlikely that humans exposed 
to 2-butoxyethanol or 2-butoxyethanol acetate in environmental, or hazardous waste site scenarios would 
experience endocrine effects. 
Dermal Effects. No studies were located regarding dermal effects in humans after inhalation or oral exposure 
to 2-butoxyethanol, but dermal effects in humans after direct dermal exposure to neat 2-butoxyethanol 
included rigidity of the skin and decreased skin vohrme and skinfold thickness (Johanson et al. 1988). Slight 
erythema was noted during skin patch tests with 2-butoxyethanol acetate in humans (Jacobs et al. 1989), 
although a human sensitivity study in 201 persons with 10% 2-butoxyethanol showed no overt effect (CMA 
1992; Greenspan et al. 1995). The 10% concentration was tested because it is the highest concentration found 
in cosmetics. Concentrations as high as 50% 2-butoxyethanol can be found in cleaning products which are 
intended to be diluted before use (OECD 1997). 
In studies of 2-butoxyethanol in animals, dermal effects included necrosis of the tail tip in nonpregnant female 
rats at ≥250 ppm for up to 7 hours (Nelson et al. 1984) and in pregnant rats at 200 ppm for 6 hours per day 
during gestation (Tyl et al. 1984) in inhalation studies; in rats after a single oral dose of 1,000 mg/kg (Dow 
1981); and in pregnant rats after dermal contact with 1.4 mL/day during gestation (Hardin et al. 1984). The 
cause of necrosis of the tail tip was not clearly stated, but possibly it is associated with the effects of 2-butoxy-
ethanol on the red blood cells and subsequent vascular response. 
In other oral studies of 2-butoxyethanol in animals, dermal effects consisted of rough coat in rats that died at 
≥ 530 mg/kg (Carpenter et al. 1956), piloerection in rats at >1,3 10 mg/kg (Olin 1976), and pale coloration of 
the skin in rats at 600 mg/kg/day during gestation (NTP 1989). The rough coats and piloerection may be 
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related to neurotoxicity. Histological examination of skin revealed no dermal lesions in rats at 
≤470 mg/kg/day or in mice at ≤ 1,306 mg/kg/day (females) in drinking water for 13 weeks (NTP 1993). 
In other dermal studies of 2-butoxyethanol in animals, dermal effects consisted of strong skin irritation in 
guinea pigs after application of unspecified doses (Eastman Kodak 1988); necrosis of epidermis and dermis in 
rabbits at ≥ 72 mg/kg for 8 hours (Duprat and Gradiski 1979); hyperemia, edema, slight exfoliation, and/or 
slight to moderate irritation in rabbits after dermal contact with undiluted or unspecified concentrations of 
2-butoxyethanol (Dow 1958, 1959,1981; Eastman Kodak 1988; Rohm and Haas 1983); necrosis and 
erythema in rabbits at ≥541 mg/kg for 6 hours (Union Carbide 1980a), at 902 mg/kg for 24 hours (Union 
Carbide 1980b), and at ≥18 mg/kg (for erythema) and ≥271 mg/kg (for necrosis) after nine applications 
(Union Carbide 1980a); slight to moderate erythema in rabbits at ≥ 10 mg/kg/day for 6 hours per day for 
90 days (CMA 1983); and capillary congestion in rabbits after dermal contact with 0.01 mL of undiluted 
2-butoxyethanol (Union Carbide 1980b). 
The dermal irritation of 2-butoxyethanol and 2-butoxyethanol acetate have been studied in New Zealand 
rabbits using both the Draize protocol (24-hour occluded exposure) and the European Economic Communities 
protocol (4-hour occluded exposure) (Zissu 1995). For both protocols, 0.5 mL of undiluted compound was 
placed on the skin. 2-Butoxyethanol was considered a severe irritant by the Draize protocol, and an irritant by 
the European Economic Communities protocol. 2-Butoxyethanol acetate was considered a moderate irritant 
by the Draize protocol, and non-irritating by the European Economic Communities protocol. 
In dermal studies of 2-butoxyethanol acetate in animals, mild to moderate erythema, indicating mild irritation, 
was observed in rabbits after dermal contact with undihtted 2-butoxyethanol acetate (Jacobs et al. 1989; 
Truhaut et al. 1979). 
The data indicate that skin contact of humans with high concentrations of 2-butoxyethanol or 2-butoxyethanol 
acetate may result in skin irritation. 
Ocular Effects. Eye irritation was experienced by humans exposed experimentally by inhalation to 2-butoxy­
ethanol at ≥ 113 ppm for 4-8 hours (Carpenter et al. 1956), probably due to direct contact of the eyes with the 
2-butoxyethanol vapor. A woman who ingested 391-469 mg/kg 2-butoxyethanol exhibited isocoric light 
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Ocular effects have been observed in animals after inhalation, oral, dermal, and ocular exposure to 2-butoxy-
ethanol. Periocular wetness occurred during inhalation exposure of pregnant rats at ≥ 25 ppm and in pregnant 
rabbits at ≥ 100 ppm during gestation (Tyl et al. 1984). The periocular wetness was probably due to direct 
contact of the eyes with 2-butoxyethanol vapor. Slightly increased ocular secretions were observed in 2 dogs 
exposed to 415 ppm 2-butoxyethanol intermittently for 12 weeks (Werner et al. 1943b). A reddish ocular 
discharge accompanied by yellow discoloration of the sclera occurred in rabbits exposed to 400-411 ppm for 
7 hours per day for 1-2 days (Dow 1986); these effects may have been secondary to the hemolytic property of 
2-butoxyethanol. In other inhalation studies of 2-butoxyethanol in animals, ophthalmological examination 
revealed no effects in dogs exposed to 200 ppm for 31 days (Carpenter et al. 1956) or in rats exposed for 
6 hours per day to ≤245 ppm for 9 days or to ≤77 ppm for 13 weeks (Dodd et al. 1983). 
In oral studies of 2-butoxyethanol in animals, ocular effects consisted of palpebral closure in rats at 
2,000 mg/kg (Dow 1981) and chromodacryorrhea in pregnant rats at 600 mg/kg/day during gestation (NTP 
1989). However, histological examination of the eyes revealed no lesions in rats treated with ≤885 mg/kg/day 
by gavage for 6 weeks (Eastman Kodak 1983; Krasavage 1986), or in rats at ≤470 mg/kg/day, or mice at 
≤ 1,306 mg/kg/day in the drinking water for 13 weeks (NTP 1993). 
In studies of 2-butoxyethanol instilled into the eyes of rabbits, severe irritation, moderate to extensive 
conjunctivitis, moderate cornea1 damage, and/or slight iritis were observed (Dow 1958, 1959,198 1; Kennah et 
al. 1989a; Rohm and Haas 1983; Union Carbide 1980b). In dermal studies, grey iris was observed in rabbits 
at 902 mg/kg for 6 hours (Union Carbide 1980a) or for 24 hours (Union Carbide 1980b); lacrimation at 
2,000 mg/kg and a yellow cornea at 500 mg/kg occurred in rabbits (Olin 1976). For 2-butoxyethanol acetate, 
slight conjunctival redness and discharge were observed in rabbits after ocular instillation (Truhaut et al. 
1979). 
In a study designed to evaluate the use of in vitro cytotoxicity data for predicting the ocular irritancy potential 
of chemicals, BALB/c 3T3 cells were grown overnight, then exposed for 30 minutes to 10-100% (volume in 
culture) 2-butoxyethanol (Kennah et al. 1989b). Growth of the cells with 2-butoxyethanol compared to a 
control culture was recorded. The concentration at which the growth of the cells was inhibited by 50% 
compared to controls was calculated and compared to in vivo eye irritancy tests (Kennah et al. 1989a). A 
linear relationship was observed, although the in vivo tests indicated greater irritancy than would have been 
predicted from the cytotoxicity tests. Other in vitro test systems have been investigated using 2-butoxyethanol, 
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The data indicate that exposure to vapors of 2-butoxyethanol or direct ocular contact with liquid 2-butoxy-ethanol 
would be irritating to the eyes of humans. 
Body Weight Effects. No studies were located regarding body weight effects in humans after inhalation, oral, 
or dermal exposure to 2-butoxyethanol or 2-butoxyethanol acetate. However, effects on body weight have 
been observed in animals after inhalation, oral, and dermal exposure to 2-butoxyethanol or after oral exposure 
to 2-butoxyacetic acid. 
In inhalation studies on 2-butoxyethanol in animals, weight loss, or decreased body weight gain was observed 
in rats at ≥523 ppm for 4 hours and at ≥ 83 ppm for 9 days (Dodd et al. 1983); in pregnant rats at 2 100 ppm 
and pregnant rabbits at 200 ppm for 6 hours per day during gestation (Tyl et al. 1984); in dogs at 385 ppm for 
8 or 25 days (Carpenter et al. 1956); and in mice at 400 ppm for 60 days (Carpenter et al. 1956). Two dogs 
exposed to 415 ppm 2-butoxyethano17 hours per day 5 days per week for 12 weeks gradually lost 6-9% of 
their body weights (Werner et al. 1943b). No control body weight data were provided, although the study 
authors indicate that the other dogs in the study gained weight or remained constant throughout the study 
period. 
In oral studies of 2-butoxyethanol in animals, weight loss, or reduced body weight gain was observed in rats at 
a gavage dose of 1,000 mg/kg/day for 4 days (Grant et aI 1985), at 885 mg/kg/day by gavage for 6 weeks 
(with decreased food consumption) (Eastman Kodak 1983; Krasavage 1983), at 265 mgIkg/day in drinking 
water for 2 weeks (with decreased water consumption), at 443 mg/kg/day in drinking water for 60 days (NTP 
1993) (with decreased water consumption), and at ≥367 mg/kg/day for 13 weeks (with decreased water 
consumption in 1 of these studies) (Carpenter et al. 1956; NTP 1993), and in mice at 12,750 mg/kg/day in 
drinking water for 2 weeks (Heindel et al. 1990). In rats treated with 2-butoxyethanol in the diet for 
91-93 days, body weight gain was decreased by 53% in males at 919 mg/kg/day and by 45% in females at 
976 mg/kg/day (Weil and Carpenter 1963). Body weight gain was decreased by as much as 91% at day 1 of 
the study in males at 188 mg/kg/day but was only 9% lower than controls by the end of the study. The 
188-mg/kg/day dose in males was also associated with about an 18% decrease in food intake. No effects on 
body weight gain were noted at 28 mg/kg/day in males and at 222 mg/kg/day in females. Pregnant rats 
exhibited decreased gestational weight gain (as well as decreased food and water intake) at  ≥150 mg/kg/day 
during gestation (NTP 1989), as did pregnant mice at ≥ 1,000 mg/kg/day during gestation (Hardin et al. 1987; 
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In dermal studies of 2-butoxyethanol, decreased body weight gain was observed in pregnant rats at 
0.48 mL/day during gestation (Hardin et al. 1984) and in rats at 200 mg/kg for 24 hours (Dow 1959). 
For 2-butoxyethanol acetate, no effect on body weight was noted in rats or rabbits exposed by inhalation 
intermittently to 400 ppm for 1 month or to 100 ppm for 10 months (Truhaut et al. 1979). For 2-butoxyacetic 
acid, rats given single gavage dose ≥174 mg/kg had decreased weight gain during the first 2 days after 
treatment at all doses, but the weight gain returned to normal by day 14 (Foster et al. 1987). 
Effects on body weight do not appear to be a concern for humans exposed to 2-butoxyethanol, 2-butoxyethanol 
acetate, or 2-butoxyacetic acid in environmental or hazardous waste site scenarios. 
Metabolic Effects. The only information regarding metabolic effects of 2-butoxyethanol comes from case 
reports of humans who ingested household cleaning agents containing 2-butoxyethanol. The metabolic effects 
consisted of metabolic acidosis and hypoxemia with lactic acidosis in the known alcohol and trichloroethylene 
abuser who ingested 650 mg/kg (Bauer et al. I992), metabolic acidosis and hypokalemia in a patient who 
ingested 467-933 mg/kg (Rambourg-Schepens et al. 1988), and metabolic acidosis in another patient who 
ingested 391-469 mg/kg (Gijsenbergh et al. 1989). Significant acid-base disturbance was observed in a man 
following ingestion of 1,006-l ,341 mg/kg 2-butoxyethanol in a concentrated glass cleaner (Gualtieri et al. 
1995). A second ingestion of the glass cleaner (1,341 mg/kg 2-butoxyethanol) 12 days later did not result in 
metabolic disturbances. After the second ingestion, hemodialysis and ethanol treatment were initiated within 
8 hours after exposure, but it is unclear how much time elapsed before treatment of first injection. It is to be 
expected that metabolism of significant quantities of 2-butoxyethanol to 2-butoxyacetic acid would cause 
metabolic acidosis. 
Whether or not humans exposed to 2-butoxyethanol in environmental or hazardous waste site scenarios would 
have metabolic effects cannot be determined based on the limited available data. 
Other Systemic Effects. No studies were located regarding other systemic effects in humans after inhalation, 
oral, or dermal exposure to 2-butoxyethanol. In animal studies on 2-butoxyethanol, other systemic effects 
consisted of reduced food consumption at ≥ 100 ppm and reduced water consumption at 200 ppm in pregnant 
rats exposed to 2-butoxyethanol vapors for 6 hours per day during gestation (Tyl et al. 1984); decreased water 
consumption in rats at ≥ 152 mg/kg/day and in mice at ≥150 mg/kg/day in drinking water for 2 weeks (Heindel 
et al. 1990; NTP 1993); dehydration in mice at ≥376 mg/kg/day in drinking water for 2 weeks (NTP 1993); 
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decreased food and water intake at ≥150 mg/kg/day, and coldness to the touch at 600 mg/kg/day in pregnant 
rats given gavage doses during gestation (NTP 1989); decreased water consumption in rats at ≥ 444 mg/kg/day 
in drinking water for 21 days (Exon et al. 1991); decreased food consumption in rats at 885 mg/kg/day by 
gavage for 6 weeks (Eastman Kodak 1983; Krasavage 1986); decreased water consumption in rats at 
≥ 128 mg/kg/day in drinking water for 13 weeks (NTP 1993); decreased food intake in rats fed 2-butoxyethanol in 
the diet at ≥188 mg/kg/day for males and 976 mg/kg/day for females (Weil and Carpenter 1963); 
and decreased water consumption in mice at 700 mg/kg/day in drinking water for up to 25 weeks (Heindel et 
al. 1990). 
Although decreased food and water consumption may have been due to unpalatability of 2-butoxyethanol in 
the dietary and drinking water studies, these effects were also observed in animals after inhalation or gavage 
treatment. Furthermore, the decreased body weight gain observed in animals in some studies cannot be 
completely attributed to decreased food or water intake. Nevertheless, decreased water consumption and 
decreased food intake do not appear to be effects of concern in humans exposed to 2-butoxyethanol under any 
scenario. 
Immunological and Lymphoreticular Effects. No studies were located regarding immunological and 
lymphoreticular effects in humans after inhalation or oral exposure to 2-butoxyethanol or 2-butoxyethanol 
acetate. Slight erythema, but no allergic reaction, was noted on skin-patch tests with 2-butoxyethanol acetate 
in humans (Jacobs et al. 1989). A human sensitivity study in 201 individuals with 10% 2-butoxyethanol 
showed no overt effect (CMA 1992; Greenspan et al. 1995). The 10% concentration was tested because it is 
the highest concentration found in cosmetics. Concentrations as high as 50% 2-butoxyethanol can be found in 
cleaning products which are intended to be diluted before use (OECD 1997). 
The information on immunological effects of 2-butoxyethanol in animals consists of the following findings: 
no effect on the immune system was found in rats at gavage doses of ≤400 mg/kg/day for 2 days following 
immunization with trinitrophenyl-lipopolysaccharide (TNP-EPS) (Smialowicz et al. 1992); and no IgG change 
compared with controls in antibody production or delayed-type hypersensitivity response after-challenge with 
anti-keyhole limpet hemocyanin; also, no adverse effects on natural killer cell function or splenocyte 
production of cytokines, or thymus and spleen weights were observed. No effect on thymus or spleen weight, 
and no histopathological lesions in the thymus were observed in rats given ≤ 506 mg/kg/day for 21 days (Exon 
et al. 199 1). 2-Butoxyethanol has also tested negative for dermal sensitization in guinea pigs using the 
maximized Magnusson and Kliman test (Zissu 1995). 
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Several studies in animals describe effects on the spleen, all of which are probably related to the hematological 
effect of 2-butoxyethanol and the resultant accumulation of lysed red blood cells in the spleen. 
In inhalation studies on 2-butoxyethanol in animals, splenic effects consisted of increased spleen weight in 
pregnant rats at 200 ppm for 6 hours per day during gestation (Tyl et al. 1984). However, histological 
examination of the spleen, mediastinal lymph nodes, and thymus revealed no lesions in rats exposed 
intermittently to ≤177 ppm for 13 weeks (Dodd et al. 1983). 
In oral studies on 2-butoxyethanol in animals, effects on lymphoreticular organs consisted of increased spleen 
weight in pregnant rats at ≤100 mg/kg/day during gestation (NTP 1989), in young and adult rats at 
≥ 125 mg/kg by gavage (Ghanayem et al. 1987a, 1987b) or 125 mg/kg/day for up to 12 days (Ghanayem et al. 
1992), and increased spleen weight accompanied by extramedullary hematopoiesis at ≥ 500 mg/kg/day for 
4 days (Grant et al. 1985). In addition, splenic congestion, secondary to hematological effects, at 
≥ 222 mg/kg/day and increased spleen weight and enlarged dark spleens at ≥ 443 mg/kg/day were observed in 
rats treated by gavage for 6 weeks, but no histological lesions were seen in any lymphoreticular organs 
(Eastman Kodak 1983; Krasavage 1986). Decreased thymus weight occurred in mice at ≥ 370 mg/kg/day in 
drinking water for 2 weeks (NTP 1993). Bone marrow hyperplasia at ≥281 mg/kg/day, hematopoietic cell 
proliferation at ≥ 363 mg/kg/day, increased hemosiderin pigmentation in the spleen at ≥ 129 mg/kg/day, and 
decreased thymus weight at ≥ 367 mg/kg/day were found in rats given 2-butoxyethanol in drinking water for 
13 weeks (NTP 1993). None of these effects occurred in mice similarly exposed at ≤ 1,306 mg/kg/day. 
In dermal studies on 2-butoxyethanol in animals, effects on Iymphoreticular organs consisted of congestion in 
the spleen, erythrocytic infiltration, and white atrophic pulp in rabbits at ≥ 72 mg/kg/day for 8 hours (Duprat 
and Gradiski 1979); engorged spleen in rabbits at ≥ 406 mg/kg (Carpenter et al. 1956); and enlarged spleen in 
rabbits at 902 mg/kg for 6 hours (Union Carbide 1980a) and dark red spleens at ≥451 mg/kg for a 24-hour 
exposure (Union Carbide 1980b). 
For 2-butoxyethanol acetate, no gross or histopathological lesions were found in the spleen of rats or rabbits 
exposed by inhalation intermittently to 400 ppm for 1 month or to 100 ppm for 10 months, in rats at 
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The limited available data in humans and animals indicate that exposure to 2-butoxyethanol or 2-butoxy-ethanol 
acetate under any scenario would not result in immunological effects; however, lymphoreticular effects 
in the spleen and bone marrow, which are probably attributable to the hemolytic effects of 2-butoxyethanol, 
may occur in humans exposed to high levels of 2-butoxyethanol. 
Neurological Effects. Humans exposed experimentally by inhalation to 2-butoxyethanol for 4-8 hours 
experienced headache at 98 ppm and disturbed taste sensation at 113 and 195 ppm (Carpenter et al. 1956). 
Case reports of intentional poisoning indicate that coma can result from the ingestion of ≥467 mg/kg 
2-butoxyethanol (Bauer et al. 1992; Gijsenbergh et al. 1989; Litovitz et al. 1991; Rambourg-Schepens et al. 
1988). 
Neurological effects have been observed in animals after inhalation, oral, and dermal exposure to 2-butoxyethanol. 
In inhalation studies of 2-butoxyethanol in animals, neurological effects consisted of loss of 
coordination in rats at ≥523 ppm for 4 hours (Dodd et al. 1983), extreme weakness in dogs at 617 ppm for 
2 days, weakness and apathy in dogs at 385 ppm for 8 or 28 days (Carpenter et al. 1956), excessive salivation 
in dogs at 400 ppm for 5 days (Dow 1972, 1986), and poor coordination of the extremities and loss of 
equilibrium in rabbits at 400 ppm 2-butoxyethanol for 7 hours per day on l-2 days (Dow 1986). 
In oral studies of 2-butoxyethanol in animals, neurological effects consisted of sluggishness, prostration, and 
narcosis in rats that died after gavage doses ≥530 mg/kg (Carpenter et al. 1956) and drowsiness, sluggishness, 
lethargy, muscle flaccidity, and/or ataxia in rats at 252-9,000 mg/kg/day (Dow 1959, 1981; Eastman Kodak 
1983; Krasavage 1986; Olin 1976; Union Carbide 1980b). Ataxia was reported in rats following a single 
gavage dose of 500 mg/kg (Sivarao and Mehendale 1995). Moderate to severe weakness and prostration was 
observed directly after dosing in guinea pigs given a single gavage dose of 1,000 mg/kg 2-butoxyethanol, a 
dose that resulted in the death of one of five males, and one of five females (Shepard 1994b). Slight weakness 
was observed directly after dosing at 500 mg/kg, a dose at which all treated guinea pigs survived. Lethargy 
also was observed in pregnant rats treated at 600 mg/kg/day by gavage during gestation (NTP 1989) and in 
rats at ≥443 mg/kg/day for 6 weeks (Eastman Kodak 1983; Krasavage 1986), and lethargy and failure to right 
were observed in pregnant mice treated at ≥1,500 mg/kg/day by gavage during gestation (Wier et al. 1987). 
In dermal studies of 2-butoxyethanol in animals, neurological effects consisted of prostration and narcosis 
prior to death in rabbits at ≥72 mg/kg for 8 hours (Duprat and Gradiski 1979); muscle flaccidity at 1,000 and 
2,000 mg/kg and anorexia and no spontaneous movement at 2,000 mg/kg prior to death in rabbits treated with 
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2-butoxyethanol for 24 hours on abraded skin (Olin 1976); ataxia progressing to moderate-to-marked
 
inactivity prior to death in pregnant rats at 1.4 mL/day during gestation (Hardin et al. 1984); and nystagmus
 
and convulsion prior to death in rabbits at 902 mg/kg (Union Carbide 1980a).
 
For 2-butoxyethanol acetate, no clinical signs of neurotoxicity and no histopathological lesions in the brain
 
were found in rats or rabbits exposed by inhalation intermittently to 400 ppm for 1 month or to 100 ppm for
 
10 months, in rats at unspecified single gavage doses, or in rabbits exposed dermally at ≤ 10,000 mg/kg for
 
24 hours (Truhaut et al. 1979).
 
The data indicate that humans exposed to sufficient quantities of 2-butoxyethanol by any route may experience
 
lethargy, but more serious neurological effects would not be expected to occur in humans exposed to
 
2-butoxyethanol or 2-butoxyethanol acetate under environmental or hazardous waste site scenarios.
 
Reproductive Effects. No studies were located regarding reproductive effects in humans after inhalation,
 
oral, or dermal exposure to 2-butoxyethanol or 2-butoxyethanol acetate.
 
Reproductive effects have been observed in animals after inhalation, oral, and dermal exposure to 2-butoxyethanol.
 
In inhalation studies, reproductive effects consisted of reduced maternal gravid uterine weight,
 
decreased percentages of viable implants and in live fetuses per litter, and an increase in non-viable implants in
 
pregnant rats, and decreased total implants and implant viability in pregnant rabbits at 200 ppm during
 




In oral studies on 2-butoxyethanol in animals, reproductive effects consisted of decreased sperm concentration
 
(with no effects on spermatid heads, spermatid counts, or percent mobile sperm) in male rats at
 
≥ 281 mg/kg/day in drinking water for 13 weeks (NTP 1993); testicular atrophy and decreased body weight
 
gain were observed in rats fed 2-butoxyethanol in the diet at 188 mg/kg/day for about 90 days (Weil and
 
Carpenter 1963); altered estrous cycles (more time spent in diestrus) with no change in total cycle length in
 
female rats at ≥363 mg/kg/day in the drinking water for 13 weeks (NTP 1993); vaginal bleeding at
 
200-600 mg/kg/day and increased resorptions and implantation loss at ≥ 200 mg/kg/day in rats during
 
gestation (NTP 1989); decreased incidence of viable litters in pregnant mice at 1,180 mg/kg/day by gavage
 
during gestation (Hardin et al. 1987; Schuler et al. 1984); a green or red vaginal discharge at
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and a decrease in the number of litters produced per breeding pair and litter size in mating pairs of mice at 
≥ 1,300 mg/kg/day in drinking water for 21 weeks (Heindel et al. 1990). Cross-breeding experiments indicated 
that these effects were due to effects on the females (Heindel et al. 1990). 
In dermal studies on 2-butoxyethanol in animals, the only reproductive effect consisted of a slight increase in 
testicular weight of male rabbits at 150 mg/kg/day for 6 hours per day for 90 days (CMA 1983). Histological 
examination of reproductive organs of males and females revealed no lesions. 
For 2-butoxyethanol acetate, no histopathological lesions were found in testes or ovaries in rats or rabbits 
exposed by inhalation intermittently to 400 ppm for 1 month or to 100 ppm for 10 months, in rats exposed 
orally at unspecified single gavage doses, or in rabbits exposed dermally to ≤10,000 mg/kg for 24 hours 
(Truhaut et al. 1979). 
The data indicate that reproductive effects might be a concern for pregnant women exposed to high levels of 
2-butoxyethanol. Based on the findings in male animals, little concern is indicated for reproductive effects in 
men. 
Developmental Effects. No studies were located regarding developmental effects in humans after 
inhalation, oral, or dermal exposure to 2-butoxyethanol or 2-butoxyethanol acetate. No studies were located 
regarding developmental effects in animals after exposure to 2-butoxyethanol acetate by any route. However, 
developmental effects have been observed in animals after inhalation, oral, and dermal exposure to 2­
butoxyethanol. 
In inhalation studies on 2-butoxyethanol in animals, the developmental effects consisted of retarded skeletal 
ossification in the offspring of pregnant rats at ≥ 100 ppm and in pregnant rabbits at 200 ppm for 6 hours per 
day during gestation (Tyl et al. 1984). In oral studies, the developmental effects consisted of decreased fetal 
body weight of the offspring of pregnant rats at ≥300 mg/kg/day and decreased gravid uterine weight of rat 
dams at 600 mg/kg/day during gestation (NTP 1989), and some evidence of cleft palate in the-fetuses of 
pregnant mice given ≥1,000 mg/kg/day during gestation (Wier et al. 1987). In a reproductive toxicity study in 
male and female mice, decreased pup weight was observed in all mating pairs at ≥700 mg/kg/day in drinking 
water for 21 weeks (Heindel et al. 1990). A crossover mating trial indicated that the reproductive effects could 
be attributed primarily to an effect on the female. In dermal studies on 2-butoxyethanol, no developmental 
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With the exception of decreased pup weight observed in mice at 700 mg/kg/day (Heindel et al. 1990), 
developmental effects reported occurred at 2-butoxyethanol doses that resulted in moderate to severe maternal 
toxicity (Hardin et al. 1987; NTP 1989; Tyl et al. 1984; Wier et al. 1987). 
2-Butoxyethanol has been shown to have developmental toxicity in an in vitro assay using the fresh water 
coelenterate Hydra attenuatu (Bowden et al. 1995; Johnson et al. 1984), whereas both 2-butoxyethanol 
(Bowden et al. 1995; Giavini et al. 1993) and 2-butoxyacetic acid (Giavini et al. 1993; Rawlings et al. 1985) 
have been shown to be embryotoxic in rat embryo culture. A significant increase in malformations 
(anomalous encephalon, hypoplasia of the branchial arches, unrotated) was observed only at the highest 
concentration of 2-butoxyethanol (l2.5 mM) used in this study, but not at 6.25 mM (Giavini et al. 1993). 
Malformations noted following exposure to 2-butoxyacetic acid at concentrations of 0.8 mM and greater were 
anomalous encephalon and irregular disposition of the somites (Giavini et al. 1993); however, another study 
found abnormalities at 5 mM 2-butoxyacetic acid (no statistics done), but not at 2 mM (Rawlings et al. 1985). 
Based on the in vitro data, Bowden et al. (1995) suggested that 2-butoxyethanol “presents a teratogenic 
potential that in vivo is masked by maternal toxicity.” 
The available data indicate that low birth weights and delayed ossification might be concerns for the offspring 
of pregnant women exposed to high levels of 2-butoxyethanol. 
Genotoxic Effects. No increases in micronuclei or sister chromatid exchanges were observed in varnish 
production workers exposed to both 2-ethoxyethanol and 2-butoxyethanol (Sohnlein et al. 1993). Postshift 
biological monitoring for the acetic acids in urine indicated that urinary levels of 2-ethoxyacetic acid 
(53.8 mg/L) were higher than urinary levels of 2-butoxyacetic acid (16.4 mg/L). One report of a 2-butoxyethanol 
test in a rat primary hepatocyte test was located (McGregor 1984). [14C]2-Butoxyethanol was tested 
for 2 hours at concentrations up to 0.1% in the culture medium. Significant increases in nuclear and DNA-
associated radioactivity at two low-dose levels were observed, with the maximum response 1.3 times the 
control levels. 2-Butoxyethanol was reported not to induce sister chromatid exchange in Chinese hamster 
ovary cells exposed to concentrations up to 0.25% for 2 hours in the presence of metabolizing enzymes (S9) 
and for 5 hours in the absence of S9 (Tyler 1982). 2-Butoxyethanol and 2-butoxyacetic acid did not result in 
mutagenic effects in Chinese hamster ovary cells exposed for 5 hours (Chiewchanwit and Au 1995). The 
maximum non-toxic concentrations studied were 1% for 2-butoxyethanol and 6.5% for 2-butoxyacetic acid. 
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The mutagenic effect of 2-butoxyethanol was investigated using bacteriophage T4D with Escherichia coli B, 
CR63, and K12 (Kvelland 1988). No mutagenic activity was observed, but 2-butoxyethanol had a severe 
toxic effect on phage yield. 2-Butoxyethanol was negative for mutation in Salmonella typhimurium strains 
TA98, TAlOO, and TA102 both with and without rat S-9 activation (Hoflack et al. 1995). In S. typhimurium 
strain TA97a, 2-butoxyethanol tested positive for mutation both with and without S-9 activation. The 
mutation assay of 2-butoxyethanol in strain TA97a was repeated by Gollapudi et al. (1996). In this study, 
2-butoxyethanol was negative for mutations both with and without rat S-9 metabolic activation, and it was 
negative in E. coli WP2uvrA strain. Gollapudi et al. (1996) suggested that Hoflack et al. (1995) found 
positive results because they used 2-butoxyethanol contaminated with higher levels of peroxides, which test 
positive in strain TA97a. The 2-butoxyethanol used by Gollapudi et al. (1996) contained 23 ppm of peroxides 
which was measured just before the tests. The 2-butoxyethanol used by Hoflack et al. (1995) contained less 
than 50 ppm peroxides according to the manufacturer, but the actual concentrations of peroxides may have 
been higher since measurements were not made immediately prior to testing. Gollapudi et al. (1996) 
concluded that peroxides and/or experimental variables probably account for the difference in results observed 
in their study and in the study by Hoflack et al. (1995). In vitro genotoxic effects are shown in Table 2-13. 
Cancer. No studies were located regarding carcinogenic effects in humans or animals after exposure to 
2-butoxyethanol, 2-butoxyethanol acetate, or 2-butoxyacetic acid by any route. However, structure-activity 
studies with 2-butoxyethanol and eight other glycol ethers were conducted with a cellular leukemia transplant 
model in male Fischer 344 rats to determine the chemotherapeutic potential of these glycol ethers (Dieter et al. 
1990). 2-Butoxyethanol was administered ad libitum in the drinking water to male rats at doses of 0, 3, or 
6 mg/mL. Treatment was begun after the rats were injected with the leukemic transplant. Untreated transplant 
control rats and untreated non-transplant controls were also included. Treatment continued for 55-65 days, at 
which time the animals were killed and blood was analyzed. 2-Butoxyethanol had no effect on the progression 
of the leukemic transplant. 
2-Butoxyethanol and 2-butoxyethanol acetate have not been classified for carcinogenic effects by the 
Department of Health and Human Services (DHHS), the National Toxicology Program (NTP), the 
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2.6 BIOMARKERS OF EXPOSURE AND EFFECT 
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have been 
classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC 1989). 
Due to a nascent understanding of the use and interpretation of biomarkers, implementation of biomarkers as 
tools of exposure in the general population is very limited. A biomarker of exposure is a xenobiotic substance 
or its metabolite(s), or the product of an interaction between a xenobiotic agent and some target molecule(s) or 
cell(s) that is measured within a compartment of an organism (NAWNRC 1989). The preferred biomarkers of 
exposure are generally the substance itself or substance-specific metabolites in readily obtainable body fluid(s) 
or excreta. However, several factors can confound the use and interpretation of biomarkers of exposure. The 
body burden of a substance may be the result of exposures from more than one source. The substance being 
measured may be a metabolite of another xenobiotic substance (e.g., high urinary levels of phenol can result 
from exposure to several different aromatic compounds). Depending on the properties of the substance (e.g., 
biologic half-life) and environmental conditions (e.g., duration and route of exposure), the substance and all of 
its metabolites may have left the body by the time samples can be taken. It may be difficult to identify 
individuals exposed to hazardous substances that are commonly found in body tissues and fluids (e.g., 
essential mineral nutrients such as copper, zinc, and selenium). Biomarkers of exposure to 2-butoxyethanol 
and 2-butoxyethanol acetate are discussed in Section 2.6.1. 
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an 
organism that, depending on magnitude, can be recognized as an established or potential health impairment or 
disease (NASKNRC 1989). This definition encompasses biochemical or cellular signals of tissue dysfunction 
(e.g., increased liver enzyme activity or pathologic changes in female genital epithelial cells), as well as 
physiologic signs of dysfunction such as increased blood pressure or decreased lung capacity. Note that these 
markers are not often substance specific. They also may not be directly adverse, but can indicate potential 
health impairment (e.g., DNA adducts). Biomarkers of effects caused by 2-butoxyethanol and 2-butoxyethanol 
acetate are discussed in Section 2.6.2. 
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism’s ability to 
respond to the challenge of exposure to a specific xenobiotic substance. It can be an intrinsic genetic or other 
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effective dose, or a target tissue response. If biomarkers of susceptibility exist, they are discussed -in Section 
2.8, Populations That Are Unusually Susceptible. 
2.6.1 Biomarkers Used to Identify or Quantify Exposure to 2-butoxyethanol 
The presence of 2-butoxyacetic acid in the urine is the accepted biomarker of exposure for both 2-butoxyethanol 
and 2-butoxyethanol acetate (Johanson et al. 1989) and has been used in surveys of occupational 
exposure, although 2-butoxyethanol has also been detected in blood and urine (Angerer et al. 1990; Haufroid 
et al. 1997; Johanson 1988; Johanson and Boman 1991; Johanson and Femstrom 1986; Johanson and 
Johnsson 1991; Johanson et al. 1986a, 19881989; Jiinsson and Steen 1978; Rettenmeier et al. 1993; Sakai et 
al. 1994; Vincent et al. 1993). These have also been used as biomarkers of exposure in animal experiments 
(Ghanayem et al. 1987a, 1987b, 1987c, 1992; Medinsky et al. 1990; Romer et al. 1985; Sabourin et al. 
1992a, 1992b, 1993). More recently, analytical methods have been able to detect 2-butoxyacetic acid in 
human blood (Johanson and Johnsson 199 1) Urinalysis for 2-butoxyacetic acid should include detection of 
glutamine conjugates since the amount of conjugate detected in urine can be equal to or greater than the 
amount of free 2-butoxyacetic acid (Rettenmeier et al. 1993; Sakai et al. 1994) 
For practical purposes, estimates of exposure can best be made from 2-butoxyacetic acid levels in the urine. 
Based on the work of Johanson (1988), 2-butoxyacetic acid is the appropriate biomarker of exposure for the 
following reasons: it is not normally in human urine, it can be reliably assayed with current methods, levels in 
the urine are not affected by hemolytic activity, the elimination half-life (4-7 hours) reflects exposure over the 
workday, and urine collection is non-invasive. Possible sources of variation and error inherent in the 
biological monitoring of 2-butoxyacetic acid in the urine include variable uptake during inhalation exposure 
caused by changes in workload, or during dermal exposure caused by changes in temperature and humidity, 
and changes in excretion caused by alcohol consumption or other personal habits (e.g., smoking) (Johanson 
and Boman 199 1; Johanson et al. 198 8). Inter-individual variation in the rates of absorption, distribution, 
metabolism, and excretion may also influence the evaluation of 2-butoxyacetic acid in the urine of exposed 
individuals. For example, a genetic polymorphism in the CYP 2El gene may possibly result in differences in 
the metabolism of 2-butoxyethanol; this speculation is based on the results of one study in which urinary 
levels of free butoxyacetic acid (conjugates were not measured) were measured in 30 c1/c1 homozygotes and 
one c1/c2 heterozygote (Haufroid et al. 1997). Persons heterozygous for the c2 allele may produce less 2­
butoxyacetic acid, and more ethylene glycol than persons homozygous for the c1 allele; however, ethylene 
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investigation. Studies indicate that the concentration of 2-butoxyacetic acid in the urine may not be linearly 
correlated with the absorbed dose; however, for individuals, it is related to absorbed dose and thus is a useful 
measure (Johanson 1988; Johanson et al. 1986a). Since these studies examined only free 2-butoxyacetic acid, 
it is unknown how much conjugated 2-butoxyacetic acid was in the urine. Because some (15-27% worst case) 
dermal absorption may occur from vapor exposure, 2-butoxyacetic acid in the urine resulting from ambient air 
concentrations of 2-butoxyethanol may represent both pulmonary and dermal absorption (Corley et al. 1997; 
Johanson and Boman 1991). Individual monitoring throughout the work day (urine samples prior to and after 
the workshift) may be a good choice for widescale biological monitoring in the occupational setting. 
2-Butoxyethanol has been shown to increase human plasma osmolality in vitro (Browning and Curry 1992). 
The osmolal gap is frequently used in the evaluation of a patient who has accidentally or intentionally ingested 
a glycol ether or related compound (Gijsenbergh et al. 1989). The presence of an elevated osmolal gap 
indicates the presence of significant blood levels of the toxic compound. This is not an indicator that is 
specific to 2-butoxyethanol or 2-butoxyethanol acetate and should be used in conjunction with other biomarker 
assays. 
2.6.2 Biomarkers Used to Characterize Effects Caused by 2-Butoxyethanol 
Hematotoxic effects are the characteristic biomarker of effect for 2-butoxyethanol exposure of animals 
(Bartnik et al. 1987; Ghanayem et al. 1987a, 1987b). In animals 2-butoxyethanol-induced hemolytic anemia 
is accompanied by a dose- and time-dependent decrease in the number of circulating red blood cells and 
decreases in hemoglobin concentration and hematocrit (Ghanayem et al. 1987a, 1987b). Hemolysis has been 
shown to be preceded by erythrocyte swelling (Ghanayem et al. 1989). Thus, hematological evaluations could 
be useful in monitoring effects of 2-butoxyethanol exposure. Work by Ghanayem et al. (1990b) indicates that 
using an impedance-based hematology analyzer allows for the detection of the erythrocytic swelling early after 
exposure that is undetectable by laser-based analyzer. Both analyzers were able to detect the subsequent 
decrease in red blood cell concentration signaling hemolytic effects (Ghanayem et al. 1990b). Thus, routine 
hematology using an appropriate hematology analyzer could be useful in detecting early hemolytic effects after 
2-butoxyethanol exposure. 
2-Butoxyethanol has been shown to increase human plasma osmolality in vitro (Browning and Curry 1992). 
The osmolal gap is frequently used in the evaluation of a patient who has accidentally or intentionally ingested 
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associated with metabolic acidosis, which has been observed in humans after ingestion of 2-butoxyethanol 
(Bauer et al. 1992; Gijsenbergh et al. 1989; Rambourg-Schepens et al. 1988). This is not an indicator that is 
specific to 2-butoxyethanol or 2-butoxyethanol acetate and should be used in conjunction with other biomarker 
assays. 
The use of urinary D-glucaric acid as a biomarker of effect following exposure to 2-butoxyethanol has been 
examined in 12 or 13 foundry workers exposed to the compound in paints and 18 unexposed controls (Collinot 
et al. 1996). Increased urinary D-glucaric acid is a nonspecific indicator of an increase in the activity of the 
glucuronic acid enzyme pathway. Urinary levels of D-glucaric acid were measured both in the summer and 
winter, and exposure concentrations were measured only in winter when they were expected to be higher 
because of reduced ventilation. Urinary concentrations of D-glucaric acid in nmol/hour were 2,095±991 in 
controls, 3,888±2,284 in the exposed workers during summer, and 5,792±2,387 in the exposed workers 
during winter. The values were significantly different from controls at levels of p<0.05 during summer and 
p<0.01 during winter. When the groups were divided into smokers and nonsmokers, the smokers showed a 
higher level of D-glucaric acid than the nonsmokers The exposure concentrations never exceeded 7.5 ppm, 
and the study authors indicated that other substances were undetectable (detection limits not stated). Although 
measurement of D-glucaric acid is not an effect specific to 2-butoxyethanol exposure, the study authors 
concluded that it was more sensitive than a standard blood count. 
2.7 INTERACTIONS WITH OTHER CHEMICALS 
Data describing the interaction of 2-butoxyethanol or 2-butoxyethanol acetate with other chemicals are scarce. 
Simulations of human pharmacokinetics of co-exposure to ethanol (0.1% in the blood) during an 8-hour 
exposure to 20 ppm 2-butoxyethanol with no exercise predict that the arterial levels of 2-butoxyethanol will be 
elevated as a result of a decrease in elimination rate (Johanson 1986, 1991a; Johanson and Naslund 1988). 
Because the increase in 2-butoxyethanol is due to decreased elimination and not increased uptake, the rise and 
fall of blood concentrations of 2-butoxyethanol are slower in the ethanol co-administration model than in the 
increased workload model. A study in rats indicated that co-administration of ethanol and 2-butoxyethanol 
resulted in a higher blood level and a prolonged blood elimination time of 2-butoxyethanol than administration 
of 2-butoxyethanol alone (Romer et al. 1985). The prolonged retention of 2-butoxyethanol was considered to 
be due to inhibition of metabolism of 2-butoxyethanol to 2-butoxyacetaldehyde via competition with ethanol 
for alcohol dehydrogenase, the enzyme common to the metabolism of both ethanol and 2-butoxyethanol. 
Based on these results in rats, the study authors concluded that the elimination of 2-butoxyethanol could be 
 
 
255 2-BUTOXYETHANOL AND 2-BUTOXYETHANOL ACETATE 
2. HEALTH EFFECTS 
inhibited in humans after consumption of alcoholic beverages and simultaneous exposure to 2-butoxyethanol. 
As discussed in Section 2.9.3, administration of ethanol after 2-butoxyethanol exposure can be used to control 
the production of toxic metabolites and to promote conjugation of the parent compound to nontoxic products 
of elimination such as the glucuronide and sulfate conjugates of 2-butoxyethanol. 
Hemolysis is a critical effect of exposure to 2-butoxyetbanol, but it is unknown whether 2-butoxyethanol 
interacts with other hemolytic agents, such as naphthalene, the toxicity of which is reviewed in the ATSDR 
Toxicological Profile for Naphthalene (ATSDR 1995b). 
2.8 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 
A susceptible population will exhibit a different or enhanced response to 2-butoxyethanol than will most 
persons exposed to the same level of 2-butoxyethanol in the environment. Reasons may include genetic 
makeup, age, health and nutritional status, and exposure to other toxic substances (e.g., alcohol and cigarette 
smoke). These parameters may result in reduced detoxification or excretion of 2-butoxyethanol, or 
compromised function of target organs affected by 2-butoxyethanol. Populations who are at greater risk due 
to their unusually high exposure to 2-butoxyethanol are discussed in Section 5.6, Populations With Potentially 
High Exposure. 
Since the hemolytic effect of 2-butoxyethanol is caused by the action of the toxic metabolite 2-butoxyacetic 
acid, presumably on the red cell membrane, populations that are unusually susceptible to the toxic effects of 
2-butoxyethanol would be those that have increased metabolism to 2-butoxyacetic acid and decreased 
excretion of 2-butoxyacetic acid. Persons whose red blood cell walls are less resistant to the effects of 
2-butoxyacetic acid would also be more sensitive to 2-butoxyethanol. However, erythrocytes from normal, 
aged, sickle-cell anemia, and hereditary spherocytosis patients were resistant to the hemolytic effects of 
2-butoxyacetic acid in vitro (Udden 1996; Udden and Patton 1994). Since erythrocytic swelling has been 
shown to precede hemolysis in rats after 2-butoxyethanol exposure, Udden and Patton (1994) investigated the 
possibility that increased deformability of erythrocytes in humans could predispose the individual to 2-butoxy­
ethanol toxicity. They exposed erythrocytes from normal, aged, sickle-cell anemia, and hereditary spherocy-tosis 
patients to 2-butoxyacetic acid, the hemolytic metabolite of 2-butoxyethanol, in vitro under conditions 
that cause hemolysis of rat erythrocytes. No increase in hemolysis, changes in mean cellular volume or 
morphology, or deformability were found in any of the human erythrocytes. However, further definition of the 
metabolic or structural differences that render human erythrocytes more resistant to the effects of 2-butoxy­
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ethanol compared to rat erythrocytes may also point to characteristics in the human population that may 
indicate increased susceptibility. It is unknown whether people with a genetic predisposition to hemolytic 
anemia from other causes (such as glucose-6-phosphate dehydrogenase mutations) will be more susceptible to 
2-butoxyethanol-induced hemolysis. 
In rats, Ghanayem et al. (1987a, 1990a) have shown that susceptibility to the hematotoxic effects of 2-butoxy­
ethanol increases with increasing age. Investigation of the respiratory excretion and urinary metabolites of 
young (4-5 weeks old) and adult (9-13 weeks old) rats indicated that adult rats excreted a significantly lower 
proportion of the administered dose as respiratory CO2 and eliminated less in the urine as the 2-butoxyethanol­
glucuronide; more was eliminated as 2-butoxyacetic acid. No studies of this kind have been done in humans. 
However, it is possible that people of advanced age or with altered hepatic conjugating enzymes, reduced 
respiratory capacity, or compromised renal status could be at greater risk for toxic reactions to 2-butoxyethanol 
exposure. 
Some incomplete and very tentative results on the influence of a CYP2El Polymorphism on the metabolism of 
2-butoxyethanol are discussed in Section 2.3.3 Metabolism. 
2.9 METHODS FOR REDUCING TOXIC EFFECTS 
This section will describe clinical practice and research concerning methods for reducing toxic effects of 
exposure to 2-butoxyetbanol. However, because some of the treatments discussed may be experimental and 
unproven, this section should not be used as a guide for treatment of exposures to 2-butoxyethanol. When 
specific exposures have occurred, poison control centers and medical toxicologists should be consulted for 
medical advice. The following text provides specific information about treatment following exposures to 
2-butoxyethanol: Ellenhom and Barceloux 1988. 
2.9.1 Reducing Peak Absorption Following Exposure 
Human exposure to 2-butoxyethanol or 2-butoxyethanol acetate can occur by inhalation, oral, or dermal 
contact. General recommendations for reducing absorption of 2-butoxyethanol or 2-butoxyethanol acetate 
following acute high-level inhalation exposure have included moving the patient to fresh air and monitoring 
for respiratory distress (Ellenhorn and Barceloux 1988); washing exposed skin after high level air exposure is 
probably a good idea since there can be some dermal absorption from 2-butoxyethanol vapors as well (Corley 
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et al. 1997). In the case of eye exposure, irrigation with copious amounts of water or saline have been 
recommended (Ellenhorn and Barceloux 1988). The removal of contaminated clothing and a thorough 
washing of exposed areas with soap and water have also been recommended (Ellenhorn and Barceloux 1988). 
Induction of emesis may be indicated following recent substantial ingestion of 2-butoxyethanol or 2-butoxyethanol 
acetate unless the patient is or could rapidly become comatose or convulsive (Ellenhorn and Barceloux 
1988). Furthermore, the use of emetics may result in aspiration pneumonitis. Gastric lavage has been 
recommended, but charcoal and cathartics may be ineffective (Ellenhorn and Barceloux 1988). Gastric lavage 
and induced emesis using syrup of ipecac have been used in the treatment of accidental poisoning of children 
(Dean and Krenzelok 1992). 
2.9.2 Reducing Body Burden 
As discussed in Section 2.3 on Toxicokinetics, following absorption into the blood, 2-butoxyethanol is rapidly 
distributed throughout the body. Since 2-butoxyethanol is slightly hydrophilic, it is not preferentially 
distributed to lipid-rich tissues. 2-Butoxyethanol toxicity results from the formation of 2-butoxyacetic acid in 
the liver, through alcohoValdehyde dehydrogenases. Dealkylation to ethylene glycol may also account for 
some toxicity. Detoxification pathways generally involve the formation of the sulfate and glucuronide 
conjugates of the parent compound and conjugation and excretion of the active metabolite 2-butoxyacetic acid. 
Exhalation is a minor route for excretion of CO2 from 2-butoxyacetic acid and ethylene glycol, but metabolites 
are primarily excreted in the urine. Studies in humans and animals indicate that both exhalation and urinary 
excretion occur in several phases, with half-lives of minutes to hours. Hence, 2-butoxyethanol and its 
metabolites have relatively short half-lives in the body, and while some of these metabolites are toxic, 
substantial body burdens are not expected. 
It is possible that methods could be developed to enhance detoxification and elimination pathways for the 
parent compound, in preference to oxidation pathways leading to 2-butoxyacetic acid, to aid in ridding the 
body of what has been absorbed prior to the production of toxic metabolites. 
2.9.3 Interfering with the Mechanism of Action for Toxic Effects 
The toxicity of 2-butoxyethanol has been shown to be dependent on the production of 2-butoxyacetic acid via 
alcohoYaldehyde dehydrogenases through the metabolic intermediate butoxyacetaldehyde. Methods successful 
in interfering with the mechanism of action for toxic effects are those that interfere with the metabolic 
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processes responsible for producing 2-butoxyacetic acid. For instance, treatment of rats with pyrazole, an 
alcohol dehydrogenase inhibitor, provided protection against the hematotoxic effect of 2-butoxyethanol 
(Ghanayem et al. 1987b). Inhibition of the metabolism of 2-butoxyethanol to butoxyacetaldehyde increased 
conjugation of the parent compound and urinary excretion of the sulfate or glucuronide detoxification 
products. Similar results were observed with cyanamide, an aldehyde dehydrogenase inhibitor. Based on 
observations that 2-butoxyethanol-induced hemolytic anemia was age-dependent, with older rats being more 
susceptible than younger rats, Ghanayem et al. (1987a) speculated that increased susceptibility of older rats 
may have been related, in part, to compromised elimination of 2-butoxyacetic acid. Inhibition of renal 
clearance by the pretreatment of rats with probenecid, an inhibitor of organic acid transport in the proximal 
renal tubules, significantly increased the half-life of 2-butoxyacetic acid, indicating the importance of renal 
transport in 2-butoxyacetic acid detoxification (Ghanayem et al. 1990a). Thus, increasing renal transport in 
exposed individuals might reduce the residence time of the toxic metabolite in the body, consequently reducing 
the opportunity for toxic reactions. 
Ethanol has been shown to block the metabolism of 2-butoxyethanol to 2-butoxyacetic acid through 
competitive inhibition of alcohol dehydrogenase (Romer et al. 1985). Administration of ethanol after 
2-butoxyethanol exposure can be used to control the production of toxic metabolites and to promote 
conjugation of the parent compound to nontoxic products of elimination such as the glucuronide and sulfate 
conjugates. This approach has been recommended for clinical therapy for 2-butoxyethanol poisoning 
(Buckley et al. 1993). 
2.10 ADEQUACY OF THE DATABASE 
Section 104(I)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether adequate 
information on the health effects of 2-butoxyethanol and 2-butoxyethanol acetate is available. Where 
adequate information is not available, ATSDR, in conjunction with the National Toxicology Program (NTP), 
is required to assure the initiation of a program of research designed to determine the health effects (and 
techniques for developing methods to determine such health effects) of 2-butoxyethanol and 2-butoxyethanol 
acetate. 
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would reduce 
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the uncertainties of human health assessment. This definition should not be interpreted to mean that all data 
needs discussed in this section must be filled. In the future, the identified data needs will be evaluated and 
prioritized, and a substance-specific research agenda will be proposed. 
2.10.1 Existing Information on Health Effects of 2-Butoxyethanol 
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to 
2-butoxyethanol and 2-butox yethanol acetate are summarized in Figures 2- 12 and 2- 13, respectively. The 
purpose of these figures is to illustrate the existing information concerning the health effects of 2-butoxyethanol 
and 2-butoxyethanol acetate. Each dot in the figure indicates that one or more studies provide 
information associated with that particular effect. The dot does not necessarily imply anything about the 
quality of the study or studies, nor should missing information in this figure be interpreted as a “data need.” A 
data need, as defined in ATSDR’s Decision Guide for Identifying Substance-Specific Data Needs Related to 
Toxicological Profiles (ATSDR 1989), is substance-specific information necessary to conduct comprehensive 
public health assessments. Generally, ATSDR defines a data gap more broadly as any substance-specific 
information missing from the scientific literature. 
Virtually all of the information regarding health effects in humans comes from experimental studies of 
volunteers exposed by inhalation or dermally to 2-butoxyethanol, or case reports of accidental or intentional 
poisoning in humans who ingested household products containing 2-butoxyethanol. Exposures to 2-butoxyethanol 
and 2-butoxyethanol acetate occur in minting and silk screening shops, at furniture manufacturers, in 
auto body shops, or anywhere that large-scale painting, inking, furniture stripping, or metal stripping or 
cleaning occurs. In addition, since 2-butoxyethanol and 2-butoxyethanol acetate are contained in many all-purpose 
cleaning agents, exposure occurs through window, car and floor washing. Consumer products 
containing 2-butoxyethanol consist primarily of all-purpose cleaners, but some paints, inks, furniture staining 
and stripping products, and cosmetics also contain these chemicals. Inhalation and dermal absorption are the 
main routes of exposure, although accidental or intentional poisoning also occurs. 
As seen in Figure 2-l 2 for 2-butoxyethanol, inhalation and oral information for humans is available describing 
acute-duration systemic and neurological effects. A case report describing the death of a woman following 
ingestion of a cleaner containing 2-butoxyethanol is also available. A study report of genotoxic effects in 
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available. Information describing the effects of human dermal exposure is limited, consisting of acuteduration 
systemic and immunological effects. Inhalation, oral, and dermal studies in animals have provided 
information on death, acute- and intermediate-duration systemic effects, and immunological and 
lymphoreticular, neurological, reproductive, and developmental effects. 
For 2-butoxyethanol acetate, data describing health effects in humans are limited to a dermal irritancy study 
(Figure 2- 13). Animal studies with 2-butoxyethanol acetate are extremely limited but provide some 
information on death; acute-duration systemic effects; and immunological and lymphoreticular, neurological, 
reproductive, and developmental effects after inhalation and oral exposure. In addition, information exists on 
intermediate-duration systemic effects after inhalation exposure. Dermal studies in animals provide 
information on death; acute-duration systemic effects; and immunological and lymphoreticular, neurologic, 
and reproductive effects. It should be noted that the information for 2-butoxyethanol acetate is contained in 
only two studies. 
2.10.2 Identification of Data Needs 
Acute-Duration Exposure. There are reports on the health effects resulting from acute exposure in a 
limited number of studies of humans, and more from animals exposed to 2-butoxyethanol via the inhalation, 
oral, and dermal routes. In humans exposed by inhalation to 2-butoxyethanol, nasal, throat, and eye irritation, 
and possibly emesis have been identified as effects (Carpenter et al. 1956). In humans who ingested 2-butoxy­
ethanol, respiratory, cardiovascular, hematological, hepatic, renal, ocular, and metabolic effects have been 
identified (Bauer et al. 1992; Gijsenbergh et al. 1989; Gualtieri et al. 1995; Litovitz et al. 1991; Rambourg-
Schepens et al. 1988). Death also occurred in one of these cases (Litovitz et al. 1991). Very little information 
exists for health effects resulting from dermal exposure of humans, and the data indicate minor local dermal 
effects and no dermal sensitivity (CMA 1992; Greenspan et al. 1990; Johanson et al. 1988). The primary 
target organs for acute exposure are the hematological, hepatic, renal, and lymphoreticular (spleen) systems. 
In acute-duration inhalation studies in animals, systemic effects have been observed as follow; respiratory 
effects (Carpenter et al. 1956; Dodd et al. 1983; Dow 1986; Kane et al. 1980; Tyl et al. 1984), gastrointestinal 
effects (Carpenter et al. 1956; Dow 1986), hematological effects (Carpenter et al. 1956; Dodd et al. 1983; 
Sabourin et al. 1992a; Tyl et al. 1984; Werner et al 1943a), hepatic effects (Carpenter et al. 1956; Dodd et al. 
1983; Dow 1986), renal effects (Carpenter et al. 1956; Dodd et al. 1983; Doe 1984; Dow 1986; Nelson et al. 
1984; Tyl et al. 1984; Werner et al. 1943a), ocular effects (Dow 1986; Tyl et al. 1984), and body weight 
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effects (Carpenter et al. 1956; Dodd et al. 1983; Dow 1972; Tyl et al. 1984). The acute inhalation data were 
sufficient to derive an acute inhalation MRL of 6 ppm based on a NOAEL of 50 ppm for hematological effects 
in rats in the study by Tyl et al. (1984). 
In acute-duration oral studies in animals, systemic effects have been observed as follows: respiratory effects 
(Carpenter et al. 1956; Dow 1981; NTP 1989; Union Carbide 1980b; Wier et al. 1987), gastrointestinal 
effects (Olin 1976; Shepard 1994b; Union Carbide 1980b), hematological effects (Carpenter et al. 1956; 
Corley et al. 1994; Ghanayem and Sullivan 1993; Ghanayem et al. 1987a, 1987b, 1990b, 1992; Grant et al. 
1985; NTP 1989; Sivarao and Mehendale 1995), muscular effects secondary to neurotoxicity (Olin 1976), 
hepatic effects (Carpenter et al. 1956; Ghanayem et al. 1987b, 1992; Grant et al. 1985; NTP 1989; Olin 
1976; Union Carbide 1980b), renal effects (Carpenter et al. 1956; Dow 1959; Ghanayem et al. 1987a, 1987b 
Grant et al. 1985; NTP 1989; Olin 1976; Sivarao and Mehendale 1995; Union Carbide 1980b), possible 
dermal effects (Dow 1981; NTP 1989; Olin 1976), ocular effects (Dow 1981; NTP 1989), and body weight 
effects (Grant et al. 1985; Hat-din et al. 1987; Heindel et al. 1990; NTP 1989, 1993; Union Carbide 1980b; 
Schuler et al. 1984; Wier et al. 1987). The acute oral data were sufficient to derive an acute oral MRL of 
0.4 mg/kg/day based on a LOAEL of 32 mg/kg for hematological effects in rats in the study by Ghanayem et 
al. (1987b). 
In acute-duration dermal studies in animals, systemic effects have been observed as follows: respiratory 
effects (Duprat and Gradiski 1979; Union Carbide 1980b), gastrointestinal effects (Union Carbide 1980b), 
hematological effects (Bartnik et al. 1987; Carpenter et al. 1956; Duprat and Gradiski 1979; Hardin et al. 
1984; Union Carbide 1980a), muscular effects secondary to neurotoxicity (Olin 1976), hepatic and renal 
effects (Carpenter et al. 1956; Duprat and Gradiski 1979; Olin 1976; Union Carbide 1980a, 1980b), dermal 
effects (Dow 1959; Duprat and Gradiski 1979; Hardin et al. 1984; Rohm and Haas 1983; Union Carbide 
1980a, 1980b; Zissu 1995), ocular effects (Dow 1959; Kennah et al. 1989a; Olin 1976; Rohm and Haas 
1983; Union Carbide 1980a, 1980b), and body weight effects (Dow 1959; Hardin et al. 1984; Union Carbide 
1980a). 
Information is also available for levels that cause death in a number of animals species following inhalation 
exposure (Carpenter et al. 1956; Dodd et al. 1983; Dow 1986; Nelson et al. 1984; Sabourin et al. 1992a; Tyl 
et al. 1984; Werner et al. 1943a), oral exposure (Carpenter et al. 1956; Dow 1959, 1981; Eastman Kodak 
1983,1988; Hardin et al. 1987; Heindel et al. 1990; Kennedy and Graepel 1991; Krasavage 1986; NTP 1989; 
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Shepard 1994b; Smyth et al. 194 l), and dermal exposure (Carpenter and Condra 196 1; Carpenter et al. 1956; 
Dow 1959; Duprat and Gradiski 1979; Eastman Kodak 1988; Olin 1976; Union Carbide 1980a, 1980b) to 
2-butoxyethanol. Studies have shown that rats are particularly sensitive to the hematotoxic effects of 
2-butoxyethanol, compared to humans (Bartnik et al. 1987; Ghanayem and Sullivan 1993; Udden 1994). 
However, since numerous data are available regarding systemic effects in animals, more studies on species-specific 
systemic effects, particularly hematotoxicity, after acute-duration exposure by inhalation, oral, and 
dermal routes in animals would not be particularly useful. Doses or concentrations that would result in 
hematological effects in humans are not known, and it would be unethical to find out by direct experiments on 
humans; however, there may be a place for more in in vitro experiments on fresh human blood. 
The only information regarding health effects in bumans resulting from acute exposure to 2-butoxyethanol 
acetate is a study by Jacobs et al. (1989), who found mild erythema in humans after acute dermal exposure. 
Very few data are available describing health effects in animals following inhalation, oral, or dermal exposure 
for acute-duration exposure. The data found are principally contained in three articles (Jacobs et al. 1989; 
Truhaut et al. 1979; Zissu 1995). Although hematology was performed in the acute-duration inhalation study 
conducted in rats and rabbits by Truhaut et al. (1979), only one exposure concentration was used, and selected 
organs were examined only for gross pathology. No effects were observed in rats, and hemoglobinuria and/or 
hematuria were the only effects noted for rabbits. For an acute-duration oral study on 2-butoxyethanol acetate 
in rats conducted by Truhaut et al. (1979), LD50 data were provided, gross and histological examinations were 
performed, and hemoglobinuria and renal effects were observed, but the doses used were not specified. In the 
acute dermal study in rabbits conducted by Truhaut et al. (1979), an LD50 value was determined, gross and 
histological examinations were performed, and hematological and renal effects were observed at 
≥ 3,191 mg/kg. In the study by Jacobs et al. (1989), the only information provided was that dermal exposure 
of rabbits to 2-butoxyethanol acetate resulted in slight erythema. 2-Butoxyethanol acetate was considered a 
moderate irritant by the Draize protocol and non-irritating by the European Economic Communities protocol 
(Zissu 1995). 
Although 2-butoxyethanol acetate is readily metabolized to 2-butoxyethanol and both compounds are 
metabolized by the same pathways, the limited data indicate that dose-response data for the acetate may be 
different from that for 2-butoxyethanol. For example, the oral LD50 values for male Wistar rats were reported 
to be 1,590 mg/kg for 2-butoxyethanol (Olin 1976) and 3,000 mg/kg for 2-butoxyethanol acetate in olive oil 
(Truhaut et al. 1979). The contribution of a vehicle effect on the difference in toxicity between 2-butoxyethanol and 
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the two compounds. Other toxicological data for 2-butoxyethanol acetate are too limited to permit comparison 
with the toxicological data for 2-butoxyethanol for the same species, strains, and exposure conditions. 
Additional animal or human data on the toxic effects of 2-butoxyethanol acetate by all routes would be useful 
in assessing the human risk of exposure to 2-butoxyethanol acetate. Characterization of the relative toxicity of 
2-butoxyethanol acetate compared to 2-butoxyethanol would aid in the use of data already generated for 
2-butoxyethanol in predicting risk factors of exposure to the acetate form. In addition, clarification of species-
specific toxicity, similar to that observed for 2-butoxyethanol, would aid in understanding the risk associated 
with exposure to 2-butoxyethanol acetate. 
Intermediate-Duration Exposure. No studies were located regarding health effects in humans 
following intermediate-duration exposure to 2-butoxyethanol by inhalation, oral, or dermal routes. Studies 
were located regarding systemic effects in animals following intermediate-duration exposure to 2-butoxyethanol 
by inhalation, oral, and dermal routes. In intermediate-duration inhalation studies in animals, systemic 
effects have been observed as follows: respiratory effects (Carpenter et al. 1986; Werner et al. 1943b), 
gastrointestinal effects, renal effects, body weight effects (Carpenter et al. 1956), and hematological effects 
(Carpenter et al. 1956; Dodd et al. 1983; Werner et al. 1943b). The intermediate inhalation data were 
sufficient to derive an intermediate inhalation MRL of 3 ppm based on a NO&L of 25 ppm for hematological 
effects in rats in the study by Dodd et al. (1983). In intermediate-duration oral studies in animals, systemic 
effects have been observed as follows: gastrointestinal effects (NTP 1993), hematological effects (Eastman 
Kodak 1983; Krasavage 1986; Nagano et al. 1979,1984; NTP 1993), hepatic effects and renal effects 
(Carpenter et al. 1956; Eastman Kodak 1983; Heindel et al. 1990; Krasavage 1986; NTP 1993; Weil and 
Carpenter 1963), and body weight effects (Carpenter et al. 1956; NTP 1993; Weil and Carpenter 1963). The 
intermediate oral data were sufficient to derive an intermediate oral MRL of 0.07 mg/kg/day for hepatic effects 
in rats based on the study by NTP (1993). Only one intermediate-duration dermal study was located. In this 
study (CMA 1983), rabbits were treated dermally for 90 days at ≤ 150 mg/kg, and comprehensive hematology 
and histological examinations were performed for all relevant systemic organs. The only treatment-related 
effects were slight to moderate erythema and edema at ≥ 10 mg/kg/day. 
The hematological system is the primary target for 2-butoxyethanol toxicity. Therefore, further animal studies 
designed to confirm and extend the data of Dodd et al. (1983) for inhalation exposure, and animal studies for 
intermediate-duration exposure by oral administration would be helpful in defining the NOAEL for 
hematological, hepatic, and renal effects, since these effects occurred at the lowest doses tested (the 
intermediate oral MRL is based on a LOAEL). Additionally, although some data exist that describe health 
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effects of 2-butoxyethanol in rabbits after intermediate dermal exposure (CMA 1983), studies using higher 
doses might define target organs and doses that cause bematological effects. These data are important, since 
dermal exposure to 2-butoxyethanol vapor and aqueous solutions is a primary route of human exposure. 
Furthermore, there are populations surrounding hazardous waste sites that might be exposed to 2-butoxy-ethanol for 
intermediate durations. 
No studies were located regarding health effects in humans after inhalation, oral, or dermal intermediate-duration 
exposure to 2-butoxyethanol acetate. No studies were located regarding health effects in animals 
after intermediate-duration oral or dermal exposure to 2-butoxyethanol acetate. Limited data are available 
describing health effects in animals following intermediate-duration inhalation exposure. The data found are 
contained in one article (Truhaut et al. 1979). In this study, in which rats and rabbits were exposed to only one 
concentration of 2-butoxyethanol acetate (400 ppm for II month or 100 ppm for 10 months), histological 
examinations of several organs identified serious hematological (hemoglobinuria) and renal effects in rats and 
rabbits. Additional studies defining dose-response data for these and other possible effects of 2-butoxyethanol 
acetate after intermediate-duration exposure and clarifying how it relates to 2-butoxyethanol would be useful 
in predicting human toxicity to 2-butoxyethanol acetate exposure. 
Chronic-Duration Exposure and Cancer. Statistically significant changes in hematocrit (decrease) 
and mean corpuscular hemoglobin concentration (increase) were reported in men occupationally exposed to 
0.46-0.75 ppm 2-butoxyethanol for l-6 years (Haufroid et al. 1997). The changes were small, showed no 
relationship to exposure concentration and were still within normal biological variability. Although the effects 
may be early indicators of potential adverse effects in humans, and they are consistent with effects in animals, 
ATSDR considers the average exposure (0.6 ppm) to be a NOAEL. This study serves as the basis of the 
chronic-duration inhalation MRL of 0.2 ppm. No effects on serum creatinine, urinary retinol binding protein, 
or serum transaminase levels were noted. 
No studies were located regarding health effects in humans or animals after chronic inhalation, oral, or dermal 
exposure or in animals after chronic inhalation exposure to 2-butoxyethanol or 2-butoxyethanol acetate. The 
primary targets for adverse systemic effects of 2-butoxyethanol following acute- and intermediate-duration 
exposure are the hematological and renal systems. Since chronic low-level exposure to 2-butoxyethanol and 
the acetate form by the inhalation, oral, or dermal routes is possible for populations living near waste sites 
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2-butoxyethanol and 2-butoxyethanol acetate in animals would be useful in defining potential adverse health 
effects. 
No studies were located regarding carcinogenic effects in humans or animals after exposure to 2-butoxyethanol 
and 2-butoxyethanol acetate by any route. These compounds have not been classified for carcinogenic 
effects by the Department of Health and Human Services (DHHS), the National Toxicology Program (NTP), 
the International Agency for Research on Cancer (IARC), or the Environmental Protection Agency (EPA). 
Histological examination of comprehensive organs and tissues in animals in chronic studies performed by any 
route of exposure would be useful in determining potential carcinogenic effects of 2-butoxyethanol or 
2-butoxyethanol acetate; however, the genotoxicity data available for 2-butoxyethanol suggest that it is 
unlikely to cause cancer by damaging DNA. 
Genotoxicity. The only in vivo study was in workers exposed to both 2-butoxyethanol and the structurally 
related 2-ethoxyethanol (Sohnlein et al. 1993). No increases in micronuclei or sister chromatid exchanges 
were observed in these workers. Several reports of in vitro studies were found (Chiewchanwit and Au 1995; 
Gollapudi et al. 1996; Hoflack et al. 1995; Kvelland 1988; McGregor 1984; Tyler 1982). [14C]2-Butoxy-ethanol 
was positive in a test that monitored increases in DNA-associated radioactivity in rat primary 
hepatocytes (McGregor 1984). However, 2-butoxyethanol was negative in tests of mutagenicity with bacteria 
(Kvelland 1988) and sister chromatid exchange (Tyler 1982) or mutations (Chiewchanwit and Au 1995) in 
Chinese hamster ovary cells, with or without metabolic activation. 2-Butoxyethanol was negative for mutation 
in Salmonella typhimurium strains TA98, TA100, and TA102 both with and without rat S-9 activation 
(Hoflack et al. 1995). In S. typhimurium strain TA97a 2-butoxyethanol tested positive for mutation both with 
and without S-9 activation. The mutation assay of 2-butoxyethanol in strain TA97a was repeated by 
Gollapudi et al. (1996). In this study, 2-butoxyethanol was negative for mutations both with and without rat 
S-9 metabolic activation, and it was negative in E. coli WP2uvrA strain. Gollapudi et al. (1996) suggested 
that Hoflack et al. (1995) found positive results because they used 2-butoxyethanol contaminated with higher 
levels of peroxides, which test positive in strain TA97a. The 2-butoxyethanol used by Gollapudi et al. (1996) 
contained 23 ppm of peroxides which was measured just before the tests. The 2-butoxyethanol used by 
Hoflack et al. (1995) contained less than 50 ppm peroxides; the information was provided by the manufacturer, 
so the actual concentrations of peroxides may have been higher. Gollapudi et al. (1996) concluded 
that peroxides and/or experimental variables probably account for the difference in results observed in their 
study and the study by Hoflack et al. (1995). The available data suggest that 2-butoxyethanol is not 
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genotoxicity of 2-butoxyethanol acetate. Further studies of 2-butoxyethanol and 2-butoxyethanol acetate in 
vivo and in vitro would more fully determine the genotoxic potential of these compounds. 
Reproductive Toxicity. No studies were located regarding reproductive effects in humans after 
inhalation, oral, or dermal exposure to 2-butoxyethanol or 2-butoxyethanol acetate. 
For 2-butoxyethanol, two inhalation (800 ppm for 3 hours; ≤ 867 ppm for 4 hours; ≤245 ppm for 9 days; 
≤77 ppm for 13 weeks) studies (Dodd et al. 1983; Doe 1984), several oral (≤500 mg/kg administered once; 
500 or 1,000 mg/kg for 4 days; ≤346 or ≤627 mg/kg/day for 2 weeks) studies (Eastman Kodak 1983; Exon et 
al. 1991; Ghanayem et al. 1987; Grant et al. 1985; Heindel et al. 1990; Krasavage 1986; Nagano et al. 1979, 
1984; NTP 1993), and two dermal (doses up to 150 mg/kglday for 90 days or 18-361 mg/kg/day for 11 days) 
studies (CM4 1983; Union Carbide 1980a) in animals measured testicular weight and/or performed 
histological examination of male reproductive organs and found no effect. However, one intermediateduration 
oral (≤443 mg/kg/day for 60 days) study found decreased sperm concentration in male rats (NTP 
1993), and a go-day study reported testicular atrophy in rats (Weil and Carpenter 1963). In the go-day dermal 
study (doses of up to 150 mg/kg/day) in rabbits (CMA 1983), there was only a slight increase in testicular 
weight of rabbits. Reproductive effects (implantation loss, decreases in live fetuses, and/or increase in 
nonviable implants) have been found in pregnant rats and rabbits exposed to 2-butoxyethanol(200 ppm) by 
inhalation during gestation (Tyl et al. 1984). In oral (≤ 363 mg/kg/day for 13 weeks) studies, female rats, but 
not female mice, had altered estrous cycles (NTP 19939, although the total duration of the cycle was not 
altered. Pregnant rats (treated with 600 mg/kg/day on gestation days 9-l 1 or 1 l-13) had vaginal bleeding, 
increased resorptions, and implantation loss (NTP 1989), and pregnant mice (treated with 1,180 mg/kg/day on 
gestation days 6-13) had decreases in viable litters (Hardin et al. 1987; Schuler et al. 1984) and increased 
resorptions (Wier et al. 1987). In a breeding-pair study in male and female mice (treated with 1,300 or 
2,100 mg/kg/day for 21 weeks), there was a decrease in the number of litters produced per pair that was found 
to be a result of effects on female reproduction in cross-mating experiments (Heindel et al. 1990). However, 
in the NTP (1993) drinking water study, histological examination of female rat and mouse reproductive organs 
(NTP 1993), and vaginal cytology evaluations of rats and/or mice revealed no pathology. Histological 
examination of the reproductive organs of female rabbits in the go-day dermal study by CMA (1983) also 
revealed no pathology. Since several studies that performed histological examination of reproductive organs 
of animals exposed by all routes were negative, additional studies of this kind do not appear to be useful. One 
oral continuous breeding study was performed in mice, a drinking water study (Heindel et al. 1990) that has 
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studies in two species conducted by the inhalation and dermal routes (which are the two routes most relevant 
for humans) would help to complete the picture of reproductive effects of 2-butoxyethanol in animals and help 
to determine whether 2-butoxyethanol exposure presents a reproductive hazard to humans. 
For 2-butoxyethanol acetate, no gross pathological lesions were found in the testes or ovaries of rats or rabbits 
exposed to 400 ppm for 4 hours and no gross or histopathological lesions were found in the testes or ovaries 
of rats or rabbits exposed by inhalation intermittently to 400 ppm for 1 month or 100 ppm for 10 months, in 
rats at unspecified single gavage doses, or in rabbits exposed dermally at ≤ 10,000 mg/kg for 24 hours 
(Truhaut et al. 1979). However, no reproductive function studies were located. 
The results of both 2-butoxyethanol and 2-butoxyethanol acetate studies indicate that further histological 
examination of male and female reproductive organs would not be particularly useful, but reproductive studies 
in mated pairs of two species exposed to 2-butoxyethanol acetate by all routes would be useful to determine 
the reproductive toxicity potential of this compound. 
Developmental Toxicity. No studies were located regarding developmental effects in humans after 
inhalation, oral, or dermal exposure to 2-butoxyethanol or 2-butoxyethanol acetate. 
Developmental effects have been observed in animals after inhalation, oral, and dermal exposure to 2-butoxy­
ethanol. In inhalation studies on 2-butoxyethanol in animals, the developmental effects consisted of retarded 
skeletal ossification in the offspring of pregnant rats and pregnant rabbits (Tyl et al. 1984). In oral studies, the 
developmental effects consisted of decreased fetal body weight of the rats and decreased gravid uterine weight 
of the rat dams (NTP 1989), some evidence of cleft palate in the fetuses of pregnant mice (Wier et al. 1987), 
and decreased pup weight in the offspring of mating pairs of rats (Heindel et al. 1990). In dermal studies, no 
developmental effects were observed in the offspring of pregnant rats exposed at 0.48 mL/day during 
gestation (Hardin et al. 1984). A higher dermal dose (1.4 mL/day) caused mortality of the dams. With the 
exception of decreased pup weight observed in mice (Heindel et al. 1984), developmental effects reported 
occurred at 2-butoxyethanol doses that resulted in moderate to severe maternal toxicity (Hardin et al. 1987; 
NTP 1989; Tyl et al. 1984; Wier et al. 1987). An additional developmental study on 2-butoxyethanol by the 
dermal route in another species (mouse or rabbit) would be useful, since dermal exposure to 2-butoxyethanol 
in cleaning solutions is a primary route of exposure in the general population. 
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No studies were located regarding developmental effects in animals after inhalation, oral, or dermal exposure 
to 2-butoxyethanol acetate. Studies of the developmental toxicity of this compound by inhalation, oral, and 
dermal routes would be useful in predicting potential developmental toxicity, and relating the toxicity of 
2-butoxyethanol acetate to 2-butoxyethanol. 
Immunotoxicity. No studies were located regarding immunological and lymphoreticular effects in humans 
after inhalation or oral exposure to 2-butoxyethanol or 2-butoxyethanol acetate. Slight erythema, but no 
allergic reaction, was noted on skin-patch tests with 2-butoxyethanol acetate in humans (Jacobs et al. 1989). 
A limited human dermal sensitivity study in 201 persons with 10% 2-butoxyethanol showed no overt effect 
(CMA 1992). The 10% concentration was tested because it is the highest concentration found in cosmetics. 
2-Butoxyethanol has also tested negative for dermal sensitization in guinea pigs using the maximized 
Magnusson and Kliman test (Zissu 1995). 
In two oral studies, the information on immunological effects of 2-butoxyethanol in animals consists of the 
findings that no effect on the immune system was found in rats (Exon et al. 1991; Smialowicz et al. 1992), and 
no effect on thymus and spleen weight and no histopathological lesions in the thymus were observed in rats 
(Exon et al. 1991). 
Studies in animals describe effects on the spleen, many of which are related to the hematological effect of 
2-butoxyethanol. In inhalation studies, splenic effects consisted of increased spleen weight of pregnant rats 
(Tyl et al. 1984). In oral studies, splenic and other lymphoreticular effects in animals consisted of increased 
spleen weight (Eastman Kodak 1983; Ghanayem et al. 1987a, 1987b, 1992; Grant et al. 1985; Krasavage 
1986; NTP 1989), extramedullary splenic hematopoiesis (Grant et al. 1985), splenic congestion and enlarged 
dark spleens (Eastman Kodak 1983; Krasavage 1986), hemosiderosis in the spleen, decreased thymus weight, 
and bone marrow hyperplasia and increased hematopoiesis (NTP 1993). In dermal studies on 2-butoxyethanol 
in animals, effects on lymphoreticular organs consisted of congestion in the spleen, erythrocytic infiltration, 
and white atrophic pulp (Duprat and Gradiski 1979); engorged spleen (Carpenter et al. 1956); and enlarged 
and dark red spleen (Union Carbide 1980a, 1980b). 
One reasonably thorough study examined immune function in rats orally dosed at up to 400 mg/kg/day 
2-butoxyethanol twice after immunization with trinitrophenyl-lipopolysaccharide (TNP-LPS) (Smialowicz et 
al 1992). Compared with controls, the 2-butoxyethanol had no adverse effect on antibody production, delayed 
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Since the effects on the spleen and bone marrow are secondary to the hemolytic effects of 2-butoxyethanol, 
and since a number of studies performed histological examination of lymphoreticular organs, additional 
studies on lymphoreticular effects do not appear to be useful. However, the potential for immunotoxicity of 
2-butoxyethanol has not been sufficiently studied. A battery of immunotoxicity tests conducted by all routes, 
but particularly by the inhalation and dermal routes (the most relevant routes for humans) would help to 
determine whether 2-butoxyethanol is immunotoxic. 
For 2-butoxyethanol acetate, no gross or histopathological lesions were found in the spleen of rats or rabbits 
exposed by inhalation intermittently to 400 ppm for 1 month or to 100 ppm for 10 months, in rats at 
unspecified single gavage doses, or in rabbits exposed dermally at ≤ 10,000 mg/kg for 24 hours (Truhaut et al. 
1979). Studies such as those suggested for 2-butoxyethanol would be helpful not only in defining the effect of 
2-butoxyethanol acetate on the immune system, but also in relating it to the toxicity of 2-butoxyethanol. 
Neurotoxicity. The only information on neurological effects in humans exposed to 2-butoxyethanol is that 
humans exposed experimentally by inhalation experienced headache and disturbed taste sensation (Carpenter 
et al. 1956), and that people who intentionally ingested household cleaning agents containing 2-butoxyethanol 
became comatose (Bauer et al. 1992; Gijsenbergh et al. 1989; Eitovitz et al. 1991; Rambourg-Schepens et al. 
1988). 
Neurological effects have been observed in animals after inhalation, oral, and dermal exposure to 2-butoxyethanol. 
In inhalation studies of 2-butoxyethanol in animals, neurological effects consisted of loss of 
coordination (Dodd et al. 1983), extreme weakness and apathy (Carpenter et al. 1956), excessive salivation 
(Dow 1972, 1986), and poor coordination of the extremities and loss of equilibrium (Dow 1986). In oral 
studies of 2-butoxyethanol in animals, neurological effects consisted of sluggishness, prostration, narcosis, 
lethargy, failure to right, and/or ataxia (Carpenter et al. 1956; Dow 1959, 198 1; Eastman Kodak 1983; 
Krasavage 1986; NTP 1989; Olin 1976; Sivarao and Mehendale 1995; Shepard 1994b; Union Carbide 
1980b; Wier et al. 1987). In dermal studies of 2-butoxyethanol in animals, neurological effects consisted of 
prostration, narcosis, convulsion, nystagmus, anorexia, lack of spontaneous movement, and/oFinactivity 
(Duprat and Gradiski 1979; Hardin et al. 1984; Olin 1976; Union Carbide 1980a). Most of these effects 
occurred in animals prior to death at high lethal doses. In intermediate-duration inhalation (Dodd et al. 1983) 
oral (Eastman Kodak 1983; Krasavage 1986; NTP 1993), and dermal (CMA 1983) studies, comprehensive 
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For 2-butoxyethanol acetate, no clinical signs of neurotoxicity and no histopathological lesions in the brain 
were found in rats or rabbits exposed by inhalation intermittently to 400 ppm for 1 month or to 100 ppm for 
10 months, in rats at unspecified single gavage doses, or in rabbits exposed dermally at ≤ 10,000 mg/kg for 
24 hours (Truhaut et al. 1979). 
A battery of neurological and behavioral tests in animals after inhalation, oral, and dermal exposure would 
help to determine whether 2-butoxyethanol and 2-butoxyethanol have more subtle neurobehavioral effects. 
Epidemiological and Human Dosimetry Studies. Studies of human populations exposed to 
2-butoxyethanol or 2-butoxyethanol acetate primarily involve evaluations of kinetic parameters and 
biomonitoring for occupational exposure after inhalation or dermal exposure (Angerer et al. 1990; Haufroid et 
al. 1997; Johanson and Boman 1991; Johanson and Johnsson 1991; Johanson et al. 1986a, 1988; Rettenmeier 
et al. 1993; Sakai et al. 1994; Vincent et al. 1993). Hematological effects have been examined in a small 
group of men occupationally exposed to 2-butoxyethanol and methyl ethyl ketone (Haufroid et al. 1997). 
Small but statistically significant changes in hematocrit (decrease) and mean corpuscular hemoglobin 
concentration (increase) that were still within normal biological variability were reported. Although the effects 
may be early indicators of potential adverse effects in humans, and they are consistent with effects in animals, 
ATSDR considers the average exposure (0.6 ppm) to be a NOAEL. This study serves as the basis of the 
chronic-duration inhalation MRL of 0.2 ppm. The study authors indicated that the hematological effects 
should be confirmed in additional populations exposed to 2-butoxyethanol. One study regarding genotoxicity 
and exposure assessment in workers exposed to both 2-butoxyethanol and 2-ethoxyethanol (Sohnlein et al. 
1993) is available. Occupational exposure to 2-butoxyethanol and 2-butoxyethanol acetate by the inhalation 
or dermal route comprises a large proportion of the potential exposure in the population. Thus, 
epidemiological studies of humans exposed occupationally, or at or near hazardous waste sites would provide 
valuable information on the potential toxicity of the compound. This information would be useful, especially 
in light of the apparent species differences in relative toxicity. 
Biomarkers of Exposure and Effect 
Exposure. The presence of 2-butoxyacetic acid in the urine is the accepted biomarker of exposure for both 
2-butoxyethanol and 2-butoxyethanol acetate (Johanson et al. 1989), and it has been used as a biomarker in 
surveys of occupational exposure; 2-butoxyethanol in the blood and urine or 2-butoxyacetic acid and its 
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Johanson and Boman 199 1; Johanson and Fernstrom 1986; Johanson and Johnsson 199 1; Johanson et al. 
1986a, 1988, 1989; Jiinsson and Steen 1978; Rettenmeier et al. 1993; Sakai et al. 1994; Vincent et al. 1993). 
These have also been used as biomarkers of exposure in animal experiments (Ghanayem et al. 1987a, 1987b, 
1987c, 1992; Medinsky et al. 1990; Romer et al. 1985; Sabourin et al. 1992a, 1992b, 1993). More recently, 
analytical methods have been able to detect 2-butoxyacetic acid in human blood (Johanson and Johnsson 
1991). These biomarkers are unique, relatively short-lived, and serve well for monitoring exposure. However, 
the exact relationship between blood or urine levels of these compounds and exposure by the inhalation, oral, 
or dermal routes is still not clear; some of this may be due to measurement of only free 2-butoxyacetic acid in 
the urine rather than the total of free and conjugates. Additional studies of exposure and blood and urine 
levels of these compounds would be helpful in predicting the health effects of exposure in the occupational 
setting, and in instances of exposure of populations near waste sites, or those using consumer products 
containing 2-butoxyethanol or the acetate form. An exploratory study of the role of genetic polymorphism of 
CYP 2El on 2-butoxyethanol metabolism by humans would also be useful. Haufroid et al. (1997) looked at 
urinary metabohtes in a small sample of humans exposed to 2-butoxyethanol; the subject included 30 c1/c1 
homozygotes and one c1/c2 heterozygote. Individuals beterozygous for the c2 allele may produce less 
2-butoxyethanol acid, and more ethylene glycol than individual homozygous for the c1 allele; however, 
ethylene glycol and its metabolites were not measured in the urine in this study and only free butoxyacetic acid, 
not conjugates, was measured. 
Effect. Monitoring of hematological parameters may be useful as a biomarker of effect of 2-butoxyethanol 
and 2-butoxyethanol acetate. Toxic effects occur in the red blood cells and are either from 2-butoxyethanol or 
its metabolites (Bartnik et al. 1987; Ghanayem et al. 1987a, 1987b). However, hematological effects are not 
specific to 2-butoxyethanol. The tests cannot be relied upon to find preclinical disease, but may be useful in 
identifying changes that are early indicators of effects Furthermore, these markers of effect may not be useful 
for long periods following cessation of exposure, nor do they distinguish between acute and chronic exposure. 
The use of urinary D-glucaric acid as a biomarker of effect following exposure to 2-butoxyethanol has been 
examined in foundry workers exposed to the compound in paints (Collinot et al. 1996). Although 
measurement of D-glucaric acid is not an effect specific to 2-butoxyethanol exposure, the study authors 
concluded that it was more sensitive than a standard blood count. Further investigation of possible biomarkers 
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Absorption, Distribution, Metabolism, and Excretion. Data from both humans (Angerer et al. 
1990; Johanson and Boman 199 1; Johanson and Johnsson 1991; Johanson et al. 1986a, 1989) and rats 
(Johanson 1994; Sabourin et al. 1992a) indicate that 2-butoxyethanol is rapidly and extensively absorbed 
through the lungs. No studies were located regarding pulmonary absorption in other animal species. Although 
no experimentally acquired data were available on gastrointestinal absorption of 2-butoxyethanol in humans, 
some data are available from case reports of oral poisonings, which suggest that absorption from the 
gastrointestinal system is rapid (Bauer et al. 1992; Gijsenbergh et al. 1989; Gualtieri et al. 1995; Litovitz et 
al. 1991; Rambourg-Schepens et al. 1988). Data from rat studies corroborate these results (Corley et al. 1994; 
Ghanayem et al. 1987c; Medinsky et al. 1990), but no data were available for other animal species. Studies in 
humans exposed experimentally (Corley et al. B 997; Johanson and Boman 199 1; Johanson et al. 1988) or 
occupationally (Vincent et al. 1993) indicate that 2-butoxyethanol can be absorbed through the skin, both from 
the vapor and from the liquid form. Results suggest that persons that expose large portions of their skin to the 
liquid form of 2-butoxyethanol are at risk of absorbing acutely toxic doses. In vitro studies using human skin 
also indicate dermal absorption (Bartnik et al. 1987; Dugard et al. 1984). Data from rats (Bartnik et al. 1987; 
Sabourin et al. 1992b, 1993) and guinea pigs (Johanson and Fernstrom 1986) exposed dermally support this 
conclusion. An in vitro study using skin from humans, rats, and pigs shows that the absorption of neat 2­
butoxyethanol was initially slower than from aqueous solutions, such as all purpose cleaners (Bartnik et al. 
1987). 
No information on distribution of 2-butoxyethanol to tissues in humans was located. Following absorption 
into the body, 2-butoxyethanol was widely distributed from the blood to tissues of rats after inhalation 
(Johanson 1994), oral (Ghanayem et al. 1987b, 1987c), and dermal (Bartnik et al. 1987) exposure. 
There is no evidence to suggest that the route of admiuistration has any substantial effect on the subsequent 
metabolism of 2-butoxyethanol in animals, although the route of administration and the dose may alter the 
relative amounts of individual metabolites (Medinsky et al. 1990; Sabourin et al. 1992a, 1992b, 1993). 
2-Butoxyacetic acid (free or glycine or glutamine conjugates) is the major blood and urinary metabolite of 
2-butoxyethanol in humans after inhalation exposure (Johanson and Johnsson 199 1; Johansouet al. 1986a), 
while oxalate, formed from metabolism of ethylene glycol (a hydrolysis product of 2-butoxyethanol), was 
found in the urine of a patient after ingestion (Rambourg-Schepens et al. 1988). 2-Butoxyacetic acid is also 
the major urinary metabolite in rats, guinea pigs, dogs, rabbits, dogs, and monkeys exposed to 2-butoxyethanol 
by inhalation (Carpenter et al. 1956). Other metabolites in rats after inhalation, oral, or dermal 
exposure are expired CO2, ethylene glycol, and glucuronide and sulfate conjugates of 2-butoxyethanol in the 
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urine, and 2-butoxyacetic acid and 2-butoxyethanol-glucuronide conjugate in the bile (Corley et al. 1994; 
Ghanayem et al. 1987c; Sabourin et al. 1992a, 1992b, 1993). Based on the rat data, metabolic pathways have 
been elucidated. 2-Butoxyethanol is oxidized via alcohol dehydrogenase to the aldehyde, then further oxidized 
to 2-butoxyacetic acid by aldehyde dehydrogenase. 2-Butoxyacetic acid can then be detoxified by conjugation 
with glycine or glutamine, or it can be broken down to CO2. 2-Butoxyethanol can also be metabolized to 
ethylene glycol, another toxic glycol ether, or it can be directly detoxified by conjugation and excreted. 
Biotransformation of 2-butoxyethanol to 2-butoxyacetic acid is necessary for 2-butoxyethanol-induced 
toxicity. It is clear, however, that the metabolic pathway can be influenced, thus altering the amount of toxic 
metabolites and subsequent toxicity. Additional studies on conditions that favor detoxification of the parent 
compound through conjugation over metabolism of the parent compound to its toxic metabolite 2-butoxyacetic 
acid would be useful in not only understanding the toxic reactions after exposure, but may also suggest ways 
to prevent or minimize toxicity after exposure. These studies might include the examination of the effects of 
polymorphism of CYP 2El in humans on the metabolism of 2-butoxyethanol to follow up one study in which 
a person with one alternate allele had less free 2-butoxyacetic acid in urine than 30 with 2 copies of a common 
allele (Haufroid et al. 1997). 
Respiratory excretion of 2-butoxyethanol consists of expired CO2 and unchanged parent compound (Bartnik et 
al. 1987; Ghanayem et al. 1987a; Medinsky et al. 1990; Sabourin et al. 1992a, 1992b, 1993). However, 
urinary excretion of 2-butoxyethanol, 2-butoxyacetic acid, ethylene glycol, and the conjugates is the primary 
route in both humans and animals (Bartnik et al. 1987; Carpenter et al. 1956; Ghanayem et al. 1987a, 1987b, 
1987c; Gijsenbergh et al. 1989; Johanson 1994; Johanson and Johnsson 1991; Johanson et al. 1986a, 1988; 
Jijnsson and Steen 1978; Rambourg-Schepens et al. 1988; Rettenmeier et al. 1993; Sabourin et al. 1992a, 
1992b, 1993; Sakai et al. 1994; Vincent et al. 1993). 2-Butoxyethanol, 2-butoxyacetic acid, and the 
glucuronic conjugate of 2-butoxyethanol are also excreted in the bile (Ghanayem et al. 1987a, 1987b, 1987c). 
Fecal excretion is a minor route (Bartnik et al. 1987; Ghanayem et al. 1987b, 1987c; Medinsky et al. 1990; 
Sabourin et al. 1992a, 1992b, 1993). 
The absorption of 2-butoxyethanol acetate has not been extensively studied, although in humans 
occupationally exposed to the acetate, 2-butoxyacetic acid was detected in the urine (Johanson et al. 1989), 
and absorbed doses of the acetate were calculated for rabbits exposed dermally (Truhaut et al. 1979). No 
studies regarding distribution of 2-butoxyethanol acetate were located. The metabolism of 2-butoxyethanol 
acetate has not been extensively studied, presumably because 2-butoxyethanol acetate is assumed to be 
metabolized to 2-butoxyethanol in the body, and then to follow the same pathway as 2-butoxyethanol, since 
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2-butoxyacetic acid has been detected in human urine after 2-butoxyethanol acetate exposure (Johanson et al. 
1989). Other than detection of 2-butoxyacetic acid in urine in humans occupationally exposed to 2-butoxy-ethanol 
acetate, no studies were located regarding excretion of the acetate form. 
The absorption, distribution, metabolism, and excretion of 2-butoxyethanol are relatively well understood, 
leading to a number of PBPK models (Corley 1996; CorIey et al. 1994; Johanson 1986,199 1 a; Johanson and 
Naslund 1988; Shyr et al. 1993). These models have been validated with acute- and intermediate-duration 
pharmacokinetic data. Chronic pharmacokinetic data would be useful so that the models could be validated for 
chronic exposure. Additional studies designed to define the differences and similarities between 2-butoxyethanol 
and its acetate with regard to absorption, distribution, metabolism, and excretion would be useful to 
establish these parameters for to 2-butoxyethanol acetate. 
Comparative Toxicokinetics. Qualitatively, absorption, metabolism, and excretion appear to be similar 
in humans and laboratory animals (see discussion above). However, quantitative variations in absorption, 
metabolism, and excretion of 2-butoxyethanol have been observed with respect to age in rats (Ghanayem et al. 
1987a). In addition, the efficiency of absorption of 2-butoxyethanol and excretion of 2-butoxyacetic acid after 
inhalation exposure differs for several animal species (Carpenter et al. 1956). However, the absorption, 
distribution, metabolism, and excretion of 2-butoxyetbanol after inhalation, oral, and dermal exposure have 
been studied extensively only in rats. Further studies that focus on the age-related and species-related 
differences and their implications for human health would be useful. Additionally, in vitro studies using 
human tissue and further research into PBPK modeling in animals would contribute significantly to the 
understanding of the kinetics of 2-butoxyethanol and would aid in the development of pharmacokinetic models 
of exposure in humans. 
Methods for Reducing Toxic Effects. Development of methods and practices that are specific for 
2-butoxyethanol or 2-butoxyethanol acetate would be useful for reducing peak absorption, and body burden, 
and for interfering with the mechanism of action following 2-butoxyethanol or 2-butoxyethanol acetate 
exposure. With regard to accidental or intentional poisoning, hemodialysis (Gijsenbergh et al.-1989), gastric 
lavage, and emesis have been used in the prevention of toxicity (Dean and Krenzelok 1992), and 
administration of ethanol has been suggested as appropriate therapy (Buckley et al. 1993). Based on animal 
studies, the administration of inhibitors of alcohol dehydrogenase and aldehyde dehydrogenase may also be 
appropriate (Ghanayem et al. 1987b). Since 2-butoxyethanol metabolites are thought to play the major role in 
the toxicity, more information is needed about their interaction with cell membranes and cellular 
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macromolecules. This information would help the development of methods for possible prevention of 
2-butoxyethanol-induced toxicity. Special attention should be paid to the production of toxic metabolites, and 
preferential metabolism to detoxification products. 
2.10.3 Ongoing Studies 
The open literature contained preliminary reports of ongoing studies in two areas. In an abstract, Raymond et 
al. (1994) reported immediate and late effects of acute exposure to 2-butoxyethanol in seven clerical workers. 
Severe, immediate eye and upper respiratory irritation, presyncope, and nausea were observed. Exposure 
resulted from floor stripping with undiluted 2-butoxyethanol in a small room with little ventilation. The 
symptoms suggest exposure at 100-300 ppm. All seven workers recovered within several days but noticed 
skin lesions (cherry angiomas) and recurrent upper respiratory irritation beginning 3 months later. In another 
preliminary report, the flow properties of rat red blood cells were investigated after oral exposure to 
50-500 mg/kg 2-butoxyethanol (Kurantsin-Mills et al. 1992). The physical characteristics of the red blood 
cells were determined at 0.5,2, and 4 hours after treatment. Membrane and cellular changes were noted that 
compromise the flow properties of the cells, thus possibly affecting microcirculation, possibly resulting in 
hemolysis. 
The Chemical Manufacturer’s Association is working with the EPA to develop an RfC and an RfD for 
2-butoxyethanol. A draft IRIS support document is available (CMA 1997b). 
NTP has nearly completed lifetime bioassays of 2-butoxyethanol in mice and rats. The study is undergoing 
peer review and should provide information on both carcinogenic potential and systemic effects. 
No studies regarding the health effects of 2-butoxyethanol or 2-butoxyethanol acetate were reported in the 
CRISP Data Base of the National Institutes of Health. 
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3.1 CHEMICAL IDENTITY 
Information regarding the chemical identity of 2-butoxyethanol and 2-butoxyethanol acetate is located in 
Tables 3-l and 3-2, respectively. 
3.2 PHYSICAL AND CHEMICAL PROPERTIES 
Information regarding the physical and chemical properties of 2-butoxyethanol and 2-butoxyethanol acetate is 
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4.1 PRODUCTION 
Glycol ethers consist of a large group of organic solvents that are widely used in formulating cleaning products 
and protective coatings (Browning and Curry 1994; Rowe and Wolf 1982; Vincent et al. 1993). 2-Butoxy-ethanol, 
one of the simplest glycol monoalkyl ethers, is commonly encountered and massively produced for use 
in several industries (Dow 1993; Gibson 1984; Rowe and Wolf 1982). Approximately 130 million pounds of 
2-butoxyethanol were produced in the United States in both 1972 and 1975 (HSDB 1997). Data on 
production volumes between 1975 and 1983 were not found. However, there was a significant overall increase 
in production during that period, with 2-butoxyethanol being the largest volume glycol ether produced in 1983 
(HSDB 1997); reportedly more than 230 million pounds were produced (Gibson 1984 as cited in Ghanayem et 
al. 1987b). Domestic production of 2-butoxyethanol reached 27 1 million pounds in 1984 (HSDB 1997) and 
increased to over 300 million pounds in 1986 (NIOSII 1990). A production volume of 408.5 million pounds 
of 2-butoxyethanol has been estimated for 1995 (CMA 1997a). Significantly lower and relatively constant 
production of 2-butoxyethanol acetate was reported for the period 1972-l 977, with production volumes in 
1972,1975, and 1977 of 13.4 million pounds, 11 million pounds, and 11 million pounds, respectively 
(NIOSH 1990). More recent production data for 2-butoxyethanol acetate could not be found in the available 
literature. 
Major producers of 2-butoxyethanol are Dow Chemical, USA (Midland, Michigan); Eastman Chemical Co., 
Texas Eastman Co. Division (Longview, Texas); Occidental Petroleum Corporation, Oxy Petrochemicals, Inc. 
(Dallas, Texas); Shell Chemical Co. (Geismar, Louisiana); and Union Carbide Corporation, Solvents and 
Intermediates (Seadrift, Texas) (HSDB 1997; SRI 1997; USITC 1992). The Occidental Petroleum 
Corporation and the Tennessee Eastman Division of the Eastman Chemical Co. (Kingsport, Tennessee) are 
major producers of 2-butoxyethanol acetate (HSDB 1997; SRI 1997). Recent data showing the combined 
production volume of 2-butoxyethanol acetate for these producers were not located. Both compounds are 
included in the reports of the Toxics Release Inventory (TRI) database (EPA 1995) as part of the required 
generic reporting of all ethylene glycol ethers. Therefore, information pertaining to the releases of the 
individual compounds to the environment are not available. 
Ethylene glycol monoalkyl ethers are not manufactured as pure compounds but must be separated from the 
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2-butoxyethanol: reaction of ethylene oxide with anhydrous butyl alcohol in the presence of a catalyst and 
direct alkylation of ethylene chlorohydrin or ethylene glycol using sodium hydroxide and an alkylating agent 
such as dibutyl sulfate (HSDB 1997; NOSH 1990; Rowe and Wolf 1982). By far the dominant method of 2­
butoxyethanol production is treatment of butyl alcohol with ethylene oxide. Information on older products 
indicates that there may be a considerable difference in the purity of 2-butoxyethanol manufactured in the 
United States, particularly between industrial and technical formulations. Depending on the production 
process, manufacturer, and chemical grade of the material, 2-butoxyethanol may contain impurities such as 
sodium hydroxide (caustic), ethylene glycol, diethylene glycol, and diethylene glycol monobutyl ether (Dow 
1958; Eastman Kodak 1988). Dowanol EB Crude, an industrial formulation, was reported to contain 0.25% 
sodium hydroxide (caustic) (Dow 1958). Ektasolve, a technical grade formulation with >99% purity, was 
reported to contain 0.2% (w/w) each of ethylene glycol, diethylene glycol, and diethylene glycol monobutyl 
ether (Eastman Kodak 1988). Total impurity levels in 2-butoxyethanol from different manufacturers have 
been reported to range from ppm levels to l-2% (w/w) (Dow 1972; Eastman Kodak 1983,1988). 
2-Butoxyethanol acetate is predominantly produced by treatment of 2-butoxyethanol with acetic acid. 
Treatment with acetic acid anhydride or acetic acid chloride are secondary, minor methods of production. 
4.2 IMPORT/EXPORT 
The most recent import and export data found for 2-butoxyethanol indicate that imports into the United States 
increased significantly from a negligible amount in 1972 to 89,000 pounds in 1984 (HSDB 1997). Export 
volumes also increased significantly from 9 million pounds in 1972, to 12 million pounds in 1975, to 71 
million pounds in 1984 (HSDB 1997). No quantitative import or export data were found in the available 
literature for 2-butoxyethanol acetate. The National Trade Data Bank (NTDB 1997) reports import/export 
data for monobutyl ethers of mono or di-ethylene glycols rather than specific data for 2-butoxyethanol or 2­
butoxyethanol acetate. 
4.3 USE 
2-Butoxyethanol is used extensively in the production of cleaning agents and as a general solvent because it 
exhibits properties of both alcohols and ethers (Gibson 1984 as cited in Ghanayem et al. 1987b). It is used in 
formulating industrial and household cleaners, metal cleaners, silicone caulks, and protective surface coatings 
such as spray lacquers, quick-dry lacquers, enamels, varnishes, and latex paints (Dow 1993; HSDB 1997; 
Lewis 1993; NIOSH 1990; Rempel et al. 1991; Tichenor and Mason 1988; Vincent et al. 1993). It is also 
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used in inks, degreasers, paint thinners, and paint stripping formulations (Hahn and Werschulz 1986; 
Lehmann et al. 1986; Yamano et al. 1991). 2-butoxyethanol has optimum properties (i.e., well-balanced 
distribution of hydrophilic and hydrophobic groups, complete miscibility with water at room temperature, and 
an appropriate rate of evaporation) for the production, storage, and application of aqueous coating systems 
(Appelt 1990). 2-Butoxyethanol is also a component of dry-cleaning compounds (Lewis 1993). In the textile 
industry, 2-butoxyethanol is used as a dye component to prevent spotting during fabric printing and dyeing 
(HSDB 1997; Lewis 1993). 2-Butoxyethanol is also used in liquid soaps and cosmetics (Rowe and Wolf 
1982). Based on information provided to the IDA, 2-butoxyethanol was found in 111 cosmetic products in 
1994 at concentrations up to 10% (Cosmetic Ingredient Review Expert Panel 1996). The emulsifying 
properties of soap are improved when 2-butoxyethanol is included in the formulation as a mutual solvent for 
“soluble” mineral oils (Lewis 1993). Functioning as a coupling agent, the compound stabilizes immiscible 
ingredients in metal cleaning products, textile lubricants, hydraulic fluids, cutting oils, and liquid household 
cleaning products (HSDB 1997; NIOSH 1990; Rowe and Wolf 1982; Vincent et al. 1993). 2-Butoxyethanol 
is used as a chemical intermediate in the synthesis of acetate esters as well as phthalate and stearate 
plasticizers (Dow 1993; HSDB 1997); it is also used as a component of some adhesives (FDA 1993a). In 
1972, the use pattern for 2-butoxyethanol was as follows: solvent for protective coatings, 41%; other solvent 
uses, 3 1%; solvent for metal cleaners and liquid household cleaners, 18%; synthesis of 2-butoxyethanol 
acetate, 9%; and synthesis of di(2-butoxyethyl) phthalate, 1% (HSDB 1997). The pattern for consumption in 
1984, which did not include household cleaners was as follows: coatings solvents, 65%; intermediates, 20%; 
and miscellaneous solvents, 15% (HSDB 1997). Minor applications include the use of 2-butoxyethanol as a 
solvent or co-solvent in pesticide formulations (Dow 1993; Leaf 1985 as cited in NIOSH 1990) and 
automotive brake fluids (Leaf 1985 as cited in NIOSH 1990). Nearly half of the more than 740 products 
containing 2-butoxyethanol marketed in the United States in 1977 were intended for household use; the 
average concentration of 2-butoxyethanol in these household products was 2.8% (Consumer Products Safety 
Commission 1977). The concentration of 2-butoxyethanol used in industrial and household window cleaning 
agents has been found to range from 1% to 30% by volume (Vincent et al. 1993). 
2-Butoxyethanol acetate is primarily used as a high-boiling, retarder solvent (i.e., an active, slow-evaporating 
solvent which ensures smooth film formation) for nitrocellulose lacquers, acrylic enamels, epoxy resins, and 
multicolor lacquers (Leaf 1985 as cited in NIOSH 1990; Lewis 1993). 2-Butoxyethanol acetate is also a film-
coalescing aid for polyvinyl acetate latex and is used in some ink and spot remover formulations (Leaf 1985 as 
cited in NIOSH 1990; Lewis 1993). In addition, the chemical is used in inks, degreasers, paints, and paint 
thinner formulations (Lehman et al. 1986) and as a component of some adhesives (FDA 1993a). The 
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concentration of 2-butoxyethanol acetate as a retarder solvent in coating formulations is generally l-5% by 
volume (Leaf 1985 as cited in NIOSH 1990). Current information on the use pattern for 2-butoxyethanol was 
not located in the available literature. 
4.4 DISPOSAL 
Regulations governing the treatment and disposal of wastes containing 2-butoxyethanol or 2-butoxyethanol 
acetate are detailed in Chapter 7. A recommended method of disposal for small amounts of 2-butoxyethanol 
involves mixing the compound with more flammable solvents to improve combustion, and then atomizing the 
mixture in an incinerator (IRPTC 1985). In a preliminary investigation of the photodegradation of 2-butoxy­
ethanol, Minero et al. (1989) concluded that in the presence of semiconductor particles (titanium dioxide 
[(TiO2]), degradation is very rapid and effective. A qantitative formation of carbon dioxide was observed. 
Their investigation also concluded that under the proper conditions, an iodine-doped organic polymer 
(polyphenylacetylene) can catalyze 70-l 00% photooxidation of 2-butoxyethanol (Minero et al. 1989). No 
data were found in the available literature on the amounts of 2-butoxyethanol or 2-butoxyethanol acetate 
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5.1 OVERVIEW 
2-Butoxyethanol has been identified in at least 20 of the 1,430 current or former EPA NPL hazardous wastes 
sites (HazDat 1996). However, the number of sites evaluated for 2-butoxyethanol is not known. The 
frequency of these sites within the United States can be seen in Figure 5-l. 
2-Butoxyethanol acetate has not been identified in any of the 1,430 current or former EPA NPL hazardous 
wastes sites (HazDat 1996). However, the number of sites evaluated for 2-butoxyethanol acetate is not 
known. 
2-Butoxyethanol and 2-butoxyethanol acetate do not occur naturally. Little quantitative information was 
found in the available literature characterizing the release of these chemicals to the environment. 2-Butoxyethanol 
and 2-butoxyethanol acetate may be released to air, water, or soil from facilities where they are 
manufactured or processed. However, information about the release of 2-butoxyethanol is not available in the 
TRI database because the database contains such information only for the general toxic chemical category of 
glycol ethers and not for specific glycol ethers (EPA 1995). No information is available in the TRI database 
on the amount of 2-butoxyethanol acetate released to air, water, or soil by facilities that manufacture or 
process this compound because this compound is not included under SARA, Title III, and therefore, is not 
among the chemicals that facilities are required to report (EPA 1995). 
2-Butoxyethanol and 2-butoxyethanol acetate may also be released to the environment from facilities that use 
these chemicals in the production of other materials, including resins, lacquers, varnishes, enamels, dry-cleaning 
compounds, soap, emulsifying agents, inks, and (to a minor extent) herbicides. These chemicals may 
also be directly released to the atmosphere by evaporation during the use of these products in occupational or 
household settings. There is a potential for atmospheric release of 2-butoxyethanol and 2-butoxyethanol 
acetate from hazardous waste sites; however, no data were found in the available literature. 2-Butoxyethanol 
is released to water via leachates from municipal landfills and hazardous waste sites (Dunlap et al. 1976a, 
1976b; Stonebreaker and Smith 1980). It has been detected in surface water samples at 2 of the 20 NPL sites 
and in groundwater in samples at 7 of the 20 NPL sites where 2-butoxyethanol has been detected in some 
environmental media (HazDat 1996). It may also be directly released to air, soil, and plants during application 
of herbicides that contain this chemical and to surface water when sprayed in excessive amounts or drift occurs 
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(Dow 1993). 2-Butoxyethanol is also released to soil at hazardous waste sites. It has been detected in the soil 
samples at 3 of the 20 NPL sites and in sediment samples at 1 of the 20 NPL sites where this compound has 
been found in some environmental media (HazDat 1996). No information was found on detection of 
2-butoxyethanol acetate in surface water, groundwater, or soil at any NPL hazardous waste sites. 
Information on the transport and partitioning of 2-butoxyethanol and 2-butoxyethanol acetate is derived 
primarily from their physical and chemical properties (see Table 3-3 and 3-4). Any 2-butoxyethanol or 
2-butoxyethanol acetate in the atmosphere would be almost exclusively in the vapor phase (Eisenreich et al. 
198 1). They may be partitioned to soil and water by wet or dry deposition, with wet deposition 
predominating. Because of the relatively short atmospheric half-lives (<1 day) of these chemicals, they are not 
transported long distances in the atmosphere (Grosjean 1990; Howard 1993). Both 2-butoxyethanol and 
2-butoxyethanol acetate volatilize only slowly from water, with the rate of volatilization somewhat slower for 
2-butoxyethanol (Thomas 1990). These compounds remain in water primarily in the dissolved state with very 
little partitioning to suspended solids and sediment; the amount removed by sorption is somewhat higher for 
2-butoxyethanol acetate than for 2-butoxyethanol (Swann et al. 1983). Based on bioconcentration factors 
(BCFs) estimated from quantitative structure-activity relationships (ASTER 1995a, 1995b), bioconcentration 
in aquatic organisms is not a significant process for either 2-butoxyethanol or 2-butoxyethanol acetate. 
Neither compound is expected to biomagnify in the food chain. The partitioning of 2-butoxyethanol and 
2-butoxyethanol acetate from moist and dry soil to the atmosphere by volatilization is negligible. Both 
compounds are mobile in soil and leach to groundwater, with 2-butoxyethanol expected to leach more readily 
than 2-butoxyethanol acetate (Swann et al. 1983). 
The most significant chemical reaction of 2-butoxyethanol or 2-butoxyethanol acetate in air is with 
photochemically generated hydroxyl radicals. Estimated atmospheric half-life values for 2-butoxyethanol 
range from 3.28 to 32.8 hours (Grosjean 1990; Howard et al. 1991). The atmospheric half-life value for 
2-butoxyethanol acetate has been estimated to be approximately 18 hours (Grosjean 1990). The products of 
reaction of 2-butoxyethanol and 2-butoxyethanol acetate with hydroxyl radicals have not been identified. 
Neither photolysis nor reaction with ozone or nitrate radicals is an important atmospheric traniformation 
process for these compounds (Grosjean 1990; Howard 1993). Aerobic biodegradation appears to be the most 
important transformation process for both 2-butoxyethanol and 2-butoxyethanol acetate in water (Dow 1993; 
Price et al. 1974; Waggy et al. 1994; Zahn and Wellens 1980), with the biodegradation half-life of 2-butoxyethanol 
in natural bodies of surface waters estimated to be in the range of 7-28 days (Howard et al. 199 1). 
The intermediate products of aerobic biodegradation of 2-butoxyethanol and 2-butoxyethanol acetate have not 
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been identified. However, by analogy with enzymatic degradation products found in human and animal 
studies, both compounds may be degraded to carbon dioxide and water via 2-butoxyacetic acid (Ghanayem et 
al. 1987c; Johanson et al. 1988). Neither direct photolysis nor hydrolysis is an important transformation 
process for these compounds in water (ASTER 1995a, 1995b; Harris 1990; Howard 1993). Because fugacity 
models predict that <1% of these compounds will partition into soil (ASTER 1995a, 1995b), little research 
has been conducted to determine their fate in this medium. By analogy with the fate of 2-butoxyethanol and 
2-butoxyethanol acetate in water, it is possible that aerobic biodegradation may be the most important 
transformation process for these compounds in soil and sediment, with the rate of aerobic biodegradation 
decreasing with increasing depth (i.e., decreasing availability of oxygen). Consequently, both compounds may 
persist longer in deeper soils and sediments. 
Except for occupational settings, data on levels of 2-butoxyethanol or 2-butoxyethanol acetate in the 
environment are very limited. Little information was found in the available literature on concentrations of 
2-butoxyethanol in ambient air, surface water, sediment, or soil in the United States. In indoor air, 2-butoxyethanol 
has been found at an average concentration of 0.214 ppb volume per volume (v/v) (1.03 c(g/ m3) (Shah 
and Heyderdahl 1988; Shah and Singh 1988). 2-Butoxyethanol has been found at a concentration of 23 µg /L 
in one surface water sample collected near the Valley of the Drums, Kentucky (Stonebreaker and Smith 1980). 
2-Butoxyethanol has also been detected in one groundwater sample collected beneath a municipal landfill; 
however, the concentration was not reported (Dunlap et al. 1976a, 1976b). 2-Butoxyethanol has also been 
found in drinking water in six U.S. cities and in finished water from advanced waste treatment plants in six 
U.S. cities; however, no concentrations were reported (Lucas 1984). In other environmental media, 2-butoxy­
ethanol has been found in waste water effluents at concentrations up to 100 µg /L (Jungclaus et al. 1976). No 
information was found in the available literature on concentrations of 2-butoxyethanol acetate in ambient or 
indoor air; surface water, groundwater, or drinking water; or sediment or soil. There may be a potential for 
contamination of food with 2-butoxyethanol and 2-butoxyethanol acetate from labeling and packaging 
materials or processing activities (FDA 1993a, 1993b, 1993c) or from the minor use of herbicides containing 
2-butoxyethanol (Dow 1993; Leaf 1985 as cited in NIQSH 1990); however, no information was found in the 
available literature on detection of these compounds in food. It should be noted that the amounts of 2-butoxy­
ethanol and 2-butoxyethanol acetate found by chemical analysis are not necessarily the amounts that are 
bioavailable. 
The general population is exposed to 2-butoxyethanol and 2-butoxyethanol acetate primarily via inhalation or 
dermal absorption during use of common household products containing this compound as a solvent (see 
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Section 4.3). Non-occupational exposures to 2-butoxyethanol may also occur via ingestion of contaminated 
drinking water supplies (Lucas 1984). 
Occupational exposures to 2-butoxyethanol and 2-butoxyethanol acetate also occur primarily via inhalation or 
dermal absorption. Estimates from the National Occupational Exposure Survey (NOES) conducted by the 
National Institute of Occupational Safety and Health (NIOSH) indicate that from 1981 to 1983 more than 
2 million workers were potentially exposed to 2-butoxyethanol, and more than 150,000 workers were 
potentially exposed to 2-butoxyethanol acetate (NIOSH 1989b). In addition to occupational exposures related 
to the production, processing, or handling of these chemicals, workers may be exposed to 2-butoxyethanol and 
2-butoxyethanol acetate in a wide variety of occupations in which products containing these compounds are 
used. These occupations include janitors.and cleaners, painters, mechanics, nurses and health aids, 
construction workers, printing machine operators, and furniture and wood finishers. 
5.2 RELEASES TO THE ENVIRONMENT 
5.2.1 Air 
2-Butoxyethanol may be released to the atmosphere via emissions or effluents at sites where it is 
manufactured, processed, or used in the production of a wide variety of other materials (see Sections 4.1 and 
4.3). These products include nitrocellulose resins, spray and quick drying paints and lacquers, varnishes, 
enamels, dry cleaning compounds, varnish and textile spot removers (in printing and dyeing), soap solutions, 
cosmetics, window cleaning agents, and emulsifying agents (Appelt 1990; Lewis 1993; NIOSH 1990; Rowe 
and Wolf 1982; Vincent et al. 1993); silicone caulk (Tichenor and Mason 1988); and herbicides (Dow 1993; 
BPA 1993b; Leaf 1985 as cited in NIOSH 1990). 2-Butoxyethanol may also be directly released to the 
atmosphere by evaporation during the use of these products. 
Similarly, 2-butoxyethanol acetate may be released to the atmosphere via emissions or effluents at sites where 
it is manufactured, processed, or used in the production of paints, lacquers, thinners, inks, resins, and other 
materials (Lewis 1993; NIOSH 1990) (see Sections 4.1 and 4.3). It may also be directly released to the 
atmosphere by evaporation during the use of these products. The atmospheric emission rate of 2-butoxyethanol 
acetate (Butyl Cellosolveacetate) from painting operations at a Janesville, Wisconsin, automobile 
assembly facility was estimated at 13.3 liters/hour (3.5 gallons/hour) (Sexton and Westberg 1980). 
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No information is available in the TRI database on the amount of 2-butoxyethanol released to the atmosphere 
by facilities that manufacture or process this compound because the database contains such information only 
for the general toxic chemical category of glycol ethers and not for specific glycol ethers (EPA 1995). No 
information is available in the TRI database on the amount of 2-butoxyethanol acetate released to the 
atmosphere by facilities that manufacture or process this compound because this compound is not included 
under SARA, Title III; it is therefore not among the chemicals that facilities are required to report (EPA 1995). 
There is a potential for atmospheric release of 2-butoxyethanol and 2-butoxyethanol acetate from hazardous 
waste sites. However, no information was found on detection of these chemicals in air at any NPL hazardous 
waste sites (HazDat 1996). 
5.2.2 Water 
2-Butoxyethanol and 2-butoxyethanol acetate may be released to water by facilities that manufacture, process, 
or use these compounds in the production of other materials (see Sections 4.1 and 4.3). Information on 
releases to water from facilities that manufacture or process 2-butoxyethanol is not available in the TRI 
database because the database contains such information only for the general toxic chemical category of glycol 
ethers and not for specific glycol ethers (EPA 1995). No information is available in the TRI database on the 
amount of 2-butoxyethanol acetate released to water by facilities that manufacture or process this compound 
because this compound is not included under SARA, Title III; it is therefore not among the chemicals that 
facilities are required to report (EPA 1995). 
2-Butoxyethanol may be released to water in leachates from municipal landfills and hazardous waste sites 
(Dunlap et al. 1976a, 1976b; Stonebreaker and Smith 1980). 2-Butoxyethanol has been detected in surface 
water samples at 2 of the 20 NPL sites and in groundwater samples at 7 of the 20 NPL sites where 2-butoxy-ethanol 
has been detected in some environmental medium (HazDat 1996). No information was found on 
detection of 2-butoxyethanol acetate in surface water or groundwater at any NPL hazardous waste sites 
(HazDat 1996). 
2-Butoxyethanol may also be directly released to surface water when excessive amounts are sprayed or drift 
occurs during application of herbicides that contain this compound (Dow 1993). Direct release of 
2-butoxyethanol to surface water may also occur during outdoor use of consumer products that contain this 
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5.2.3 Soil 
2-Butoxyethanol and 2-butoxyethanol acetate may be released to soil by facilities that manufacture, process, 
or use these compounds in the production of other materials (see Sections 4.1 and 4.3). Information on 
releases to soil from facilities that manufacture or process 2-butoxyethanol is not available in the TRI database 
because the database contains such information only for the general toxic chemical category of glycol ethers 
and not for specific glycol ethers (EPA 1995). No information is available in the TRI database on the amount 
of 2-butoxyethanol acetate released to soil by facilities that manufacture or process this compound because 
this compound is not included under SARA, Title III and therefore, is not among the chemicals that facilities 
are required to report (EPA 1995). 
2-Butoxyethanol and 2-butoxyethanol acetate may also be released to the soil and sediment at hazardous waste 
sites. 2-Butoxyethanol has been detected in soil samples at 3 of the 20 NPL sites and in sediment samples at 1 
of the 20 NPL sites where this compound has been found in some environmental medium (HazDat 1996). No 
information was found on detection of 2-butoxyethanol acetate in soil or sediment at any NPL hazardous 
waste sites (HazDat 1996). 
2-Butoxyethanol may also be directly released to soil during application of herbicides that contain this 
compound (Dow 1993). Direct release of 2-butoxyethanol to soil may also occur during outdoor use of 
consumer products that contain this chemical (e.g., liquid cleaners, varnishes, paints); however, these releases 
are not expected to be significant. 
5.3 ENVIRONMENTAL FATE 
5.3.1 Transport and Partitioning 
The vapor pressure of 2-butoxyethanol is 0.76 mm Hg at 20°C (HSDB 1995; Lewis 1993) and 0.88 mm Hg 
at 25°C (Dow 1993). The vapor pressure of the acetate is 0.375 mm Hg at 20°C (HSDB 1995; Weber et al. 
1981). Based on these vapor pressures, both compounds would be present almost exclusively in the vapor 
phase in the atmosphere (Eisenreich et al. 198 1). Compounds in the vapor phase are transported from the 
atmosphere to land and water by both wet deposition (via rain and snow scavenging) and dry deposition (via 
vapor exchange across the water and soil surfaces during impaction) (Bidleman 1988). Physical transport by 
wet deposition of both compounds is more important than transport arising from dry deposition since both 
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compounds are water soluble. The rate of transport of the compounds from one point to another point in the 
atmosphere will determine their ability to participate in long-distance transport. The longer the persistence 
time (or half-life) of a chemical in the atmosphere, the farther it is transported in air. The half-life of both 
chemicals is <1 day (see Section 5.3.2.1), indicating that neither is transported long distances in the air. 
The unitless air/water partition coefficient or Henry’s law constant (H) for 2-butoxyethanol in a 0.3M sodium 
chloride solution is 1.42x10-4 at 37°C (Johanson and Dynesius 1988). Conversion of this unitless value to the 
units commonly used for H (Thomas 1990) gives a value of 3.61x10-6  atm- m3/mol. Other values ranging from 
2.08x10-8  (HSDB 1995; SRC 1994) to 5.44x10-6  atm- m3/mol (ASTER 1995a) for 2-butoxyethanol in water 
at 25 ºC have been estimated. Values of H ranging from 6.74x10-7  to 1.56x10-5  atm- m3/mol (ASTER 1995b; 
Howard 1993; SRC 1994) have been estimated for 2-butoxyethanol acetate. Based on volatility 
characteristics associated with H (Thomas 1990), the volatilization of both compounds from water is slow, 
with the volatility of 2-butoxyethanol being somewhat less than that of the acetate. Based on estimated Koc 
values of 62 and 186 for 2-butoxyethanol and 2-butoxyethanol acetate, respectively (ASTER 1995a, 1995b), 
the concentrations of both compounds are expected to be higher in water primarily in the dissolved state. Very 
little would be expected to partition into suspended solids and sediment in water, although 2-butoxyethanol 
acetate would be adsorbed to suspended solids and sediment to a greater extent than would 2-butoxyethanol 
(Swarm et al. 1983). 
From quantitative structure-activity relationships, the bioconcentration factors (BCFs) for 2-butoxyethanol 
and 2-butoxyethanol acetate in fathead minnows (Pimephales promelas) have been estimated to be 2 and 9, 
respectively (ASTER 1995a, 1995b). Therefore, bioconcentration of either compound in aquatic organisms is 
not important. No information was located that would suggest that either compound biomagnifies in the food 
chain. This is not surprising, considering that the low Kow values (see Tables 3-3 and 3-4) indicate low 
probability of lipid uptake. 
Mackay Level 1 modeling was used to estimate the distribution of 2-butoxyethanol in various environmental 
compartments (air, soil, water, biota, suspended solids, sediment) (Staples 1997). The model uses physical 
properties (aqueous solubility, vapor pressure, soil and sediment distribution coefficient, biota concentration 
factor) and the assumption that environmental compartments are approximately proportional in size to the 
natural environment. The model calculates the general distribution of 2-butoxyethanol following the release of 
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water, with <0.1%, 2%, <0.1 %, <0.1 %, and 2% found in air, soil, biota, suspended solids, and sediment, 
respectively. 
The transport of the two compounds from moist and dry soil to air via volatilization is negligible because of 
the low values for Henry’s law constant and vapor pressure. The estimated Koc values of 62 and 186 for 
2-butoxyethanol and 2-butoxyethanol acetate, respectively (ASTER 1995a, 1995b), suggest that both 
compounds would be mobile in soils and would leach from soil to groundwater, although the leachability of 
2-butoxyethanol is higher than that of 2-butoxyethanol acetate (Swann et al. 1983). 
5.3.2 Transformation and Degradation 
5.3.2.1 Air 
The direct photolysis of 2-butoxyethanol in the atmosphere is not important since it does not absorb sunlight 
available in the troposphere (Howard 1993; Silverstein and Bassler 1963). The reactivity of 2-butoxyethanol 
with three important atmospheric reactants produced by photochemical reactions was estimated from 
structure-reactivity relationships (Grosjean 1990). The rates of reaction of 2-butoxyethanol with ozone and 
nitrate radicals were estimated to be too slow to be important (Grosjean 1990). The reactions of ozone and 
nitrate radicals with 2-butoxyethanol acetate, will also be negligible. The rate constant for reaction of 
2-butoxyethanol with hydroxyl radicals has been estimated to range from 2.1 to 2.3x10-11  cm3/molecule-set 
(Grosjean 1990; SRC 1995). If the average concentration of hydroxyl radicals during a 24-hour day is 
assumed to be 5x105 molecules/ cm3, the half-life (first order kinetics) for 2-butoxyethanol can be estimated to 
range from approximately 3.28 to 32.8 hours (Grosjean 1990; Howard et al. 1991; Lyman 1990; SRC 1995). 
Therefore, 2-butoxyethanol does not persist in the atmosphere. Based on a structure-reactivity relationship 
method (Atkinson 1987), the rate constant for the reaction of 2-butoxyethanol acetate with hydroxyl radicals 
in the atmosphere was estimated to be 2.1x10-11 cm3/molecule-set (Howard 1993; SRC 1995). Assuming an 
average (24-hour) day hydroxyl radical concentration of 5x105  molecules/ cm3, the half-life (first order 
kinetics) for this reaction is approximately 18 hours (Grosjean 1990; Lyman 1990; SRC 1995). Therefore, 
2-butoxyethanol acetate also does not persist in the atmosphere. The products of reaction of 2-butoxyethanol 
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5.3.2.2 Water 
Functional groups in both alcohols and ethers are generally resistant to hydrolysis (Harris 1990). Therefore, 
hydrolysis of 2-butoxyethanol, which contains both alcohol and ether functional groups, is not expected. The 
estimated hydrolysis half-life (first order kinetics) for 2-butoxyethanol acetate of >1,000 days (ASTER 1995a) 
indicates that the hydrolysis of 2-butoxyethanol acetate in water is also not expected. 2-Butoxyethanol does 
not absorb light of wavelength >290 nm (Silverstein and Bassler 1963). Therefore, photolysis of this 
compound by absorption of sunlight is not important. Aerobic biodegradation screening studies with filtered 
sewage for inocula and theoretical biological oxygen demand (BODT) as a measure of complete 
biodegradation (mineralization of the compound to carbon dioxide and water) indicated 5% mineralization of 
2-butoxyethanol in 5 days (Dow 1993), 57-74% in 10 days (Dow 1993; Price et al. 1974), and 72-88% in 
20 days (Dow 1993; Price et al. 1974). The Organization for Economic Cooperation and Development 
(GECD) recommends a closed bottle biodegradation test with settled sewage as microbial inoculum for 
determining the biodegradation potential of organic chemicals. The biodegradation of 2-butoxyethanol was 
determined using the OECD test procedure, to be 47% in 5 days, 70% in 15 days, and 75% in 28 days (Waggy 
et al. 1994). Thus, the tests used both in the United States and in Europe to determine the biodegradation 
potential of organic chemicals indicate that 2-butoxyethanol is readily biodegradable. The aerobic 
biodegradation half-life (first order kinetics) of 2-butoxyethanol in natural bodies of surface water has been 
estimated to be in the range of 7-28 days, compared to an estimated aqueous anaerobic biodegradation halflife 
(first order kinetics) ranging from 28 days to 16 weeks (Howard et al. 1991). Hydrolysis is not likely to be 
an important transformation mechanism for 2-butoxyethanol (ATSDR 1995b). The biodegradation half-life 
(first order kinetics) of 2-butoxyethanol in groundwater has been estimated to range from 14 days to 8 weeks, 
based on the estimated aerobic biodegradation (unacclimated aqueous) half-life for this compound (Howard et 
al. 1991). The intermediate products of aerobic biodegradation of 2-butoxyethanol were not identified in any 
of the screening tests. However, as observed in human and animal studies (Johanson et al. 1989), 2-butoxy-ethanol 
acetate may enzymatically hydrolyze to 2-butoxyethanol and acetic acid as a result of biodegradation. 
By analogy to animal metabolism (Ghanayem et al. 1987c)< it is possible that any 2-butoxyethanol formed 
may undergo further enzymatic oxidation (e.g., via dehydrogenase) to the butoxyacetaldehydeand finally to 2­
butoxyacetic acid before being degraded to carbon dioxide and water. 
Biodegradation studies were conducted using the Zahn-Wellens screening test (a batch method in which 
biodegradation by activated sludge is determined indirectly by measurement of chemical oxygen demand 
and/or dissolved organic carbon removal). This study indicated that under the test conditions, the 
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biodegradation of 2-butoxyethanol acetate was 90% within 6.5 days, with a degradation rate of 12% per day 
as determined by measurement of chemical oxygen demand (Zahn and Wellens 1980). No lag period was 
observed for onset of biodegradation in the Zahn-Wellens test. Therefore, the acetate will biodegrade easily in 
natural bodies of surface water, but no estimate of biodegradation half-life was located in the literature. 
5.3.2.3 Sediment and Soil 
On the basis of a fugacity model, it has been estimated that 2-butoxyethanol partitions into different 
environmental compartments as follows: 15.98% into air, 0.05% into soil, 83.93% into water, and 0.04% into 
sediment (ASTER 1995a). 2-Butoxyethanol acetate partitions differently into environmental compartments as 
follows: 35.1% into air, 0.26% into soil, 64.37% into water, and 0.24% into sediment (ASTER 1995b). 
Neither compound was predicted to partition into suspended solids or aquatic biota (ASTER 1995a, 1995b). 
Because of these low partition probabilities into soil and sediment, little research effort has been made to 
elucidate the fate of either compound in these media. As discussed in Section 5.3.2.2, 2-butoxyethanol does 
not have any chromophoric group to absorb sunlight incident on the terrestrial surface. Therefore, photolysis 
of 2-butoxyethanol present in moist soil is not likely. Drawing an analogy from water (see Section 5.3.2.2), it 
can be concluded that, barring any catalytic effect by component(s) in moist soil or sediment, hydrolysis of 
2-butoxyethanol or 2-butoxyethanol acetate is not significant. Aerobic screening studies in water (see Section 
5.3.2.2) suggest that aerobic biodegradation is the most important transformation process for both compounds 
in soil and sediment. The aerobic biodegradation half-life (first order kinetics) of 2-butoxyethanol in soil has 
been estimated to be 7-28 days (Howard et al. 1991). However, for some soils, as the availability of oxygen 
decreases with the increase in depth of soil or sediment, the rate of aerobic biotransformation of both 
compounds decreases. Therefore, both compounds may persist longer in deeper soils and sediments. By 
direct analogy to estimates of aqueous biodegradation rates (Howard et al. 199 l), the rate of anaerobic 
biodegradation of 2-butoxyethanol in soil may be on the order of 4 times slower than aerobic biodegradation 
(half-life estimates range from 4 to 16 weeks). 
5.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT 
5.4.1 Air 
Information on levels of 2-butoxyethanol in air is very limited. 2-Butoxyethanol was reported among 
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however, no concentrations were given (Welch and Watts 1990). Analysis of data from the National Ambient 
Volatile Organic Compounds (VOCs) Database indicates that, for 14 samples, the daily arithmetic mean and 
median indoor atmospheric concentrations of 2-butoxyethanol in a non-industrial office setting were 
0.214 ppb (v/v) (1.03 µg /m3) and 0.075 ppb (0.36 µg /m3), respectively (Shah and Heyderdahl 1988; Shah and 
Singh 1988). 2-Butoxyethanol was found in only 1 of 6 samples of indoor air from 14 homes in northern 
Italy, at a concentration of 1.7 ppb (8 µg /m3) (DeBortoli et al. 1986). 
No information was found in the available literature on concentrations of 2-butoxyethanol acetate in air. 
5.4.2 Water 
Very little information was found in the available literature on concentrations of 2-butoxyethanol in water. 
2-Butoxyethanol was detected at a concentration of 23 µg /L in 1 of 7 surface water samples collected in 1979 
near The Valley of the Drums, Kentucky, where an estimated 100,000 drums of industrial waste were stored, 
buried, or dumped between 1967 and 1977 (Stonebreaker and Smith 1980). In Japan, 2-butoxyethanol has 
been found at concentrations of 1,310 and 5,680 ppb ( µg/L) in surface water from the Hayashida River 
(Uasuhara et al. 1981). The contamination was attributed to effluents from the leather industry. 2-Butoxyethanol 
has also been found in one groundwater sample from an aquifer beneath a municipal landfill in 
Norman, Oklahoma (concentration not given) (Dunlap et al. 1976a, 1976b). 2-Butoxyethanol was identified 
as a contaminant in drinking water in Cincinnati, Ohio; Philadelphia, Pennsylvania; Miami, Florida; New 
Orleans, Louisiana; Ottumwa, Iowa; and Seattle, Washington. It was also found in finished water from 
advanced waste treatment plants in Pomona, Escondido, Lake Tahoe, and Orange County, California; Dallas, 
Texas; and Washington, DC. Concentrations were not reported (Lucas 1984). 
Library searching of mass spectral data from water and soil samples from U.S. hazardous waste sites taken 
between late 1987 and mid-1989 identified 2-butoxyethanol in 110 samples (Eckel et al. 1996). The total 
number of samples examined was not stated, and the study authors indicate that these data represent minimum 
occurrences. Although the medium in which the compound was found was not indicated, the properties of 2­
butoxyethanol led the study authors to suggest that it was most likely to have been found in water. Among the 
glycol ethers and related compounds for which the study authors searched, 2-butoxyetbanol was found most 
frequently. Ethylene glycol mono acetate and tripropylene glycol monoethyl ether, were the second and third 
most frequently identified chemicals. 
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No information was found in the available literature on the concentrations of 2-butoxyethanol acetate in 
surface water, groundwater, or drinking water. 
5.4.3 Sediment and Soil 
No information was found in the available literature on concentrations of 2-butoxyethanol or 2-butoxyethanol 
acetate in sediment or soil. 
5.4.4 Other Environmental Media 
2-Butoxyethanol was found in waste water from a tire plant at an approximate concentration of 
0.03 (±0.009) mg/L (Jungclaus et al. 1976). The detection of 2-butoxyethanol in groundwater underlying a 
municipal landfill site suggests that this compound may be present in landfill leachates (Dunlap et al. 1976a, 
1976b). 
In the 1970s, it was estimated that more than 740 products marketed in the United States contained 2-butoxy­
ethanol, at an average concentration of 2.8%; approximately half of these were products for household use 
(Consumer Products Safety Commission 1977). In a 1978-l 982 survey in the Federal Republic of Germany, 
both 2-butoxyethanol and 2-butoxyethanol acetate were found to occur in 0.4% of 275 different organic 
solvents commonly used for inks, degreasers, paints, and thinners (concentrations not reported) (Lehmann et 
al. 1986). A paint stripping formulation was found to contain 35% 2-butoxyethanol (Hahn and Werschulz 
1986), whereas the concentration of 2-butoxyethanol in four different paint thinners was found to range from 
0%(3 samples) to 5% (w/w) (1 sample) (Yamano et al. 1991). 2-Butoxyethanol has also been found as a 
volatile organic emission from silicone caulk (Ticbenor and Mason 1988). An epoxy resin contained 7% 
solvents (2-butoxyethanol, xylene, and methyl-n-amyl ketone) (Rempel et al. 1991). While not detected in a 
machine cutting fluid prior to use, 2-butoxyethanol was found in the used fluid at a concentration of 
0.060 µg /g (60 ppb) (Yasuhara et al. 1986). In a recent survey in France of 1,242 cleaning agent 
formulations, 10% of the formulations contained 2-butoxyethanol (concentration range, 0.2-80% by volume); 
approximately 50% of window-cleaning agent formulations tested contained 2-butoxyethanol (concentration 
range, l-30% by volume) (Vincent et al. 1993). The concentration of 2-butoxyethanol in aqueous coating 
systems may vary between 2% and 5%, depending on the formulation (Appelt 1990). The concentration of 
2-butoxyethanol acetate used as a retarder solvent m coating formulations is generally l-5% by volume (Leaf 
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No information was found in the available literature on concentrations of 2-butoxyethanol or 2-butoxyethanol 
acetate in food. The estimated BCFs of 2-butoxyethanol and 2-butoxyethanol acetate of only 2 and 9, 
respectively, in fathead minnows (Pimephales promelaas) (ASTER 1995a, 1995b), and the evidence against 
biomagnification of these compounds in the food chain (see Section 5.3.1), indicate that these compounds 
would not be present in most foods. There is a potential for contamination of food with these compounds, 
however, from labeling, packaging, and processing activities Both 2-butoxyethanol and 2-butoxyethanol 
acetate are indirect food additives that may be used as components of adhesives (FDA 1993a). 2-Butoxyethanol 
may also be used as a solvent in materials intended for packaging, transporting, holding, or otherwise 
contacting dry food (FDA 1993b). 2-Butoxyethanol may also be used in washing or to assist in the peeling of 
fruits and vegetables with lye, and in flume water (at concentrations not to exceed 1 µg /rnL) for washing sugar 
beets (FDA 1993c). There may also be a potential for contamination of plant foods from the minor use of 
herbicides containing 2-butoxyethanol (Dow 1993; EPA 1993b; Leaf 1985 as cited in NIOSH 1990). A 
scheme that considered factors such as production volume, pattern of usage, possible fate in the environment, 
likelihood of the chemical entering the food chain, mechanism of entry into the food chain, persistence and 
accumulation in the food chain, and toxicity, was used to prioritize chemicals for their potential to contaminate 
food. A low priority score was obtained for 2-butoxyethanol on the basis of this scheme (Wearne et al. 1996). 
Among the 70 chemicals ranked, it was ranked lower than 45 chemicals, higher than 8 chemicals, and was 
given the same ranking as 16 other chemicals. 
5.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE 
The general population is exposed to 2-butoxyethanol primarily by inhalation of vapors or dermal absorption 
during use of common household products that contain this compound as a solvent. At room temperature, 
2-butoxyethanol is a liqluid with a relatively low vapor pressure (see Table 3-3) and is readily absorbed 
through the skin (Bartnik et al. 1987; Dugard et al. 1984; Johanson 1988; Johanson and Boman 1991; 
Johanson et al. 1988, 1989; NIOSH 1990). Therefore, dermal absorption may be the primary route of 
exposure in cases where protective gloves or other clothing are not worn when using products containing 
2-butoxyethanol. It was estimated that approximately half of the more than 740 products 
containing 2-butoxyethanol that were marketed in the United States in the 1970s were intended for household 
use. The average concentration of 2-butoxyethanol in these products was 2.8% (Consumer Products Safety 
Commission 1977). Common household products that contain glycol ethers include acrylic polymers, paints, 
brake fluids, waxes, cleaning agents, shampoos, degreasing agents, wood finishes, and silicone caulks (Appelt 
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Similarly, the widespread use of 2-butoxyethanol acetate as a solvent in a wide variety of household products 
such as inks, stains, paints, lacquers, varnishes, thinners, and degreasers (Lehmann et al. 1986; Lewis 1993; 
NIOSH 1990) can result in general population exposure through inhalation of vapors and dermal absorption. 
Non-occupational exposures to 2-butoxyethanol may also occur via ingestion, particularly among populations 
with contaminated drinking water supplies (Lucas 1984). 
No quantitative information was found in the available literature on general population exposures to 2-butoxy­
ethanol or 2-butoxyethanol acetate in the United States. 
Occupational exposures to 2-butoxyethanol and 2-butoxyethanol acetate occur via both inhalation of vapors 
and dermal absorption (Angerer et al. 1990; Johanson et al. 1989; Sohnlein et al. 1993; Vincent et al. 1993, 
1996). Because these compounds are liquids at room temperature with relatively low vapor pressures (see 
Tables 3-3 and 3-4), and are readily absorbed through the skin (Bartnik et al. 1987; Dugard et al. 1984; 
Johanson 1988; Johanson and Boman 1991; Johanson et al. 1988,1989; NIOSH 1990), dermal absorption 
may be predominant or may contribute significantly to overall exposure. Absorption from excessive contact 
with skin and eyes may occur, particularly when proper protective clothing is not worn. 
OSHA requires employers of workers who are occupationally exposed to 2-butoxyethanol to maintain 
employee exposure at or below the permissible exposure limit (PEL) of 50 ppm (OSHA 1974). The American 
Conference of Governmental Industrial Hygienists (ACGlH) has recommended a time-weighted average 
threshold limit value (TWA-TLV) of 25 ppm for occupational exposure to 2-butoxyethanol (ACGIH 1994). 
The National Institute of Occupational Safety and Health (NIOSH) has set recommended exposure limits 
(RELs) of 5 ppm for both 2-butoxyethanol and 2-butoxyethanol acetate (NIOSH 1990, 1992). The REL is 
expressed as a time-weighted average (TWA) exposure for up to 10 hours per day over a 40-hour work week. 
These standards were set taking into account that airborne or direct exposure by the cutaneous route 
contributes to overall exposure. The NIOSH RELs prohibit direct dermal contact because 2-butoxyethanol 
and 2-butoxyethanol acetate are readily absorbed through the skin (NIOSH 1990). 
Data from the National Occupational Exposure Survey (NOES) conducted by NIOSH from 1980 to 1983 
indicate that an estimated 2,139,292 workers in 2,259 industry/occupation categories were potentially exposed 
to 2-butoxyethanol in the United States from 1981 to 1983, and an estimated 150,892 workers in 
236 industry/occupation categories were potentially exposed to 2-butoxyethanol acetate (NIOSH 1989b). 
These numbers do not include workers potentially exposed to trade-name compounds that contain 2-butoxy­
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ethanol or 2-butoxyethanol acetate. Occupations with the greatest potential for exposure to 2-butoxyethanol 
included janitors and cleaners; nurses and health aides; hairdressers and cosmetologists; printing, spray 
painting, metal plating, laundry, dry cleaning, and textile sewing-machine operators; electricians; mining 
workers; heating, air conditioning, and refrigeration mechanics; electrical power installers and repairers; bus, 
truck, aircraft, and stationary-engine mechanics; garage and service-station workers; miscellaneous food-
preparation workers; plumbers, pipefitters, and steam fitters; automobile mechanics; clinical laboratory 
technologists and technicians; motor-vehicle assemblers; funeral directors; vehicle washers and equipment 
cleaners; painters; construction workers; telephone installers and repairers; and furniture and wood-finishers. 
Occupations with the greatest potential for exposure to 2-butoxyethanol acetate included wood-furniture 
assemblers and finishers; mining, textile sewing, spray painting, printing, and miscellaneous machine 
operators; secretaries; janitors and cleaners; automobile-body and related repairers; painters; construction 
workers; and heavy-equipment, bus, truck, and stationary engine mechanics (NIOSH 1989b). 
A survey of chemical exposure in the workplace in Denmark estimated that there were a total of 
55,000 exposures to 2-butoxyethanol in 1989 (Brandorff et al. 1995). The industry groups in which 
exposures occurred were as follows: the manufacture of fabricated metal parts; electrical machinery and 
apparatus; the manufacture of transport equipment; painters and carpenters; construction, publishing, and 
printing; wholesale trade; the manufacture of textiles and leather; the manufacture of wood and furniture; the 
manufacture of chemicals; the manufacture of paints, petroleum, and bitumen products; the manufacture of 
non-metallic mineral products; the manufacture of precision and optical instruments; the manufacture of 
plastic; boat building and repair; personal services, cleaning, and hair dressing; sewage and refuse disposal; 
agriculture, hunting, and forestry; and health services and pharmacies. 
There is rather extensive information in the available literature documenting occupational exposures to 
2-butoxyethanol. Extremely low exposures have been reported for non-industrial office settings. Data from 
the National Ambient VOCs database indicate that for 14 samples from non-industrial offices, the daily mean 
and median indoor atmospheric concentrations of 2-butoxyethanol were 0.2 14 ppb (v/v) (1.03 µg / m3) and 
0.075 ppb (0.36 µg /m3), respectively (Shah and Heyderdahl 1988; Shah and Singh 1988). Higher levels of 
exposure have been found in other occupational settings. Representative information on inhalation exposures 
of 2-butoxyethanol in various occupations in the United States is summarized in Table 5-l. These data 
indicate that personal exposures above the NIOSH REL of 5 ppm (24 mg/ m3) have been found in silk 
screening, printing, furniture production, and asbestos/mastic removal, with maximum exposures of 36, 8.3, 
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legally enforceable standard for 2-butoxyethanol, is 50 ppm (242 mg/ m3) (OSHA 1974). A maximum 
exposure to 2-butoxyethanol acetate of 0.75 ppm (4.9 mg/ m3) was reported for workers in a screen printing 
operation in the United States (Clapp et al. 1984). No other reports of occupational exposure to 
2-butoxyethanol acetate in the United States were found in the available literature. 
Exposures to 2-butoxyethanol and 2-butoxyethanol acetate were also found in a 1983 survey of 336 Belgian 
businesses (Veulemans et al. 1987a). In this study, 2-butoxyethanol was found in 25 of 94 air samples from 
sites using printing pastes; 10 of 8 1 samples where painting was done; 1 of 20 samples from automobile 
repair shops; and 17 of 67 samples from various other industrial sites where materials such as varnishes, 
sterilization agents, and cleaning agents were used. The geometric mean atmospheric concentrations (mg/ m3) 
and ranges of 2-butoxyethanol at various sites were as follows: printing shops, 4.1 (0.8 ppm), range 1.5-17.7 
(0.3-3.7 ppm); painting areas, 18.8 (3.9 ppm), range 3.4-93.6 (0.7-19.4 ppm); automobile repair shops, 5.9 
(1.2 ppm) (one sample); various other industries, 8.5 (1.8 ppm), range 0.2-1,775 (<0.1-367 ppm). 2-Butoxy-ethanol 
acetate was found in 4 of 94 samples from sites using printing pastes, and in 3 of 67 samples from 
various other industrial sites using materials such as varnishes, sterilization agents, and cleaning agents. The 
geometric mean atmospheric concentrations (mg/m3) of 2-butoxyethanol acetate were 12.7 (2.6 ppm) at these 
sites using printing pastes and 10.6 (2.2 ppm) at other industrial sites, respectively; corresponding 
concentration ranges (mg/ m3) were 4.6-26.5 (1.0-5.5 ppm) and 8.9-11.7 (1.8-2.4 ppm). 
Veulemans et al. (1987b) also performed a field study of the urinary excretion of ethoxyacetic acid (EAA) 
during repeated daily exposure to the ethyl ether of ethylene glycol and the ethyl ether of ethylene glycol 
acetate. The urinary excretion of EAA was studied in a group of five women daily exposed to the ethyl ether 
of ethylene glycol and the ethyl ether of ethylene glycol acetate during 5 days of normal production and 7 days 
after a 12-day production stop. The workers were exposed to a complex solvent mixture containing different 
ethylene glycol derivatives, esters, alcohols, ketones, and trichloroethane. 2-Butoxyethanol (mean 
concentration of 3.3 mg/ m3; maximum concentration of 5.7 mg/ m3) was one of the chemicals that the workers 
were exposed to. 
In a survey of occupational exposure to glycol ethers in France that used both atmospheric and biological 
monitoring, the highest level of exposure to 2-butoxyethanol was among persons cleaning cars (Vincent et al. 
1996). The average concentration of 2-butoxyethanol in air was 1.8 ppm, with pre- and post-shift urinary 
concentrations of 2-butoxyacetic acid of 15.1 and 96.5 mg/g creatinine, respectively. The study authors 
indicated that exposure of these workers was predominantly by dermal absorption. 
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Based on measurements of air concentrations of 2-butoxyethanol in occupational settings and the levels found 
in consumer products, OECD (1997) has estimated mg/kg/day doses for various occupations and consumer 
activities. These dose estimates are presented in Table 5-2. Silk screening with a product containing 50% 2­
butoxyethanol resulted in the highest dose estimate (18.2 mg/kg/day), followed by cleaning with a product 
containing 30% 2-butoxyethanol (l3.7 mg/kg/day). Painting for 6 hours with a coating containing 1.5% 2­
butoxyethanol resulted in an estimated dose of 1.05 mg/kg/day. This report suggested that indirect exposure 
of the public to 2-butoxyethanol in the environment would be limited to the use of products containing 2­
butoxyethanol in public places. Because of the low volatility of 2-butoxyethanol and its high biodegradability, 
they concluded that exposure in the environment would be minimal. 
Because both 2-butoxyethanol and 2-butoxyethanol acetate are readily absorbed through the skin (Bartnik et 
al. 1987; Dugard et al. 1984; Johanson 1988; Johanson and Boman 1991; Johanson et al. 1988,1989; NIOSH 
1990; Truhaut et al. 1979), environmental monitoring of breathing zone or air concentrations in the work area 
of these substances generally is not adequate to assess overall exposures to these compounds. Biological 
monitoring of the toxic metabolite, 2-butoxyacetic acid, in urine is considered preferable (Angerer et al. 1990; 
Johanson 1988; Johanson et al. 1989; Sohnlein et aL 1993; Vincent et aJ. 1993). Methods are available for 
the determination of 2-butoxyethanol in blood and urine (Johanson et al. 1986a; Smallwood et al. 1984) (see 
Chapter 6); however, the utility of 2-butoxyethanol as a biomarker of exposure is limited because of its short 
half-life (40 minutes) in blood and the small portion of the absorbed dose (<0.03%) excreted unchanged in 
urine (Johanson et al. 1986a, 1988). In contrast, the half-life of urinary 2-butoxyacetic acid was reported to be 
5.77 hours after a controlled, 2-hour inhalation exposure to 2-butoxyethanol, with the amount of 
2-butoxyacetic acid excreted in urine corresponding to 15-55% of the absorbed dose of 2-butoxyethanol 
(Johanson et al. 1986a). 2-Butoxyethanol acetate is rapidly metabolized to 2-butoxyethanol in the body, also 
resulting in 2-butoxyacetic acid in urine (Johanson 1988; Johanson et al. 1989). Thus, 2-butoxyacetic acid 
provides a measure of exposure to both 2-butoxyethanol and its acetate. Conjugates of 2-butoxyacetic acid 
with glutamine in urine have also been measured as a biomarker of exposure to 2-butoxyethanol and 2-butoxy­
ethanol acetate; most exposed people excrete a combination of free and conjugated butoxyacetic acid 
(Rettenmeier et al. 1993; Sakai et al. 1994). The results of several recent studies evaluating o&upational 
exposures to 2-butoxyethanol and 2-butoxyetbanol acetate by environmental and biomonitoring are 
summarized below. 
Twelve workers in a varnish production facility were found to be exposed to 2-butoxyethanol at an average 
concentration of 1 .1 ppm (5.3 mg/ m3); individual exposures ranged from <0.1-8.1 ppm (<0.5-39 mg/ m3) 
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(Angerer et al. 1990). Internal exposure was estimated through biological monitoring of 2-butoxyethanol in 
blood and 2-butoxyacetic acid in urine, where average post-shift (end of work shift) concentrations of these 
compounds were found to be 121.3 µg /L. and 10.5 mg/L respectively. A markedly lower pre-shift (beginning 
of work shift) concentration of 2-butoxyacetic acid in the urine (3.3 mg/L) was reported. Most of the 
exposure was attributed to dermal absorption. 
In a study in Germany, 19 workers in the varnish production industry were evaluated for occupational 
exposures to glycol ethers on the first 2 days of the work week, after an exposure-free weekend (Sohnlein et al. 
1993). Urine samples of the workers were collected on the morning of the first day (preshift) and at the end of 
the second day (postshift). Daily mean concentrations of 2-butoxyethanol from personal air monitoring were 
0.5 ppm (2.4 mg/ m3) on the first day and 0.6 ppm (2.9 mg/ m3) on the second day; corresponding daily 
concentration ranges were <0. l-l .4 ppm (<0.5-6.8 mg/ m3) and <0. l-l.0 ppm (<0.5-4.8 mg/ m3). The mean 
urinary 2-butoxyacetic acid concentration was 0.2 mg/L on Monday pre-shift and 16.4 mg/L on Tuesday post-shift, 
with corresponding ranges of <0.02-l .3 mgL and 0.8-60.6 mg/L. Results of personal air monitoring 
were too low to account for the post-shift biological monitoring results, indicating the need to conduct 
biological monitoring to allow more reliable assessment of overall exposure to 2-butoxyethanol. 
Similar conclusions were drawn in a recent study conducted in France to evaluate the occupational exposures 
to 2-butoxyethanol of 16 cleaning women and 13 automobile cleaners using window cleaning agents (Vincent 
et al. 1993). Concentrations of 2-butoxyethanol in the window cleaning preparations used by these workers 
ranged from 0.9% to 21.2% by volume. Cleaners of new cars experienced the highest exposures, with time-
weighted average concentrations of 2-butoxyetbanol from personal samples ranging from <0.10 to 7.33 ppm 
(<0.5-35.4 mg/ m3). 2-Butoxyacetic acid concentrations in post-shift urinary samples ranged from <12.7 to 
371 mg/g creatinine, compared to a range of <2-98.6 mg/g creatinine in pre-shift samples; average 
2-butoxyacetic acid concentrations in post- and pre-shift minary samples ranged from <2 to 178 mg/g 
creatinine and from <2 to 34.7 mg/g creatinine, respectively. Average urinary 2-butoxyacetic acid 
concentrations for specific job categories correlated well with work practices (i.e., utilization time and daily 
quantity of window cleaning agent used). Among workers with the highest exposures, the average 2-butoxy-ethanol 
time-weighted average concentration and the average 2-butoxyacetic acid urinary concentration were 
2.33 ppm (11.3 mg/ m3) and 111.3 mg/g creatinine, respectively. The authors noted that the high 
concentrations of urinary 2-butoxyacetic acid, relative to the 2-butoxyethanol time-weighted average 
concentrations, indicated that dermal absorption was the predominant route of worker exposure. They 
concluded that for workers in these occupations not wearing protective gloves, environmental sampling 
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probably underestimates the 2-butoxyethanol exposure due to dermal absorption, and that biomonitoring of 
urinary 2-butoxyacetic acid appears to be the best method for estimating overall exposures 
Only one study (Johanson et al. 1989) involving biological monitoring of exposures to 2-butoxyethanol 
acetate was found in the available literature. 2-Butoxyethanol acetate was found in personal air samples from 
5 of 19 workers in 4 Swedish silk screen printing facilities at an average time-weighted average concentration 
of 2.9 mg/ m3 (0.44 ppm) (range, 0.1-10 mg/m3 [0.015-1.5 ppm]). 2-Butoxyacetic acid was found in the urine 
of 12 of the 19 workers at an average concentration of 8 mol/L (1.2 mg/L) (range, 4-29 mol/L or 
0.6-4.2 mg/L). 
5.6 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES 
Workers in occupations involving the production, processing, or use of 2-butoxyethanol or 2-butoxyethanol 
acetate, or of products containing these substances (see Section 5.5), have the potential to be occupationally 
exposed to higher concentrations of these substances than the general population. People who live near 
hazardous waste sites containing 2-butoxyethanol or 2-butoxyethanol acetate and people who live in areas 
where drinking water is contaminated with 2-butoxyethanol and 2-butoxyethanol acetate may also be subject 
to exposures; however, no data were found in the available literature to characterize such exposures. 
Among the general population, users of household products containing 2-butoxyethanol or 2-butoxyethanol 
acetate (see Section 5.5) and populations who live in areas where drinking water is contaminated with 
2-butoxyethanol or 2-butoxyethanol acetate may be exposed to these chemicals; however, no data were found 
in the available literature to characterize such exposures. Failure to wear proper protective clothing (e.g., 
gloves) will increase the potential for high dermal exposures among both the general and worker populations. 
5.7 ADEQUACY OF THE DATABASE 
Section 104(I)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether adequate 
information on the health effects of 2-butoxyethanol and 2-butoxyethanol acetate is available. Where 
adequate information is not available, ATSDR, in conjunction with the NTP, is required to assure the initiation 
of a program of research designed to determine the health effects (and techniques for developing methods to 
determine such health effects) of 2-butoxyethanol. 
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The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would reduce 
the uncertainties of human health assessment This definition should not be interpreted to mean that all data 
needs discussed in this section must be filled. In the future, the identified data needs will be evaluated and 
prioritized, and a substance-specific research agenda will be proposed. 
5.7.1 identification of Data Needs 
Physical and Chemical Properties. Several important physical properties of 2-butoxyethanol and 
2-butoxyethanol acetate have yet to be experimentally determined. These include their octanol-water and soil-water 
partition coefficients, Henry’s law constants, and bioconcentration factors in aquatic organisms. These 
data are important in estimating the fate of the released compounds in the environment and in determining the 
potential for human exposure. However, reliable estimated values for these parameters are available (ASTER 
1995a, 1995b; Howard 1993; HSDB 1995; Lyman et al. 1982) and there is no critical need for experimental 
confirmation of the estimated values. 
Production, Import/Export, Use, Release, and Disposal. Because 2-butoxyethanol and 2-butoxyethanol 
acetate are contained in a broad array of products that are widely used in the home and in industry (see 
Sections 4.3 and 5. l), the risk for human exposure may be substantial. The most recent U.S. production data 
available indicate an increase in production volume of 2-butoxyethanol from approximately 130 million 
pounds in 1972 to 271 million pounds in 1984 (Gibson 1984 as cited in Ghanayem et al 1987b; HSDB 1995), 
to more than 300 million pounds in 1986 (NIOSH 1990), and to 408.5 million pounds in 1995 (CMA 1997a). 
The production volume for 2-butoxyethanol acetate showed a slight decrease from approximately 13.4 million 
pounds in 1972 to 11 million pounds in both 1975 and 1977 (HSDB 1995; MOSH 1990). More recent 
production data, as well as data on projections of future production volumes are needed. Similarly, there is a 
need for recent import/export data for both 2-butoxyethanol and 2-butoxyethanol acetate. The most recent 
import/export data found for 2-butoxyethanol were from 1984 and indicated an increasing trend in exports 
from 9 million pounds in 1972 to 71 million pounds in 1984 (Gibson 1984 as cited in Ghanayem et al. 
1987b); no import/export data for 2-butoxyethanol acetate were found in the available literature. Information 
on the uses of 2-butoxyethanol and 2-butoxyethanol acetate is extensive and appears to be adequate. 
Additional information is needed to characterize releases to the environment of 2-butoxyethanol and 2-butoxy­




315 2-BUTOXYETHANOL AND 2-BUTOXYETHANOL ACETATE 
5. POTENTIAL FOR HUMAN EXPOSURE 
According to the Emergency Planning and Community Right-to-Know Act of 1986,42 U.S.C. Section 11023, 
industries are required to submit chemical release and off-site transfer information to the EPA. The Toxics 
Release Inventory (TRI), which contains information for 1994, became available in May of 1996. This 
database will be updated yearly and should provide a list of industrial production facilities and emissions. 
Currently, no information is available in the TRI database for 2-butoxyethanol because the database contains 
such information only for the general toxic chemical category of glycol ethers and not for specific glycol ethers 
(EPA 1995). No information is available in the TRL database for 2-butoxyethanol acetate because this 
chemical is not included under SARA, Title III, and therefore is not among the chemicals that facilities are 
required to report (EPA 1995). There is a need for such information in order to assess the potential for human 
exposure to these chemicals from their release from industrial production facilities. Limited or no information 
was found in the available literature on current disposal methods (including efficiencies, the need for 
improvement, and the amount disposed of) for 2-butoxyethanol; no information in these areas was found for 
2-butoxyethanol acetate. Additional information on disposal methods and the amounts of 2-butoxyethanol 
and 2-butoxyethanol acetate disposed of by each method is needed. 
Environmental Fate. There is a paucity of experimental data regarding the environmental fate of 
2-butoxyethanol and 2-butoxyethanol acetate. Fates of these two compounds estimated from their 
physicochemical properties indicate that a few critical areas need further elucidation. Although it has been 
estimated that hydrolysis of 2-butoxyethanol acetate is not an important fate process in the environment 
(ASTER 1995b), experimental confirmation of the rate of hydrolysis under conditions typically found in water 
and moist soil (pH 5-9) would be helpful. If hydrolysis of 2-butoxyethanol acetate is found to be an important 
fate detetmining process, it would be important to identify the products of hydrolysis and assess the health and 
environmental impacts of the degradation products. Biodegradation studies in natural bodies of water and soil 
would also be helpful. Both experimental screening studies (Dow 1993; Price et al. 1974; Zahn and Wellens 
1980) and estimated half-life values of 7-28 days (Howard et al. 1991) indicate that biodegradation of 
2-butoxyethanol and 2-butoxyethanol acetate is one of the important fate determining processes in water and 
soil. However, biodegradation screening studies conducted with sewage water as inocula may be used to 
predict the biodegradability under conditions used in water treatment plants. These studies may not be 
suitable for estimating biodegradability of organic compounds in natural bodies of water and soil. Therefore, 
it would be helpful to experimentally determine the rates of biodegradation of both of these compounds in soil 
and natural bodies of water (e.g., by river die-away experiments), and to identify the biodegradation products 
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Bioavailability. 2-Butoxyethanol and 2-butoxyethanol acetate are known to be absorbed following 
inhalation, ingestion, and dermal contact (Bartnik et al. 1987; Corley et al. 1997; Dugard et al. 1984; 
Johanson 1988; Johanson and Boman 1991; Johanson et al. 1988,1989; NIOSH 1990; Truhaut et al. 1979). 
The environmental factors that may influence the bioavailability of 2-butoxyethanol and 2-butoxyethanol 
acetate from contaminated air, water, soil, or plant material have not been studied. Because these compounds 
are not strongly sorbed to soil or sediments (see Section 5.3.1), sorption may not be a significant determinant 
in assessing the bioavailability of 2-butoxyethanol and 2-butoxyethanol acetate from different soils or waters. 
There is a need for data characterizing the factors that affect the bioavailability of these compounds from 
environmental media. 
Food Chain Bioaccumulation. 2-Butoxyethanol and 2-butoxyethanol acetate do not bioconcentrate 
significantly in fish (ASTER 1995a, 1995b). The low estimated BCF and Kow values of 2-butoxyethanol and 
2-butoxyethanol acetate (see Section 5.3.1 and Tables 3-3 and 3-4), and the ease with which these compounds 
are metabolized in higher trophic level animals (see Section 2.3) indicate that these compounds will not 
biomagnify in the food chain. Experimental data on BCFs and food chain bioaccumulation, however, are very 
limited. Additional data would be desirable. 
Exposure Levels in Environmental Media. No data were found in the available literature on 
concentrations of 2-butoxyethanol and 2-butoxyethanol acetate in ambient outdoor or indoor air. Because of 
the short half-lives (<1 day; see Section 5.3.2.1) of these chemicals in the atmosphere, neither compound will 
persist in the atmosphere or be transported long distances. Consequently, significant ambient outdoor 
concentrations would be expected only in areas near potential emission sources (e.g., production facilities, 
disposal sites). Data on ambient outdoor and indoor air concentrations of 2-butoxyethanol and 2-butoxyethanol 
acetate near potential emission sources and at background sites in the United States would be useful. 
Because of the widespread use of household products containing 2-butoxyethanol and 2-butoxyethanol 
acetate, additional data on indoor air concentrations of these compounds would be useful to assess indoor 
exposures of the general population. 2-Butoxyethanol was found in drinking water in a U.S. survey that 
included Washington, DC, and cities in California, Texas, Ohio, Pennsylvania, Florida, Louisiana, Iowa, and 
Washington; however, concentrations were not reported (Lucas 1984). Because of the relatively widespread 
2-butoxyethanol contamination of U.S. drinking water indicated by this survey, more recent data are needed to 
assess the potential for exposure of the general public from this source. Data on levels of 2-butoxyethanol 
acetate in drinking water would also be desirable. 2-Butoxyetbanol was detected at a concentration of 23 µg /L 
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100,000 drums of industrial waste were disposed of between 1967 and 1977 (Stonebreaker and Smith 1980). 
Examination of mass spectral libraries of data from water and soil samples from U.S. hazardous wasted sites 
taken between late 1987 and mid-1989 identified 2-butoxyethanol in 110 samples (Eckel et al. 1996). The 
media in which the compound was found was not indicated. No other data were found in the available 
literature on the levels of 2-butoxyethanol or 2-butoxyethanol acetate in surface or groundwater, or in soil or 
sediment; such data would be useful to assess the potential for exposure from these media. The low estimated 
BCF and KOW,values of 2-butoxyethanol and 2-butoxyethanol acetate (see Section 5.3.1 and Tables 3-3 and 
3-4), and the ease with which these compounds are metabolized in higher trophic level animals (see Section 
2.3) indicate that these compounds will not biomagnify in the food chain and, consequently, that 
concentrations in food will be insignificant; however, there may be some potential for food contamination from 
packaging and washing procedures (see Section 5.4.4). The minor use of 2-butoxyethanol in herbicides (see 
Section 4.3) may also present the potential for food contamination by this compound. Data on concentrations 
of 2-butoxyethanol and 2-butoxyethanol acetate in food would be useful to confirm that consumption of 
contaminated foods is not a significant route of exposure. 
2-Butoxyethanol has been detected in surface water (2 sites), groundwater (7 sites), soil (3 sites) and sediment 
(1 site) out of 20 of the 1,430 current or former EPA National Priorities List (NPL) hazardous wastes sites 
where it has been detected in some environmental media, whereas 2-butoxyethanol acetate has not been 
detected at any of the current or former NPL hazardous waste sites (HazDat 1996). The number of sites 
evaluated for these substances is not known, however. No data were found in the available literature on the 
concentrations of 2-butoxyethanol and 2-butoxyethanol acetate at NPL sites in any medium. 
Reliable monitoring data for the levels of these substances in contaminated media at hazardous waste sites 
(and background sites) are needed. The information obtained on levels of 2-butoxyethanol and 2-butoxy-ethanol 
acetate in the environment can be used in combination with the known body burdens of 2-butoxy-ethanol and 2­
butoxyethanol acetate to assess the potential risks of adverse health effects in populations living 
in the vicinity of hazardous waste sites. 
No information was found in the available literature on estimates for human intake of 2-butoxyethanol or 
2-butoxyethanol acetate from the various environmental media. Such information is necessary to estimate the 
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Exposure Levels in Humans. Because both 2-butoxyethanol and 2-butoxyethanol acetate are readily 
absorbed through the skin (Bartnik et al. 1987; Dugard et al. 1984; Johanson 1988; Johanson and Boman 
199 1; Johanson et al. 1988,1989; NJOSH 1990; Truhaut et al. 1979), environmental monitoring of breathing 
zone or work area air concentrations of these substances generahy is not found to be adequate to assess overall 
exposures to these compounds. Biological monitoring of the toxic metabolite, 2-butoxyacetic acid, in urine is 
considered preferable (Angerer et al. 1990; Johanson 1988; Sohnlein et al. 1993; Vincent et al. 1993). 
Limited data on urinary 2-butoxyacetic acid concentrations are available for occupationally exposed groups of 
the population (see Section 5.5); however, more extensive biomonitoring of workers in a broad range of 
occupations with potentially high exposures would be useful. Data on urinary 2-butoxyacetic acid 
concentrations in control groups and in the general population are not available. In addition, biomonitoring 
data are not available for populations living near hazardous waste sites where 2-butoxyethanol or 
2-butoxyethanol acetate are known to be present. These data would be useful in assessing whether this group 
is being exposed to 2-butoxyethanol or 2-butoxyethanol acetate at levels higher than the general population. 
This information is necessary for assessing the need to conduct health studies on these populations. 
Exposure Registries. No exposure registries for 2-butoxyethanol or 2-butoxyethanol acetate were 
located. These substances are not currently among the compounds for which subregistries have been 
established in the National Exposure Registry. These substances will be considered in the future when 
chemical selection is made for subregistries to be established. The information that is amassed in the National 
Exposure Registry facilitates the epidemiological research needed to assess adverse health outcomes that may 
be related to exposure to these substances. 
5.7.2 Ongoing Studies 
A search of the Federal Research in Progress database (FEDRIP 1995) indicates that no research studies are in 
progress to fill the data gaps discussed in Section 5.7.1. The Consumer Products Safety Commission is 
working on a report concerning the uses of ethylene glycol ethers including 2-butoxyethanol. 
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The purpose of this chapter is to describe the analytical methods that are available for detecting, and/or 
measuring, and/or monitoring 2-butoxyethanol, 2-butoxyethanol acetate, their metabolites, and other 
biomarkers of exposure and effect to these compounds. The intent is not to provide an exhaustive list of 
analytical methods. Rather, the intention is to identify well-established methods that are used as the standard 
methods of analysis. Many of the analytical methods used for environmental samples are the methods 
approved by federal agencies and organizations such as EPA and the National Institute for Occupational 
Safety and Health (NIOSH). Other methods presented in this chapter are those that are approved by groups 
such as the Association of Official Analytical Chemists (AOAC) and the American Public Health Association 
(APHA). Additionally, analytical methods are included that modify previously used methods to obtain lower 
detection limits, and/or to improve accuracy and precision. 
6.1 BIOLOGICAL SAMPLES 
Analytical methods for the determination of 2-butoxyethanol, 2-butoxyethanol acetate, and metabolites in 
biological matrices are shown in Table 6-l. The method of determination in almost all of the methods is gas 
chromatography (GC) with either electron capture detection (ECD) or flame ionization detection (FID). One 
of the reported methods used high performance liquid chromatography (HPLC) in conjunction with ultraviolet 
absorbance detection. 2-Butoxyethanol can be isolated from blood or urine by extraction and analysis 
(Johanson et al. 1986a; Smallwood et al 1984). The metabolites of 2-butoxyethanol and 2-butoxyethanol 
acetate include 2-butoxyacetic acid and conjugates of 2-butoxyacetic acid, including the conjugate with 
glutamine. 2-Butoxyacetic acid and its conjugates are isolated from urine or blood by extraction and are 
derivatized to increase volatility for GC separation and detection (Begerow et al. 1988; Groeseneken et al. 
1989; Johanson 1989; Johanson and Johnsson 1991; Jijnsson and Steen 1978; Sakai et al. 1994) or to enhance 
detectability for HPLC determinations (Rettenmeier et al. 1993). HPLC has been applied to simultaneously 
analyze both free 2-butoxyacetic acid and conjugated 2butoxyacetic acid in the urine (Rettenmeier et al. 
1993). Following extraction and derivatization to trimethylsilyl derivatives, free 2-butoxyacetic acid and 
2-butoxyacetylglutamine were determined by HPLC. Measurement of both butoxyacetic acid forms allowed 
for calculation of total butoxyacetic acid. A single gas chromatographic determination of free urinary 
2-butoxyacetic acid and total urinary 2-butoxyacetic acid has been described (Sakai et al. 1994). In this 
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biological monitoring of 2-butoxyethanol exposure (refer to sections 2.3 “Toxicokinetics” and 2.6 “Biomarkers 
of Exposure and Effect”). It is noteworthy, however, that biological monitoring studies typically 
measure only free 2-butoxyacetic acid. Since a substantial fraction of 2-butoxyacetic acid is eliminated as the 
amino acid conjugate, exposure levels to 2-butoxyethanol would be underestimated in these typical biological 
monitoring studies. 
6.2 ENVIRONMENTAL SAMPLES 
Routine analyses for the glycol ethers in water, including 2-butoxyethanol and its acetate are often not 
completed because frequently used general-purpose GC/MS methods designed to measure priority pollutants 
do not readily detect these compounds (Eckel et al. 1996). For example, recovery of 2-butoxyethanol was 
6.7% by EPA method 625 for semivolatiles. 
Analytical methods specific for the determination of 2-butoxyethanol and 2-butoxyethanol acetate in 
environmental matrices are shown in Table 6-2. The method of determination in all of the methods is GC in 
conjunction with either flame ionization detection (FID) or mass spectrometric (MS) detection. Sample 
preparation methods for air samples are based on the adsorption of the target compounds onto a sorbent such 
as charcoal (Guest et al. 1985; NIOSH 1994a; OSHA 1990) or Amberlite XAD-7 (Andersson et al. 1982) 
followed by elution of the compounds with a solvent. Carbon disulfide has been used to recover non-polar 
analytes from charcoal but fails to recover the more polar 2-butoxyethanol and 2-butoxyethanol acetate 
(Fracchia et al. 1977; Mueller and Miller 1979). As a result, solvents such as 5% methanol in 
dichloromethane are used and provide good recoveries of both target compounds (NIOSH 1994a; OSHA 
1990). Although thermal desorption is frequently used to recover volatile analytes from sorbents, this 
technique often fails with charcoal because the temperature required for volatilization of strongly adsorbed 
compounds results in the decomposition of the analytes, especially in the presence of water (Cocheo et al. 
1987). Adsorbed samples generally appear to be stable9 but NIOSH (1994a) recommends freezer storage of 
samples until elution to minimize any decomposition. High concentrations of less volatile analytes and water 
can impact the retention of 2-butoxyethanol and 2-butoxyethanol acetate on charcoal, so the analyst must be 
aware that premature breakthrough could result under these conditions and when large air volumes are 
sampled (NIOSH 1994a; Posner and Okenfuss 198 1). The analytic methods for determining 2-butoxyethanol 
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Preparation methods for water samples are based on purge and trap (Michael et al. 1991), solvent extractions 
(Jungclaus et al. 1976; Nguyen et al. 1994; Yasuhara et al. 1981), or direct injection (Beihoffer and Ferguson 
1994). High concentrations of dissolved solids in sample extracts can contaminate the GC injector or column 
after only a few analyses (Beihoffer and Ferguson 1994), so adequate quality control procedures should be in 
place. Yasuhara et al. (198 1) included a vacuum distillation step of highly polluted river water prior to solvent 
extraction to avoid the contamination of the extract with high molecular weight, non-volatile compounds. The 
method of determination steps of all of the methods found for water were based on GC/FID or GC/MS. 
6.3 ADEQUACY OF THE DATABASE 
Section 104(I)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether adequate 
information on the health effects of 2-butoxyethanol or 2-butoxyethanol acetate is available. Where adequate 
information is not available, ATSDR, in conjunction with the NTP, is required to assure the initiation of a 
program of research designed to determine the health effects (and techniques for developing methods to 
determine such health effects) of 2-butoxyethanol and 2-butoxyethanol acetate. 
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would reduce 
the uncertainties of human health assessment. This definition should not be interpreted to mean that all data 
needs discussed in this section must be filled. In the future, the identified data needs will be evaluated and 
prioritized, and a substance-specific research agenda will be proposed. 
6.3.1 Identification of Data Needs 
Methods for Determining Biomarkers of Exposure and Effect. Methods are available for the 
determination of 2-butoxyethanol in blood and urine (Johanson et al. 1986a; Smallwood et al. 1984). The 
utility of 2-butoxyethanol as a biomarker of exposure is limited because of its short elimination half-time in 
blood (40 minutes) and the small fraction of the absorbed dose (less than 0.03%) excreted unchanged in urine 
(Johanson 1988; Johanson et al. 1986a). In contrast, the half-time of urinary 2-butoxyacetic acid was reported 
to be 5.77 hours after a controlled, 2-hour exposure to 2-butoxyethanol (Johanson et al. 1986a). The amount 
of 2-butoxyacetic acid excreted in urine corresponded to 17-55% of the absorbed dose of 2-butoxyethanol and 
will thus serve as a sensitive marker of exposure (Johanson et al. 1986a). Sensitive and reproducible methods 
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for 2-butoxyacetic acid are available. No methods were found for the determination of 2-butoxyethanol 
acetate in physiological matrices, but this ester is rapidly metabolized to 2-butoxyethanol in the body resulting 
in 2-butoxyacetic acid in urine (Johanson 1988; Johanson et al. 1989). Thus, 2-butoxyacetic acid will provide 
measures of exposure to both 2-butoxyethanol and its acetate. Conjugates of 2-butoxyacetic acid with 
glutamine have been measured in urine and methods exist to determine the 2-butoxyacetic acid glutamine 
conjugate (Rettenmeier et al. 1993) or 2-butoxyacetic acid after hydrolysis of the conjugate (Sakai et al. 1994). 
The method of Sakai et al. (1994) permits the calculation of 2-butoxyacetic acid conjugate concentrations 
based on determinations of 2-butoxyacetic acid with and without hydrolysis; this method provides 
measurements of total (2-butoxyacetic acid and 2-butoxyacetic acid conjugates) and free 2-butoxyacetic acid, 
respectively. No new methods are needed. 
Methods for Determining Parent Compounds and Degradation Products in Environmental 
Media. Methods exist for the determination of 2-butoxyethanol in air (Andersson et al. 1982; NJOSH 
1994a; OSHA 1990), groundwater (Beihoffer and Ferguson 1994), river water (Yasuhara et al. 198 l), and 
waste water (Jungclaus et al. 1976; Michael et al. 1991; Nguyen et al. 1994). Methods also exist for the 
determination of 2-butoxyethanol acetate in air (NJOSH 1994a; OSHA 1990). Limits of detection (LOD) for 
these compounds in air are in the sub-ppm range. Only one reported method for 2-butoxyethanol in water 
appeared to be characterized, and an LOD of less than 0.4 ppm (1.9 mg/m3) was claimed (Beihoffer and 
Ferguson 1994). Additional information is needed about the method LODs for 2-butoxyethanol in water and 
waste water; additional methods are needed for other matrices (i.e., wastes, soils). No method was found for 
2-butoxyethanol acetate in a matrix other than ah-; additional methods for other matrices are needed. No 
studies were found in which the concentrations of these two compounds were determined in foods. Methods 
are needed if contamination of foodstuffs and the resultant human exposure via ingestion is of concern. 
6.3.2 Ongoing Studies 
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The national regulations and guidelines regarding 2-butoxyethanol and 2-butoxyethanol acetate in air, water, 
and other media are summarized in Table 7-l. 
An MRL of 6 ppm has been derived for acute-duration inbalation exposure (14 days or less) to 
2-butoxyethanol, based on a NOAEL of 50 ppm for hematotoxicity in pregnant rats (Tyl et al. 1984). An 
MRL of 3 ppm has been derived for intermediate-duration inhalation exposure to 2-butoxyethanol, based on a 
NOAEL of 25 ppm for hematotoxicity in rats (Dodd et al. 1983). An MRL of 0.2 ppm has been derived for 
chronic inhalation exposure (365 days or longer) to 2-butoxyethanol, based on a NOAEL in humans for 
statistically significant decreased hematocrit aud increased mean corpuscular hemoglobin concentrations 
(Haufroid et al. 1992). The observed changes were still witbin the range of normal human variability. 
An MRL of 0.4 mg/kg/day has been derived for acute-duration oral exposure to 2-butoxyethanol, based on a 
LOAEL of 32 mg/kg for hematotoxicity in 16-month old rats (Ghanayem et al. 1987a). An MRL of 
0.07 mg/kg/day has been derived for intermediate-duration oral exposure to 2-butoxyethanol, based on a 
LOAEL of 69 mg/kg/day for mild hepatic toxicity in rats (NTP 1993). 
There is no reference dose (RfD) for 2-butoxyethanol or 2-butoxyethanol acetate. A risk assessment to 
establish a reference concentration (RfC) for 2-butoxyethanol is under review by an EPA Workgroup (IRIS 
1995). 
OSHA requires employers of workers who are occupationally exposed to 2-butoxyethanol to institute 
engineering controls and work practices to reduce employee exposure and maintain it at or below permissible 
exposure limits (PEL). The PEL for 2-butoxyethanol is 50 ppm (OSHA 1974). Workers exposed to 
2-butoxyethanol should wear personal protective equipment such as gloves, coveralls, and goggles to protect 
exposure to the skin (OSHA 1974). NIOSH recommends that industrial hygiene surveys be completed at 
work places where airborne exposure to 2-butoxyethanol or 2-butoxyethanol acetate may occur (NIOSH 
1990). If exposure levels are at or above one-half the recommended exposure limit (REL = 5 ppm), NIOSH 
recommends that a program of personal monitoring be instituted so that the exposure of each worker can be 
estimated. If exposure levels are at or greater than the REL, or if there is a potential for skin contact, NIOSH 
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2-Butoxyethanol is regulated under the Clean Water Act’s Effluent Guidelines as stated in Title 40, Part 414 
of the Code of Federal Regulations. The point source category for which 2-butoxyethanol is controlled as a 
bulk organic chemical is organic chemicals, plastics, and synthetic fibers (EPA 1987). 
Both 2-butoxyethanol and 2-butoxyethanol acetate are regulated under the Clean Air Act, including National 
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9. GLOSSARY 
Acute Exposure-Exposure to a chemical for a duration of 14 days or less, as specified in the Toxicological 
Profiles. 
Adsorption Coefficient (Koc)-The ratio of the amount of a chemical adsorbed per unit weight of organic 
carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium. 
Adsorption Ratio (Kd)-The amount of a chemical adsorbed by a sediment or soil (i.e., the solid phase) 
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a 
fixed solid/solution ratio. It is generally expressed in micrograms of chemical sorbed per gram of soil or 
sediment. 
Bioconcentration Factor (BCF)-The quotient of the concentration of a chemical in aquatic organisms at a 
specific time or during a discrete time period of exposure divided by the concentration in the surrounding 
water at the same time or during the same period. 
Cancer Effect Level (CEL)-The lowest dose of chemical in a study, or group of studies, that produces 
significant increases in the incidence of cancer (or tumors) between the exposed population and its appropriate 
control. 
Carcinogen-A chemical capable of inducing cancer. 
Ceiling Value-A concentration of a substance that should not be exceeded, even instantaneously. 
Chronic Exposure-Exposure to a chemical for 365 days or more, as specified in the Toxicological Profiles. 
Developmental Toxicity-The occurrence of adverse effects on the developing organism that may result from 
exposure to a chemical prior to conception (either parent), during prenatal development, or postnatally to the 
time of sexual maturation. Adverse developmental effects may be detected at any point in the life span of the 
organism. 
Embryotoxicity and Fetotoxicity-Any toxic effect on the conceptus as a result of prenatal exposure to a 
chemical; the distinguishing feature between the two terms is the stage of development during which the insult 
occurred. The terms, as used here, include malformations and variations, altered growth, and in utero death. 
EPA Health Advisory-An estimate of acceptable drinking water levels for a chemical substance based on 
health effects information. A health advisory is not a legally enforceable federal standard, but serves as 
technical guidance to assist federal, state, and local officials. 
Immediately Dangerous to Life or Health (IDLH)-The maximum environmental concentration of a 
contaminant from which one could escape within 30 min without any escape-impairing symptoms or 
irreversible health effects. 
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9. GLOSSARY 
Immunologic Toxicity-The occurrence of adverse effects on the immune system that may result from 
exposure to environmental agents such as chemicals 
In Vitro-Isolated from the living organism and artificially maintained, as in a test tube. 
In vivo-Occurring within the living organism. 
Lethal Concentration(10) (LCLO)-The lowest concentration of a chemical in air which has been reported to 
have caused death in humans or animals. 
Lethal Concentration(50) (LC50)-A calculated concentration of a chemical in air to which exposure for a 
specific length of time is expected to cause death in 50% of a defined experimental animal population. 
Lethal Dose(10) (LDLO)-The lowest dose of a chemical introduced by a route other than inhalation that is 
expected to have caused death in humans or animals. 
Lethal Dose(50) (LD50)-The dose of a chemical which has been calculated to cause death in 50% of a defined 
experimental animal population. 
Lethal Time(50) (LT50)-A calculated period of time within which a specific concentration of a chemical is 
expected to cause death in 50% of a defined experimental animal population. 
Lowest-Observed-Adverse-Effect Level (LOAEL)-The lowest dose of chemical in a study, or group of 
studies, that produces statistically or biologically significant increases in frequency or severity of adverse 
effects between the exposed population and its appropriate control. 
Malformations-Permanent structural changes that may adversely affect survival, development, or function. 
Minimal Risk Level-An estimate of daily human exposure to a dose of a chemical that is likely to be 
without an appreciable risk of adverse noncancerous effects over a specified duration of exposure. 
Mutagen-A substance that causes mutations. A mutation is a change in the genetic material in a body cell. 
Mutations can lead to birth defects, miscarriages, or cancer. 
Neurotoxicity-The occurrence of adverse effects on the nervous system following exposure to chemical. 
No-Observed-Adverse-Effect Level (NOAEL)-The dose of chemical at which there were no statistically or 
biologically significant increases in frequency or severity of adverse effects seen between the exposed 
population and its appropriate control. Effects may be produced at this dose, but they are not considered to be 
adverse. 
Octanol-Water Partition Coefficient (Kow)-The equilibrium ratio of the concentrations of a chemical in 
n-octanol and water, in dilute solution. 
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9. GLOSSARY 
q1*-The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the 
multistage procedure. The ql* can be used to calculate an estimate of carcinogenic potency, the incremental 
excess cancer risk per unit of exposure (usually µg /L for water, mg/kg/day for food, and µg / m3 for air). 
Reference Dose (RfD)-An estimate (with uncertainty spanning perhaps an order of magnitude) of the daily 
exposure of the human population to a potential hazard that is likely to be without risk of deleterious effects 
during a lifetime. The RfD is operationally derived from the NOAEL (from animal and human studies) by a 
consistent application of uncertainty factors that reflect various types of data used to estimate RfDs and an 
additional modifying factor, which is based on a professional judgment of the entire database on the chemical. 
The RfDs are not applicable to nonthreshold effects such as cancer. 
Reportable Quantity (RQ)-The quantity of a hazardous substance that is considered reportable under 
CERCLA. Reportable quantities are (1) 1 pound or greater or (2) for selected substances, an amount 
established by regulation either under CERCLA or under Sect. 3 11 of the Clean Water Act. Quantities are 
measured over a 24-hour period. 
Reproductive Toxicity-The occurrence of adverse effects on the reproductive system that may result from 
exposure to a chemical. The toxicity may be directed to the reproductive organs and/or the related endocrine 
system. The manifestation of such toxicity may be noted as alterations in sexual behavior, fertility, pregnancy 
outcomes, or modifications in other functions that are dependent on the integrity of this system. 
Short-Term Exposure Limit (STEL)-The maximum concentration to which workers can be exposed for up 
to 15 min continually. No more than four excursions are allowed per day, and there must be at least 60 min 
between exposure periods. The daily TLV-TWA may not be exceeded. 
Target Organ Toxicity-This term covers a broad range of adverse effects on target organs or physiological 
systems (e.g., renal, cardiovascular) extending from those arising through a single limited exposure to those 
assumed over a lifetime of exposure to a chemical. 
Teratogen-A chemical that causes structural defects that affect the development of an organism. 
Threshold Limit Value (TLV)-A concentration of a substance to which most workers can be exposed 
without adverse effect. The TLV may be expressed as a TWA, as a STEL, or as a <1. 
Time-Weighted Average (TWA)-An allowable exposure concentration averaged over a normal 8-hour 
workday or 40-hour workweek. 
Toxic Dose (TD50)-A calculated dose of a chemical, introduced by a route other than inhalation, which is 
expected to cause a specific toxic effect in 50% of a defined experimental animal population. 
Uncertainty Factor (UF)-A factor used in operationally deriving the RfD from experimental data. UFs are 
intended to account for (1) the variation in sensitivity among the members of the human population, (2) the 
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from data 
obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using LOAEL data rather 
than NOAEL data. Usually each of these factors is set equal to 10. 
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ATSDR MINIMAL RISK LEVEL
 
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 9601 
et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99-4991, 
requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with the US. 
Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most commonly 
found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological profiles for each 
substance included on the priority list of hazardous substances; and assure the initiation of a research program 
to fill identified data needs associated with the substances. 
The toxicological profiles include an examination, summary, and interpretation of available toxicological 
information and epidemiologic evaluations of a hazardous substance. During the development of toxicological 
profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to identify the target 
organ(s) of effect or the most sensitive health effect(s) for a specific duration for a given route of exposure. 
An MRL is an estimate of the daily human exposure to a hazardous substance that is likely to be without 
appreciable risk of adverse noncancer health effects over a specified duration of exposure. MRLs are based on 
noncancer health effects only and are not based on a consideration of cancer effects. These substance-specific 
estimates, which are intended to serve as screening levels, are used by ATSDR health assessors to identify 
contaminants and potential health effects that may be of concern at hazardous waste sites. It is important to 
note that MRLs are not intended to define clean-up or action levels. 
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor 
approach. They are below levels that might cause adverse health effects in the people most sensitive to such 
chemical-induced effects. MRLs are derived for acute (1-14 days), intermediate (15-364 days), and chronic 
(365 days and longer) durations and for the oral and inhalation routes of exposure. Currently, MRLs for the 
dermal route of exposure are not derived because ATSDR has not yet identified a method suitable for this 
route of exposure. MRLs are generally based on the most sensitive chemical-induced end point considered to 
be of relevance to humans. Serious health effects (such as irreparable damage to the liver or kidneys, or birth 
defects) are not used as a basis for establishing MRLs. Exposure to a level above the MRL does not mean 
that adverse health effects will occur. 
 
 
A-2 2-BUTOXYETHANOL AND 2-BUTOXYETHANOL ACETATE 
APPENDIX A 
MRLs are intended only to serve as a screening tool to help public health professionals decide where to look 
more closely. They may also be viewed as a mechanism to identify those hazardous waste sites that are not 
expected to cause adverse health effects. Most MRLs contain a degree of uncertainty because of the lack of 
precise toxicological information on the people who might be most sensitive (e.g., infants, elderly, nutritionally 
or immunologically compromised) to the effects of hazardous substances. ATSDR uses a conservative (i.e., 
protective) approach to address this uncertainty consistent with the public health principle of prevention. 
Although human data are preferred, MRLs often must be based on animal studies because relevant human 
studies are lacking. In the absence of evidence to the contrary, ATSDR assumes that humans are more 
sensitive to the effects of hazardous substance than animals and that certain persons may be particularly 
sensitive. Thus, the resulting MRL, may be as much as a hundredfold below levels that have been shown to be 
nontoxic in laboratory animals. 
Proposed MRLs undergo a rigorous review process: Health Effects/MRL Workgroup reviews within the 
Division of Toxicology, expert panel peer reviews, and agencywide MRL Workgroup reviews, with 
participation from other federal agencies and comments from the public. They are subject to change as new 
information becomes available concomitant with updating the toxicological profiles. Thus, MRLs in the most 
recent toxicological profiles supersede previously published levels. For additional information regarding 
MRLs, please contact the Division of Toxicology, Agency for Toxic Substances and Disease Registry, 1600 
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Dose endpoint used for MRL derivation: 50 ppm - hematological effects 
[X] NOAEL [ ] LOAEL 
Uncertainty factors used in MRL derivation: 9 
[ ] 1 [ ]3 [ ] 10 (for use of a LOAEL)
 
[ ] 1 [X] 3 [ ] 10 (for extrapolation from animals to humans)
 
[ ] 1 [X] 3 [] 10 (for human variability)
 
An uncertainty factor of 3 for animal to human extrapolation because in vitro data show that human red blood
 




Concentrations of 2-butoxyacetic acid that caused hemolysis of rat red blood cells did not cause hemolysis of
 
human red blood cells (Bartnik et al. 1987). For example, following a 60 minute exposure of rat red blood
 
cells to 7.5 mM 2-butoxyacetic acid 100% hemolysis was observed. Following a 60 minute exposure of
 
human red blood cells to 15 mM 2-butoxyacetic acid, no hemolysis was observed (Bartnik et al. 1987). An in
 
vitro study measuring more sensitive endpoints of red blood cell effects, mean cell volume and hematocrit, has
 
also shown rat red blood cells to be more sensitive to 2-butoxyacetic acid compared to human red blood cells
 
(Ghanayem and Sullivan 1993). For example, following a 1 hour exposure to 2 mM 2-butoxyacetic acid,
 
mean corpuscular volume was about 150% of controls in rat red blood cells, and 105% of controls in human
 
red blood cells, hematocrit was about 155% of controls in rat red blood cells, and 105% of controls in human
 
red blood cells. Red blood cells of rabbits, hamsters, mice and baboons were also sensitive to the red blood
 
cell effects of 2-butoxyacetic acid, while red blood cells of cats, pigs, dogs, and guinea pigs were not sensitive
 
the effects of 2-butoxyacetic acid (Ghanayem and Sullivan 1993). This in vitro data is also supported by the
 
Carpenter et al. (1956) study in which erythrocyte osmotic fragility, an effect observed in animals, was not
 
observed in humans exposed by inhalation to ≤ 195 ppm 2-butoxyethanol for 4-8 hours. In addition, an in
 
vitro study showed that human erythrocytes were resistant to the hemolytic effects of 2-butoxyacetic acid, the
 
hemolytic metabolite of 2-butoxyethanol (Udden 1994).
 
An uncertainty factor of 3 for human variability was used because the results of in vitro data suggest that 2­
butoxyethanol does not cause significant hemolysis of normal and potentially susceptible erythrocytes (Udden
 
1996). Udden (1994) reported that red blood cells in humans (including the elderly and patients with
 




Was a conversion factor used from ppm in food or water to a mg/body weight dose?
 
If so, explain: Not applicable.
 
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: The 
human equivalent dose (HEC) was calculated using Formula 4-48 from Interim Methods for Derivation of 
Inhalation Reference Concentrations and Application of Inhalation Dosimetry, EPA (1994). Though 2­
butoxyethanol is a Category 2 gas (i.e., water soluble and accumulates in blood), the equation in the EPA 
(1994) document for extrarespiratory effects of Category 2 gases is presently under review and the 
recommended equation is that for Category 3 gases: 
NOAEL[HEC]  = NOAEL[ADJ] x (Hb/g)A  / (Hb/g)H 
where: 
NOAEL[HEC] = the NOAEL human equivalent concentration 
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observed in rats of both sexes exposed to 245 ppm, but this staining was never observed again. Female rats 
exposed to 86 ppm showed significantly higher liver weights. Male and female rats of the 245 ppm group also 
showed increased liver weights. Decreased mean body weight gains (% not provided) were also found. A 
14-day postexposure recovery showed substantial reversal of the affected blood parameters. In another study, 
nonpregnant rats were exposed to 250 ppm or greater 2-butoxyethanol by inhalation for 6.5 hours (Nelson et 
al. 1984). The exposed rats exhibited hematuria 4-6 hours after onset of exposure at all concentrations 
(LOAEL = 250 ppm). Surviving rats in each dose group had necrotic tail tips 1 week after exposure. New 
Zealand White rabbits (n=24) were exposed to 2-butoxyethanol vapors by inhalation on Gd 6-l 8 at 
concentrations 0,25,50, 100, or 200 ppm for 6 hours per day (Tyl et al. 1984). The animals were observed 
for clinical signs throughout the study. Food and water were withheld during exposures. Maternal body 
weights were taken on Gd 0,6,9, 12, 15, 1821, and 29. The animals were sacrificed on Gd 29 after 
obtaining blood samples. Hematology and organ weights (uterus, liver, thymus, spleen, and kidney) were 
evaluated. Hematologic determinations in rabbits indicated no apparent treatment-related changes in any 
parameter evaluated. Statistically significant increases in hemoglobin content (13.5 g/dL versus 12.4 g/dL in 
controls) and hematocrit were seen at 100 ppm but not at 200 ppm, suggesting to the authors a biphasic 
response of the hematological system to 2-butoxyethanol exposure in rabbits Therefore, 100 ppm appears to 
be a LOAEL and 50 ppm appears to the NOAEL for hematological effects in the rabbits, but the authors did 
not present a mechanism to explain the apparent biphasic response that these effects were not seen at 200 
ppm. 
The data indicating that humans are less susceptible to 2-butoxyethanol-induced hemolysis are as follows: In 
vitro experiments designed to examine the effect of 2-butoxyethanol on human and rat erythrocytes (Bartnik et 
al. 1987), and in vitro experiments designed to examine the effect of 2-butoxyacetic acid on the erythrocytes 
of various mammalian species (including human species) indicated species-dependent sensitivity to the 
hemolytic effects of 2-butoxyethanol and 2-butoxyacetic acid. In this regard, rodents, rabbits, and baboons 
were more sensitive than pigs, dogs, cats, guinea pigs, and humans. 
In its Threshold Limit Value (TLV) recommendation, tbe American Conference of Governmental Industrial 
Hygienists (ACGIH) stated that “anemia is not an uncommon condition in the human population. (ACGIH 
199 1). ACGIH (199 1) recommended that exposures to 2-butoxyethanol be maintained below levels that are 
found to cause blood changes in experimental animals. Based on this recommendation, the TLV-TWA was 
established at 25 ppm. 
Agency Contact (Chemical Manager): Olivia Harris 
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Chemical name(s): 2-Butoxyethanol 
CAS Number(s): 111-76-2 
Date: June 1998 
Profile status: Draft 3 
Route: [X] Inhalation [ ] Oral 
Duration: [ ] Acute [X] Intermediate [ ] Chronic 
Key to figure: 42 
Species: Rat 
MRL: 3 [ ] mg/kg/day  [X] ppm [ ] mg/m3 
Reference: Dodd et al. 1983 
Experimental design: Fischer 344 rats (16 male, 16 female) were exposed for 90 days, 6 hours per day, 5 days 
per week to 2-butoxyethanol target concentrations rof 0,5,25, or 75 ppm (mean average concentrations 
determined by gas chromatography to be 0,5,25, or 77 ppm, respectively). Rats were observed for signs of 
toxicity during exposure and 14 days postexposure. Necropsies were performed on animals that died and on 
survivors killed at the end of the observation period. For bematology evaluation only, 6 rats/sex/group were 
killed after 6 weeks. Biological assessments included daily animal observations, body weight and organ 
(kidney, liver, lungs and testes) weight determinations, and ophthalmologic, hematologic, and gross pathologic 
examinations. In addition, RBC osmotic fragility tests, serum chemistries, urinalysis, and histologic 
examination of selected tissues of the high BE concentrations were assessed. No deaths occurred throughout 
the study. There were no clinical signs of toxicity observed. There was a transient decrease in body weight 
gain (exposure weeks 24; data not shown) of females exposed to 77 ppm 2-butoxyethanol. After 6 weeks 
(3 1 exposures), female rats exposed to 77 ppm had slight but significant decreases (13% below control 
values) in red blood cell counts (RBC) and hemoglobin (HGB) accompanied with an 11% increase above 
control value in mean corpuscular hemoglobin (MCH). At the end of the 90-day study, the hematologic 
effects seen in the female exposed rats either lessened or returned to control value ranges. The only significant 
hematologic finding in male rats was a 5% decrease in RBC at 77 ppm after 66 exposures. The red blood cell 
osmotic fragility tests of both 2-butoxyethanol-treated rats and controls were similar. No treatment-related 
differences were found in body weight, organ weights, urine or serum chemistries, gross lesions, or 
microscopic lesions in males or females. 
Effects noted in study and corresponding doses: 
25 ppm = mid dose (NOAEL) 
77 ppm= high dose (Serious LOAEL: female rats had 13% decrease in red blood cells 
(RBC) 
and 4% decrease in hemoglobin [HGB] accompanied with an 11% increase above 
control value in mean corpuscular bemoglobin [MCH]; male rats had a 5% decrease 
in RBC) 
Dose endpoint used for MRL derivation: 25 ppm - hematological effects 
[X] NOAEL [ ] LOAEL 
Uncertainty factors used in MRL derivation: 9 







2-BUTOXYETHANOL AND 2-BUTOXYETHANOL ACETATE A-8 
APPENDIX A 
[ ] 1 [X] 3 [ ] 10 (for extrapolation from animals to humans) 
[ ] 1 [X] 3 [ ] 10 (for human variability) 
An uncertainty factor of 3 for animal to human extrapolation was used because in vitro data show that human 
red blood cells are much less sensitive to the hemolytic effects of the 2-butoxyethanol metabolite, 2-butoxy-acetic 
acid. Concentrations of 2-butoxyacetic acid that caused hemolysis of rat red blood cells did not cause 
hemolysis of human red blood cells (Bartnik et al. 1987). For example, following a 60 minute exposure of rat 
red blood cells to 7.5 mM 2-butoxyacetic acid 100% hemolysis was observed. Following a 60 minute 
exposure of human red blood cells to 15 mM 2-butoxyacetic acid, no hemolysis was observed (Bartnik et al. 
1987). An in vitro study measuring more sensitive endpoints of red blood cell effects, mean cell volume and 
hematocrit, has also shown rat red blood cells to be more sensitive to 2-butoxyacetic acid compared to human 
red blood cells (Ghanayem and Sullivan 1993). For example, following a 1 hour exposure to 2 mM 2­
butoxyacetic acid, mean corpuscular volume was about 150% of controls in rat red blood cells, and 105% of 
controls in human red blood cells, hematocrit was about 155% of controls in rat red blood cells, and 105% of 
controls in human red blood cells. Red blood cells of rabbits, hamsters, mice and baboons were also sensitive 
to the red blood cell effects of 2-butoxyacetic acid, while red blood cells of cats, pigs, dogs, and guinea pigs 
were not sensitive the effects of 2-butoxyacetic acid (Ghanayem and Sullivan 1993). This in vitro data is also 
supported by the Carpenter et al. (1956) study in which erythrocyte osmotic fragility, an effect observed in 
animals, was not observed in humans exposed by inhalation to ≤ 195 ppm 2-butoxyethanol for 4-8 hours. In 
addition, an in vitro study showed that human erythrocytes were resistant to the hemolytic effects of 
2-butoxyacetic acid, the hemolytic metabolite of 2-butoxyethanol (Udden 1994). 
An uncertainty factor of 3 for human variability was used because the results of in vitro data suggest that 2­
butoxyethanol does not cause significant hemolysis of normal and potentially susceptible erythrocytes (Udden 
1996). Udden (1994) reported that red blood cells in humans (including the elderly and patients with 
hereditary spherocytosis and sickle cell disease) were not susceptible to 2-butoxyacetic acid-induced 
hemolysis. 
Was a conversion factor used from uum in food or water to a mg/body weight dose? 
If so, explain: Not applicable. 
If an inhalation study in animals, list conversion factors used in determining human eauivalent dose: 
The human equivalent dose (HEC) was calculated using Formula 4-48 from Interim Methods for Derivation of 
Inhalation Reference Concentrations and Application of Inhalation Dosimetry, EPA (1994). Though 2­
butoxyethanol is a Category 2 gas (i.e., water soluble and accumulates in blood), the equation in the EPA 
(1994) document for extrarespiratory effects of Category 2 gases is presently under review and the 
recommended equation is that for Category 3 gases: 
NOAEL[HEC]  = NOAEL[ADJ] x (Hb/g)A  / (Hb/g)H 
where: 
NOAEL[HEC] = the NOAEL human equivalent concentration 
NOAEL[ADJ] = the NOAEL adjusted for duration (see below) 
(Hb/g)A = blood/gas partition coefficient for animals 
(Hb/g)H = blood/gas partition coefficient for humans 
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(Hb/g)A = not available 
(Hb/g)H = 7965 (Johanson and Dynesius 1988). 
Because a blood/gas partition coefficient was not available for rats, a default of 1 was used for the ratio of 
partition coefficients. 
NOAEL[HEC]  = 25 ppm x (1) 
NOAEL[HEC] = 25 ppm 
Was a conversion used from intermittent to continuous exnosure? If so. exulain: No adjustment for 
intetmittent exposure was used because 2-butoxyethanol and its major metabolite, 2-butoxyacetic acid, are 
eliminated from the body within 24 hours. In addition, because of the high blood/gas partition coefficient 
(7965) relative to a low fat/blood partition coefficient (0.77 Jepson et al. 1992) blood concentrations would be 
expected to reach periodicity (i.e., the periodic steady state is such that the concentration versus time profile is 
the same for every week) during intermediate-duration exposure (EPA 1994). 
Other additional studies or pertinent information that lend support to this MRL: In addition to the 
hematologic effects, a transient decrease in body weight was observed in females early in the study. In light of 
the results of Dodd et al. (1983) after acute inhalation exposure of rats to doses up to 245 ppm, and the more 
severe hematological effects observed, accompanied by changes in liver weight, respiratory effects, and 
decreased body weight gain, it seems reasonable to accept the effect seen in the intermediate inhalation 
exposure experiment as being the most sensitive indicator of toxicity. No other suitable supporting studies 
were found. 
In its Threshold Limit Value (TLV) recommendation, the American Conference of Governmental Industrial 
Hygienists (ACGIH) stated that “anemia is not an uncommon condition in the human population. (ACGIH 
199 1). ACGIH (1991) recommended that exposures to 2-butoxyethanol be maintained below levels that are 
found to cause blood changes in experimental animals. Based on this recommendation, the TLV-TWA was 
established at 25 ppm. 
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because the changes in both hematocrit and mean corpuscular hemoglobin concentration were in the range of 
normal clinical values, the effect was considered a NOAEL. Normal clinical values of hematocrit are reported 
for males as 40-54%, with a level of 30% or less considered to indicate moderate to severe anemia (Fischbach 
1992). Normal clinical values of mean corpuscular hemoglobin concentration are reported as 3 l-37 g 
hemoglobin/dL (Fischbach 1992). Increased mean corpuscular hemoglobin concentrations often indicates 
spherocytosis, while decreased mean corpuscular hemoglobin concentrations may indicate macrocytic anemia, 
chronic blood loss anemia, or pyridoxine-responsive anemia (Fischbach 1992). None of the red blood cell end 
points were correlated with internal exposure as assessed by urinary free 2-butoxyacetic acid. [Although as 
noted above a significant fraction of BAA in urine may have been conjugated.] Serum creatinine and urinary 
retinol binding protein were not affected. No difference was observed for serum alanine transaminase or 
serum aspartate transaminase. The statistics in this paper seem odd. 
Dose and end point used for MRL derivation: 
[X] NOAEL [] LOAEL 
0.6 ppm 
Uncertainty Factors used in MRL derivation: 3 
[x] 1 [ ] 3 [ ] 10 (for use of a LOAEL) 
[x] 1 [ ] 3 [ ] 10 (for extrapolation from animals to humans) 
[ ] 1 [x] 3 [ ] 10 for human variability 
An uncertainty factor of 3 for human variability was used because the results of in vitro data suggest that 2­
butoxyethanol does not cause significant hemolysis of normal and potentially susceptible erythrocytes (Udden 
1996). Udden (1994) reported that red blood cells in humans (including the elderly and patients with 
hereditary spherocytosis and sickle cell disease) were not susceptible to 2-butoxyacetic acid-induced 
hemolysis. At the end of a 90-day inhalation study, the hematologic effects seen in the female exposed rats 
either lessened or returned to control value ranges (Dodd et al 1983). 
Was a conversion used from ppm in food or water to a mg/body weight dose? 
If so, explain: Not applicable 
If an inhalation study in animals, list the conversion factors used in determining human equivalent dose: Not 
applicable 
Other additional studies or pertinent information which lend suuuort to this MRL: 
There are no additional chronic studies in either humans or animals. 
Agency Contact (Chemical Manager): Olivia Harris 
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Chemical name(s): 2-Butoxyethanol 
CAS Number(s): 111-76-2 
Date: June 1998 
Profile status: Draft 3 
Route: [ ] Inhalation [X] Oral 
Duration: [X] Acute [ ] Intermediate [ ] Chronic 
Key to figure: 28 
Species: Rat 
MRL: 0.4 [X] mg/kg/day [ ] ppm [ ] mg/m3 
Reference: Ghanayem et al. 1987a 
Experimental design: Young (4-5 weeks) and adult (9-13 weeks, 5-6 months, and 16 months) rats were 
dosed with 0,32,63, 125,250, or 500 mg/kg 2-butoxyethanol by gavage. Hemotoxicity and metabolism and 
excretion of 2-butoxyethanol was monitored for 48 hours. Animals were killed at 24 and 48 hours after 
treatment and spleen, liver, kidney, testes, and urinary bladder were weighed, fixed, and examined. 
Histopathological results were presented for the control, 125,250, and 500 mg/kg dose group. 
Effects noted in study and corresuonding doses: In younger rats, 125 mg/kg caused no effect on hematological 
parameters. At 500 mg/kg, RBC, HGB, and HCT were decreased, although not as much as in the older rats. 
In older rats, 2-butoxyethanol at 125 mg/kg causes severe acute hemolytic anemia resulting in significant 
decreases at 8 and 24 hours after treatment in RBCs, HGB, and HCT, and increases 8 hours after 
administration in the concentration of free plasma hemogliobin. At 4 hours, peak increases in free plasma 
hemoglobin were seen in both younger and older rats dosed with 500 mg/kg. Secondary to the hemolytic 
effects, 2-butoxyethanol also caused hemoglobinuria in 16-month-old rats at ≥32 mg/kg, in 6-month-old rats 
at ≥63 mg/kg, and in younger rats (4-13 weeks) at ≥125 mg/kg. Other effects secondary to hemolysis 
consisted of histopathologic changes in the liver and kidney, including focal coagulative necrosis of 
hepatocytes at 250 mg/kg (l/6) and hemoglobin casts in the proximal tubules of the kidney at 125 mg/kg in 
adult (9-13 weeks) rats; these effects were not seen in young (4-5 weeks) rats even at 500 mg/kg. These 
effects of 2-butoxyethanol were dose- and time-dependent, and were more severe at 24 hours after treatment 
that at 48 hours after treatment. The onset of the development of hemoglobinuria followed the decline in the 
concentration of free HGB in the plasma. Both the hemolytic effects and the secondary effects of 
2-butoxyethanol were age-dependent, with older rats being more sensitive than younger rats. The 4-5­
week-old rats and 9-13-week-old rats were treated with 500 mg/kg/day 2-butoxyethanol, and reticulocytes and 
leukocytes were counted up to 48 hours after treatment. Adult rats exhibited neutrophilic leukocytosis and 
mild lymphopenia within 4 hours. This was not detected at 48 hours. An absolute increase in reticulocyte 
count occurred at 48 hours after dosing. Thus, 
32 mg/kg = LOAEL. 
Dose endpoint used for MRL derivation: 32 mg/kg - hematological effects 
[ ] NOAEL [X] LOAEL 
Uncertainty factors used in MRL derivation: 90 
[ ] 1 [ ] 3 [X] 10 (for use of a LOAEL)
 
[ ] 1 [X] 3 [ ] 10 (for extrapolation from animals to humans)
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Since the 32 mg/kg dose in the Ghanayem et al. (1987a) study caused hemoglobinuria only in the aged rats, 
the uncertainty factor used for human variability was 3 since the LOAEL is for the most sensitive population. 
Also, in vitro data show that human red blood cells are much less sensitive to the hemolytic effects of the 2-
butoxyethanol metabolite, 2-butoxyacetic acid. Concentrations of 2-butoxyacetic acid that caused hemolysis 
of rat red blood cells did not cause hemolysis of human red blood cells (Bartnik et al. 1987). For example, 
following a 60 minute exposure of rat red blood cells to 7.5 mM 2-butoxyacetic acid 100% hemolysis was 
observed. Following a 60 minute exposure of human red blood cells to 15 mM 2-butoxyacetic acid, no 
hemolysis was observed (Bartnik et al. 1987). An in vitro study measuring more sensitive endpoints of red 
blood cell effects, mean cell volume and hematocrit, has also shown rat red blood cells to be more sensitive to 
2-butoxyacetic acid compared to human red blood cells (Ghanayem and Sullivan 1993). For example, 
following a 1 hour exposure to 2 mM 2-butoxyacetic acid, mean corpuscular volume was about 150% of 
controls in rat red blood cells, and 105% of controls in human red blood cells, hematocrit was about 155% of 
controls in rat red blood cells, and 105% of controls in human red blood cells. Red blood cells of rabbits, 
hamsters, mice and baboons were also sensitive to the red blood cell effects of 2-butoxyacetic acid, while red 
blood cells of cats, pigs, dogs, and guinea pigs were not sensitive the effects of 2-butoxyacetic acid 
(Ghanayem and Sullivan 1993). This in vitro data is also supported by the Carpenter et al. (1956) study in 
which erythrocyte osmotic fragility, an effect observed in animals, was not observed in humans exposed by 
inhalation to ≤195 ppm 2-butoxyethanol for 4-8 hours. 
An uncertainty factor of 3 was used for human variability because the LOAEL is from a sensitive 
subpopulation (older animals). Also, an uncertainty factor of 3 for human variability was used because the 
results of in vitro data suggest that 2-butoxyethanol does not cause significant hemolysis of normal and 
potentially susceptible erythrocytes (Udden 1996). Udden (1994) reported that red blood cells in humans 
(including the elderly and patients with hereditary spherocytosis and sickle cell disease) were not susceptible to 
2-butoxyacetic acid-induced hemolysis. 
Was a conversion factor used from ppm in food or water to a mg/body weight dose? If so, explain: 
Not applicable. 




Was a conversion used from intermittent to continuous exposure?
 
If so, explain: Not applicable
 
Other additional studies or pertinent information that lend support to this MRL: Since the severity of 
hemoglobinuria in the 16-month-old rats increased as the dose levels increased and since hemoglobinuria 
occurred in younger rats only at higher doses (Ghanayem et al. 1987a), the 32 mg/kg dose was considered to 
be a less serious LOAEL. The use of the 32 mg/kg as a Less serious LOAEL for the derivation of the acute 
oral MRL is supported by a study in pregnant rats, in which no hematological effects were found at a similar 
dose of 30 mg/kg/day given for 3 days during gestation (NTP 1989) (see discussion below). Since the 
32 mg/kg dose in the Ghanayem et al. (1987a) study caused hemoglobinuria only in the aged rats, the 
uncertainty factor used for human variability was 3, since the LOAEL is for the most sensitive population. 
Furthermore, since humans appear to be less susceptible to 2-butoxyethanol-induced hemolysis (see below), 
the uncertainty factor used for extrapolation from animals to humans was 3. 
Hemolytic anemia is the characteristic toxic reaction to 2-butoxyethanol in animals. Sperm-positive 
Fischer 344 rats (27-33 per dose group) were administered 0,30, 100, and 200 mg/kg/day 2-butoxyethanol 
(BE) in distilled water by gavage for Gd 9-11 (NTP 1989). The biological effects of BE on dams were 
assessed during treatment as well as 24 hours after treatment and on Gd 20, and on fetuses at sacrifice 
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(Gd 20); 22-24 females per group were confirmed pregnant. At sacrifice on Gd 12 or 20, each pregnant 
female was examined by counting number of corpora Butea, and weighing body, liver, right and left kidney, 
spleen and uterus. For females sacrificed on Gd 20, the uterine contents were also evaluated (i.e., number of 
implantation sites, resorptions, and dead and live fetuses). The fetuses were sexed and examined for external 
and visceral malformations. Maternal and fetal blood (pooled by litter) was analyzed for red (BBC) and white 
(WBC) blood cell counts, hemoglobin (HGB), hematocrit (HCT), mean corpuscular hemoglobin (MCH), 
mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC) and platelet count. 
RBC count and corresponding measures of HCT and HGB were significantly reduced in the 100 and 
200 mg/kg/day dose groups at approximately 24 hours after the final dose. MCHC was significantly 
decreased at the high dose group. The blood dyscrasia produced at approximately 24 hours after the last 
treatment also included increases in reticulocytes (%RBC), WBC count, platelet count, MCV, and MCH in the 
100 and 200 mg/kg/day dose groups. On Gd 20, maternal hematological end points recovered toward control 
values, although a majority of values remained different from controls on the 100 and 200 mg/kg/day dose 
groups RBC counts measured on Gd 20 in the 100 and 200 mg/kg/day dose groups of each treatment period 
were still significantly lower than control values, but counts had increased since cessation of treatment (i.e., at 
200 mg/kg/day dose group), the RBC count increased to 9 1% of control levels by Gd 20. Similarly, 
reticulocytes declined from values measured earlier in the 100 and 200 mg/kg/day dose groups, but were still 
significantly above the control level. Corrected WBC count measured on Gd 20 after dam treatment was 
similar across dose groups. Platelet counts determined at the end of the study after treatment showed a 
significant decreasing trend with dose which appeared to be determined by a nonsignificant decreasing trend 
with the high-dose group below the control count. The MCV and MCH on Gd 20 exhibited significant 
dose-related trends with the values of the two highest dose groups significantly greater than the control values. 
Calculated values of MCHC showed significant decreasing dose-related trends with the high-dose group 
values lower than controls. The changes in MCHC with treatment, although significant at the high-dose 
group, were relatively slight. The maternal hematological profiles at 24 hours after final treatment and at 
Gd 20 indicate that 2-butoxyethanol-induced hemolysis triggered a compensatory hematopoietic response 
leading to reticulocytosis. Furthermore, recovery was more complete by Gd 20 for dams treated on Gd 9-l 1 
than those exposed to Gd 1 l-l 3. 
In a similar experiment by NTP (1989), sperm-positive female Fischer 344 rats (29-31 per dose group) were 
administered 0,30, 100, and 300 mg/kg/day 2-butoxyethanol in distilled water by gavage for Gd 1 l-13. The 
biological effects of BE on dams were assessed during treatment as well as 24 hours after treatment and on 
Gd 20, and on fetuses at sacrifice (Gd 20). Maternal and fetal blood (pooled by litter) was analyzed for red 
(BBC) and white (WBC) blood cell counts, hemoglobin (HGB), hematocrit (HCT), mean corpuscular 
hemoglobin (MCH), mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC) 
and platelet count. RBC count and corresponding measures of HCT and HGB were significantly reduced in the 
100 and 300 mg/kg/day dose groups at approximately 24 hours after the final dose. MCHC was significantly 
decreased at the high dose group. The blood dyscrasia produced at approximately 24 hours after the last 
treatment also included increases in reticulocytes (%RBC), WBC count, platelet count, MCV, and MCH in the 
100 and 300 mg/kg/day dose groups. On Gd 20, maternal hematological end points recovered toward control 
values, although a majority of values remained different from controls on the 100 and 300 mg/kg/day dose 
groups. RBC counts measured on Gd 20 in the 100 and 300 mg/kg/day dose groups of each treatment period 
were still lower than control values, but counts had increased since cessation of treatment (i.e., at 
300 mg/kg/day dose group), the RBC count increased from about 45% of control levels at 24 hours after the 
final treatment to 80% of control levels by Gd 20. Similarly, reticulocytes declined from values measured 
earlier in the 100 and 300 mg/kg/day dose groups, but were still significantly above the control level. 
Corrected WBC count measured on Gd 20 after dam treatment still exhibited a significant increasing trend 
with dose which appeared to be determined by a nonsignificant increase in the high-dose group. Platelet 
counts determined at the end of the study after treatment showed a significant increase at the high dose. The 
MCV and MCH on Gd 20 exhibited significant dose-related trends with the values of the two highest dose 
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groups greater than the control values. Calculated values of MCHC showed significant decreasing 
dose-related trends with the high-dose group values lower than controls. The changes in MCHC with 
treatment, although significant at the high-dose group, were relatively slight. The maternal hematological 
profiles at 24 hours after final treatment and at Gd 20 indicate that BE-induced hemolysis triggered a 
compensatory hematopoietic response leading to reticulocytosis. Furthermore, recovery was more complete by 
Gd 20 for dams treated on Gd 9-l 1 than those exposed to Gd 11-13. Thus, 30 mg/kg/day was the NOAEL 
for hematological effects in both experiments in the NTP (1989) study, lending support for the use of the 
LOAEL of 32 mg/kg for hematological effects in the aged rats in the Ghanayem et al. (1987a) study for the 
derivation of the acute oral MRL. 
In another study (Ghanayem et al. 1992) male Fischer 344 rats (n=6) received by gavage 125 mg/kg/day 
2-butoxyethanol for 1,2, 3,6, or 12 consecutive days. Controls received 5 mL water/kg body weight daily for 
12 consecutive days. Twenty-four hours after tbe last dose, blood samples were collected for hematological 
measurements and determination of blood ATP concentration. Spleen and liver were removed and weighed. 
Organ weight per 100 g body weight ratios were calculated. Treatment of rats with 2-butoxyethanol daily 
(125 mg/kg/day) for l-3 consecutive days resulted in a time-dependent increase in the hemolysis of 
erythrocytes. However, when daily treatment with 2-butoxyethanol continued beyond 3 days, the number of 
erythrocytes began to rebound and approached pretreatment levels within 12 days despite continued daily 
exposure, suggesting development of tolerance to the hemolytic effect of 2-butoxyethanol. Mean cell volumes 
(MCV), ATP concentration, and the number of reticulocytes increased to the sixth day and then decreased on 
the twelfth day. Liver weight/body weight ratios were minimally affected by repeated dosing, declined on 
days 3 and 6, but increased on day 12 as compared to controls. Spleen weight increased in a time-dependent 
manner. 
In other studies, hematotoxic effects were observed at similar or higher doses. For instance, hemoglobinuria 
was observed in rats receiving one dose of 126 mg/kg (Corley et al. 1994); hemolysis was observed in rats 
receiving one dose of 250 mg/kg, and reduced BBC, hematocrit, and increased MCV and reticulocytes, and 
mean corpuscular hemoglobin in the presence of increased liver and spleen weight were observed in rats at 
500 mg/kg/day after 1 or 4 days (Ghanayem and Sullivan 1993; Ghanayem et al. 1987b; Grant et al. 1985). 
Hepatic and renal histopathology similar to that observed in Ghanayem et al. (1987a) at 125 mg/kg/day was 
also observed at 500 mg/kg/day after one dose (Ghanayem et al. 1987b). 
Agency Contact (Chemical Manager): Olivia Harris 
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Chemical name(s) : 2-Butoxyethanol
 CAS Number(s): 111-76-2 
Date: June 1998 
Profile status: Draft 3 
Route: [ ] Inhalation [X] Oral 
Duration: [ ] Acute [X] Intermediate [ ] Chronic 
Key to figure: 90
 Species: Rat 
MRL: 0.07 [X] mg/kg/day [ ] ppm [ ] mg/m3 
Reference: NTP 1993 
Experimental design: F344/N rats (10 males, 10 females) were given targeted concentrations of 0,750, 
1,500,3,000,4500, or 6,000 ppm 2-butoxyethanol in drinking water daily for 13 weeks. Actual doses, 
determined by the authors from drinking water consumption and body weight data, were: 0,69, 129,281, 
367, and 452 mg/kg/day for males and 0, 82, 151, 304, 363, and 470 mg/kg/day for females. Animals were 
observed twice daily and weighed at the start of the studies, weekly thereafter, and at necropsy. Clinical 
observations were recorded weekly. Water consumption by cage was measured twice a week. Complete 
necropsies were performed on all animals in the base studies. The heart, liver, right kidney, lung, thymus, and 
right testis were weighed, examined for gross lesions, fixed or embedded in paraffin, and stained for 
microscopic examination. The protocol for the 13-week studies required that tissues be examined 
microscopically in all control animals, animals in the highest dose group with at least 60% survivors, and all 
animals in the higher-dose group (inclusive of early deaths and survivors). In the clinical pathology study, 
20 males and 20 females per dose group were used. On days 5 and 21, blood samples were collected for the 
clinical pathology and hematology studies. Week- 13 analyses were conducted on samples obtained from rats 
in the base studies. Urinalysis was done on week- 13 samples collected overnight from the base study animals. 
In the sperm morphology and vaginal cytology evaluations, males were evaluated for necropsy body and 
reproductive tissue weights, and spermatozoa1 data. Females were evaluated for necropsy body weight, 
estrous cycle length, and percentage of cycle spent in the various stages. 
Effects noted in study and corresponding doses: Hematological effects were noted at ≥ 82 mg/kg/day in 
females and at 281 mg/kg/day in males, but no hematological effects were found in males at 69 or 
129 mg/kg/day. Females were more sensitive than males to the hematological effects. Hepatic effects were 
also noted at ≥ 82 mg/kg/day in females and ≥ 69 mg/kg/day for males. The hepatic effects included 
significantly increased levels of serum alkaline phosphatase in high dose males (452 mg/kg/day) at 3 weeks 
and in females at 363 and 470 mg/kg/day at 13 weeks, and in serum alanine aminotransferase in males at 
452 mg/kg/day and in females at 363 and 470 mg/kg/day at week 13. Histological examination of livers 
revealed hepatocellular alterations (hepatocytes that stained more eosinophilic and lacked the amphophilic to 
basophilc granularity of the cytoplasm) at all doses (≥ 69 mg/kg/day for males and ≥ 82 mg/kg/day for 
females). The changes may be indications of early degeneration changes in hepatocytes. Centrilobular 
hepatocellular degeneration was observed in males at ≥ 281 mg/kg/day and in females at ≥ 304 mg/kg/day; and 
brown to green granular pigment staining strongly positive for iron in Kupffer’s cell cytoplasm in males at 
452 mg/kg/day and in females at ≥ 151 mg/kg/day. Renal effects were also seen in males and females. Renal 
effects included moderate increases in blood urea nitrogen in males at ≥ 69 mg/kg/day at week 3 and at 
≥ 281 mg/kg/day at week 13 and in females at ≥ 304 mg/kg/day at week 13; increases in blood creatinine in 
females at ≥304 mg/kg/day at week 13; decreases in total blood protein in males at ≥281 mg/kg/day at week 
13 and in females at ≥ 151 mg/kg/day at weeks 3 and 13; decreases in blood albumin in males at 
≥281 mg/kg/day at week 13 and in females at ≥ 363 mglkg/day at week 3 and at ≥304 mg/kg/day at week 13; 
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males at ≥ 69 mg/kg/day and in females at ≥151 mg/kg/day at week 13. However, histological examination of 
the kidneys and urinary bladder revealed no pathological lesions. The renal effects observed in rats may have 
reflected dehydration, since drinking water consumption was decreased. Thus, the 69 mg/kg/day dose in male 
rats is a less serious LOAEL for both hepatic and renal effects, and therefore is an appropriate dose for the 
derivation of the intermediate oral MRL. 
69 mg/kg/day = 	 low dose in males (LOAEL for hepatic and renal effects) - hepatocellular alteration, 
moderate increased blood urea nitrogen. 
82 mg/kg/day = 	 low dose in females - decreased RBC, HCT, HGB; hepatocellular alteration; 
decreased urine volume. 
Dose endpoint used for MRL derivation: 69 mg/kg/day - hepatic effects 
[ ] NOAEL [X] LOAEL
 
Uncertainty factors used in MRL derivation: 1000
 
[ ] 1 [ ] 3 [X] 10 (for use of a LOAEL)
 
[ ] 1 [ ] 3 [X] 10 (for extrapolation from animals to humans)
 
[ ] 1 [ ] 3 [X] 10 (for human variability)
 
Was a conversion factor used from ppm in food or water to a mg/body weight dose?
 
If so, explain: Doses in mg/kg/day were calculated by NTP (1993) from drinking water consumption and
 
body weight data in the experimental animals
 




Was a conversion used from intermittent to continuous exposure? If so. exulain: Not applicable. 
Other additional studies or pertinent information that lend support to this MRL: 
In the same study by NTP (1993), groups of 10 male and 10 female B6C3F1 mice were given targeted 
concentrations of 0,750, 1,500,3,000,4500, or 6,000 ppm 2-butoxyethanol in drinking water daily for 
13 weeks. Actual doses were: 0, 118,223,553,676, and 694 mg/kg/day for males and 0, 185,370,676, 
86 1, and 1,306 mg/kg/day for females. Animals were observed twice daily and weighed at the start of the 
studies, weekly thereafter, and at necropsy. Clinical observations were recorded weekly. Water consumption 
by cage was measured twice a week. Complete necropsies were performed on all animals in the base studies. 
The heart, right kidney, lung, thymus, and right testis were weighed, examined for gross lesions, fixed or 
embedded in paraffin, and stained for microscopic examination” The protocol for the 13-week studies required 
that tissues be examined microscopically in all control animals, animals in the highest dose group with at least 
60% survivors, and all animals in the higher-dose group (inclusive of early deaths and survivors). In the sperm 
morphology and vaginal cytology evaluations, males were evaluated for necropsy body and reproductive tissue 
weights, and spermatozoa1 data. Females were evaluated for necropsy body weight, estrous cycle length, and 
percentage of cycle spent in the various stages. Clinical chemistry, urinalysis, and hematological evaluations 
were not performed for the mice. The only effect observed in mice was decreased body weight gain in male 
mice at t ≥53 mg/kg/day and in female mice at ≥ 676 mg/kg/day. No hepatic or renal effects were found in the 
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The only other comprehensive intermediate oral study was conducted in adult male albino rats (COBS CD 
(SD)BR) that were given undiluted 2-butoxyethanol by gavage in doses of 0,222,443, or 885 mg/kg/day, 
5 days per week over a 6-week period (Eastman Kodak 1983; Krasavage 1986). Body weights and feed 
consumption were recorded. Clinical signs of toxicity and deviations from normal appearance and behavior 
were observed. Mortality was checked daily and dead animals were necropsied; tissues (lung, heart, thymus, 
kidneys, liver, spleen, brain, salivary glands, stomach, cecum, colon, duodenum, jejunum, ileum, pancreas, 
esophagus, adrenal glands, pituitary, thyroid, parathyroid, trachea, mesenteric lymph nodes, testes, 
epididymides, prostate, seminal vehicles, coagulating gland, bone marrow, tongue, and nasal cavities) were 
collected for histologic examination. Eyes were fixed in tinker’s solution. Organ weights of liver, kidneys, 
heart, testes, brain, and spleen were determined. The LOAEL (serious) for hematological effects was 
222 mg/kg/day, and there was no NOAEL for that effect Hepatic and renal effects associated with the 
hemolytic effects occurred at 443 mg/kg/day (less serious LOAEL), but not at 222 mg/kg/day, and included 
hemosiderin disposition and an increase in alkaline phosphatase activity. 
Agency Contact (Chemical Manager): Olivia Harris 

 




Public Health Statement 
This chapter of the profile is a health effects summary written in non-technical language. Its intended audience 
is the general public especially people living in the vicinity of a hazardous waste site or chemical release. If 
the Public Health Statement were removed from the rest of the document, it would still communicate to the lay 
public essential information about the chemical. 
The major headings in the Public Health Statement are useful to find specific topics of concern. The topics are 
written in a question and answer format. The answer to each question includes a sentence that will direct the 
reader to chapters in the profile that will provide more information on the given topic. 
Chapter 2 
Tables and Figures for Levels of Significant Exposure (LSE) 
Tables (2-l) 2-2, and 2-3) and figures (2- 1 and 2-2) are used to summarize health effects and illustrate 
graphically levels of exposure associated with those effects. These levels cover health effects observed at 
increasing dose concentrations and durations, differences in response by species, minimal risk levels (MRLs) 
to humans for noncancer end points, and EPA’s estimated range associated with an upper- bound individual 
lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. Use the LSE tables and figures for a quick review of 
the health effects and to locate data for a specific exposure scenario. The LSE tables and figures should 
always be used in conjunction with the text. All entries in these tables and figures represent studies that 
provide reliable, quantitative estimates of No-Observed-Adverse-Effect Levels (NOAELs), 
Lowest-Observed-Adverse-Effect Levels (LOAELs), or Cancer Effect Levels (CELs). 
The legends presented below demonstrate the application of these tables and figures. Representative examples 
of LSE Table 2-l and Figure 2-1 are shown. The numbers in the left column of the legends correspond to the 
numbers in the example table and figure. 
LEGEND 
See LSE Table 2-l 
(1) 	Route of Exposure One of the first considerations when reviewing the toxicity of a subs_tance using 
these tables and figures should be the relevant and appropriate route of exposure. When sufficient data 
exists, three LSE tables and two LSE figures are presented in the document. The three LSE tables 
present data on the three principal routes of exposure, i.e., inhalation, oral, and dermal (LSE Table 2- 1, 
2-2, and 2-3, respectively). LSE figures are limited to the inhalation (LSE Figure 2-l) and oral (LSE 
Figure 2-2) routes. Not all substances will have data on each route of exposure and will not therefore 
have all five of the tables and figures. 
(2) 	Exposure Period Three exposure periods - acute (less than 15 days), intermediate (15-364 days), and 
chronic (365 days or more) are presented within each relevant route of exposure. In this example, an 
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occurring from a known length of exposure, locate the applicable exposure period within the LSE table 
and figure. 
(3) 	 Health Effect The major categories of health effects included in LSE tables and figures are death, 
systemic, immunological, neurological, developmental, reproductive, and cancer. NOAELs and 
LOAELs can be reported in the tables and figures for all effects but cancer. Systemic effects are further 
defined in the “System” column of the LSE table (see key number 18). 
(4) 	Key to Figure Each key number in the LSE table links study information to one or more data points 
using the same key number in the corresponding LSE figure. In this example, the study represented by 
key number 18 has been used to derive a NOAEL and a Less Serious LOAEL (also see the 2 “18r” data 
points in Figure 2-l). 
(5) 	Species The test species, whether animal or human, are identified in this column. Section 2.5, 
“Relevance to Public Health,” covers the relevance of animal data to human toxicity and Section 2.3, 
“Toxicokinetics,” contains any available information on comparative toxicokinetics. Although NOAHLs 
and LOAELs are species specific, the levels are extrapolated to equivalent human doses to derive an 
MRL. 
(6)	  Exposure Frequency/Duration The duration of the study and the weekly and daily exposure regimen are 
provided in this column This permits comparison of NOAELs and LOAELs from different studies. In 
this case (key number 18), rats were exposed to 1 ,1 ,2,2-tetrachloroethane via inhalation for 6 hours per 
day, 5 days per week, for 3 weeks. For a more complete review of the dosing regimen refer to the 
appropriate sections of the text or the original reference paper, i.e., Nitschke et al. 198 1. 
(7) 	System This column further defines the systemic effects These systems include: respiratory, 
cardiovascular, gastrointestinal, hematological, muscmoskeletal, hepatic, renal, and dermal/ocular. 
“Other” refers to any systemic effect (e.g., a decrease in body weight) not covered in these systems. In 
the example of key number 18, 1 systemic effect (respiratory) was investigated. 
(8) 	NOAEL A No-Observed-Adverse-Effect Level (NOAEL) is the highest exposure level at which no 
harmful effects were seen in the organ system studied. Key number 18 reports a NOAEL of 3 ppm for 
the respiratory system which was used to derive an intermediate exposure, inhalation MRL of 0.005 
ppm (see footnote “b”). 
(9) 	LOAEL A Lowest-Observed-Adverse-Effect Level (LOAEL) is the lowest dose used in the study that 
caused a harmful health effect. LOAELs have been classified into “Less Serious” and “Serious” effects. 
These distinctions help readers identify the levels of exposure at which adverse health effects first 
appear and the gradation of effects with increasing dose. A brief description of the specific endpoint 
used to quantify the adverse effect accompanies the LOAEL. The respiratory effect reported in key 
number 18 (hyperplasia) is a Less serious LOAEL of 10 ppm. MRLs are not derived from Serious 
LOAELS. 
(10) Reference The complete reference citation is given in chapter 8 of the profile. 
(11) CEL A Cancer Effect Level (CEL) is the lowest exposure level associated with the onset of 
carcinogenesis in experimental or epidemiologic studies. CELs are always considered serious effects. 
The LSE tables and figures do not contain NOAELs for cancer, but the text may report doses not 
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(12) Footnotes Explanations of abbreviations or reference notes for data in the LSE tables are found in the 
footnotes. Footnote “b” indicates the NOAEL of 3 ppm in key number 18 was used to derive an MRL 
of 0.005 ppm. 
LEGEND 
See Figure 2-1 
LSE figures graphically illustrate the data presented in the corresponding LSE tables. Figures help the reader 
quickly compare health effects according to exposure concentrations for particular exposure periods. 
(13) Exposure Period The same exposure periods appear as in the LSE table. In this example, health effects 
observed within the intermediate and chronic exposure periods are illustrated. 
(14) Health Effect These are the categories of health effects for which reliable quantitative data exists. The 
same health effects appear in the LSE table. 
(15) Levels of Exposure concentrations or doses for each health effect in the LSE tables are graphically 
displayed in the LSE figures. Exposure concentration or dose is measured on the log scale “y” axis. 
Inhalation exposure is reported in mg/ m3 or ppm and oral exposure is reported in mg/kg/day. 
(16) NOAEL In this example, 18r NOAEL is the critical endpoint for which an intermediate inhalation 
exposure MBL is based. As you can see from the LSE figure key, the open-circle symbol indicates to a 
NOAEL for the test species-rat” The key number B 8 corresponds to the entry in the LSE table. The 
dashed descending arrow indicates the extrapolation from the exposure level of 3 ppm (see entry 18 in 
the Table) to the MRL of 0.005 ppm (see footnote “b” in the LSE table). 
(17) CEL Key number 38r is 1 of 3 studies for which Cancer Effect Levels were derived. The diamond 
symbol refers to a Cancer Effect Level for the test species-mouse. The number 38 corresponds to the 
entry in the LSE table. 
(18) Estimated Upper-Bound Human Cancer Risk Levels This is the range associated with the upper-bound 
for lifetime cancer risk of 1 in 10,000 to 1 in 10,OOO,OOO. These risk levels are derived from the EPA’s 
Human Health Assessment Group’s upper-bound estimates of the slope of the cancer dose response 
curve at low dose levels (q1*). 
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Chapter 2 (Section 2.5) 
Relevance to Public Health 
The Relevance to Public Health section provides a health effects summary based on evaluations of existing 
toxicologic, epidemiologic, and toxicokinetic information. This summary is designed to present interpretive, 
weight-of-evidence discussions for human health end points by addressing the following questions. 
1 . What effects are known to occur in humans? 
2 . What effects observed in animals are likely to be of concern to humans? 
3 . What exposure conditions are likely to be of concern to humans, especially around hazardous waste
 sites? 
The section covers end points in the same order they appear within the Discussion of Health Effects by Route 
of Exposure section, by route (inhalation, oral, dermal) and within route by effect. Human data are presented 
first, then animal data. Both are organized by duration (acute, intermediate, chronic). In vitro data and data 
from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also considered in this section. If 
data are located in the scientific literature, a table of genotoxicity information is included. 
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using 
existing toxicokinetic, genotoxic, and carcinogenic data. ATSDR does not currently assess cancer potency or 
perform cancer risk assessments. Minimal risk levels (MRLs) for noncancer end points (if derived) and the 
end points from which they were derived are indicated and discussed. 
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public 
health are identified in the Data Needs section. 
Interpretation of Minimal Risk Levels 
Where sufficient toxicologic information is available, we have derived minimal risk levels (MRLs) for 
inhalation and oral routes of entry at each duration of exposure (acute, intermediate, and chronic). These 
MRLs are not meant to support regulatory action; but to acquaint health professionals with exposure levels at 
which adverse health effects are not expected to occur in humans. They should help physicians and public 
health officials determine the safety of a community living near a chemical emission, given the concentration 
of a contaminant in air or the estimated daily dose in water. MRLs are based largely on toxicological studies 
in animals and on reports of human occupational exposure. 
MRL users should be familiar with the toxicologic information on which the number is based. Chapter 2.5, 
“Relevance to Public Health,” contains basic information known about the substance. Other sections such as 
2.7, “Interactions with Other Substances,” and 2.8, “Populations that are Unusually Susceptible” provide 
important supplemental information. 
MRL users should also understand the MRL derivation methodology. MRLs are derived using a modified 
version of the risk assessment methodology the Environmental Protection Agency (EPA) provides (Barnes and 
Dourson 1988) to determine reference doses for lifetime exposure (RfDs). 
To derive an MRL, ATSDR generally selects the most sensitive endpoint which, in its best judgement, 
represents the most sensitive human health effect for a given exposure route and duration. ATSDR cannot 
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make this judgement or derive an MRL unless information (quantitative or qualitative) is available for all 
potential systemic, neurological, and developmental effects. If this information and reliable quantitative data 
on the chosen endpoint are available, ATSDR derives an MRL using the most sensitive species (when 
information from multiple species is available) with the highest NOAEL that does not exceed any adverse 
effect levels. When a NOAEL is not available, a Lowest-observed-adverse-effect level (LOAEL) can be used 
to derive an MRL, and an uncertainty factor (UF) of 10 must be employed. Additional uncertainty factors of 
10 must be used both for human variability to protect sensitive subpopulations (people who are most 
susceptible to the health effects caused by the substance) and for interspecies variability (extrapolation from 
animals to humans). In deriving an MRL, these individual uncertainty factors are multiplied together. The 
product is then divided into the inhalation concentration or oral dosage selected from the study. Uncertainty 
factors used in developing a substance-specific MRL are provided in the footnotes of the LSE Tables. 



